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ABSTRACT 
 
Introduction: Prevention of mother-to-child transmission (PMTCT) has potential to eliminate new 
HIV infections among infants. Yet, in many settings in sub-Saharan Africa, women are unable to 
adhere to PMTCT recommendations due to social constraints. One such factor may be intimate 
partner violence (IPV), or any actions taken by a relationship partner that cause physical, sexual, or 
psychological harm. Despite theoretical and empirical rationale for understanding the links between 
IPV and PMTCT adherence, few studies in the extant literature have explored this association. 
 
Methods: This thesis draws upon four distinct studies that interface using an overall mixed method 
study design. The first study is a systematic review of the literature around women’s experience of 
lifetime IPV and adherence to anti-retroviral treatment (ART). The second study is formative 
qualitative research with pregnant women, health workers, and other local stakeholders that explores 
how IPV may be related to PMTCT in the urban Johannesburg setting. The third study is a deeper 
qualitative examination of women living with both IPV and HIV, aiming to understand the 
mechanisms that link partner violence to PMTCT behaviors using a social constructionist lens. The 
final study is a quantitative cohort study nested within a randomized control trial testing an 
intervention for IPV in pregnancy. Using regression techniques and structural equation modeling, I 
aim to determine the association between IPV and ART adherence in pregnancy and postpartum and 
identify pathways that mediate the relationship between partner violence and PMTCT. 
 
Results: This doctoral research contributes several new findings to the extant literature around 
PMTCT. I find that IPV is related to ART adherence among HIV-positive women in extant 
literature, with meta-analysis showing significantly worse odds of ART uptake, self-reported 
adherence, and viral suppression among women reporting lifetime IPV. In one of first of studies 
among women in sub-Saharan Africa, I learn that impact of IPV on ART adherence in pregnancy 
and postpartum is marked. I identify several mechanisms through which IPV influences PMTCT 
adherence. Mental health emerges as a robust pathway linking IPV to worse adherence in both 
qualitative and quantitative papers. Partner non-disclosure due to IPV can impede adherence, or 
women can navigate this challenge through hiding their HIV status or medication. Women 
experiencing IPV may attend fewer antenatal clinic visits, leading to worsened adherence. An 
unexpected finding was that women in our qualitative and quantitative studies were resilient and 
used strategies to adhere despite IPV. Motherhood seems to be a central feature of women who are 
resilient to the effects of IPV on adherence. 
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Conclusion: The findings of this research have implications for research, policy, and practice. 
Research should incorporate social factors, such as IPV, into future studies testing PMTCT 
adherence interventions. Clinical practice and HIV programs should recognize that partner-level 
dynamics such as IPV may drive persistent gaps in PMTCT coverage. HIV policy urgently needs to 
incorporate ethical and safety considerations for women who experience IPV around the time of 
pregnancy. Women living with recent or past IPV are highly resilient and often want to protect their 
own health and that of their children. Only by recognizing and addressing their experience within the 
context of HIV care can future PMTCT programs and studies ensure maternal and infant health. 
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Chapter 1. Introduction 
 
 
 
 
 
 
 
 
 
Photo credit: Fhatawani Tshikororo, Local stakeholders 
introducing themselves during the Safe & Sound launch event.
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A. Background 
There is potential for antiretroviral treatment (ART) to improve maternal health and reduce HIV 
infection among infants to as low as 1% (Lehman et al., 2009; Mofenson, 2010b). However, new 
infant HIV infections continue to occur throughout sub-Saharan Africa (UNAIDS, 2016a). 
Successful prevention of mother-to-child HIV transmission (PMTCT) requires a complex series 
of health behaviors throughout pregnancy and after birth, and only a small portion of women 
complete what is called the “PMTCT cascade” (Padian et al., 2011).  
There are many reasons for challenges in PMTCT adherence, including stigma (Turan & 
Nyblade, 2013; Watts et al., 2010), substance use (Nachega et al., 2012), poverty (Mepham et al., 
2011), clinic waiting times and transport costs (Bwirire et al., 2008), and weak health systems 
(Luo et al., 2007; Pai & Klein, 2009). Another key driver of drop-offs in the PMTCT cascade 
may be fears and experiences of intimate partner violence (IPV). IPV is experienced by 30% of 
women globally, and poses immense cost to human rights, health, and economies across the 
world (Devries et al., 2013b). 
 
B. Justification for the Research 
Over the past two decades, research has shown increasingly strong links between IPV and HIV. 
Early on, researchers theorized that a similar risk environment heightens women’s IPV risk and 
increases HIV acquisition (Maman et al., 2000). Empirical research has since shown that HIV-
positive women have higher odds of experiencing IPV than HIV-negative counterparts 
(McDonnell et al., 2003; Ntaganira et al., 2008; Were et al., 2011). Even when adjusting for other 
key predictors, such as sexual behavior, women who report IPV are more likely to be HIV-
positive (Dude, 2011; Dunkle et al., 2004b; Fonck et al., 2005; Kayibanda et al., 2012; Maman et 
al., 2002; Silverman et al., 2008). The robust cross-sectional associations between IPV and HIV 
are consistent in studies among pregnant women (Shamu et al., 2011). More importantly, the 
association has been confirmed in longitudinal studies that show IPV to be associated with 
incident HIV infection (Decker et al., 2009; Jewkes et al., 2010; Kouyoumdjian et al., 2013). In a 
systematic review of the literature, Li et al. pooled extant longitudinal data to show that women 
have 28% increased risk of incident HIV infection if they experienced IPV (2014).  
Despite confirmation that IPV is related to incident HIV infection, much less is known 
about the effect of IPV on health of women already living with HIV. Preliminary evidence from 
exploratory studies suggests IPV leads to worse HIV-related health outcomes for women, 
including: lower CD-4 counts (Jewkes et al., 2015; Schafer et al., 2012), greater incidence of 
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opportunistic infection (Liebschutz et al., 2000; Nava et al., 2011), detectable viral loads (Nava et 
al., 2011; Schafer et al., 2012), and greater risk of mortality (Weber et al., 2012). Yet, most of 
these studies have been conducted with small samples in the United States (U.S.) and few have 
included pregnant women. 
Understanding the relationship between IPV and HIV behaviors in South Africa is 
critical, given the high prevalence of both IPV and HIV in this setting. An estimated 25 – 35% of 
South African pregnant women report experiencing recent physical or sexual IPV (Groves et al., 
2012; Hoque et al., 2009; Mbokota & Moodley, 2003). Similarly, antenatal HIV prevalence 
across South Africa is high, with estimates in Johannesburg reaching 29% (Wabiri et al., 2016). 
 
C. Key Concepts 
Intimate partner violence 
The World Health Organization (2010, p.3) defines IPV as any “behavior within an intimate 
relationship that causes physical, sexual, or psychological harm, including acts of physical 
aggression, sexual coercion, psychological abuse and controlling behaviors”. IPV is one type of 
“violence against women” which includes many forms of gender-based violence such as: non-
partner sexual violence, forced sexual initiation, female genital mutilation, honor killings, and 
human trafficking (UN General Assembly, 2016). I use the term “IPV” instead of other terms 
used in the literature (“domestic violence,” “family violence”, “partner abuse”, “wife beating”, 
etc.) because it is a precise term that denotes the perpetrator and the cause of the health problem. 
IPV comprises multiple forms of violence caused by an intimate partner: (WHO, 2010) 
• Physical IPV is defined by the U.S. Centers for Disease Control as physical force by an 
intimate partner with the potential for causing death, disability, injury, or harm (Breiding 
et al., 2015). In practice, this includes forms of physical harm such as hitting, kicking, 
pushing, shoving, choking, pulling hair, or burning.  
• Sexual IPV is defined by the WHO (2014) as any sexual act “using coercion… or rape, 
defined as the physically forced or otherwise coerced penetration of the vulva or anus with 
a penis, other body part or object”. (WHO, 2014).  
• Psychological IPV includes incidents when a partner insults, belittles, intimidates, or 
humiliates a woman (Heise & Garcia Moreno, 2002). An important refinement of the 
understanding of psychological IPV is the addition of financial abuse, or the control of 
assets or economic earning potential as a strategy of power and control (Adams et al., 
2008). Longitudinal research from the U.S. suggests that physical and psychological IPV 
is correlated with episodes of financial abuse (Postmus et al., 2012).  
 16 
• Controlling behaviors are related but distinct from these other forms of IPV. These can 
include isolating a woman from family or friends, monitoring movements, or limiting her 
access to health services (WHO, 2012). 
 
New Child HIV Infections 
In 2011, an estimated 330,000 children became newly infected globally, primarily due to vertical 
transmission (UNAIDS, 2012). When mothers are not given access to essential PMTCT services, 
the rate of HIV transmission to infants is estimated to be 25-40% (De Cock et al., 2000). In the 
absence of treatment, an infant infected through vertical transmission of HIV is unlikely to live 
past five months (Marston et al., 2011). HIV transmission can occur at multiple timepoints 
around the time of pregnancy, including during gestation, during delivery, or through 
breastfeeding in the postpartum phase (Fowler et al., 2010). 
HIV has also been identified as a leading cause of maternal mortality in South Africa 
(Kruger & Bhagwanjee, 2003; Moodley et al., 2011; Moran & Moodley, 2012; Ramogale et al., 
2007) and elsewhere (Abdool-Karim et al., 2010; Gorman, 2013; Graham & Newell, 1999). This 
extraordinary burden of disease led the Joint United Nations Programme on HIV/AIDS 
(UNAIDS) to call for a 90% reduction of mother-to-child transmission (MTCT) and a halving of 
maternal HIV-related deaths by 2015 (UNAIDS, 2011). Since the launch of the 2011 UNAIDS 
Global Plan, considerable progress has been made. In 21 priority countries over the 2009-2014 
period, rates of new HIV infections among children declined by 48% (UNAIDS, 2016a). 
However, MTCT still occurs among 14% of mother-infant dyads, with the majority of new 
infections occurring during the breastfeeding phase (UNAIDS, 2016a). Of infants and children 
living with HIV, the majority (an estimated 94%) live in Sub-Saharan Africa (Mofenson, 2010a).  
 
The PMTCT Cascade  
Effective PMTCT requires women to access a number of steps (Fig. 1). Because only a 
proportion of women reach each subsequent step, this process is termed the “PMTCT cascade”, 
with women dropping out along the pathway to full PMTCT coverage (Stringer et al., 2010).  
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Navigating the PMTCT cascade begins with a woman attending antenatal care and 
accessing HIV testing. For those testing HIV-positive in the antenatal setting, initiation of ART 
must occur. To protect the fetus from vertical transmission, the woman must adhere to ART and 
use safe feeding practices until the time of cessation of breastfeed. To ensure her infant is able to 
obtain medication, in the case of infant HIV infection, the mother should access “early infant 
diagnosis” – a term for HIV testing that generally occurs at 6 weeks postpartum and at least once 
more after breastfeeding cessation. Missing any single step of the PMTCT cascade can lead to 8 
to 20-fold increases in HIV transmission to the infant (Becquet et al., 2009; Brocklehurst, 2002; 
Watts et al., 2010). 
An important shift in global PMTCT policy has been the move towards a programmatic 
approach called Option B+. This clinical protocol advises that HIV programmes immediately 
start lifelong ART treatment for mothers testing HIV-positive during antenatal care. It was 
initiated by Malawi as a strategy to ensure rapid ART initiation without the need for timely CD-4 
testing (Schouten et al., 2011). In essence, most settings had an extra PMTCT step that lay 
between E and F in Figure 1 – requiring women to CD-4 test in advance of starting ART, with 
only those women with a low CD-4 count (≤ 350 cells/µL) eligible to start treatment. In a 
systematic review, this single CD-4 testing step was associated with losses to follow-up for one-
third of PMTCT patients (Wettstein et al., 2012), creating considerable pragmatic rationale for 
skipping it altogether. There are also important benefits in starting lifelong treatment regardless of 
CD-4 count, as the woman’s morbidity and mortality declines and a discordant male partner is 
less likely to contract HIV during the perinatal phase (Cohen et al., 2011; Hargrove et al., 2010). 
Figure 1 PMTCT Cascade 
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The PMTCT Cascade in South Africa 
South Africa has made significant strides towards reducing mother-to-child transmission from 
14% in 2009 to an estimated 4.3% in 2016 (Goga et al., 2016). However, these numbers 
underestimate HIV transmission because they exclude those infants who die before 6 weeks. A 
stronger estimate is “MTCT or death”, or the idea that an infant either acquires HIV or dies, a 
joint measure estimated to be 6.2% (Goga et al., 2016). Indeed, few studies accurately measure 
utilization of PMTCT interventions because program data is often comprised of simple tallies 
rather than following mother-infant pairs throughout the cascade (Mate et al., 2009; Stringer et 
al., 2008). In one four-country study following 27 938 women through the entire cascade, an 
estimated 54% of South African pregnant women complete all steps (Stringer et al., 2010). Only 
13.6% of 446 mother-infant pairs in South Africa received all recommended PMTCT 
interventions (Dramowski et al., 2011).  
National program data suggests that an estimated 83% of eligible South African pregnant 
women are receiving ART for their own health (WHO et al., 2013). Yet, studies using routine 
clinic data present a more pessimistic picture. In Johannesburg clinics, for example, only 65% of 
300 pregnant women eligible for ART actually initiated treatment before delivery (Clouse et al., 
2013b). In another Johannesburg clinical sample, only 21% of 72 eligible women initiated ART 
within 60 days of learning their HIV serostatus (Schnippel et al., 2015). After giving birth, 49% 
of 358 Cape Town patients initiating ART in pregnancy were lost to follow-up or missed a 
postpartum ART visit (Phillips et al., 2014). Moreover, only 25% of infants in a Johannesburg 
study of 289 mother-infant pairs received adequate protection during breastfeeding (Technau et 
al., 2014), a phase when absence of maternal ART or infant prophylaxis results in considerable 
risk of MTCT (Bulterys et al., 2010). Early infant diagnosis is crucial for ensuring infants with 
HIV access immediate treatment. While national program data suggests the current coverage of 
early infant diagnosis across South Africa may be as high as 88% (WHO et al., 2013), only 55% 
of HIV-exposed infants in a national representative South Africa study of 9 803 infants had HIV 
testing documented on their clinic record (Woldesenbet et al., 2015). 
These numbers suggest an urgent need to better understand the PMTCT cascade and to 
identify important drivers of HIV-positive women’s ability to adhere to ART around the perinatal 
phase. 
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D. Overall Aim and Specific Objectives 
The overall aim of the doctoral research is: To explore how IPV influences adherence to 
prevention of mother-to-child (PMTCT) services. I studied ART adherence in HIV-positive, 
pregnant and postpartum women who were and were not experiencing IPV by nesting research 
within an ongoing trial around IPV in pregnancy. The mixed method research was designed to 
achieve the following specific objectives: 
 
Objective 1. To investigate the effect of IPV on ART adherence in the extant literature. 
Objective 2. To explore mechanisms through which IPV may impact ART adherence in 
pregnancy and postpartum. 
Objective 3. To determine the association between IPV and self-reported ART adherence 
in pregnancy and postpartum. 
 
Together, the PhD aimed to bolster the evidence base with additional data around IPV and ART 
adherence among HIV-positive pregnant and postpartum women. The long-term goal of this 
doctoral work is to influence HIV programs to address IPV, particularly when targeting pregnant 
women in resource-constrained settings.  
 
E. Organization of the Thesis 
Following this introduction in Chapter 1, Chapter 2 presents a conceptual framework for 
understanding PMTCT within a broader social and structural context. I examine evidence around 
IPV prevalence and health impacts. Next, I detail the extant knowledge around how IPV is related 
to HIV and explore what is known about how IPV may impact PMTCT behaviors specifically. 
Lastly, I highlight gaps in the literature to set the stage for how this doctoral research can inform 
the field. 
Chapter 3 describes the methodology for this doctoral research. In particular, four papers 
presented in this thesis are described. Since the thesis is a mixed method study, I demonstrate 
how the qualitative and quantitative components of the study interacted to create a cohesive 
answer to a single area of research inquiry. 
Chapters 4-8 comprise three peer-reviewed publications and a final manuscript for 
future submission that serve as the results section of the thesis: 
Chapter 4 is a systematic review of 13 studies that examine the relationship between IPV 
and ART adherence and related health behaviors among women. Along with PhD Supervisors 
and a Masters Student that I mentored, we show a robust association between women’s lifetime 
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experience of IPV and worse HIV treatment adherence. Meta-analytic techniques allow us to 
compare association between IPV and HIV outcomes across studies. Meta-analysis suggests that 
IPV worsens ART uptake, adherence, and viral suppression. 
Chapter 5 contains a manuscript exploring the relationship between IPV and HIV 
outcomes in a formative, qualitative study of pregnant women and key informants, such as health 
workers and representatives of non-governmental organizations. We identify multiple pathways 
that appear to link women’s experience of IPV with HIV behaviors and HIV-related health. These 
pathways include mental health, relationship control, and partner disclosure. However, because 
the sample comprises only five women living with IPV, this paper formed only a preliminary 
understanding of these phenomena. 
Chapter 6 is a deeper qualitative exploration of how IPV intersects with PMTCT in the 
lives of pregnant and postpartum women. We interviewed 32 women living with HIV and 
experiencing recent or lifetime IPV. Women expressed how IPV worsened mental health and 
partner disclosure, both of which inhibited their ability to adhere to treatment and recommended 
PMTCT care. However, there were also many women who stayed committed to PMTCT despite 
experiencing IPV, suggesting that resilience strategies like focusing on the motherhood identity 
can be protective. 
Chapter 7 examines quantitative data from a cohort of 265 women recruited during their 
antenatal care and followed up to 24 weeks postpartum. We learn that a large proportion of 
women with and without IPV are adherent to ART, but that IPV intensity predicts lower odds of 
adherence. The negative relationship between IPV and adherence seems to hold in both 
pregnancy and postpartum. Using structural equation modeling, we learn that mental health is a 
key mechanism through which IPV worsens ART adherence.  
Chapter 8 synthesizes the key findings of the doctoral research in light of extant 
literature. Using a mixed method approach, findings from across the four papers are integrated in 
this interpretive step. I also point out specific ways the research can inform future interventions 
and suggest potential policy implications. I consider how these data contribute to theory and note 
next steps for research. 
Chapter 9 summarizes key recommendations for policy, research, clinical practice, and 
theory. These recommendations are based on the evidence gaps filled by this thesis. In this 
chapter, I conclude by reiterating the challenges to infant and maternal health in settings where 
women are unable to safely adhere to PMTCT. I summarize how IPV may influence women’s 
efforts to adhere to PMTCT steps and call for IPV to be better incorporated in HIV health 
services. 
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This literature review will synthesize current knowledge around PMTCT and IPV in pregnancy. 
Prevalence data are presented from a global perspective and then from sub-Saharan African 
literature. Next, I present the growing evidence base around the links between IPV and HIV 
acquisition and treatment outcomes. I then review the existing knowledge around how IPV may 
influence PMTCT uptake – examining quantitative and qualitative studies, theoretical 
associations, and plausible pathways. Lastly, I highlight gaps in the evidence base and suggest 
how this doctoral research may answer research questions that remain unaddressed in extant 
literature. 
 
A. Conceptual Framework 
Theoretical Perspectives on PMTCT  
PMTCT literature to date has largely been informed by biomedical research paradigms that 
position health behaviors as individual actions by passive healthcare recipients (Betancourt et al., 
2010). Because PMTCT research often draws from individual-level theory, it often fails to 
embrace key social and structural factors that effect women’s health choices (Busza et al., 2012; 
Hampanda, 2012; Phillips & Pirkle, 2011).  
In order to overcome this gap in theory around PMTCT, my research synthesizes several 
existing theories from the health care. One underlying theory is Andersen’s Behavioral Model of 
Health Services Utilization (Andersen, 1995). The Behavioral Model posits that health care 
utilization is framed by multiple aspects of an individual’s life: the initial predisposition for 
people to uptake health care, factors that enable or hinder health care uptake, and a person’s 
perceived need for care (Andersen, 1995). Gelberg and Andersen adapted the Behavioral Model 
for vulnerable populations to understand the use of health services and health outcomes among 
marginalized groups (Gelberg et al., 2000). The main insight of the Behavioral Model for 
Vulnerable Populations is that individuals who are marginalized (such as homeless, poor, 
substance users, or mentally ill) may have different needs and access to resources than the general 
population (Stein et al., 2007). A potential shortcoming of the Behavioral Model for Vulnerable 
Populations is that it lumps all considerations around health care utilization into the broad 
categories of “predisposing” and “enabling” factors. This ‘long-list’ approach limits our ability to 
tease out various important constructs or to understand how drivers work together to inhibit 
health care utilization. 
To address this shortcoming, I adapted the Behavioral Model using the Socio-Ecological 
Framework (Figure 2). The socio-ecological framework is an organizing principle that is often 
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used to denote various levels of factors that influence health: structural, institutional, relationship, 
and individual. A socio-ecological approach acknowledges factors outside the individual patient 
influence HIV-related health (Montgomery et al., 2012), and is widely used in IPV research 
because it incorporates many complex factors that influence partner violence (Heise & Fulu, 
2014; WHO, 2010). Similarly, scholars have framed PMTCT using a socio-ecological model, in 
recognition that PMTCT health behaviors can be influenced at multiple “levels” of the individual, 
their family, and their society (Busza et al., 2012; Gourlay et al., 2013b; Wingood et al., 2013b). 
The socio-ecological model suggests that “individual” factors are the personal characteristics or 
behaviors that impact one’s health. “Relationship” factors are the dyadic partnership issues that 
frame health outcomes. “Institutional” factors include the clinic characteristics that either 
facilitate or hinder health care utilization. “Structural” refers to the broader social or community 
factors that impact on health. This lens recognises that similar structural factors underpin both 
IPV and HIV (Maman et al., 2000) and that broader social and societal factors shape how women 
are able to adhere to ART (Hirsch, 2007). 
The dyadic nature of our adapted framework extends beyond a traditional socio-
ecological model to detail particular relationship contexts that frame IPV experiences and, 
ultimately, HIV outcomes (Montgomery et al., 2012). Based on extant literature, I theorize that 
intimate relationships in particular frame the ways that IPV may impact PMTCT uptake among 
pregnant and postpartum women. Literature suggests that partner dynamics influence HIV 
prevention and treatment adherence (Burton et al., 2010; Higgins et al., 2014), as well as 
experience of IPV (Conroy, 2014). Given the strong bidirectional links between IPV and HIV 
(Colombini et al., 2016; Gielen et al., 1997; Jewkes et al., 2010; Kouyoumdjian et al., 2013; 
Maman et al., 2016; Mulrenan et al., 2015b; Shamu et al., 2014), it is appropriate to view both 
conditions as mutually-reinforcing, dyadic drivers of PMTCT.  
One theory that underpins this dyadic view of PMTCT is the theory of gender and power 
(Connell, 1985), which postulates that unequal power dynamics limit the ability of women to 
exercise personal control in relationships (Amaro & Raj, 2000). The theory highlights that gender 
power inequities in society limit women’s ability to enact safe and equitable forms of sexuality 
(Connell, 1987; Wingood & DiClemente, 2000b). For understanding PMTCT, this means that 
women may have less control over choices like whether to use condoms, where to give birth, or 
how to adhere to HIV medications (Hampanda, 2012). Empirically, this has been demonstrated 
through the Sexual Relationship Power Scale (SRPS), a validated measure based on the theory of 
gender and power (Pulerwitz et al., 2000). Women who have less power in relationships as 
assessed by SRPS have higher rates of HIV (Bermudez et al., 2010; Dunkle et al., 2004a; Hahm 
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et al., 2012; Wingood & DiClemente, 2000a; Wingood et al., 2000) and IPV (Filson et al., 2010), 
but this measure has yet to be applied to PMTCT. 
Because HIV in pregnancy has health implications for the infant, my theoretical model 
also incorporates the intergenerational aspects of IPV and HIV. When women are unable to 
adhere to PMTCT, the risk of transmission of HIV to the infant is increased (Cooper et al., 2002). 
Infants born to mothers who report IPV in pregnancy are more likely to have low birth weight, 
frequent illness, or not survive (Alio et al., 2009b; Hill et al., 2016; Karamagi et al., 2007a). In 
order to achieve global goals to improve maternal and child health, programs should account for 
IPV as a cause of morbidity and mortality among women and their infants. 
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Figure 2. Conceptual Framework (adapted from Andersen's Behavioral Model of Health Care Utilization) 
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Factors Associated with PMTCT Uptake and Retention/adherence 
There may be many reasons that women find it challenging to maintain PMTCT. Drawing upon 
sub-Saharan African literature on PMTCT uptake and adherence, I argue that health care 
utilization for an HIV-positive woman in the perinatal phase is influenced by multiple socio-
ecological considerations. 
 
Structural Factors 
Structural factors include those broader societal conditions that frame health care utilization. 
Structural drivers of health care are defined in different ways, but most scholars agree that this 
category comprises policy, social, and cultural conditions. In the case of PMTCT behaviors, 
structural drivers include material constraints that make it challenging for women to adhere to 
medication and clinic visits. For example, PMTCT seems to be influenced by poverty (Jones et 
al., 2005; Mepham et al., 2011) and food insecurity (Awiti Ujiji et al., 2011; Kirsten et al., 2011) 
since women have competing demands that may take precedence over PMTCT behaviors. Gender 
inequality frames women’s access to PMTCT services, either because women have 
disproportionately less education around PMTCT or because they cannot access permission or 
financial resources required to attend clinic (Ghanotakis et al., 2012; Lubega et al., 2013; Maman 
et al., 2001; Ngarina et al., 2015). HIV-related stigma is a structural factor that has increasingly 
been noted to influence PMTCT in multiple sub-Saharan African settings (Bond et al., 2002; 
Bwirire et al., 2008; Mepham et al., 2011; Turan et al., 2011; Turan & Nyblade, 2013; Watts et 
al., 2010). Weak health systems, particularly in resource-constrained settings, also drive PMTCT 
behaviors (Barker et al., 2011; Luo et al., 2007; Pai & Klein, 2009). Lack of education has been 
noted as a barrier to PMTCT in some settings (Ayuo et al., 2013; Delvaux et al., 2009; Kuonza et 
al., 2010), although it is generally examined at the level of the individual woman rather than at 
the structure level. 
 
Institutional Factors 
Much of the PMTCT literature to date has focused on understanding and ameliorating 
institutional factors, or the clinic-level considerations around health care utilization. For example, 
negative attitudes on the part of health service providers has been noted as a barrier to PMTCT 
both during pregnancy and postpartum (Duff et al., 2010; Stinson & Myer, 2012; Varga & 
Brookes, 2008). This can include direct verbal abuse from health providers or patient perceptions 
that health workers may not maintain confidentiality (Chinkonde et al., 2009; O'Gorman et al., 
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2010). Related, but distinct, from provider attitudes is the skill required to communicate complex 
health messages. Provider ability to clearly communicate the steps required in PMTCT – 
especially as global guidelines are rapidly shifting – is a barrier to patient engagement (Ferguson 
et al., 2012; Kirsten et al., 2011; Watson-Jones et al., 2012).  
Competing demands frame the economic concerns around attending the health facility at 
the time of PMTCT. Although many countries offer PMTCT services at no charge, transport costs 
to the facility can reduce adherence and retention in care (Bwirire et al., 2008; Duff et al., 2010; 
Kirsten et al., 2011). Distance to the clinic can also serve as an institutional barrier to PMTCT 
(Chinkonde et al., 2009; Duff et al., 2010; Kiarie et al., 2003; Painter et al., 2004). Stock outs and 
missing test kits can preclude staff from offering HIV testing (Kinuthia et al., 2011). When clinics 
are few or far apart, this can also be viewed as a structural barrier to PMTCT, since it indicates a 
weak health system with inadequate geographical coverage. Long clinic waiting times are another 
barrier (Chinkonde et al., 2009; Duff et al., 2010; Painter et al., 2004; Theilgaard et al., 2011; 
Winestone et al., 2012), which similarly may be driven by weak health systems. 
 
Relationship Factors 
Relationship factors have begun to receive attention in the PMTCT literature. These are 
conceptualized as including relationships with partners, extended family, and with children. 
Gender inequalities around accessing household resources can make women’s PMTCT decisions 
dependent on family dynamics (O'Gorman et al., 2010).  
Partnership dynamics are a newer addition to PMTCT literature, but multiple aspects of 
intimate partnerships seem to influence health behaviors. Women who do not have a partner seem 
to have more control over PMTCT decisions (Eide et al., 2006). While the involvement of the 
male partner may increase the chance of successful PMTCT (Farquhar et al., 2004a; Kiarie et al., 
2003; Nassali et al., 2009a; Peltzer et al., 2010b), it is plausible that studies showing male 
involvement are simply measuring a proxy for higher-quality, equitable relationships. 
Interventions are starting to be tested to improve male partner support. A Kenyan study reported a 
2-fold increase in male partner HIV testing among those taking part in a home-based couples 
testing intervention (Krakowiak et al., 2016).  While the intervention did not show an effect on 
facility delivery or breastfeeding, it is nevertheless encouraging that a randomized control trial 
was able to increase male testing – an important element of male partner support.  
Fears of stigma and discrimination from male partners can reduce women’s uptake and 
adherence to PMTCT services during pregnancy (Kirsten et al., 2011; Turan et al., 2011; Turan et 
al., 2012) and postpartum phases (Jones et al., 2005; Nassali et al., 2009b; Oladokun et al., 2006). 
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Women anticipating a poor reaction from partners may strategically choose non- disclosure 
(Spangler et al., 2014). A systematic review of qualitative and quantitative literature found that 
many women have a “legitimate fear of disclosing one’s status” to a partner and need to hide HIV 
in order to stay safe (hIarlaithe et al., 2014:S522). (hIarlaithe et al., 2014) 
Social support from others beyond the male partner is important for PMTCT and is 
associated with maternal adherence to ART in South African cross-sectional research (Peltzer et 
al., 2011). Lack of social support also seems to impact on women’s adherence to PMTCT 
postpartum in other African settings (Chinkonde et al., 2009; Kasenga et al., 2010). Conversely, 
pressure from family members limits how HIV-positive women are able to choose safe 
breastfeeding methods (Falnes et al., 2011).  
 
Personal Characteristics 
Individual characteristics occur at the level of the women herself. Mental health is one important 
factor driving women’s individual PMTCT behaviors. A prospective cohort of 103 women in 
South Africa found that depression predicted treatment failure among postpartum, HIV-positive 
women in bivariate analysis (Hoffmann et al., 2016). Depression was associated with worsened 
adherence in cross-sectional study of 167 HIV-positive pregnant women in South Africa (Psaros 
et al., 2014). In qualitative research in Zambia, depression and hopelessness emerged as a major 
barrier to women’s ART uptake – with much of this mental health-adherence relationship due to 
partner concerns around violence (Murray et al., 2009). Qualitative research from Malawi, 
Kenya, and Tanzania reveals that mental health can pose a barrier to women’s uptake of PMTCT 
services (Chinkonde et al., 2009; Delva et al., 2010b; Theilgaard et al., 2011). It is important to 
note that while this dissertation examines mental health at the individual level, others have 
theorized its importance at the social or structural levels of women’s lives (Aneshensel et al., 
1991). 
 When women use active coping strategies, instead of avoidant ones, their mental health 
outcomes improve (Kotze et al., 2013). Alcohol and substance use may serve as a type of 
avoidant coping, and both have been linked to PMTCT use (Kreitchmann et al., 2012; Mellins et 
al., 2008). It is important to note that no association between alcohol and PMTCT has been 
observed in sub-Saharan African settings. 
Personal beliefs and knowledge can also frame PMTCT uptake and adherence. A 
mother’s desire to protect the infant’s health can facilitate PMTCT adherence (Myer et al., 2012; 
Stinson & Myer, 2012; Theilgaard et al., 2011). On the other hand, many women view PMTCT 
as being only for the infant, which can make it challenging for ongoing adherence postpartum 
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(Colvin et al., 2014). Not all women believe that ART can truly protect her infant from infection, 
leading to worsened PMTCT adherence (Duff et al., 2010; Kiarie et al., 2003; Levy, 2009; Painter 
et al., 2004). In a more extreme version, beliefs that ART could cause the infant harm or increase 
HIV transmission rates further reduce PMTCT use (Stinson & Myer, 2012; Towle & Lende, 
2008).  
 
PMTCT Wrap-up  
The socio-ecological version of Health Care Utilization Theory helps characterize the current 
literature around PMTCT. However, one factor that has been poorly explored to date is women’s 
experience of IPV. This relationship-level factor forms a core hypothesis of this doctoral 
research, namely that IPV around the time of pregnancy may have a negative impact on women’s 
ability to adhere to HIV treatment. 
 
B. Intimate Partner Violence   
Prevalence of Intimate Partner Violence 
IPV is prevalent in many settings throughout the globe, and in the past two decades, researchers 
have made strides in its measurement and identifying its health effects on the lives of women. 
 
Global prevalence of IPV 
A World Health Organization multi-country study found that between 15% to 71% of women 
experience physical and/or sexual IPV during their lifetime (Garcia-Moreno et al., 2006). A meta-
analysis of data from 141 studies in 81 countries suggests that the global prevalence of lifetime 
physical and/or sexual IPV among women is 30% (Devries et al., 2013b). The 2015 Global 
Burden of Disease study found that past-year IPV was reported among 16.3% of women 
(Forouzanfar et al., 2016).  
 
Sub-Saharan African prevalence of IPV 
Sub-Saharan Africa has among the highest prevalence of IPV globally (Devries et al., 2013b). 
Population-based studies show that 30% of women in Southern Africa, 66% of women in Central 
Africa, and 39% of women in East Africa have experienced lifetime physical and/or sexual IPV 
(Devries et al., 2013b). In one of the first studies among men, the International Men and Gender 
Equality Survey (IMAGES) found that 39% of men had enacted IPV in their lifetime in Rwanda 
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(Barker et al., 2015). Lifetime IPV data from 
primarily population-based studies is presented in 
Figure 3 (Barchi, 2011; Garcia-Moreno et al., 
2006; Gass et al., 2011b; Hindin et al., 2008b; 
Kishor & Bradley, 2012; MacQuarrie et al., 2013; 
Msuya et al., 2014; Nankinga et al., 2015; Simona 
et al., 2015; Wekwete et al., 2014).  
 
South African prevalence of IPV 
In South Africa, population-based surveys 
estimate that 19.0 - 31.8% of women experience 
IPV in their lifetime (Jewkes et al., 2002; Seedat 
et al., 2009). Large studies among South African 
men found that 27.5 – 31.8% report IPV 
perpetration (Dunkle et al., 2006; Gupta et al., 
2008), and 27.6% of South African men report that 
they have ever raped (Jewkes et al., 2011).  
Recent cross-sectional surveys conducted within specific populations present higher 
prevalence of IPV. In a clinical sample of 169 women, 47% reported lifetime IPV (Hansrod et al., 
2015). In a school-based sample, 39% of 311 adolescent females reported past 3-month physical 
IPV (Russell et al., 2014). In a respondent-driven sampling study of 751 adolescent males, 40% 
of those in Johannesburg reported perpetrating past-year physical and/or sexual IPV (Peitzmeier 
et al., 2016). In a cross-sectional study of 2 603 men in an informal settlement near Johannesburg, 
56% enacted physical and/or sexual IPV in the past year (Hatcher et al., 2016a). Respondent-
driven sampling among 428 men in Cape Town found that 42% perpetrated recent IPV 
(Townsend et al., 2011). 
 
Prevalence of Intimate Partner Violence in Pregnancy 
IPV in pregnancy is measured either during the pregnancy itself or as recent violence in the 12 
months leading up to data collection. Although I have conceptualized IPV as comprising 
physical, sexual, and/or psychological forms of violence, most studies measure IPV in pregnancy 
using only physical or sexual definitions. Removing psychological forms of violence from the 
definition of IPV helps with consistency of reporting because psychological violence is rather 
Figure 3. Lifetime IPV prevalence in sub-Saharan Africa 
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challenging to define. A number of studies measure IPV in pregnancy as any partner violence that 
occurred in the 12 months leading up to birth (e.g., Bailey & Daugherty, 2007; Dietz et al.,1997; 
Gao et al., 2008). Many studies collapse past-year IPV and IPV during pregnancy into a single 
group during analyses (Heaman, 2005; Leung et al., 1999). Throughout the thesis, I attempt to 
delineate between past-year IPV and IPV during the pregnancy wherever possible.  
 
Global Prevalence of IPV in Pregnancy 
A systematic review of studies from 19 countries globally found that IPV in pregnancy ranged 
from 2.0 – 13.5% (Devries et al., 2010). Clinical samples report that IPV prevalence in pregnancy 
ranges from 0.9 – 20.1% in North America (Daoud et al., 2012; Gazmararian et al., 1996) and 1.8 
- 5.0% in Western Europe (Bacchus et al., 2004a; Hedin et al., 1999).  
Postpartum physical and/or sexual IPV varies considerably depending on the location and 
sample. In a prospective cohort in Brazil, 2% of women reported postpartum physical and/or 
sexual IPV (Silva et al., 2015). Population-based research from China and the U.S. similarly 
estimates IPV postpartum at between 1-2.5% (Guo et al., 2004; Martin et al., 2001). In small 
clinical samples in the U.S. and Western Europe, IPV postpartum is estimated to range from 10-
24% (Gielen et al., 1994; Hedin, 2000; Romito et al., 2009). 
  
Sub-Saharan African Prevalence of IPV in 
Pregnancy 
The prevalence of IPV in pregnancy in sub-
Saharan Africa studies ranges from 2% to 57% 
(Shamu et al., 2011). Population-based data 
suggests that between 3% and 13.5% of sub-
Saharan African women experience IPV in 
pregnancy (Devries et al., 2010). The WHO 
Multicountry Study found that IPV occurred in 
pregnancy among 32.5% of women in 
Tanzania, 31.1% of women in Ethiopia, and 
48.9% of women in Namibia (Pallitto et al., 
2013). In a cross-sectional clinical sample of 2 
042 pregnant women in Zimbabwe, 15.9% 
reported IPV during pregnancy (Shamu et al., 
Figure 4. Prevalence of physical IPV in pregnancy 
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2013b). Figure 4 presents data from population-based and clinical studies of IPV in pregnancy 
across sub-Saharan Africa (Devries et al., 2010; Groves et al., 2012; Pallitto et al., 2013; Shamu 
et al., 2011). Missing data in the figure, represented in gray, is due to limited resources for this 
specific type of research in several sub-Saharan African countries. 
 
South African Prevalence of IPV in Pregnancy 
There are an increasing number of studies examining prevalence of IPV in pregnancy or in the 
period leading up to pregnancy. A longitudinal South African study among 445 women in Durban 
found that 21% experienced physical and/or sexual IPV in pregnancy (Groves et al., 2015). A 
longitudinal study in Cape Town among 544 women learned that 28% reported physical IPV and 
14% sexual IPV in the past year leading up to the antenatal clinic visit at 28-32 weeks gestation 
(Koen et al., 2014). The follow-up data from that study reported prevalence of any IPV in 
pregnancy (physical, sexual, and/or psychological) as 32% (Koen et al., 2016). In Durban, a 
longitudinal study among 570 pregnant women identified any IPV in pregnancy (again defined as 
physical, sexual, and/or psychological) in 35% of the cohort (Mbokota & Moodley, 2003). A 
household sample of 340 pregnant women in a rural area near Durban found that 25% had 
experienced physical, sexual, and/or psychological IPV in pregnancy (Hoque et al., 2009). 
Other South African studies of pregnant women have been cross-sectional in design and 
are non-representative in nature. These studies are helpful, however, in their measurement of 
recent physical and/or sexual IPV. In a clinical sample of 1 395 women in Soweto (in 
Johannesburg), 31% reported past-year physical and/or sexual IPV at their antenatal visit (Dunkle 
et al., 2004b). A cross-sectional Cape Town study measuring past-4-months physical and/or 
sexual IPV among 119 pregnant women noted prevalence of 25%, a rate that likely only included 
violence experienced during the current pregnancy (Eaton et al., 2012). In a Cape Town cross-
sectional study among 623 HIV-positive pregnant women, 16.3% reported past-year physical 
and/or sexual IPV (Bernstein et al., 2016).  
Postpartum, 22% of women in the Durban longitudinal study reported physical and/or 
sexual IPV in the four months after delivery (Groves et al., 2015). However, no other studies 
have, to my knowledge, measured postpartum IPV in South Africa. 
 
Health impacts of IPV in Pregnancy  
IPV has widespread consequences on physical, sexual, reproductive, and mental health of 
women. The Global Burden of Disease study confirms that in 2015, a total of 186 000 deaths and 
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13 803 000 disability-adjusted life years could be attributed to IPV, representing a higher burden 
of disease than factors such as lead, sugar-sweetened beverages, and drug use (Brugha & Murray, 
2016). In South Africa, IPV is among the top ten risk factors for burden of disease (Brugha & 
Murray, 2016), placing it among the priority health issues in the 2012 Lancet Health in South 
Africa series (Mayosi et al., 2012).  
Here, I examine the evidence base for the impact of IPV on women’s physical, 
sexual/reproductive, and mental health. In each of the following subsections, I start by briefly 
summarizing the literature relating IPV to women’s health outcomes in the general population, 
followed by information on IPV and women’s health in pregnancy. The final section explores 
influence of IPV experienced by the mother on infant and child health outcomes.  
 
Physical Morbidity and Mortality 
IPV leads to trauma, pain, and memory loss (Bonomi et al., 2006; Campbell, 2002; Ellsberg et al., 
2008; Garcia-Moreno et al., 2006). In a systematic review, chronic pain was significantly 
associated with lifetime IPV (Dillon et al., 2013). In a population-based study from Australia, 
pain was the physical symptom with the strongest relationship to IPV (Loxton et al., 2006). 
Dillon et al.’s systematic review notes that other chronic health conditions associated with IPV 
include fatigue, respiratory problems, diabetes, low iron, malnutrition, gastrointestinal problems, 
and cardiovascular disease (Dillon et al., 2013). In cross-sectional studies, IPV was related to 
poor sleep (El-Sheikh et al., 2013; Walker et al., 2011; Woods et al., 2010). Sleep disturbances 
are primarily mediated through the pathway of mental health, since IPV causes PTSD and 
depressive symptomology that worsen sleep quality (Rauer et al., 2010; Walker et al., 2011; 
Woods et al., 2010). 
During pregnancy, IPV may have particularly strong associations with maternal death. 
Approximately one-third of femicide globally occurs at the hands of an intimate partner (Stockl et 
al., 2013a). Research from the U.S. has found that intimate partners are responsible for two-thirds 
of the pregnancy-related violent deaths of women (Martin et al., 2007). Physical assault by a 
partner is associated with maternal death (El Kady et al., 2005). and there is a statistical 
relationship between IPV in pregnancy and attempted or completed femicide (McFarlane et al., 
2002). In South Africa, the rate of intimate femicide is 5.6 per 100 000 (Abrahams et al., 2013), 
or more than double the rate in the U.S. (Lyons, 2016). Studies in South Africa and elsewhere 
have confirmed that intimate femicide is driven in part by harmful masculinities that focus on 
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jealousy, virility, and sexual propriety (Mathews et al., 2014; Taylor, 2012) – all beliefs that can 
be heightened around the time of pregnancy for some violent men (Decker et al., 2004). 
Intimate partner violence is related to many of the causes of maternal death that are 
prominent in both resource-rich and resource-constrained settings. Placental abruption, 
antepartum hemorrhage, hypertension, and sepsis are all more common among women 
experiencing IPV around the time of pregnancy (Frances, 2013; Janssen et al., 2003; Silverman et 
al., 2006). Longitudinal research and population-based data from national health surveys confirms 
that IPV is associated with lower odds of skilled delivery(Goo and Harlow, 2012; Ononokpono 
and Azfredrick, 2014; Refaat, 2013; Singh et al., 2015; Turan et al., 2012). Each of these factors 
is, in turn, among the leading causes of maternal death according to systematic review of global 
data by the WHO (Khan et al., 2006). Maternal death is associated with IPV (Confidental enquiry 
into maternal child health, 2007), though measurement of this association is lacking in many 
settings. 
 
Sexual and Reproductive Health and Birth Outcomes 
IPV is associated with declines in reproductive health among women. One systematic review of 
cross-sectional studies from primarily resource-rich settings found strong and consistent evidence 
that IPV is associated with sexual health outcomes such as chronic pelvic pain, pain during 
intercourse, painful menses, and sexual dissatisfaction (Coker, 2007). Cohort studies find that 
women with a lifetime history of IPV have increased incidence of sexually transmitted infections 
(Johnson & Hellerstedt, 2002; King et al., 2000; Seth et al., 2015). 
In cross-sectional studies among pregnant women in resource-rich settings, IPV is 
associated with increased risk of miscarriage (Campbell, 2002; Huth-Bocks et al., 2002; 
Silverman et al., 2007) and premature labor (El Kady et al., 2005; Rodrigues et al., 2008). In a 
meta-analysis of 12 studies, IPV was associated with 48% increased odds of pre-term birth (Hill 
et al., 2016). A meta-analysis of 7 longitudinal studies showed that maternal IPV was associated 
with double the risk of pre-term birth (Shah et al., 2010).  
Women from resource-rich settings who experienced IPV in pregnancy were more likely 
to experience abruption (El Kady et al., 2005), antepartum hemorrhage (El Kady et al., 2005; 
Janssen et al., 2003), vaginal bleeding (Audi et al., 2012; Moraes et al., 2009; Silverman et al., 
2006b), high blood pressure (Silverman et al., 2006b), miscarriage (Escriba-Aguir et al., 2012), 
and intrauterine growth restriction (Janssen et al., 2003). Physical, sexual, or psychological 
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violence in pregnancy are associated with obstetric problems and premature rupture of 
membranes (Audi et al., 2012). 
These associations seem to hold in resource-constrained settings. In Cameroon’s 
population-based Demographic Health Survey, lifetime IPV was associated with 50% higher odds 
of spontaneous fetal loss after adjusting for socio-demographics (Alio et al., 2009b). In cross-
sectional Tanzanian data from the WHO Multi Country study, women with a history of IPV were 
60% more likely to have pregnancy loss and nearly twice as likely to experience an induced 
abortion in adjusted analysis (Stockl et al., 2012). Cross-sectional data from Guatemala found that 
recent IPV doubled the rates of miscarriage among pregnant women after adjusting for 
confounders (Johri et al., 2011). 
 
Mental Health 
A meta-analysis of 16 longitudinal studies found that lifetime IPV nearly doubles the rate of 
incident depressive symptoms among women (Devries et al., 2013a). Another meta-analysis of 67 
observational and experimental papers found a 3-fold increase in the odds of postpartum 
depressive symptoms among women reporting IPV during pregnancy (Howard et al., 2013). 
Similarly, cross-sectional studies from resource-rich settings found that lifetime experience of 
IPV is associated with depression (Huth-Bocks et al., 2002; Pico-Alfonso et al., 2006), and recent 
IPV was associated with a 6-fold increase in depression (Romito et al., 2005). Often IPV is 
measured in mental health studies as comprising physical and sexual forms of abuse. However, it 
is important to note that longitudinal research has confirmed that psychological and financial 
forms of IPV are strongly linked to depression (Postmus et al., 2012). 
Two systematic reviews found that IPV was associated significantly with post-traumatic 
stress disorder (PTSD) in 14 and 33 included studies, respectively (Dillon et al., 2013; Lagdon et 
al., 2014). As with depression, PTSD symptomology may be influenced by the severity and type 
of violence experienced. In a prospective cohort in the U.S., women reporting three or more types 
of IPV were nine times as likely to develop PTSD than non-abused counterparts (Houry et al., 
2006). In other longitudinal research in the U.S., experiencing psychological and physical IPV 
was associated with four times the odds of PTSD symptomology (Cavanaugh et al., 2012). Cross-
sectional studies from the U.S. and India show that sustained abuse is related to increasing levels 
of PTSD symptoms (Chandra et al., 2009; Woods et al., 2008). However, one small case control 
study from South Africa did not find a significant association between IPV and PTSD, perhaps 
because the sample of 114 women was too small to reach statistical significance (Hansrod et al., 
2015). 
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Anxiety displays a consistent association with IPV in 16 studies included in a systematic 
review (Dillon et al., 2013). Another systematic review of 15 studies found a similar significant 
association (Lagdon et al., 2014). As with other mental health sequelae, increased severity or 
frequency of violence seems to be related to greater anxiety symptomology (El-Sheikh et al., 
2013; Pico-Alfonso et al., 2004). 
Women who report IPV are more likely to have suffered from suicidal ideation than their 
non-abused counterparts (Afifi et al., 2010; Ellsberg et al., 2008; Ishida et al., 2010; Pico-Alfonso 
et al., 2006). The systematic review of longitudinal studies found an association between IPV and 
incident suicidal attempts, although the limited number of studies precluded meta-analysis 
(Devries et al., 2013a). In pooled analysis of WHO Multicountry Study data from ten countries, 
women with a lifetime history of IPV were three times more likely to have suicidal thoughts and 
four times more likely to have attempted suicide (Ellsberg et al., 2008).  
The same associations between IPV and mental health that are found in the general 
population seem to hold around the time of pregnancy. A large body of literature suggests that 
women who experienced violence in pregnancy have increased odds of reporting postpartum 
depression. A meta-analysis of 37 studies primarily from the U.S. found that lifetime physical, 
sexual, and/or psychological IPV was associated with nearly three-fold increased risk of major 
depressive disorder and 50% increased risk of postpartum depression (Beydoun et al., 2012). 
Antepartum depression was associated with lifetime “domestic violence” in a systematic review 
that included 7 studies from the U.S. and Europe (Lancaster et al., 2010). The intensity of 
violence experienced may be related to depression. In longitudinal research among 1 133 
pregnant women in Brazil, participants who experienced physical and/or sexual IPV in pregnancy 
alongside psychological violence had triple the odds of postpartum depression after adjusting for 
socio-demographics (Ludermir et al., 2010). A population-based Canadian study among 6 421 
mothers showed that threats and physical IPV starting before and continuing during pregnancy 
was associated with 4-fold increase of postpartum depression (Urquia et al., 2011). A systematic 
review of studies from Latin America suggest a linear relationship; increased severity of IPV in 
pregnancy was associated with increased depressive symptomology (Han & Stewart, 2014). 
Type of IPV in pregnancy may also have a unique influence on depression. Severe 
psychological or severe sexual violence in pregnancy was associated with 2- to 3-fold odds of 
probable depression among a clinical sample of 239 women the U.S. (Kastello et al., 2016). 
Several other cross-sectional studies have found that psychological IPV alone during pregnancy is 
a significant predictor of postpartum depression (Romito et al., 2009; Tiwari et al., 2008; 
Woolhouse et al., 2012). 
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The literature around IPV and depression in the perinatal phase from resource-rich 
settings is consistent with sub-Saharan African findings. A population-based birth cohort in South 
Africa found that of 726 women, those reporting recent IPV (physical, sexual, and/or 
psychological) had double the odds of antenatal depression, even after controlling for socio-
demographic characteristics (Brittain et al., 2015). A cross-sectional study among 1 180 pregnant 
women in Tanzania found that recent physical and/or sexual IPV is related to 3- and 4-fold higher 
odds of depressive or anxiety symptomology, respectively (Mahenge et al., 2013). A longitudinal 
study among 76 women in Nigeria found that IPV was associated with depressive symptoms at 
each of five time-points from the year before pregnancy to 12 months postpartum (Ogbonnaya et 
al., 2013). A cross-sectional study among 376 pregnant women in Egypt found that lifetime IPV 
tripled the odds of depressive/anxious symptomology (Abdelhai & Mosleh, 2015). 
With regards to trauma, a cross-sectional Tanzanian study among 1 180 pregnant women 
found that recent IPV increased odds of PTSD during pregnancy 3-fold (Mahenge et al., 2013). 
Suicidality and IPV has been less studied in the African context. One cross-sectional study amon 
842 women in Zimbabwe suggested that severe IPV (in the form of five or more events) doubled 
the odds of suicidal thoughts among postpartum women (Shamu et al., 2016). 
One cross-sectional study examined IPV and psychological distress specifically among 
HIV-infected pregnant women. The authors found that recent physical, sexual, and/or 
psychological IPV was associated 3.6 times the odds of psychological distress even after 
controlling for other predictors (Bernstein et al., 2016). No research, to our knowledge, has 
specifically examined the association between IPV and anxiety in pregnancy. 
 
Health impact of IPV in Pregnancy for Infants 
A growing body of literature demonstrates cross-sectional associations between maternal 
exposure to IPV and infant mortality. Clinical samples from the U.S. suggest that IPV in 
pregnancy is associated with increased risk of perinatal death (Coker et al., 2004; El Kady et al., 
2005; Yost et al., 2005).  
Population-based Demographic Health Survey data from Kenya suggests that 
experiencing lifetime IPV is associated with under-2 mortality (Rico et al., 2011). Similarly, 
population-based Demographic Health Survey data from Nigeria finds an association between 
each type of IPV (physical, sexual, or emotional) and infant death (Okenwa et al., 2011). In 
Ghana, Demographic Health Survey data suggests that lifetime experience of physical IPV more 
than doubles the odds of perinatal mortality (Pool et al., 2014). Studies elsewhere in resource-
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constrained settings have shown that a mother’s experience of lifetime IPV is associated with 
perinatal death (Ahmed et al., 2006) and under-5 mortality (Asling-Monemi et al., 2003).  
Infants born to mothers who report IPV in pregnancy are more likely to have low birth 
weight (Boy & Salihu, 2004; Huth-Bocks et al., 2002; Kaye et al., 2006). A meta-analysis of 15 
studies found that odds of low birth weight increased by 53% among women experiencing 
lifetime IPV (Shah et al., 2010). In the longitudinal birth cohort in South Africa, recent IPV 
among the mother was associated with smaller head circumference-for-age z-scores (Brittain et 
al., 2015). 
IPV in pregnancy is associated with worse health outcomes for children. Longitudinal 
research from the U.S. suggests that IPV in pregnancy is associated with worse overall child 
health at one year (McMahon et al., 2011). Population-based Demographic and Health Survey 
data from Kenya, Rwanda, and Honduras show associations between lifetime IPV and child 
stunting (Rico et al., 2011). Demographic and Health Survey data from eight African countries 
also suggests that beliefs supporting physical IPV (termed “wife-beating” in the survey) is 
associated with reduced odds that women will have fully vaccinated children (Singh et al., 2015). 
Population-based data from Uganda suggests that lifetime IPV is associated with double the risk 
of infant illness and diarrhea (Karamagi et al., 2007b). Fetuses and infants of women who 
experienced IPV during pregnancy may experience physical outcomes such as bruising, flesh 
wounds, and broken bones (Ezechi 2004; Valladares 2005). 
Child abuse is more likely among families with a history of IPV (Feldhaus 1997).  
Longitudinal research in the U.S. shows that maternal exposure to psychological and financial 
abuse at baseline predict use of spanking in following years (Huang et al., 2010; Postmus et al., 
2012). Cross-sectional research finds that children who witness IPV are at increased risk of 
experiencing other forms of trauma such as neglect, corporal punishment, physical maltreatment 
(Bourassa & Berube, 2007; Chan, 2011). Longitudinal research from Hong Kong found that IPV 
during pregnancy increases the odds of physical maltreatment of children three years later (Chan 
et al., 2012). Population-based, longitudinal research from the U.S. found that children witnessing 
maternal IPV were twice as likely to be reported to Child Protection Services due to child abuse 
(Casanueva et al., 2009). It is important to note that both perpetrators and survivors of IPV can be 
perpetrators of child maltreatment (Dixon et al., 2007). 
Ultimately, the relationship between IPV and parenting quality can shape child wellbeing 
and behavior. Longitudinal research from the U.S. suggests that IPV at baseline has a direct effect 
on internalizing (depression, anxiety) and externalizing (aggression) behaviors among children 
four years later (Huang et al., 2010). Importantly, IPV also operates through the pathway of 
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parenting, with spanking increasing and parenting skills decreasing for women who experienced 
IPV at baseline (Huang et al., 2010). Longitudinal research in both the U.S. and the U.K. found 
that women reporting IPV during pregnancy had children with greater internalizing behaviors 
(anxiety and depression) and behavioral problems (hyperactivity, emotion, conduct problems) 
two to four years later (Flach et al., 2011; McFarlane et al., 2014). 
 Parenting is not the only pathway linking maternal exposure to IPV to subsequent child 
outcomes. The physiological outcomes of increased prenatal stress can alter fetal neural 
development and a child’s subsequent behaviour (Wadhwa, 2005; Weinstock, 2008). IPV in 
pregnancy can also worsen the mother and infant bond, leading to child behavioral outcomes 
(Huth-Bocks et al., 2004). Lastly, the many mental health sequelae related to IPV in pregnancy 
for the mother have concomittant effects on child development (Deave et al., 2008; Murray et al., 
1996). 
 Maternal exposure to IPV throughout one’s childhood also seems to frame health 
outcomes later in life. A systematic review of 22 studies from the U.S. found that witnessing a 
mother’s experience of IPV as a child was associated with increases in risky health behaviors 
later in life such as smoking, alcoholism, illicit drug use, high number of sexual partners, and 
adolescent pregnancy (Bair-Merritt et al., 2006). A meta-analysis of 118 studies found that 
children witnessing IPV experienced by a mother had worse psychosocial functioning which 
comprised psychological, emotional, social, and academic outcomes (Kitzmann et al., 2003). A 
systematic review of 10 global studies found consistent evidence for the witnessing of IPV as a 
child and use of IPV as an adult (Gil-Gonzalez et al., 2008). These data suggest that addressing 
IPV in pregnancy and postpartum is essential if we are to alter the intergenerational transmission 
of violence across the globe. 
 
Dynamics of IPV in Pregnancy 
The dynamics of IPV before, during, and after pregnancy are not fully understood. In some 
settings, pregnancy is protective, whereas in others pregnancy seems to be a time of increased 
vulnerability to IPV. In cross-sectional data from 2 042 pregnant women in Zimbabwe, physical 
violence decreased during pregnancy, but sexual and psychological IPV consistent before 
pregnancy and during pregnancy (with sexual IPV increasing from 36 to 39% and psychological 
IPV increasing from 40 to 44%) (Shamu et al., 2013b). Increased sexual violence in late 
pregnancy was explored in a companion qualitative study that highlighted that men perceived the 
physical and emotional changes of pregnancy make women less willing to have sex and justify 
men forcing or coercing sexual encounters (Shamu et al., 2012). In the U.S. a sample of 109 
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pregnant women identified new incidents of IPV among women who had not experienced IPV 
before pregnancy (Anderson et al., 2002a). Longitudinal data from Brazil showed that 9% of 
women who experience no IPV before or during pregnancy had incident postpartum IPV (Silva et 
al., 2015). Other U.S. population-based data shows that IPV continues or even escalated in 
pregnancy (Goodwin et al., 2000). Among 1 314 women in Mexico, IPV worsened during 
pregnancy for 71% of women (Diaz-Olavarrieta et al., 2007).  
Population-based studies from the U.S. suggests that IPV before pregnancy is associated 
with higher risk of IPV during pregnancy (Charles & Perreira, 2007; Martin et al., 2001). 
Longitudinal data from the U.S. and the U.K. show that violence in pregnancy predicts continued 
abuse postpartum (Bianchi et al., 2016; Bowen et al., 2005). Similarly, population-based data 
from Canada found that women who were abused before and during pregnancy also experienced 
IPV postpartum (Daoud et al., 2012). A South African longitudinal study among 1 480 women in 
Durban found that IPV incidence was persistently high during pregnancy and the early 
postpartum period (Groves et al., 2014).  
However, other research shows important contradictions to this notion of IPV 
persistency. Longitudinal data from the U.S. and Nicaragua found that despite high levels of 
partner violence before and during pregnancy, IPV abated postpartum (Koenig et al., 2006; Macy 
et al., 2007; Salazar et al., 2009). Among 420 postpartum women in Brazil, physical IPV stopped 
after the infant was born for the majority of participants (Menezes et al., 2003).  
It may also be the case that postpartum stressors serve as triggers to increase levels of 
violence after delivery. Longitudinal research among 1 400 women in Spain suggested that 
postpartum psychological violence peaked at five months (Escriba-Aguir et al., 2013). In the 
longitudinal South African study among 1 480 women, prevalence of IPV dropped significantly 
(from 25 to 18%) during the late postpartum phase from four to nine months (Groves et al., 
2015). Both of these studies highlight potential for the early postpartum phase to be a time of 
increased IPV risk. Others have noted that when relationship stress exceeds a couple’s ability to 
cope, men may use harmful behaviors such as IPV (Groves et al., 2014; Jasinski, 2001; Romito et 
al., 2009). 
 
Factors associated with IPV in Pregnancy 
Several factors associated with IPV in pregnancy in sub-Saharan African settings. These can be 
organized by individual-level and relationship-level: 
 
Individual level predictors of IPV in pregnancy 
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• Low education level of the woman was associated with experience of IPV in pregnancy in 
a South African cross-sectional study (Hoque et al., 2009), a finding that mirrors cross-
sectional findings from other African settings (Fawole et al., 2008; Umeora et al., 2008). 
In the WHO Multi-Country Study, among non-pregnant women, the lowest and highest 
levels of education seem to be protective against IPV (Abramsky et al., 2011a).  
• Being unemployed was associated with IPV in one cross-sectional South African study 
among pregnant women (Hoque et al., 2009), again mirrored elsewhere in sub-Saharan 
Africa as measured by low socio-economic status (Ezechi et al., 2009; Umeora et al., 
2008). However, data around employment and IPV are conflicting with population-based 
studies finding income protective against IPV (Abramsky et al., 2011b; Hindin et al., 
2008a), but a study in India showing that women’s increased income predicts new 
incidents of partner violence (Krishnan et al., 2010). 
• A woman’s being diagnosed with HIV in pregnancy increases the odds of IPV in 
pregnancy (Dunkle et al., 2004b; Hoque et al., 2009). An association that has been found 
between HIV diagnosis and IPV in other cross-sectional studies from sub-Saharan Africa 
(Ezechi et al., 2009; Ntaganira et al., 2008; Olagbuji et al., 2010). However, it is important 
to note that HIV status disclosure is not always associated with IPV in African research 
(Bernstein et al., 2016).  
• Unplanned pregnancy is a risk marker of IPV since violence male partners often try to 
control reproductive health decisions like contraception (Miller et al., 2010; Pallitto et al., 
2013). Unplanned pregnancy can also lead to further episodes of violence (Jasinski, 2001). 
Women are more likely to experience psychological distress when they disagree with their 
partners about the intendedness of the pregnancy (Romito et al., 2009). Women learning 
of an unintended pregnancy alongside a new HIV diagnosis can lead to a “double 
disclosure bind,” with women anticipating harsh reactions for either condition (Crankshaw 
et al., 2014). 
• Alcohol use by the woman is associated with IPV in pregnancy in longitudinal South 
African research (Dunkle et al., 2004b), and is confirmed elsewhere (Olagbuji et al., 
2010). In the study among HIV-positive pregnant women, problem drinking by the woman 
was associated with IPV in pregnancy (Bernstein et al., 2016). Alcohol use by a partner 
has been measured as a driver of IPV in pregnancy elsewhere (Fawole et al., 2008; 
Ntaganira et al., 2008), and is confirmed in studies among South African men who are 
partnered with non-pregnant women (Abrahams et al., 2004; Gass et al., 2011a). 
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Relationship-level predictors of IPV in pregnancy 
• Relationship dynamics have been noted as important predictors of IPV around the time of 
pregnancy. In longitudinal research in South Africa, lower relationship power (or women’s 
ability to have a say in decisions and sexual choices) and higher relationship stress 
predicted IPV in pregnancy and postpartum (Groves et al., 2014). Marital status was 
protective among HIV-positive, South African pregnant women, with those married less 
likely to experience IPV than non-married counterparts (Bernstein et al., 2016). 
• History of violence in the current relationship was strongly predictive of IPV in pregnancy 
and postpartum in a longitudinal South African study (Groves et al., 2015). A history of 
earlier violence, in the form of childhood sexual abuse or forced sex at first intercourse, 
was associated with an increased risk of IPV in pregnancy in a longitudinal South African 
study (Dunkle et al., 2004b). This has been explored in other African settings, with 
previous sexual violence, experiencing abuse in childhood (Kaye et al., 2001; Ntaganira et 
al., 2008), and witnessing abuse in childhood (Kaye et al., 2001), associated with IPV in 
pregnancy. 
• Multiple partnerships is another behavior that has been strongly associated with 
perpetration of IPV in South Africa (Abrahams et al., 2004), but has not yet, to my 
knowledge, been measured among pregnant women.  
• Male partner constructs: There are many other potential factors at the relationship-level 
that may influence IPV in pregnancy, but have not yet been assessed. Male partner 
characteristics, such as his gender views and propensity towards sexual entitlement, seem 
to drive IPV in studies among non-pregnant populations (Fulu et al., 2013; Santana et al., 
2006). Also, around the time of pregnancy, concerns about paternity have been theorized 
to be an evolutionary driver of men’s use of IPV (Goetz et al., 2008). These should be 
examined within the context of female partner’s pregnancy. 
 
C. Links between IPV & HIV 
Research has shown increasingly strong links between IPV and HIV. Early on in the HIV 
epidemic, researchers agreed that a similar risk environment heightens women’s IPV risk and 
increases HIV risk (Maman et al., 2000). Over the past decade, empirical evidence has 
accumulated to suggest that IPV and HIV operate not only within a similar risk environment, but 
that IPV directly and indirectly increases HIV acquisition. In addition, HIV diagnosis can lead to 
incident episodes of violence. 
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IPV and Risk of HIV Acquisition 
Even when adjusting for other key predictors, such as sexual behavior, women who report IPV 
are more likely to be HIV-positive in cross-sectional studies across the globe (Dude, 2011; 
Dunkle et al., 2004b; Fonck et al., 2005; Maman et al., 2002; Silverman et al., 2008). Conversely, 
cross-sectional studies suggest that women living with HIV are more likely to experience IPV 
than HIV-negative women (McDonnell et al., 2003; Ntaganira et al., 2008; Were et al., 2011). 
As mentioned in Chapter 1, this robust cross-sectional association between IPV and HIV 
is consistent in studies among pregnant women (Shamu et al., 2011). More importantly, the 
association has been confirmed in longitudinal studies that show IPV to be associated with 
incident HIV infection (Decker et al., 2009; Jewkes et al., 2010; Kouyoumdjian et al., 2013). A 
meta-analysis of 5 cohort studies demonstrated a longitudinal association between IPV and 
incident HIV infection (Li et al., 2014). In the 19 cross-sectional studies included in meta-
analyses, exposure to both physical and sexual IPV predicted doubled odds of HIV infection (Li 
et al., 2014).  
The Global Burden of Disease Study (Figure 5) combines data on IPV and years lost to 
HIV disability to show that sub-Saharan Africa bears the greatest burden of disease associated 
with the IPV-HIV intersection (Brugha & Murray, 2016). This means that IPV and HIV work 
together in this setting to add considerable burden of disease to African populations. 
 
Figure 5 Global Burden of Disease data on percent of total HIV Years Lost to Disability that can be attributed to 
intimate partner violence among females 15-49 years, 2015 
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We can understand the links between IPV and HIV acquisition as being both direct and 
indirect. Directly, IPV can increase risk of HIV acquisition through damage to the epithelium 
during forced sex (Draughon, 2012). Immune activation and inflammation associated with the 
psychological trauma of IPV may also directly increase the likelihood of HIV acquisition (Heise 
& McGrory, 2016). Indirectly, a number of factors seem to link IPV in a causal manner to 
incident infection. Meta-analyses found that historical experience of sexual or psychological 
violence from a family member (including in childhood) predisposes women to risky sexual 
behaviors (Arriola et al., 2005; Norman et al., 2012). A systematic review found that physical 
IPV has a strong and consistent relationship with women’s risky sexual behaviors, such as 
condom use (Coker, 2007). Longitudinal data suggests that men who enact IPV often have a 
cluster of health behaviors (binge drinking, transactional sex or use of prostitution, multiple 
concurrent partners) that also place female partners at greater risk (Decker et al., 2009; Dunkle & 
Decker, 2013). An important refinement of this research is the finding that psychological IPV, 
even without concurrent physical or sexual violence, is a predictor of HIV infection (Kayibanda 
et al., 2012). This suggests that the threats associated with IPV, regardless of physical or sexual 
violence, can lead to riskier health behaviors and place women at heightened HIV risk. 
 
HIV and incident cases of IPV 
HIV diagnosis and subsequent partner disclosure can lead to new incidents of IPV (Campbell et 
al., 2008), although much of the evidence for this association emerges from qualitative literature 
with small samples of women. Among 8 women reporting IPV after HIV disclosure, Colombini 
et al. (2016) learned that new HIV diagnosis was a trigger for partner violence, even in 
relationships with no prior history of IPV. Mulranen et al. (2015) studied 20 postpartum women 
living with HIV in Swaziland, of whom 9 reported IPV following disclosure, and learned that 
violence resulted from acute triggers like HIV status disclosure and also from ongoing marital 
tensions around fertility. In-depth interviews with 50 HIV-positive women in the United States 
identified 3 who had experienced verbal or physical assault after disclosure (Gielen et al., 1997). 
One longitudinal study among 1 092 pregnant women in Durban learned that IPV did not increase 
postpartum among the 76.3% of women who disclosed their HIV-positive status (Maman et al., 
2016). However, those women who chose not to disclose had 5-fold increased odds of 
experiencing postpartum IPV, suggesting that non-disclosing women may be in more violent 
relationships than their counterparts who disclose. This limited empirical evidence suggests that 
HIV disclosure and subsequent IPV is an important area for further research.  
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IPV prevalence among HIV-Positive Women 
Researchers have only recently begun to measure the effect of IPV on health of women already 
living with HIV. Meta-analysis suggests that the rate of intimate partner violence among HIV-
infected women in the U.S. is 55%, or more than double the national average (Machtinger et al., 
2012c). In the longitudinal Women’s Interagency HIV Study, 48% of the 1015 HIV-positive 
women followed over 20 years reported a lifetime history of IPV (Decker et al., 2016).  In 
another U.S. cohort, 63% of HIV-infected women experienced physical and/or sexual violence, 
including but not limited to violence from a partner (Gielen et al., 2001). In cross-sectional 
clinical samples of HIV-positive women, between 44 - 68% had experienced physical and/or 
sexual abuse from intimate partners or others (Burke et al., 2005; Liebschutz et al., 2000; 
McDonnell et al., 2003; Ramachandran et al., 2010).   
 In sub-Saharan Africa, data on rates of IPV among HIV-positive women suggests a 
similar pattern. A prospective cohort of 2 836 pregnant women in Kenya found that HIV-positive 
women experienced higher rates of IPV compared to their HIV-negative counterparts (37% vs. 
26%) (Kiarie et al., 2006). Kiarie et al. (2006) also found that HIV-positive participants had 4.8 
times the odds of reporting IPV within 2 weeks postpartum, compared to HIV-negative 
counterparts. A cross-sectional study of HIV-positive, South African pregnant women found past-
year IPV prevalence to be 16.4% (Bernstein et al., 2016). In a case-control study of 169 women 
in South Africa, rates of physical and sexual IPV were higher among HIV-positive women, but 
the difference between HIV-negative counterparts did not reach statistical significance (Hansrod 
et al., 2015). 
 
Health effects of IPV among HIV-Positive Women 
Preliminary evidence from exploratory U.S. studies suggests IPV leads to worse HIV-related 
health outcomes for women. However, much of this evidence comes from small cross-sectional 
studies. In cross-sectional research among 118 women, violence and other forms of trauma were 
associated with 4.3-fold increased odds antiretroviral failure (Machtinger et al., 2012b). Among 
251 HIV-positive men and women, lifetime experience of IPV was associated with a lower CD-4 
count and having a detectable viral load (Schafer et al., 2012). Two cross-sectional studies among 
women showed that IPV was associated with a greater incidence of opportunistic infection 
(Liebschutz et al., 2000; Nava et al., 2011). Again, all of these studies have been conducted cross-
sectionally, with small samples from resource-rich settings, and none have included pregnant 
 46 
women. A longitudinal study among 2 222 women either living with HIV or at-risk of acquiring 
HIV in urban areas of the U.S. found past-year experience of abuse (including, but not limited to 
IPV) was associated with 2 times the odds of death (Weber et al., 2012). As the evidence for this 
report was presented only in a conference format, it is not clear whether the same association 
between violence and mortality holds among the HIV-positive population or whether IPV on its 
own contributes to this association. 
Few studies have examined IPV among HIV-positive populations in sub-Saharan Africa. 
One longitudinal Kenyan study among 214 female sex workers found that recent IPV was 
associated with lower risk of detectable viral load (Wilson et al., 2016). Through qualitative 
interviews, the authors discovered that resilience and a desire to stay healthy despite IPV drove 
the positive health outcomes among women living with recent violence. 
 
 
D. Impact of IPV on PMTCT uptake 
Few studies directly measure the effect of IPV on PMTCT, but theory and early empirical 
findings suggest a link. This is supported by three lines of thought. Firstly, as described in Section 
B of this chapter, health care utilization theories illustrate that unhealthy partnership dynamics, 
such as IPV, may serve as important barriers and enablers to PMTCT adherence. Secondly, 
preliminary quantitative and qualitative studies suggest that IPV and fears of IPV may make it 
more difficult for women to adhere to particular steps within the PMTCT cascade. Thirdly, 
literature highlights several plausible pathways through which IPV may hinder PMTCT. 
Preliminary studies showing influence of IPV on PMTCT 
Few studies to date have set out to measure the effect of IPV on the entire PMTCT cascade. One 
important exception is a recent cross-sectional study by Hampanda (2016) in Zambia. Hampanda 
examined the impact of IPV on several PMTCT steps among 320 women. She found that IPV 
worsens ART adherence in pregnancy, nevirapine at birth, ART adherence postpartum, and infant 
nevirapine postpartum.  
While no other similar studies on the entire PMTCT cascade, to my knowledge, exist in 
sub-Saharan Africa, it is possible to summarize the extant literature with regards to each 
individual PMTCT step. In this way, I am able to draw upon evidence from a multitude of 
existing studies that may not have been conceptualized specifically around PMTCT, but offer 
insights into the potential impact of IPV on these important health behaviors.  
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Early and Sufficient Antenatal Clinic attendance 
Studies from the U.S. suggest that women experiencing lifetime IPV are less likely to start 
antenatal care on time (Dietz et al., 1997; Thananowan & Heidrich, 2008) or choose to opt out of 
antenatal care altogether (Diaz-Olavarrieta 2002). Longitudinal research from the U.S. suggests 
that IPV leads to twice the odds of missing antenatal clinic visits or delaying care until late in the 
pregnancy, during the third trimester (Goodwin et al., 2000; Subramanian et al., 2012). 
 
HIV Testing 
Anticipated violence is associated with declines in HIV testing among pregnant women 
(Bajunirwe & Muzoora, 2005a; Maman et al., 2011a; Medley et al., 2004; Pool et al., 2001; 
Tchendjou et al., 2011; Turan et al., 2011; Turan et al., 2012). Research from Malawi and Kenya 
highlights that when women consent to an HIV test without the husband’s approval, they often 
suffer domestic violence as a consequence – regardless of their actual HIV diagnosis (Bajunirwe 
& Muzoora, 2005b; Turan et al., 2011). 
 
ART uptake & Linkage to care 
Studies in the U.S. show that a history of physical and/or sexual violence (including but not 
limited to violence from a partner) decreases the likelihood of HIV-positive women using ART 
when medically eligible (Cohen et al., 2004; Jones et al., 2010b). One cross-sectional study in 
Uganda found that IPV was associated with three times the risk of not being on ART at the time 
of the study (Osinde et al., 2011).  
Qualitative studies from sub-Saharan Africa suggest that fear and experience of IPV 
influence pregnant women’s decision to take up HIV services (Kilewo et al., 2001; Onono et al., 
2015a). A Malawian qualitative study with 52 men, women, and health providers echoed that 
concerns around IPV cause women to avoid PMTCT services (Nyasulu & Nyasulu). In South 
Africa, a qualitative study among 28 pregnant and postpartum women living with HIV illustrated 
strong fears around partner discrimination, rejection and abandonment, causing women to forgo 
HIV treatment (Stinson & Myer, 2012). 
 
Clinic attendance & Retention in Care 
In a U.S. study of 853 male and female HIV-positive patients, a lifetime history of IPV was 
associated with missed clinic visits and delayed linkage to care (Siemieniuk et al., 2010).  In 
another U.S. study of men and women, intimate partner violence predicted a higher “no show 
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rate” at the HIV clinic (Schafer et al., 2012). In a study of 116 Kenyan women, 28.5% named 
partner dynamics (including violence, negative attitudes, and lack of disclosure) as a barrier to 
access to HIV services (Otieno et al., 2010). In a qualitative study in Malawi, fear of partner 
conflict and separation was a prominent reason cited for loss-to-follow-up in PMTCT 
programmes (Bwirire et al., 2008). 
 
ART adherence 
The cross-sectional study by Hampanda in Zambia found that among 320 pregnant women, IPV 
reduced the odds of adequate adherence in pregnancy by 74%. Similarly, experiencing IPV was 
associated with 89% reduced odds of adequate adherence postpartum. In both instances, IPV was 
measured as a lifetime exposure and adequate adherence was defined as self-reported adherence 
of >80% using a visual analog scale (Hampanda, 2016). 
The remaining literature on the relationship between IPV and ART adherence emerges 
from resource-rich settings. In one site of the U.S. Women’s Interagency HIV Study, lifetime 
experience of IPV was associated with 87% lower odds of optimal ARV adherence (Connors et 
al., 2012). A greater number of lifetime traumatic events was associated with poorer adherence 
among 611 men and women in another U.S. study, although IPV was only one traumatic 
exposure measured (Mugavero et al., 2006). This relationship has been quantitatively confirmed 
by other small, cross-sectional studies in the U.S. among non-pregnant women living with HIV 
(Lopez et al., 2010; Rose et al., 2010a; Trimble et al., 2013).  
Importantly, IPV may have an indirect relationship with HIV adherence. In a Haitian study 
of 194 patients, partner conflict was not associated with adherence (Malow et al., 2013). 
However, when depression was added to the model, partner conflict was associated with 
depression, which in turn predicted poor adherence. This finding suggests that it is crucial to 
explore pathways linking IPV to PMTCT outcomes. 
 
Skilled birth attendance  
Experience of IPV in pregnancy and postpartum was associated with less use of skilled delivery 
services in Kenya in longitudinal research (Turan et al., 2012). Demographic and Health Survey 
population-based data from African settings such as Kenya, Egypt, and Zambia, and Nigeria have 
confirmed that women with lifetime exposure to IPV have 26-29% lower odds of skilled delivery 
(Goo & Harlow, 2012; Ononokpono & Azfredrick, 2014; Refaat, 2013). Similarly, Demographic 
and Health Survey data from eight African countries showed an association between supportive 
attitudes towards wife-being and lower odds of delivering in a facility (Singh et al., 2015). Skilled 
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birth attendance is particularly relevant for HIV-positive pregnant women, as it ensures that 
essential services around infant prophylaxis and infant HIV diagnosis are administered at the 
correct time. 
 
Nevirapine at birth 
The Zambian study among 320 HIV-positive women measured the effect of IPV on nevirapine at 
birth but found no significant impact (Hampanda, 2016). Similarly, in a large prospective study in 
Kenya, intimate partner violence was not associated with nevirapine use among 2836 women 
(Kiarie et al., 2006). However, “male involvement in antenatal care” predicted better adherence to 
nevirapine in one South African study (Peltzer et al., 2011).  
 
Early infant HIV diagnosis 
Few studies have examined the relationship between violence and early infant diagnosis. One 
qualitative study in Malawi among 56 women found that IPV indirectly limited women’s 
willingness to test infants because it caused them to avoid partner disclosure (Donahue et al., 
2012). 
 
Exclusive Breastfeeding or other Safe Feeding 
In a population-based sample of 118 579 U.S. women, those experiencing IPV in pregnancy or 
during the 12 months leading up to delivery were 35 - 52% less likely to breastfeed their infants 
(Silverman et al., 2006a). Using DHS data from eight sub-Saharan African countries, lifetime 
IPV victimization was adversely associated with early and exclusive breastfeeding (Misch & 
Yount, 2014). However, a systematic review conducted a decade ago saw no significant 
association between IPV and breastfeeding in papers from resource-rich settings (Bair-Merritt et 
al., 2006). 
Among HIV-positive women, the research is less developed around violence and exclusive 
breastfeeding. A prospective study in Kenya with 281 HIV-positive women did not find an 
association between IPV and safe breastfeeding (Onono et al., 2014). In Kenya, male partners 
influenced feeding choices of infants (Kiarie et al., 2003). 
 
Transmission of HIV to infants 
Few studies have measured the association between maternal experience of IPV and HIV 
transmission to infants. A case-control study in Kenya measured physical violence using a single 
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item and found no association with HIV-positive infant status (Onono et al., 2015b). Male 
antenatal attendance halved the risk of MTCT in a Kenyan study, an association that persisted 
after controlling for maternal viral loads (Aluisio et al., 2011). It is possible that there is a bi-
directional relationship between IPV and infant acquisition of HIV, since one Nigerian study 
showed that women reporting that an infant was HIV-positive had nine-fold increase in the odds 
of incident violence from a partner (Ezeanochie et al., 2011).               
Pathways from IPV to PMTCT  
Several mechanisms may underpin the association between IPV and poor PMTCT behaviors (Fig. 
6). These potential pathways can be represented using a dyadic conceptual framework, which 
posits that both individual factors and relationship characteristics influence a woman’s HIV-
related health (Montgomery et al., 2012). This framework highlights the predisposing personal 
and relationship context, including dyadic characteristics, such as marital status and relationship 
length, as well as personal characteristics like socio-demographics, clinical history, and financial 
status. The framework highlights the many types of IPV, and denotes that for this study, IPV will 
be defined as recent (past 12 months) experience of physical, sexual, and/or psychological IPV. 
 
 
Figure 6. Pathways linking IPV to PMTCT outcomes 
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Three theoretical pathways for the effects of IPV on utilization of PMTCT services are 
highlighted in this framework; relationship control, disclosure, and mental health; and represent 
thinking in the current literature on why IPV may shape PMTCT uptake.  
 
Relationship control 
The first potential pathway is relationship control, or the extent to which HIV-positive women 
may be coerced or inhibited by the partner’s controlling behavior. Relationship control by a 
partner has emerged as a barrier to health care engagement in qualitative studies (Wilson et al., 
2007). A qualitative study among 64 women in the U.S. described how violent partners control a 
woman’s ability to seek medical care by ensuring that she never goes to the clinic alone or 
insisting that they themselves speak to clinicians on behalf of the woman (Lichtenstein, 2006).  
IPV is strongly associated with men prohibiting women’s access to contraception and 
contraceptive services (Alio et al., 2009a; Fanslow et al., 2008) leading to double the odds of 
unintended pregnancy in meta-analysis (Lassi et al., 2014). Another meta-analysis of seven 
studies found that IPV halved the odds of women’s use of contraception (Maxwell et al., 2015). It 
is important to note that relationship control and IPV can also work in the opposite direction, 
causing women to seek out additional health services. For example, among 1 262 women in the 
U.S., reproductive control and IPV increased young women’s use of emergency contraception 
and testing for sexually transmitted infections (Kazmerski et al., 2015). An interesting mechanism 
for this divergence in evidence is that women experiencing IPV may increase their utilization of 
hidden forms of contraception in an effort to counter the reproductive control enacted by violent 
partners (Reed et al., 2016). Regardless of directionality of the association between IPV and 
access to health services, reproductive control, which includes forcing women to become 
pregnant or sabotaging their access to contraception, has steadily increased as an important area 
for further research and intervention (Miller et al., 2014; Silverman & Raj, 2014). 
 
Partner Disclosure 
A second pathway occurs when fear of new or continued IPV leads women to avoid disclosure of 
their HIV status to male partners (Mepham et al., 2011). In a longitudinal study of 293 pregnant, 
South African women living with HIV, authors found that experiencing two or more types of IPV 
(vs. no violence or one type) halved the odds of disclosure to a partner (Makin et al., 2008). In 
Tanzania, among 490 women who chose not to disclose, 15% listed partner conflict (violence or 
separation) as a primary reason for non-disclosure (Antelman et al., 2001). In a study of 23 
pregnant and postpartum HIV-positive women in the United States, Njie-Carr et al. found that 3 
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women with recent violence avoided partner disclosure because they feared a violent reaction 
(Njie-Carr et al., 2012). 
Non-disclosure to male partners has a significant impact on treatment adherence 
(Bajunirwe et al., 2009; Medley et al., 2004; Wouters et al., 2009), and poses a risk for sexual 
transmission of HIV if the male partner is still HIV-negative (Bond, 2010; Desgrees-du-Lou et 
al., 2009; Katz et al., 2009; Orne-Gliemann & Desgrees-Du-Lou, 2008). This is partly because 
when pregnant women do not disclose, it is challenging for them to visit the HIV clinic or take 
treatment openly (Awiti Ujiji et al., 2011). Through these pathways, non-disclosure to partners 
increases the odds of vertical transmission of HIV (Myer, 2011). In a recent systematic review of 
PMTCT, partner disclosure was associated with poor PMTCT uptake in a majority of both 
quantitative (6 of 9) and qualitative (17 of 24) studies (Gourlay et al., 2013a). Evidence from 
South Africa suggests that the average time gap between obtaining an HIV-positive test result and 
disclosing this result to a sex partner is as high as 16 months (Wong et al., 2009).  
In addition to posing as a risk factor for non-disclosure, IPV can occur as a sequela for 
those women who do choose to disclose to partners. Studies in the U.S. suggest that between 20.5 
– 33% of women newly diagnosed with HIV experience incident physical or sexual violence from 
a partner (Pence et al., 2007; Sowell et al., 2002; Zierler et al., 2000). The literature is sparser in 
sub-Saharan Africa, but several studies do exist. In a cross-sectional Nigerian study of 652 
pregnant women, 17% experienced IPV before HIV testing and 49% experienced IPV after 
testing for HIV and disclosing their status to partners (Ezechi et al., 2009). In another Nigerian 
study of 89 women, 7.9% reported violence after partner disclosure and a further 15.3% reported 
abandonment by a partner (which can be conceptualised as a form of physical and/or 
psychological abuse) (Ezegwui et al., 2009).  
However, it is important to note that not all studies show an association between HIV 
partner disclosure and subsequent IPV. In Kenya, among 1638 HIV-positive women, only 6 
experienced immediate violence in the two weeks following diagnosis (Kiarie et al., 2006). One 
reason for the discrepancy is the time of measurement. A study with 310 HIV-positive women in 
Baltimore, U.S., found that while only 4% reported immediate physical abuse following partner 
disclosure, 45% experienced IPV in the months following diagnosis (Gielen et al., 2000). 
Qualitative data among HIV-positive pregnant women support these quantitative 
findings. In Swaziland, a study among 19 postpartum women living with HIV in Swaziland, 9 
reported IPV following disclosure (Mulrenan et al., 2015b). A Tanzanian study with 62 men and 
women found that HIV disclosure was a trigger for physical and emotional IPV (Maman et al., 
2001). In Zimbabwe, a qualitative study with 64 pregnant and postpartum women suggested that 
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IPV occurs after HIV disclosure in the form of sexual coercion (Shamu et al., 2012). In Malawi, 
interviews with 9 newly-diagnosed mothers found that all experienced a severe form of partner 
conflict, such as abandonment, following partner HIV disclosure (Njunga & Blystad, 2010). One 
qualitative study in South Africa did not find that women experience partner conflict or violence 
following disclosure (Stinson & Myer, 2012). 
 
Mental Health 
Mental health is a third theoretical pathway through which IPV may inhibit PMTCT uptake. As 
synthesized in Section C.2, a well-developed body of literature shows that IPV leads to emotional 
trauma, anxiety, chronic stress, suicidal ideation, and depression among women in the general 
population. Mental health challenges, in turn, worsens adherence to ART. Longitudinal research 
confirms that depression can lead to incident occasions of non-adherence to ART (Bottonari et 
al., 2010; Kacanek et al., 2010). This association between IPV and mental health is as (if not 
more) pronounced among HIV-positive women. Cross-sectional studies from the U.S. confirm 
that among HIV-positive cohorts, women with a lifetime history of IPV have higher rates of 
depression (Illangasekare et al., 2012; McDonnell et al., 2005), anxiety (Gielen et al., 2005), and 
post-traumatic stress disorder (Axelrod et al., 1999). 
Poor mental health may impact on ART adherence among pregnant women, although one 
systematic review found no quantitative evidence to confirm this association (Gourlay et al., 
2013b). Indeed, much of the literature linking depressive symptoms to PMTCT adherence in sub-
Saharan Africa is based upon qualitative research (Chinkonde et al., 2010; Delva et al., 2010a; 
Kasenga et al., 2010; Painter et al., 2004). 
There are a number of reasons that IPV might lead to poor adherence through the mental 
health pathway. The stress of IPV may compound with the stress of HIV, making it challenging 
to adhere (Illangasekare et al., 2012). Coping skills can also be altered by mental health. In a 
longitudinal study in the U.S. among 87 HIV-positive participants, patients with depression had 
lower adherence to ART even if they had the same number of life stressors as non-depressed 
counterparts (Bottonari et al., 2010). In a cross-sectional study among 190 HIV-positive men and 
women in the U.S., IPV was related to non-adherence and to coping among women (Lopez et al., 
2010).  
IPV may serve as a barrier to health care because of feelings of denial and shame that 
preclude women to seek care openly (McCauley et al., 1998). In a large mixed-methods study of 
PMTCT adherence in Kenya, women described the difficulties of maintaining good health 
behaviors amidst the despondency and despair of coping with a new HIV diagnosis themselves 
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(Kohler et al., 2014). The diagnosis of HIV in pregnant women trigger depressive thoughts, 
denial, and self-condemnation, with some women reporting suicidal ideation around this time 
(Donahue et al., 2012; Kohler et al., 2014). Among non-pregnant women in a large U.S. 
qualitative study, IPV led to “internalization of the violence” through depression, social 
withdrawal, and feelings of helplessness (Lichtenstein, 2006). 
Women’s vulnerability to IPV prior to HIV diagnosis may create a self-image of being 
damaged, inhibiting self-care and access to regular health services (Leenerts, 1999; Rothenberg & 
Paskey, 1995). Mental health could be the link between IPV and poor self-care. Cross-sectional 
and longitudinal studies suggest that women experiencing IPV and reporting lower SRPS scores 
have increased risk of depression (Campbell et al., 1995; Hatcher et al., 2012; Nduna et al., 
2010).  
Mental health seems to mediate the relationship between IPV and adherence to ART. A 
Haitian study among men and women suggests that IPV and adherence is mediated by depression 
(Malow et al., 2013). A cross-sectional U.S. study among men who have sex with men found that 
IPV led to mental health problems, which in turn reduced ART adherence (Pantalone et al., 
2010). To my knowledge, no studies to date have explored mental health as a pathway from IPV 
to adherence among pregnant or postpartum women. 
 
E. Gaps in the Evidence Base 
There are several important gaps in the extant literature, some of which this doctoral research 
aims to answer. The research linking IPV to adherence among non-pregnant populations is 
emerging mainly from resource-rich settings. Because the studies are small and cross-sectional in 
nature, it is challenging to assess whether there is a true association between women’s experience 
of violence and ART adherence. A systematic review has yet to be conducted to better understand 
whether, and to what extent, IPV impacts HIV behaviors. Paper 1 aims to fill this gap. 
In terms of the association between IPV and PMTCT, the Hampanda (2016) paper offers 
an important set of preliminary associations in a sub-Saharan African setting. However, the 
methodology was cross-sectional in nature, limiting our ability to draw causal conclusions from 
the findings. The analysis only offers bivariate results, which means that IPV may be a marker for 
poor PMTCT behaviors rather than a causal factor driving PMTCT adherence. Both of these gaps 
are addressable in this doctoral research, as Paper 4 uses structural equation modeling within a 
longitudinal cohort of pregnant and postpartum women. 
The pathways underpinning any potential IPV and PMTCT association are also poorly 
understood. Much of the conceptual work around identifying pathways draws from non-pregnant 
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populations or from resource-rich settings. Given the high burden of both IPV and HIV in sub-
Saharan Africa, it is important to establish a richer understanding of why women’s experience of 
partner violence may be related to their HIV behaviors. In particular, qualitative research should 
establish what health workers and pregnant women themselves think about IPV in relation to 
PMTCT behaviors. Paper 2 aims to fill this gap.  
This preliminary qualitative exploration should also be complemented by a deeper set of 
interviews specifically with women who live with both IPV and HIV, in order to tease out 
potential pathways linking violence to PMTCT. The reason that a deeper qualitative study can 
add to extant literature is that while extant qualitative research has suggested an association 
between IPV and HIV, little research has explained why these two conditions may be linked. I 
aim to fill this gap in the literature in Paper 3. Similarly, in quantitative literature, an increasing 
number of studies shows an association between IPV and worsened ART adherence, but little 
data exists around the relative strengths of potential pathways linking IPV to HIV adherence 
behaviors. Paper 4 aims to fill this gap specifically among pregnant and postpartum women. 
PMTCT is largely atheorized, with existing theories focused primarily on the individual 
woman alone (Geldsetzer et al., 2016; Hampanda, 2012). Using a traditionally biomedical lens, 
many PMTCT programs view women as rational actors who are “non-compliant” if they miss 
essential health care steps (Betancourt et al., 2010). This is in opposition to many settings where 
HIV treatment and related health care decisions can be viewed as a social process, with people 
weighing the benefits of treatment with potential negative social outcomes (stigma and 
discrimination, rejection from homes, inability to access resources) (Merten et al., 2010). 
Viewing PMTCT as a social process helps incorporate IPV into the theoretical lens, since partner 
violence is necessarily a relational event. Additional empirical findings around the dyadic nature 
of PMTCT can help fill this hole in the literature. Papers 2-4 aim to speak to this theoretical gap. 
A recent systematic review identified a need for high-quality trials measuring how 
potential interventions prevent or mitigate the effects of IPV in pregnancy on women’s and infant 
health (Jahanfar et al., 2013). This doctoral research is observational in nature, and will not be 
able to measure the impact of an intervention on women’s experience of IPV. However, as the 
PhD research is nested within a randomized controlled trial of which I am Co-Principal 
Investigator (Pallitto et al., 2016), the larger body of work may begin to answer this critical 
programmatic gap. 
 
 56 
F. Synthesis of the Literature 
The extant literature has shown that IPV causes detrimental physical, mental, and reproductive 
health outcomes among women. IPV is increasingly linked to declines in birth outcomes, infant 
health, and child wellbeing. Over the recent years, researchers have better defined how IPV is 
related to incident HIV infection among women. One of the unanswered questions is how recent 
physical, sexual, and psychological IPV impacts the lives of women already living with HIV. Yet, 
preliminary evidence from small studies suggests that IPV may be a driver of worsened health 
behaviors, including those required for successful PMTCT. The extent to which HIV remains a 
global health concern means that placing IPV on the HIV research agenda could have important 
policy and practice implications. 
Alongside the myriad of poor health outcomes, IPV is also a human rights violation in its 
own right (UN General Assembly, 2016). While IPV is illegal in many settings and there are 
strong global commitments to end its use (UN General Assembly, 1979, 1993), violence from a 
male partner continues to occur in the lives of 30% of women globally (Devries et al., 2013b). 
South Africa, as a signatory of the Declaration of the Elimination of Violence against Women has 
the responsibility to prevent and respond to cases of IPV. Yet, in practice, large gaps exist to 
implementing the national and global commitments that the South African goverment has made 
(United Nations Special Rapporteur on Violence against Women, 2015). Understanding IPV in 
the lives of pregnant and postpartum women living with HIV may help spur future research and 
programs around ending IPV. 
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Chapter 3. Methodology 
 
 
 
 
 
 
 
 
 
 
 
 
 
Photo credit: Abigail Hatcher, Sensitizing a Safe & Sound 
clinic to techniques for addressing IPV in pregnancy
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The three research aims of this doctoral research were answered using quantitative and qualitative 
techniques for data collection and analysis. Together, this doctoral work aims to contribute to the 
evidence demonstrating how and to what extent IPV is a driver of PMTCT non-adherence in 
pregnant and postpartum women. Analysis for each research aim followed a sequential approach, 
with distinct data analysis plans for each paper. Thus, in this chapter, I present methodology for 
each individual manuscript.  
 
Aim 1: Assessing the effect of IPV on HIV adherence entailed a systematic review of the 
literature on IPV and ART adherence among women and a quantitative meta-analysis 
(Paper 1). 
 
Aim 2: Understanding the reasons why IPV may be related to HIV behaviors among 
pregnant and postpartum women was achieved using thematic coding of qualitative 
formative research with key informants (Paper 2) and a social constructionist analysis of 
in-depth interviews with women living with IPV and HIV (Paper 3). Elucidating the 
mechanisms underpinning the association between IPV and ART adherence also entailed 
structural equation modeling of quantitative cohort data (Paper 4). The conceptualization 
of the structural equation model was strongly informed by qualitative mechanisms 
identified in Papers 2 and 3. 
 
Aim 3: Measuring the association between IPV and ART adherence in pregnancy and 
postpartum was achieved using bivariate and multivariate regression techniques from 
quantitative data (Paper 4). Similarly, structural equation modeling provides an estimate 
of the relationship between IPV and ART adherence while controlling for key pathways. 
 
A. Mixed method strategy 
The nature of the research was sequential mixed methods, which is an approach to answering an 
area of research inquiry with both qualitative and quantitative data (Creswell & Clark, 2007). 
Qualitative and quantitative data for the four individual manuscripts were collected using a 
sequential exploratory approach (Creswell & Clark, 2007). This type of mixed method approach 
is characterized by using preliminary qualitative research to set the stage for deeper qualitative 
and quantitative research. The integration strategy was to connect the different types of data and 
analytical results so that each research phase informed the next (Creswell et al., 2011). 
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 Figure 5 presents the overall doctoral aim with a depiction of how each specific objective 
is addressed by the included manuscripts. Boxes with thicker outlines represent individual papers, 
whereas boxes with thinner outlines demonstrate a point of connecting various types of data (also 
called a “point of interface”) (Morse & Niehaus, 2009). As evidenced by the figure, quantitative 
and qualitative research were used initially to confirm the relevance of the research problem. 
Formative qualitative research was used to inform development of appropriate quantitative tools. 
Two types of qualitative research helped identify plausible pathways linking IPV to PMTCT 
adherence. These pathways were then tested quantitatively in the final quantitative manuscript. 
 
Figure 7. Mixed method study design 
 
 
Mixed Method Research Plan 
Prior to developing a protocol, a scoping review of the literature helped frame the initial research 
question. Scoping reviews are seen as best practice because they map the existing evidence base 
and define the appropriate scope for research questions (Armstrong et al., 2011). This scoping 
review led to the systematic review conducted for Paper 1.  
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The quantitative meta-analysis of Paper 1 confirmed the importance of the research 
problem, namely that IPV influences women’s HIV treatment behaviors. It offered evidence from 
resource-rich settings on the extent to which violence impacts ART adherence. The systematic 
review also suggested the major gap in literature, finding no extant studies among pregnant 
populations or in resource-constrained settings. By confirming the novelty and importance of the 
doctoral research question, I was able to proceed more confidently with my qualitative and 
quantitative data collection. 
The qualitative formative research presented in Paper 2 helped identify initial 
mechanisms linking IPV to PMTCT based on a small set of interviews with pregnant women 
themselves and a larger set of interviews with health workers and other key informants. The 
epistemological approach for this phase was to use qualitative research to gain an initial 
understanding of a new, understudied research topic - creating a explanation of why and how a 
previously unknown phenomenon occurs (Pasick et al., 2009). The findings of Paper 2 were used 
during quantitative survey development, a method of connecting data from the qualitative 
formative research with the future quantitative study (Creswell et al., 2011). 
In Paper 3, a larger sample of women living with HIV and IPV allowed for a deeper 
understanding of mechanisms linking the two conditions. Because our initial qualitative research 
on Paper 2 provided preliminary pathways, this manuscript was more explanatory in nature. The 
decision to expand the sample from a proposed 24 women to a final group of 32 allowed a testing 
of qualitative mechanisms that the early interviews presented. This type of analytical 
improvisation during the research process is central to social constructionist approaches 
(Charmaz, 2008). The iterative process allowed Paper 3 to present a “dense analyses with 
explanatory power, as well as conceptual understanding,” (Charmaz, 2008: 408). Data in this 
manuscript were presented as “merged data” (Creswell et al., 2011), with basic quantitative 
survey characteristics informing the presentation of quotes from individual participants. 
An important contribution of Paper 3 to this particular research was the elucidation of 
potential causal pathways that could be tested using quantitative data. In Paper 4, I incorporated 
all four potential pathways identified in the qualitative findings in bivariate analysis: mental 
health, partner disclosure, partner control, and health care utilization. One pathway was omitted 
quantitatively since I did not measure it in quantitative data collection: resilience.  
Blending paradigms 
Despite differences in methodologies and theoretical assumptions, qualitative and quantitative 
mixed methods research can provide a richer set of answers to an area of inquiry (Greene, 2007). 
In this doctoral research, a positivist paradigm was used during quantitative data analysis (Papers 
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1 and 4), while qualitative research was informed by socio-ecological (Paper 2) and social 
constructionist views (Paper 3). Instead of consistently using a single research paradigm, I opted 
for diverse approaches that placed value on objective and subjective findings, or 
“intersubjectivity” (Morgan, 2007). 
Points of interface 
Altogether, there were various time-points during this research when one method spoke to the 
other, or what some scholars call the “point of interface” (Morse & Niehaus, 2009). ] The point of 
interface was mainly during data analysis and data interpretation. A “multiphase design” allowed 
ample time to incorporate the formative qualitative findings from Paper 2 into the quantitative 
survey instrument. It also created space for using the meta-analytical findings of Paper 1 as a 
rationale for continued, deepened research. Paper 3 identified causal mechanisms that could be 
tested using the quantitative structural equation modeling methods in Paper 4. Similarly, Paper 3 
findings around resilience helped explain the contradictory quantitative finding that a majority of 
women are self-reporting strong ART adherence despite living in violent relationships. 
 
B. Methods for Paper 1: Systematic Review 
The first doctoral paper was a systematic review of the literature on IPV and ART adherence 
among women. 
Search strategy  
We retrieved published English language of papers via PubMed, Web of Science, CINAHL, 
PsychInfo and Proquest Thesis & Dissertation through January 2015. We used a list of defined 
constructs and search terms, which is included in the published Paper 1 (see full manuscript in 
Chapter 5). Each individual database had a tailored search strategy that adapted the systematic 
review constructs to the database input style. 
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Study selection followed a three-step process (Fig 1): title and abstract review; full text review 
and quality appraisal. First, two authors independently reviewed all identified study titles and 
abstracts.  
Duplicates and titles that do not meet the inclusion criteria were removed. The same
authors independently assessed the full papers of those abstracts that met the eligibility criteria.  
We dealt with varying 
forms of IPV (physical, sexual, 
and/or psychological) by 
including any definition of IPV 
in our search. However, we 
ensured that included studies 
measured IPV on its own (not 
combined with other forms of 
violence like childhood sexual 
violence or non-partner sexual 
violence). 
At each stage, two 
authors independently reviewed 
the studies, noting discrepancies. 
Discrepancies were resolved 
through telephonic input from 
the senior author until a 
consensus was reached. Finally, 
the reviewers manually searched 
the reference lists of included 
articles for further key studies that could potentially be included. 
Preliminary search 
An initial test of the search strategy was explored to ensure there might be eligible papers to 
analyze (Table 2). Based on this, there seemed to be adequate literature using this search strategy. 
The numbers of papers were somewhat small, but certainly enough to review in full. 
Figure 8. Study selection flow diagram 
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Data abstraction 
The following data were abstracted and summarized in tables: citation; year of publication; 
country; study design and sampling; characteristics of the study population; outcomes (adherence, 
uptake of ART, retention in care). When available odds ratios (OR) and similar estimates (e.g. 
relative risk, hazard ratio) with confidence intervals were abstracted. 
We anticipated that many studies 
would only present bivariate 
statistics, but where possible 
multivariate statistics were abstracted 
along with the different factors they 
control for.  
Data analysis 
Quantitative outcomes were entered 
into an Excel table. Pooled 
unadjusted odds ratios (OR) were 
calculated using random effects meta-
analysis metan command in STATA. 
Quality appraisal 
Quality appraisal was completed for all full texts by two independent reviewers using an adapted 
version of the CASP Quality Appraisal Checklist. Each study was judged on a rubric of twelve 
items, and a total score is provided in the summary table of study characteristics. 
Table 2. CASP Quality Appraisal Tool 
Table 1. Preliminary search results 
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Reporting 
The PRISMA Reporting Checklist was used to ensure that all aspects of systematic reviews were 
reported accurately (Table 3). 
 
Table 3. PRISMA Checklist of items to include when reporting a systematic review or meta-analysis 
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Limitations 
Several limitations of the systematic review are important to mention. We only included studies 
that examined IPV and HIV behaviors among women, although men in violent partnerships are 
also important to examine. We used a limited number of databases, but attempted to overcome 
this limitation by doing hand searches of citations for each included article. The types of IPV 
measured in each study varied, suggesting that meta-analysis may have limitations. 
 
C. Methodological Background for Papers 2-4 
Nested Study 
In order to explore the relationship between IPV and HIV-related adherence among pregnant 
women, I nested my mixed methods doctoral research within the Safe & Sound Trial. The Safe & 
Sound Trial is a randomized control trial testing the efficacy of brief empowerment counseling 
for reducing violence and improving mental health among pregnant women in urban 
Johannesburg, South Africa (Pallitto et al., 2016). As I served as Co-Principal Investigator of the 
Safe & Sound Trial, it was feasible to build the doctoral research around existing infrastructure of 
the trial. 
Safe & Sound Trial Design 
The trial conducted baseline interviews 
with pregnant women who experienced 
recent physical or sexual IPV (n=422) and 
those who do not (n=1160). Trained 
nurses then randomized women with IPV 
to receive the counseling intervention or 
an enhanced control condition. All women 
in the randomized control trial were 
followed up postpartum between 6-weeks 
and 24-weeks (Fig. 8).  
The Safe & Sound intervention 
was comprised of several elements aimed 
to reduce women’s experience of violence 
during pregnancy and postpartum. 
Described fully elsewhere (Hatcher et al., 
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Loss to follow-up 
(13.5%)
R
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n=184
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(6-24 weeks
 postpartum)
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n=181
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Parent Study Design
No Recent IPV 
n=1160
Figure 9. Safe & Sound Trial design 
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in press; Pallitto et al., 2016), the intervention included two 30-minute sessions that were tailored 
to the individual needs of women. The possible components were empathetic listening, safety 
planning, legal steps, and enhanced referrals to onwards services for IPV. HIV was not 
specifically targeted within the Safe & Sound intervention, but nurses were trained in the 
guidelines for offering PMTCT and were supportive of women who required assistance around 
HIV care and treatment. 
Study Setting 
The study setting was four antenatal clinics in the City of Johannesburg: Hillbrow Community 
Health Clinic; South Rand Hospital; Rosettenville Clinic; Yeoville Clinic. The City of 
Johannesburg is located in Region F and is comprised primarily of poor neighbourhoods with 
high rates of poverty and migrancy – both from rural South African towns and from neighbouring 
countries such as Zimbabwe, Malawi, and Swaziland. Clinics have a catchment area, denoted in 
blue, and most patients can walk or take a short mini-bus taxi to attend. Services are free of 
charge, although additional costs can be incurred if certain medications are stocked out.  
The four Safe & Sound clinics agreed to participate in the parent trial, and we obtained 
ethical and Department of Health approvals to conduct research in the sites. All four sites offer 
PMTCT in line with national guidelines. Wait times in antenatal care are often 5-6 hours given 
the high demand for these services in many catchment areas. 
 
 
Figure 8. Map of study sites 
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D. Methods for Paper 2: Formative Research  
The formative qualitative research for Paper 2 was part of a larger formative study conducted in 
advance of the Safe & Sound Trial. This paper was exploratory in nature and utilized qualitative 
research methods with key informants to better understand how IPV might be related to PMTCT. 
Data collection 
Prior to initiating the Safe & Sound trial, we conducted formative, qualitative research with a 
wide range of stakeholders with potential to take part in an IPV in pregnancy intervention. Table 
5 describes the participant 
group, data collection 
approach, and total number of 
participants. 
All in-depth 
interviews and FGDs were 
conducted in a private room in 
one of three participating 
clinics. (A fourth clinic was 
added to the parent study after 
completion of this formative 
research). I led a portion of 
qualitative interviews (n=12) 
and trained qualitative 
researchers, who were fluent 
in multiple local languages 
(Sotho, Zulu, Tswana), led the 
remainder of interviews and 
focus group discussions. 
Semi-structured discussion 
guides explored a wide range 
of topics (see Table 4). For 
the purpose of this analysis, 
the topics around PMTCT, the link between IPV and HIV-related health, and mental health were 
analyzed. Discussions were audio-recorded after obtaining participants’ permission. The research 
Table 4. Formative data collection methods 
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team was comprised of three South African researchers and myself, an American researcher who 
has lived and worked in South Africa for the past decade.  
Data analysis 
Data from electronic recordings were either transcribed directly from the English or were 
translated from a local language (Sotho, Zulu, Tswana) into English by professional 
transcriptionists. The researcher who conducted the IDI or FGD reviewed each transcript for 
accuracy and added a brief memo including personal reflections on how the interview proceeded, 
observations, and notes about key themes.  
I led a two-day computer-assisted qualitative analysis training for the research team, who 
was new to qualitative coding and write-up. The research team managed data in QSR Nvivo 10, a 
qualitative analysis software, using an analytical framework of thematic codes (Miles & 
Huberman, 1994). This was achieved through a day-long workshop that I facilitated where we 
collectively reviewed the study research questions and emerging issues of interest. Each thematic 
code was discussed among the team until consensus was reached regarding a definition for each 
code. Definitions were written in question form, to prepare for the next step of fine coding. The 
final codebook contained 23 broad codes that were applied to the database by three researchers, 
ensuring that each transcript was coded at least twice.  
Next, pairs of researchers held a series of meetings to collectively develop ‘fine codes’ 
using an inductive approach to data analysis (Hutchison et al., 2010). We developed fine codes by 
printing out a full set of excerpts and creating a list of the sub-themes emerging from the data. 
The fine codes were constantly compared to the broad code definition – ensuring that finer 
themes related to the question of interest. This process was crucial for analytical rigor as it 
allowed the opportunity for seeking out disconfirming evidence (Miles & Huberman, 1994), and 
for adding to the preliminary ‘audit trail’ of decisions made by the research team (Lincoln & 
Guba, 1985). Lastly, the reports were shared and critiqued by at least one other member of the 
team, making the writing process itself an additional form of inquiry (Richardson, 2000). 
The report themes (Table 5) explore three major aspects of designing and implementing a 
successful intervention. The first theme explores this particular setting, from a patient, 
community, and clinic perspective. The second theme touches on intervention content, with an 
emphasis on the topics that may be salient for pregnant women in this study context. This theme 
(C.5 Mental health; C.6 IPV-HIV link; C.7 PMTCT) was used to inform Paper 2 for the doctoral 
research. The third theme includes insight from participants about how we might design an 
intervention to be responsive and sustainable. 
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Limitations 
There were several limitations to this formative, qualitative research. Firstly, logistical constraints 
led to small sample sizes of each participant group. Secondly, there was potential that the 
perspective of individual researchers informed the data analysis process. Although we tried to 
limit a skewed version of the data using team analysis approaches, it is possible that certain views 
emerged more strongly during analysis and write-up. 
 
 
E. Methods for Paper 3: Social Constructionist Research  
The methods for the second qualitative paper were unique from those of the formative, qualitative 
research. Specifically, we used social constructionist research to explore pathways from IPV to 
PMTCT adherence among women who lived with both HIV and IPV. A larger sample with 
deeper exploration of emerging themes allowed us to both hypothesize new pathways and 
confirm them in later interviews. 
Qualitative Sampling 
The sample for the qualitative in-depth research was drawn purposively from the Intervention 
arm of the Safe & Sound Trial and from among women who had lifetime experience of IPV. This 
Table 5. Formative research themes 
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sample was comprised of a total of 32 women living with HIV and who had some lifetime 
exposure to partner violence (Fig. 10). In practice, this included women participating in the trial 
(ie. experiencing recent IPV), as well as women who were not eligible to enroll in the trial, but 
who had experienced IPV in their lifetime. These lifetime history participants had already 
completed a full study baseline questionnaire and agreed to be contacted about further research. 
Study nurses guided the selection of participants based on their impression of women’s 
willingness to take part in an additional interview, their knowledge of women’s experiences of 
IPV, and women’s HIV-positive status. 
 The sample included 26 women 
with recent IPV and 8 women with 
lifetime experience of IPV. Roughly equal 
numbers of participants were pregnant vs. 
postpartum at the time of interviews. In 
total, 12 participants were partially non-
adherent or taking no medication at all 
during pregnancy. A full set of participant 
characteristics is included in Chapter 7 
(Paper 3).  
 
Qualitative Data Collection 
The goal of in-depth interviews was to 
explore why and how IPV influences 
PMTCT behaviors in pregnancy and 
postpartum. It was anticipated that this 
portion of the interviews would lead to 
hypothesis development, and that one 
interview will build on the others in an effort to further explore these dynamics. As described in 
more detail in Chapter 6, the methodology for this study was informed by narrative, 
constructionist approaches to researching IPV (Allen, 2011). 
In-depth interviews were conducted face-to-face, in a private clinic room, at a convenient 
time for the woman (e.g., a time when she is already visiting the clinic for services). I conducted a 
portion of these interviews among participants who were conversant in English, a Masters student 
conducted a portion in English, and two trained Nurse Researchers conducted the remainder in a 
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South African language of the participants’ choosing (Tswana, seSotho, isiZulu). To ensure that 
interviews achieve adequate depth, the first six transcripts were reviewed jointly with the 
researchers to establish future questions, points of clarification, and initial themes. 
An in-depth interview guide explored several themes (Appendix G). Theme 1 examined 
the IPV-HIV link: what relationship between IPV and HIV in women’s lives, including participant 
perceptions of the directionality of the relationship (does HIV lead to IPV or visa versa?). Theme 
2 explored women’s perceptions of HIV-related health outcomes. For example, these questions 
unpacked how IPV frames PMTCT uptake decisions and impact of IPV and HIV on the success 
of pregnancy and health of infant.  Theme 3 dived deeper into mechanisms through which IPV 
may impact PMTCT-related health behaviors. This portion of the interview was comprised of 
semi-structured questions around relationship control, mental health, and partner disclosure.  
 
Qualitative Data Analysis 
Trained transcriptionists transcribed digitally-recorded data verbatim, and I checked a portion 
(40%) of transcripts for accuracy. Each transcript was reviewed by a researcher to ensure clarity 
and for additional detail about tone and non-verbal cues. Interviews conducted in the local 
language (Sesotho or isiZulu) were translated directly into English and reviewed for translation 
errors by the researcher who led the interview. All data collection materials were stored in a 
locked file cabinet and electronic voice files and transcripts were password protected and stored 
on an encrypted server. At the point of transcription, the lead researcher assigned a pseudonym 
unrelated to the participant’s real name for ease of analysis. The data presented here note the 
pseudonym, age, and whether the woman was pregnant or postpartum. 
To ensure that interviews achieved adequate depth and richness, the first 6 transcripts 
were reviewed jointly to establish future questions, points of clarification, and initial themes. 
Researchers reviewed full transcripts and created detailed 'memos' to highlight initial impressions 
of the data. This review process was repeated at two other time-points (upon completion of 18 
interviews and 28 interviews). Both reviews led to tweaking of the interview guides, with major 
themes retained but sub-questions altered to enhance probing and clarity. The team developed an 
initial coding framework based on the preliminary review of 6 transcripts and “sensitizing 
concepts”, or preliminary ideas around how to examine the data (Bowen, 2006).  
The coding framework was applied to all transcripts by myself and a Masters student I 
supervised using Dedoose qualitative analytic software. The focus of double-coding was to 
ensure that code application was consistent across transcripts and that code definitions were 
robust. Rather than assessing inter-rater reliability, we used a series of phone calls and in-person 
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meetings to refine codes until consensus was reached. This process led to a refined set of thematic 
codes that comprised broad topics such as relationship characteristics, experience of violence, 
HIV diagnosis, PMTCT uptake, mental health, social support, partner HIV serostatus disclosure, 
and reflections on being asked about IPV in pregnancy. Next, we established a system of fine 
codes that emerged inductively from the data. Fine codes were applied to a portion of transcripts 
by three researchers, ensuring that every transcript was double-coded. Examples of fine codes 
within the partner HIV disclosure section were: fear of partner response, reactive or polarized 
methods of disclosure, male partner denial of disclosure, concern for the child, supportive steps, 
and displaced anger. During analysis, cases that did not fit the overall picture, called “exceptional 
cases”, were actively sought out. Trustworthiness of findings was ensured by the team approach 
to data analysis, coding discussion meetings, and by presenting initial findings to groups of 
colleagues and peers.  
Limitations 
There were several limitations to this qualitative research. It is possible that other forms of IPV 
were important to women but were not brought up in the interviews. For example, little data 
emerged around contraceptive control or spiritual abuse, but it is possible that these forms of 
violence occurred. Future research would be strengthened by asking specifically about these 
forms of violence in relationships. As with any form of research, the positionality of the 
researcher can influence how participants respond. As a white, non-South African woman, it was 
crucial that I build rapport and trust with participants before exploring sensitive questions. I was 
able to establish an empathetic and containing interview environment by using trauma-informed 
skills that I learned through the study and via weekly supervision by a clinical psychologist 
throughout the research period. These skills include: managing my own emotional response, 
setting a calm tone prior to starting the interview, listening with empathy but not sympathy, 
carefully observing participant cues to detect moments where probing is too deep (e.g. looking 
away, wringing hands, being on the verge of tears). The skills I learned were then instilled in 
Nurse Researchers through regular debriefing and supervision meetings. This helped diffuse 
power differentials associated with their being employed, wealthier, black South African women 
in comparison to the study participants. 
 
F. Methods for Paper 4: Structural Equation Modeling 
The final manuscript built upon the findings from Papers 2 and 3, which posited potential 
mechanisms through which IPV impacts on ART adherence. This paper also drew upon robust 
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findings from Paper 1 that suggest IPV is associated with ART adherence among women, and 
deepened these by looking at a cohort of pregnant and postpartum participants. 
Nested Study design 
The design for Paper 4 was a quantitative study for which we recruited and followed a subset of 
women who were HIV-positive at the baseline visit of the Safe & Sound Trial. We leveraged 
existing data collection for the parent study at baseline. New data collection added for this 
doctoral research included following up women who were HIV-positive but did not experience 
violence (n=139). In Figure 11, these additional data collection methods are highlighted in gray 
shading. Thus, the PhD research adds to the parent study by examining the existing cohort from 
the perspective of HIV infection and uptake of services.  
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Study Population 
The study population was pregnant women accessing services from three antenatal clinics in 
Johannesburg. The population was comprised of a large group of antenatal clients (n=1582) 
screened for their experience of IPV in the previous 12 months. Of these, we knew a portion 
would be HIV-infected, and these women were invited to be followed-up at their 6-week routine 
postpartum clinic visit. In practice, the follow-up visits were scheduled anywhere from 6-24 
weeks postpartum. 
All participants in this PhD sub-study were HIV-positive at baseline. The subsample of 
participants with IPV was comprised of HIV-positive participants from the Safe & Sound Trial 
(i.e. reported physical and/or sexual violence at baseline) as well as HIV-positive patients who 
experienced only psychological violence at baseline. The subsample of non-IPV women was 
comprised of HIV-positive women who screened negative for recent IPV during their first 
antenatal visit.  
Eligibility 
Participants were eligible if they were over 18 years of age, were pregnant at baseline, and did not 
exhibit an immediate safety risk (suicidality or fearing for the safety of one’s children). Eligible 
participants were women who self-report at least one form of IPV in the previous 12 months 
(physical, sexual, or psychological) in the baseline interview.  It is important to note that this 
eligibility criteria is somewhat broader than the parent study, which determined eligibility by 
physical and/or sexual violence only. In other words, those women experiencing only 
psychological IPV at baseline were “reallocated” to the IPV-yes group for the current study. This 
serves to balance the group sizes, while accounting for the fact that psychological IPV has been 
shown to have similar health and behavioural effects as physical and sexual violence (Groves et 
al., 2012).
Sample size 
The sample size for this study was constrained by the sample size of the parent study, which 
aimed to recruit approximately 300 women who were HIV-infected. Based on a recent 
Johannesburg study, we assumed just over half (63%) of these women would be adherent to ART 
(El-Khatib et al., 2011). 
 From data suggesting that IPV is associated with lower odds of self-reported ART 
adherence (Adjusted odds ratio 0.75, p=0.005) (Lopez et al., 2010), we assumed that adherence 
may be reduced by up to 25% due to IPV. Thus, even after accounting for loss to follow-up, we 
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would have adequate power (> 0.80) in 
our sample to assess reductions in 
adherence similar to that seen in other 
studies, from 75% to 56% (Table 6).  
 
 
 
 
Quantitative Data Collection 
Quantitative data for both the Safe & Sound Trial and the PhD studies was collected by trained 
Nurse Researchers posted at each clinic for the duration of the study. Data were collected on 
paper forms (Appendix I) measuring the following outcomes and predictors: 
Primary exposure: IPV. To measure IPV in pregnancy and in lifetime, women were 
asked 20 items from the IPV instrument of the WHO Multi-Country Study at baseline and follow-
up (Garcia-Moreno et al., 2006). This instrument measures physical, sexual, and psychological 
IPV in the past year and throughout one’s lifetime. It was developed by our WHO collaborators, 
and has been used in sites globally to measure IPV prevalence, including in South African studies 
(Dunkle et al., 2004a; Jewkes et al., 2010; Jina et al., 2012; Townsend et al., 2011). We added 
two questions on financial violence: “Has your partner withheld money for essentials (e.g., food) 
even when he has money for other things?” “Does your partner take away your own earnings or 
savings without your permission?”. We also added one additional question to account for 
psychological violence in the form of forced exile: “Has your partner ever forced you to leave 
the house?”. The WHO instrument was analyzed as a dichotomous outcome (any physical and/or 
sexual IPV). We used Tsai et al.’s approach to generating an IPV intensity index from equally 
weighted averages of thirteen z-scores (for which each item was standardized to a mean of 0 and 
standard deviation of 1) (Tsai et al., 2016). Higher values denote greater intensity of IPV. The 
measure loaded as a single factor during confirmatory factor analysis, and the index had good 
internal reliability (baseline Chronbach’s 𝛂 = 0.86; follow-up 𝛂 = 0.88). 
Primary outcome: Self-reported postpartum ART adherence > 90% was measured using 
the 30-day Visual Analog Scale (VAS). The VAS has been validated globally (Walsh et al., 2002) 
and in South Africa (Peltzer et al., 2010a), and shows strong correlation with measures such as 
electronic medication monitoring and unannounced home pill count (Buscher et al., 2011; Oyugi 
et al., 2004). The VAS asks individuals to mark a line at the point along a continuum showing 
   Table 6. Sample size calculation 
 
Alpha N1 
(HIV+, 
IPV+) 
N=2 
(HIV+, 
IPV-) 
Proportion 
N1 >95% 
adherent 
Proportion 
N2 >95% 
adherent 
Power 
0.05 128 128 .56 .75 0.909* 
0.05 128 128 .58 .75 0.838 
0.05 128 128 .6 .75 0.739 
* denotes decrease in adherence found in similar studies 
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how much ART they have taken in the past month (Giordano et al., 2004). We converted the 
VAS scores into a dichotomous outcome of adherence (>90% vs. <90% adherence, a cut-off that 
has been used in similar studies (Mepham et al., 2011; Simoni et al., 2006)). For the final 
structural equation model, we analyzed VAS as a continuous variable (0 – 100% adherence). 
Pathways: Relationship Control. Controlling behaviors was measured using five items 
from the WHO Multicountry Study instrument about how male partners control clothing, 
movement, and access to social networks (Garcia-Moreno et al., 2006). Mental Health. Mental 
health for this study was defined as three constructs: anxiety, depression, and post-traumatic 
stress. The Hospital Anxiety and Depression Scale (HADS), a 14-item measure for assessing 
mental health in primary health care settings (Zigmond & Snaith, 1983), has been used in South 
Africa (Abratt & Viljoen, 1995), and was analyzed  as two dichotomous outcome (HADS-D score 
of >15 vs. <=15; HADS-A score of >15 vs. <=15). The Harvard Trauma Questionnaire, a 16-
item measure for post-traumatic stress disorder (PTSD) (Mollica et al., 1992), has been validated 
in South Africa (Ward et al., 2004). Each item is asked on a 4-point likert scale and scores are 
summed. It was analyzed as a dichotomous outcome using a cut-off score developed in similar 
settings (Roberts et al., 2008) (probable PTSD >28 vs. <=28). Disclosure. Two items determined 
self-reported partner disclosure at baseline and follow-up: “Does your partner know your HIV 
status?”; “Did you disclose it to him?”. Health care utilization was determined by asking 
women at follow-up to self-report the number of antenatal visits they made. 
Covariates: Socio-demographics. Questions were asked at baseline and were adopted 
from similar studies to assess socio-demographic characteristics: age, education, unemployment, 
housing type, ethnicity, migration. Food insecurity was measured using the 3-item, validated 
Household Hunger Scale (Deitchler et al., 2010), and a woman was considered food secure if she 
had no or little household hunger (score of ≤ 2). Relationship characteristics included several 
questions around the current partnership: marital status, length of time with partner, whether still 
in a relationship. Clinical characteristics at baseline. Gravidity and parity were measured by 
asking women two questions about previous pregnancies. New HIV diagnosis was assessed as 
women who test positive for the first time during this pregnancy. Clinic site refers to which clinic 
the participant attended antenatal care (Yeoville, South Rand, Hillbrow, Rosettenville), and 
clustering by clinic was accounted for in final models. 
Quantitative Data Analysis 
We conducted analyses for Paper 4 in Stata 13.1 (StataCorp LLC, College Station, TX). First, we 
examined scales for internal consistency using Cronbach’s alpha. We conducted bivariate 
analyses of the outcome variable against the exposure variable and other selected socio-
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demographic variables. Bivariate analyses (t-test, 𝝌2 test) were conducted to examine differences 
by adherence status for normally distributed variables. Nonparametric bivariate analyses (Mann-
Whitney U test) were conducted for non-normally distributed study variables (children, 
education, time with partner, time on ART, controlling behaviors, intensity of IPV, postpartum 
age at follow-up).  
To measure the association between recent IPV and adherence to HIV medication, we 
initially conducted bivariate logistic regression models. We then adjusted for socio-demographics 
associated with adherence at p ≤ 0.20, a liberal cut-off point to ensure conceptually important 
variables were retained. We report on the odds ratios and the alpha statistic at the significance 
level of 0.05. 
We next conducted Structural Equation Modelling (SEM) with maximum likelihood 
estimation to test relationships between IPV, potential mediators, and ART adherence in 
pregnancy and postpartum. First we used exploratory factor analysis to determine the correct 
measurement model for latent variables: IPV at baseline and IPV at follow-up. For indicators to 
be retained in the latent variable, each observed item needed a factor loading of at least 0.40. In 
the case of IPV at follow-up, this requirement led to the dropping of three sexual violence items. 
Thus, IPV at follow-up specifically measures intensity of physical and psychological IPV only.  
We then used bivariate regression and evidence from our previous qualitative work to 
guide preliminary model building. Model modifications were performed based on modification 
indices and theoretical plausibility. After deriving a path model solution, we regressed each 
included latent and observed variable on the following covariates: age (years); food security 
(household hunger scale); education (years completed); time since ART initiation (days). Once 
model fit was satisfactory, we trimmed non-significant paths.  
Final SEM models are presented using standardized parameters and we used Cohen's 
typology of small (≤0.10 or less), medium (0.30), and large (≥ 0.50) effect sizes to assess these 
relationships (Cohen, 1977). Measures for model fit included an absolute measure (standardized 
root-mean-square residual), a parsimonious measure (root-mean-square error of approximation) 
and an incremental measure (comparative fit index) (Bentler, 1990; Steiger, 1990). Acceptable 
model fit assumed the model met the following criteria: SRMR<0.08; RMSEA<0.08 for 
reasonable fit and <0.05 for good fit; and CFI≥0.90. We report the 𝝌2 fit statistic but note that it is 
less valuable as a measure of model fit given its tendency to inflate in large sample sizes (Hooper 
et al., 2008). 
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Limitations 
A limitation of this quantitative analysis is the use of self-reported adherence. Several methods 
allow assessment of ART adherence, but none is, as yet, considered the ‘‘gold standard’’ (Berg & 
Arnsten, 2006). Research in sub-Saharan Africa uses many measures, such as questionnaires, 
pharmacy reﬁll records, pill counts, visual analog scales, and electronic drug monitors. In most 
PMTCT and general HIV populations, self-report is used as an adherence measure due to its 
simplicity and low cost (Mills et al., 2006; Nachega et al., 2012). Nevertheless, it would be 
stronger to have an objective biomarker of adherence, such as viral loads, as the outcome. 
Mental health screening tools developed primarily in resource-rich setting may be less 
appropriate for sub-Saharan African settings (Tsai et al., 2013). Given the challenges associated 
with identifying culturally-specific cut-points for depression, anxiety, and PTSD, we included 
these symptoms as continuous variables in the final models. This choice recognizes that even 
when symptomology fails to meet a clinical diagnosis, it can lead to psychosocial effects that are 
important to consider in public health programming (Judd et al., 1998). Our brief mental health 
screener, HADS, may be a better measure for general distress than either anxiety or depression 
alone (Norton et al., 2013). 
 
G. Ethical Considerations 
The parent study received approval from the Wits Human Research Ethics Committee (HREC-
M121179) and WHO Ethics Research Committee (ERC-RPC471), found in Appendix B. 
Because this research is for degree purposes, a full HREC approval for secondary analysis was 
obtained (HREC M140451), found in Appendix A.  
 All research was conducted along the principles of informed written consent, with 
additional written consent provided for granting permission to digitally record qualitative 
interviews. Paper-based data regarding IPV and HIV (participant structured questionnaires, 
qualitative reflection notes) were stored separate to identifying information (participant follow-up 
information, socio-demographics data) and kept in a locked file cabinet kept in a locked study 
office. Data and identifying information were linked using unique participant identifier numbers. 
Electronic data (systematic review abstraction, transcription of qualitative data, abstraction of 
quantitative data) were stored in password-protected computers and online in an encrypted server 
that could only be accessed by study investigators. 
All researchers involved in the study had been trained in research ethics prior to 
commencing study activities. Given the special considerations of researching violence, all 
portions of this study adhered to the WHO ethical guidance on IPV research (WHO, 2001). The 
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parent study also established two teams for monitoring the safety of the research. The Data Safety 
Monitoring Board examined data at study midpoint, to determine whether it is in the best interest 
of participants to continue. The Study Advisory Committee was comprised of South African 
experts in IPV who have guided the intervention and research since inception.  
Three additional ethical concerns merit attention. First, there was risk associated with loss 
to reputation or stigma should a participant’s IPV or HIV status be intentionally or 
unintentionally disclosed. In response to these reputational ethical concerns, we built in a number 
of special precautions: 
- We identified a private room in each clinic where women will be screened and interviewed. 
Women were invited to meet with the Nurse Researcher at the clinic. All efforts were made to find 
a time that is safe and convenient for them. For example, if a male partner expected a woman to 
return quickly from clinic, we found an alternate convenient time to continue the questionnaire. 
- The male partners were not informed about a woman's participation in the research because of 
the potential for an abusive partner to react violently. In the case of phoning participants, and the 
risk that partners will hear them, Nurses were trained to ask “is this a safe time to speak?” before 
continuing. 
- The research was presented broadly so that the specific nature of the study was not made public. 
The title of the research was neutral “Safe & Sound”, rather than calling it a study about 
violence. Only when the participant and interviewer were alone did the qualitative researcher 
provide further information about the nature of the study.  
- All data collection materials were stored in a locked file cabinet and computers will be password 
protected to minimize the risk to participant confidentiality.  
Second, it was possible that participants would experience psychological distress related 
to recounting IPV experiences. Findings elsewhere (DePrince & Freyd, 2004; Griffin et al., 2003; 
Jorm et al., 2007) suggest the risk of distress associated with asking women about violence is 
low, and in the South African setting, risk of psychological distress is minimized if researchers 
conducting the interviews are trained to respond (Sikweyiya & Jewkes, 2012). Indeed discussing 
traumatic experiences with supportive providers can be therapeutically beneficial (Jansen et al., 
2004; Savell et al., 2006), whereas ignoring or disconfirming experience of abuse can lead to 
future psychopathology (Rieker & Carmen, 1986; Warshaw et al., 1998). Nonetheless, we 
established several mechanisms to protect participants from potential harm related to 
participation:  
- We hired a team of dedicated Nurse Researchers who participated in intensive initial and ongoing 
training. The training incorporated personal reflection, role plays, group activities on several 
topics (background of IPV, triggers of IPV in pregnancy, HIV-IPV link, resources, referral 
procedures, reporting requirements, empathic listening skills, best practice patient follow-up). A 
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dedicated Referral List developed for the trial during the formative research phase was used to 
guide onwards referrals (Appendix C). 
- We developed a distress protocol specific to women experiencing IPV. Basic elements of the 
distress protocol were employed during most interviews included in this study: a calm, non-
judgmental approach to inquiry; watching for signs of resistance when inquiring about violence to 
avoid re-traumatisation; offering tissues if participants cried; offering a break from the interview. 
In cases of severe distress, researchers were trained to invite participants to stop the interview, a 
technique that was used with one participant, and to offer supportive referrals. In the case of 
current suicidal thinking, researchers were trained to make a direct referral to a psychiatric ward 
of the nearest hospital. In this sample, no participants revealed current suicidal thinking but 
several participants recounted a history of suicidal ideation, for which researchers offered 
empathetic listening and referrals to a nearby community psychology counseling service. 
With these precautions in place, we found that the temporary difficulty in discussing sensitive 
topics led to minimal psychological harm on the part of participants. 
Lastly, there were important ethical considerations regarding the researchers themselves. 
Research on IPV is known to place researchers at risk of vicarious trauma, or the process when a 
researcher or therapeutic professional moves from a position of empathizing with a participant’s 
experience towards taking it on personally (Pearlman & Saakvitne, 1995). Because IPV is 
necessarily a traumatic event, researchers studying this topic are regularly exposed to traumatic 
material and need tools to adapt and respond to this exposure (Campbell 2002, Morrison 2007). 
Together with the Co-Principal Investigator on the trial, who is a clinical psychologist 
specializing in trauma, I developed an approach to ensure that research staff were able to be 
resilient to vicarious trauma throughout the trial. Specifically, our team implemented the 
following procedures, which have been incorporated into Guidelines for the prevention and 
management of vicarious trauma among researchers of sexual and intimate partner violence 
(Sexual Violence Research Initiative, 2015) : 
- In initial training, all staff were trained around recognizing symptoms of vicarious trauma, stress, 
and burn-out (Coles et al., 2014) 
- We used a team approach to debriefing through weekly meetings with the entire team to discuss 
difficult cases, take note of IPV treatment approach, debrief challenges, and share professional 
impact of the work. This was coupled with consistent check-ins with managers and colleagues 
which occurred informally at multiple time-points each week (Hatcher et al., 2015a). 
- We created a fund within our project to give researchers access to dedicated providers who could 
offer professional supervision (a psychologist or social worker) (Woollett & Hatcher, 2016). In 
practice fewer than half of the team members accessed this, but it was a resource that I accessed 
throughout the PhD. 
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These steps cannot ensure that vicarious trauma is eliminated altogether, but they assisted 
in enhancing staff resilience around the emotional burn-out associated with IPV research. A 
positive by-product of focusing on staff coping and supervision strategies was that our research 
team developed quite cohesive approaches to supporting one another. Ultimately, this was 
strategic for ensuring staff wellbeing and safety, but also for ensuring research quality.
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A. Introduction 
Advances in HIV care and treatment have led to remarkable health gains among those living with 
HIV. Yet, many HIV-positive patients remain out of care, fail to take up treatment, or are non-
adherent to antiretroviral therapy (ART). Such challenges with engagement in HIV are common 
among females (Lazo et al., 2007; Merenstein et al., 2008), and are responsible for a considerable 
proportion of morbidity and mortality among HIV-positive women (Poundstone et al., 2001; 
Sackoff et al., 2006).  
There are a number of reasons for poor engagement in HIV care, among which intimate 
partner violence (IPV) has received increasing attention. IPV is defined as any behavior within an 
intimate relationship that causes physical, psychological or sexual harm (WHO, 2007), and global 
prevalence among women is estimated to be 30% (Devries et al., 2013b). IPV is associated with 
HIV infection in cross-sectional (Maman et al., 2002) and prospective studies (Jewkes et al., 
2010; Kouyoumdjian et al., 2013). A meta-analysis of data from 28 studies showed that multiple 
forms of IPV are associated with incident HIV infection in women (Li et al., 2014). Research 
points to direct links between IPV and HIV infection, via forced sex, as well as indirect links, via 
heightened HIV risk among IPV perpetrators and a reduced ability for women in violent 
relationships to negotiate condom use (Decker et al., 2009; Dunkle & Decker, 2013; Stockl et al., 
2013b).  
Despite this emerging literature around HIV acquisition, less is known about the 
influence of IPV for those already living with HIV. Evidence suggests that women living with 
HIV have a high likelihood of relationship violence. Clinical samples from resource-rich settings 
estimate that 68-95% of HIV-positive women experience IPV in their lifetime (Borwein et al., 
2013; Brady et al., 2002; Cohen et al., 2000; Sowell et al., 2002; Vlahov et al., 1998). In 
resource-constrained settings, HIV-positive women are twice as likely as HIV-negative 
counterparts to report lifetime violence from a partner (Fonck et al., 2005). HIV diagnosis, in 
itself, can trigger relationship conflict and violence (Ezechi et al., 2009; Pence et al., 2007; 
Sowell et al., 2002; Zierler et al., 2000). Importantly, HIV testing, regardless of the serostatus 
outcome, can lead to violence (Hatcher et al., 2013; Shamu et al., 2014), suggesting that even this 
first step in accessing care and treatment may pose an IPV risk. 
IPV leads to declines in HIV-related health, with studies finding an association between 
IPV and virologic failure (Nava et al., 2011; Schafer et al., 2012), lower CD-4 counts (Schafer et 
al., 2012), higher incidence of opportunistic infection (Liebschutz et al., 2000; Nava et al., 2011), 
marked increase in episodic diseases (e.g. pneumonia, bronchitis, sinusitis) (Liebschutz et al., 
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2000), and greater risk of mortality (Weber et al., 2012). Negative effects on engagement in care 
and treatment may be a leading reason for IPV being associated with poor health outcomes for 
HIV-infected women.  
Several plausible mechanisms could drive the relationship between IPV and HIV-related 
engagement in care. Fear of new or continued IPV leads women to avoid disclosure of their status 
to male partners (Makin et al., 2008; Mepham et al., 2011; Tam et al., 2015), which in turn has a 
significant impact on treatment adherence (Bajunirwe et al., 2009; Medley et al., 2004; Wouters 
et al., 2009). When women are fearful of violence from their partners, they may be more likely to 
default on medications or may have other health priorities, such as physical safety, that trump 
adherence (Hatcher et al., 2014). Qualitative studies have explored how fear and experience of 
IPV influence women’s decisions to take up and stay retained in HIV services (Antelman et al., 
2001; Hatcher et al., 2014; Kilewo et al., 2001). Given the well-established links between IPV 
and mental health (Chandra et al., 2009; Ellsberg et al., 2008; Ishida et al., 2010; Mahenge et al., 
2013; Martinez et al., 2009; Pico-Alfonso et al., 2006), it is possible that poor mental health is the 
main explanation for how IPV impacts on ART adherence (Ammassari et al., 2004; Cook et al., 
2002; Starace et al., 2002; Sumari-de Boer et al., 2011). Alternately, feelings of denial and shame 
may preclude abused women’s abilities to seek care openly (McCauley et al., 1998), or partner 
control may inhibit access to medical care (Lichtenstein, 2006). 
Despite health risks associated with IPV among HIV-infected persons, IPV remains an 
understudied factor in the literature around HIV care and treatment (Gari et al., 2013). Evidence 
on the association between IPV and adherence has yet to be reviewed systematically. This study 
examined the relationships between IPV and engagement in HIV care and treatment (ie. ART 
uptake, ART adherence measured through self-report or by viral loads, and retention in HIV care) 
through a systematic review and meta-analysis. 
 
H. Methods 
A systematic review and meta-analyses were conducted on studies measuring an association 
between IPV and ART use, ART adherence (self-reported), ART adherence (viral suppression), 
and retention in HIV. The aim was to determine the extent to which IPV is related to engagement 
in HIV care and treatment among women.  
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Selection criteria 
This review follows PRISMA reporting guidelines for systematic reviews (see Table 4) (Moher et 
al., 2009). Studies were eligible for inclusion if they: 1) included adult women living with HIV; 
2) presented primary, quantitative data in a peer-reviewed manuscript based on cross-sectional, 
case control, or longitudinal data; and 3) measured the predictor of interest (IPV) and at least one 
outcome of interest. No restrictions were placed on study setting or population.  
Search strategy 
Electronic searches were conducted using the following databases: PubMed, Web of Science, 
CINAHL, and PsychoInfo. Articles in 
English or French were included if they 
had been published in peer-reviewed 
journals before or up to January 2015. 
Search terms and a full search strategy 
can be found in Chapter 3: Methodology.  
Study selection 
Using the “online search” function of 
EndNote (Reuters, 2011), all titles and 
abstracts matching the search terms were 
imported. Two authors (AMH, EMS) 
independently reviewed all identified 
study titles and abstracts. Papers were 
retained if at least one search term for 
predictor or outcome concept was found. 
Abstracts that did not meet all inclusion 
criteria were excluded and reason for 
exclusion noted. Exclusion criteria 
included publication factors and 
population characteristics (Figure 12).  
The same authors (AMH, EMS) 
independently screened full papers of all 
included abstracts. Full papers with 
discrepancy about inclusion were 
Text S2. Search Terms 
 
Constructs Search terms 
Intimate partner violence  
 
Keywords: "emotional abuse" OR "violence" OR "acquaintance rape" 
OR "sexual abuse" OR "domestic violence" OR "exposure to violence" 
OR "battered females" OR "intimate partner violence" OR "rape" OR 
“battered wom*n” OR “domestic abuse” OR “family violence” OR “family 
abuse” MESH terms: domestic violence OR partner violence OR 
battered OR spouse abuse OR spouse violence OR domestic abuse 
OR partner abuse OR sexual abus* OR sexual victimi* OR sexual 
violence OR rape 
HIV treatment 
 
Keywords: hiv" OR hiv infect* OR human immunodeficiency virus OR 
hiv-1 OR hiv-2 OR "aids" OR "antiviral drugs" OR "drug therapy" OR 
antiretroviral 
MESH terms: hiv/ OR hiv 1/ OR hiv 2 antiretroviral OR antiretroviral 
therapy, highly active OR zidovudine OR nevirapine 
Adherence and retention 
 
Keywords: adheren* OR complian* OR persisten* OR loss to follow-up 
OR LTFU OR retention OR missed visit* OR interruption OR linkage 
OR treatment failure OR "continuum of care" 
MESH terms: medication non adherence/ or adherence/compliance/ 
OR adherence/non adherence/ OR adherence/persistence/ OR 
adherence/pill taking/ OR adherence challenges/ OR adherence 
behaviours/ OR Lost to Follow-Up OR Clinic visit$ OR visit$, clinic OR 
Failure$, Treatment OR Treatment Failures OR Disease Progression 
 
PubMed search strategy 
 
1. (domestic violence or partner violence 
or battered or spouse abuse or spouse 
violence or domestic abuse or partner 
abuse or sexual abus* or sexual victimi* 
or sexual violence or rape[MeSH 
Terms]) 
2. (hiv/ or hiv 1/ or hiv 2 antiretroviral or 
antiretroviral therapy, highly active or 
zidovudine or nevirapine[MeSH Terms]) 
3. (medication non adherence/ or 
adherence/compliance/ or 
adherence/non adherence/ or 
adherence/persistence/ or 
adherence/pill taking/ or adherence 
challenges/ or adherence behaviours/ or 
Lost to Follow-Up or Clinic visit$ or 
visit$, clinic or Failure$, Treatment or 
Treatment Failures or Disease 
Progression[MeSH Terms]) 
4. 1 and 2 and 3 
 
Web of Science search strategy 
 
1. "emotional abuse" OR "violence" OR 
"acquaintance rape" OR "sexual abuse" 
OR "domestic violence" OR "exposure 
to violence" OR "battered females" OR 
"intimate partner violence" OR "rape" 
2. "hiv" OR hiv infect* OR human 
immunodeficiency virus OR hiv-1 OR 
hiv-2 OR "aids" OR "antiviral drugs" OR 
"drug therapy" OR antiretroviral 
3. adheren* OR complian* OR persisten* 
OR loss to follow-up OR LTFU OR 
retention OR missed visit* OR 
interruption OR linkage OR treatment 
failure OR "continuum of care" 
4. 1 and 2 and 3 
 
PsycInfo search strategy 
 
1. su.Exact("emotional abuse" OR 
"violence" OR "acquaintance rape" OR 
"sexual abuse" OR "domestic violence" 
OR "exposure to violence" OR "battered 
females" OR "intimate partner violence" 
OR "rape") 
2. su.Exact("hiv" OR "aids" OR "antiviral 
drugs" OR "drug therapy") 
3. su.Exact("health care utilization" OR 
"retention" OR "compliance" OR 
"persistence" OR "treatment" OR 
"medication" OR "continuum of care") 
4. 1 and 2 and 3 
 
CINAHL search strategy 
 
1. MW ( ("spousal abuse" OR "battered 
women" OR "emotional abuse" OR 
"violence" OR "acquaintance rape" OR 
"sexual abuse" OR "domestic violence" 
OR "exposure to violence" OR "battered 
females" OR "intimate partner violence" 
OR "rape") )  
2. MW ( "hiv" OR "aids" OR "antiviral 
drugs" OR "drug therapy" )  
3. MW ( "health care utilization" OR 
"retention" OR "compliance" OR 
"persistence" OR "treatment" OR 
"medication" OR "continuum of care" )  
4. 1 and 2 and 3 
Figure 13. Search terms 
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reviewed by a third author (HS) to reach consensus. Exclusion reasons were noted. No additional 
study was identified by searching the reference lists of included articles.  
Figure 10. Flow diagram 
Data extraction 
Data were extracted on study design, setting, population, sample size, measures used to 
investigate IPV, and measures used to assess engagement in HIV care. As meta-analysis required 
data from among women only and in dichotomous outcomes, authors of several papers (n=7) 
were contacted directly via email and asked to abstract 2x2 tables in Excel: numbers of women 
reporting IPV vs. not and reporting engagement in care vs. not. Authors of all seven papers 
requiring additional information were willing and able to provide these data. 
Original Search
n=757
Duplicates
n=136
Title / Abstract Screening
n=621
• Non-peer review (1)
• No analysis (29)
• Pop <18 years (43)
• Men only (20)
• Childhood Sexual 
Abuse only (40)
• Adherence to non-HIV 
medication (7)
• Adherence/uptake of 
post-exposure prophy-
laxis (49)
• Qualitative (31)
• Irrelevant (eg. animal 
research) (313)
Full Text Review
(up to January 2015)
n=75
• TOTAL Excluded (62)
• No primary data (36)
• Lacked predictor or 
outcome of interest 
(51)
• IPV measured as com-
posite with other types 
of violence (7)
• No women studied (3)
• Paper unavailable (0)
ART Adherence 
(Self-Report)
n=7
ART Uptake
n=5
• PubMed (133)
• Web of Sci (459)
• PsycInfo (86)
• CINAHL (79)
Retention in HIV Care
n=5
* 5 studies examined more than one outcome
ART Adherence 
(Viral Load Suppression)
n=7
Included
n=13*
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Quality appraisal 
A quality appraisal was conducted on all included studies using an adapted Critical Appraisal 
Skills Programme (CASP) quality appraisal tool (Table 2 in Chapter 3) (Oram et al., 2012). The 
quality appraisal form includes 15 questions about study quality for which papers received a 
numeric score representing the extent to which they met the criteria: 0 (non responsive), 1 
(partially responsive), or 2 (fully responsive).  
Data analysis 
Meta-analyses were conducted separately for dichotomous engagement in care outcomes. 
Dichotomous outcomes were deemed appropriate since key outcomes of interest were either 
inherently dichotomous (i.e. current ART use) or represented non-normally distributed 
continuous data (i.e. adherence, viral suppression). An assessment was made by the authorship 
team to ensure that “clinical heterogeneity” was acceptable to lend each outcome to meta-analysis 
(Deeks et al., 2008).  
Quantitative outcomes were extracted into an Excel table. This included details on overall 
IPV prevalence in the study, cases and non-cases among women with IPV and without IPV, and 
correlation coefficients. Pooled unadjusted odds ratio (OR) estimates (with corresponding 95% 
confidence intervals) were calculated using random effects meta-analysis in STATA (Harris et 
al., 2008). No adjustment was made for potential confounders, given that few studies reported 
covariate data. Heterogeneity among studies was estimated using the I2 statistic, with significant 
heterogeneity detected at the p<0.05 level. Sensitivity analysis for publication bias was 
undertaken through visual inspection of funnel plots (Sterne & Harbord, 2004) and Egger’s test 
statistic (with small-study effects being detectable at a conservative p<0.10 level) (Egger et al., 
1997). To aid comparison with other systematic reviews, the self-reported adherence outcome 
was transformed to a standardized mean difference (Chinn, 2000). 
 
I. Results 
Our search strategy identified 621 unique records, of which 554 were excluded during abstract 
screening (Figure 13). Full texts were obtained for 75 papers, of which 62 were excluded upon 
further screening. A total of thirteen studies measured the association between IPV and at least 
one of the primary outcomes: ART uptake, ART adherence (self-report), ART adherence (viral 
suppression), and retention in HIV care. 
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Key features of included papers  
Table 8 presents the key characteristics and outcomes of the thirteen included studies (Blackstock 
et al., 2015; Blank et al., 2015; Illangasekare et al., 2012; Kalokhe et al., 2012; Lopez et al., 2010; 
Malow et al., 2013; Ramachandran et al., 2010; Rose et al., 2010b; Ryerson Espino et al., 2015; 
Schafer et al., 2012; Siemieniuk et al., 2013b; Sullivan et al., 2015; Trimble et al., 2013). Most 
studies (n=11) were conducted in the United States and sample sizes across all studies were 
relatively small, with a median of 234 participants. All thirteen studies were cross-sectional. Most 
studies (n=12) were conducted among the general HIV-infected population, with Kalokhe et al. 
conducting their study among high-risk crack/cocaine users.  
Measures of Intimate Partner Violence 
Measures of IPV were based on self-reports across all thirteen studies. As shown in Table 1, 
several studies used brief, unvalidated screening tools to assess violence (Illangasekare et al., 
2012; Malow et al., 2013; Ramachandran et al., 2010; Rose et al., 2010b). Validated instruments 
included the Severity of Violence Against Women Scale (Schafer et al., 2012; Trimble et al., 
2013), the Conflict Tactics Scale (Lopez et al., 2010), the Slapped, Threatened, and Throw 
instrument (Kalokhe et al., 2012), and the Women’s Experience of Battering (WEB) scale 
(Blackstock et al., 2015; Ryerson Espino et al., 2015; Schafer et al., 2012; Sullivan et al., 2015). 
Ryerson Espino (2015) bolstered the WEB scale to include dimensions of forced sex and fears 
around physical safety. Siemieniuk (2010) trained clinic researchers to conduct a standardized 
screening using a single introductory question about any domestic abuse, after which women 
were considered to have IPV if they spoke in a semi-structured way about violence within a 
current or past relationship.  
Eleven studies used lifetime experience of IPV as the exposure of interest, whereas two 
analyzed IPV in the past 12 months (Illangasekare et al., 2012; Trimble et al., 2013). Although 
several other papers included measures of recent violence (past 12 months (Lopez et al., 2010; 
Ryerson Espino et al., 2015); past 5 months (Ramachandran et al., 2010)), the authors did not 
conduct analysis using the “recent violence” data.  
Ethical considerations 
Quality scores are reported in Table 8. All studies reported informed consent procedures and 
ethical review. However, Siemieniuk and Schafer were the only authors to detail specific steps 
taken by clinicians when women disclosed IPV (Schafer et al., 2012; Siemieniuk et al., 2013b). 
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Table 7. Characteristics of included papers (n=13) 
Author Year 
Sample 
size 
(women) 
Population 
group  
Type of 
study Violence Measure Outcome of interest  Country 
CASP 
Quality 
Appraisal Type of IPV Measure 
Blackstock 2015 748 Women only 
Cross-
sectional 
10 item Women's 
Experience of 
Battering  (WEB) 
Scale 
Retention (medical 
records) 
United 
States 20 
Ever, Physical and 
Psychological 
Blank* 2015 587 Women only 
Cross-
sectional 10 item (WEB) Scale 
Uptake (medical 
records), Adherence 
(self-report and viral 
suppression), Retention 
(medical records) 
United 
States 20 
Ever, Physical and 
Psychological 
Illangasekare 2012 196 Women only 
Cross-
sectional 
3 items from the 
Partner Violence 
Screen 
Uptake (medical 
records), Adherence 
(viral suppression) 
United 
States 16 
Past 12 months, Asked 
at 1 timepoint, 
Physical, 
Psychological 
Kalokhe* 2012 175 
Women & Men 
(Crack/cocaine 
users, total 343) 
Cross-
sectional 
5 items from the 
Slapped, Threatened, 
and Throw (STaT) 
instrument 
Uptake (self-report), 
Retention  (medical 
records) 
United 
States 18 
Ever, Physical, Sexual, 
Psychological 
Lopez* 2010 94 
Women & Men 
(total 190) 
Cross-
sectional 
17 item Conflict 
Tactics Scale Adherence (self-report) 
United 
States 20 
Ever, Past 12 months, 
Physical, Sexual, 
Psychological 
Malow* 2013 166 
Women & Men 
(total 194) 
Cross-
sectional 
4 items from 
(unnamed) partner 
relationship scale Adherence (self-report) Haiti 20 
Ever, Physical, 
Psychological 
Ramanchandran 2010 18 
Women & Men 
(total 56) 
Cross-
sectional 
3 items of Abuse 
Assessment Screen Uptake (self-report) 
United 
States 14 
Ever, Past 5 months, 
Physical, Sexual, 
Psychological 
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Rose* 2010 40 Women only 
Cross-
sectional 
1 item from Traumatic 
Life Events 
Questionnaire 
Adherence (self-report 
and viral suppression) 
United 
States 15 Ever, Physical 
Ryerson 
Espino* 2015 102 Women only 
Cross-
sectional 
10 item (WEB) Scale 
plus 6 additional 
items on forced sex 
and fear 
Adherence (viral 
suppression) 
United 
States 22 
Ever, Past 12 months, 
Asked at multiple 
timepoints, Physical, 
Sexual, Psychological 
Schafer 2012 64 Women only 
Cross-
sectional 
46 item Severity of 
Violence Against 
Women Scale 
(SVAWS) instrument 
and 10 item WEB 
Scale 
Adherence (viral 
suppression), Retention 
(medical records) 
United 
States 20 
Ever, Physical, Sexual, 
Psychological 
Siemieniuk 2013 339 Women only 
Cross-
sectional 
Rich single-item 
screening question, 
assessed by 
interviewer as 
physical abuse,sexual 
abuse, emotional 
abuse, isolation, 
neglect, intimidation, 
and/or financial abuse 
Uptake (medical 
records), Adherence 
(viral suppression), 
Retention (medical 
records) 
United 
States 22 
Ever, Physical, Sexual, 
Psychological 
Sullivan* 2015 564 Women only 
Cross-
sectional 10 item WEB Scale 
Adherence (viral  
suppression) 
United 
States 22 
Ever, Physical, 
Psychological 
Trimble 2013 272 Women only 
Cross-
sectional 
46 item SVAWS 
instrument Adherence (self-report) 
United 
States 21 
Past 12 months, 
Physical, Sexual 
 
* Authors contacted for raw data on outcomes of interest. 
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Current ART use 
Five studies measured current ART use. Three studies used self-report of a single question (“are 
you currently on ART?”) to assess ART use at time of interview (Blackstock et al., 2015; 
Kalokhe et al., 2012; Ramachandran et al., 2010). Two assessed current ART use via clinical data 
routinely collected in the HIV clinic (Illangasekare et al., 2012; Siemieniuk et al., 2013b).  
No individual studies found a statistically significant relationship between IPV and 
current ART use among women. Siemieniuk found that participants who experienced IPV were 
more likely to report ART non-use, but this association did not reach statistical significance 
(p=0.069) (Siemieniuk et al., 2013b). Kalokhe found lower current ART use among 343 male and 
female cocaine users who had ever experienced IPV (p=0.001), but this relationship was not 
significant among women alone (Kalokhe et al., 2012). Ramachandran found that men and 
women reporting a history of IPV were less likely to be using ART (66%) than non-abused 
counterparts (93%, p=0.04), but data were not available among women only (Ramachandran et 
al., 2010). Illangesekare found no significant association between experience of lifetime IPV and 
ART use in a sample of 196 HIV-infected women (risk ratio [RR]=0.73, 95% confidence interval 
[CI] 0.39–1.42) (Illangasekare et al., 2012). Blank found no significant relationship between 
lifetime IPV and ART use (RR=1.01, 95%CI 0.88–1.16) (Blackstock et al., 2015).  
ART adherence measured by Self-report  
Six studies included self-reported measures of ART adherence. Two used the AIDS Clinical 
Trials Group Questionnaire, which measures good adherence as greater than 90% in the past 3-
days and 30-days (Lopez et al., 2010; Ryerson Espino et al., 2015). Trimble used an adaptation of 
the Morisky Medication Adherence Scale (Trimble et al., 2013), in which good adherence was 
defined as scores of 7 or higher. Participants in Malow’s study noted the percentage of time they 
took medicine as prescribed, with good adherence defined as 95% or greater (Malow et al., 2013). 
Blank used the Case Adherence Index (CAI), dichotomized into poor adherence (=<10) or good 
adherence (>10) (Blackstock et al., 2015). Rose asked the patient’s physician to rate on a scale of 
0-10 how adherent they believed the patient to be, with good adherence assessed as >=9 (Rose et 
al., 2010b). 
Of the seven studies that assessed ART adherence using self-report, three found 
significant outcomes among women. Trimble found that mean adherence scores on the MMAS 
were significantly lower among women who reported IPV (M=5.49, SD=2.06) than among those 
without (M=6.57, SD=1.57, p<0.001) (Trimble et al., 2013). Using a dichotomous outcome, this 
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translated to lower odds of good adherence among women reporting IPV (OR=0.28, 95%CI 0.17-
0.47). Rose found poorer adherence among women with IPV as measured by the continuous 
outcome of physician-reported scale (r=-0.38, p<0.05) (Rose et al., 2010b). As a dichotomous 
outcome, women with IPV had lower odds of good adherence (OR=0.15, 95%CI 0.03-0.70). 
Blank et al. found self-reported adherence was significantly worse among women who reported 
IPV (RR=0.74, 95%CI 0.72–0.88) (Blackstock et al., 2015). Lopez found that among women, 
“extreme IPV” (e.g. use of a weapon) was associated with decreased adherence as a continuous 
variable (r=-0.26, p=0.026) (Lopez et al., 2010). When using “any IPV” as the exposure of 
interest, Lopez did not find a significant difference (OR=0.45, 95%CI 0.15-1.29). Ryerson Espino 
did not find a significant association, with a similar proportion of women reporting good 
adherence with (36.1%) and without IPV (40.0%) (Ryerson Espino et al., 2015). Malow did not 
find a significant direct association between IPV and non-adherence, but when using structural 
equation modeling, did find that partner conflict led to depression, which in turn was related to 
non-adherence (Malow et al., 2013).  
ART adherence measured by Viral Load 
Seven studies assessed adherence using patient medical records of viral load suppression. 
Dichotomized outcomes for viral load suppression used the clinically-relevant cut-off at the time 
of study: 500 copies/mL (Siemieniuk et al., 2013b), 400 copies/mL (Illangasekare et al., 2012) 
and 200 copies/mL (Blackstock et al., 2015; Blank et al., 2015; Rose et al., 2010b; Ryerson 
Espino et al., 2015; Sullivan et al., 2015).  
Of the seven studies measuring viral load suppression, three found a significant 
association with IPV. Siemieniuk found that women experiencing IPV were more likely to have 
viral loads greater than 500 copies/mL than IPV-negative counterparts (p=0.027) (Siemieniuk et 
al., 2013b). Rose et al. also found a significant association, with the frequency of IPV related to 
increased HIV viral load (r=0.44, p<0.01) (Rose et al., 2010b). Espino found viral load 
suppression significantly lower among women reporting IPV (76.4%) than their counterparts 
(93.3%, X2=4.01 p<0.05) (Ryerson Espino et al., 2015). Illangesekare found no significant 
association between viral load of >400 copies/mL among those with IPV (59.6%) or without IPV 
(61.8%) (Illangasekare et al., 2012). Odds ratios reported in Blank, Schafer, and Sullivan were 
non-significant ((OR=1.05, 95%CI 0.65-1.70); (OR=1.14, 95%CI 0.42-3.07); (OR=0.72, 95%CI 
0.47-1.10), respectively).  
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Retention in HIV care 
Five studies measured retention in HIV care. Blackstock and Blank defined retention by any 
self-reported HIV medical care in the past 6 months (Blackstock et al., 2015; Blank et al., 2015). 
Kalokhe used self-report and asked participants “In the past 12 months have you gone to a doctor 
or clinic for HIV care?” (Kalokhe et al., 2012). Siemieniuk used patient medical records and 
defined poor retention in care as ever having had an interruption in clinical care greater than 365 
days (Siemieniuk et al., 2013b). Schafer classified patients as having a high clinic no show rate 
(NSR >=33% missed visits) and low NSR (<33% missed visits) (Schafer et al., 2012). Because 
these retention measures have important conceptual differences, they were deemed too 
heterogeneous to lend this outcome to meta-analysis. 
Siemieniuk found that interruptions in clinical care were more common among women 
with a history of IPV (20.4% vs 11.9%, p=0.032) (Siemieniuk et al., 2013b). Kalokhe found that 
IPV positive participants were more likely to be out of care in the past 12 months (29.4 vs 18.8%, 
p=0.01) (Kalokhe et al., 2012). Neither Blackstock nor Blank found a significant relationship 
between IPV and any self-reported medical care in the past 6 months (OR=0.92 (0.68-1.24)) 
(Blackstock et al., 2015). Schafer found no significant relationship between IPV and a high no 
show rate among women (OR=1.11 (0.27-4.60) (Schafer et al., 2012). 
Meta-analysis of 
engagement in care 
outcomes 
Meta-analysis suggests that 
IPV is associated significantly 
with lower odds of current 
ART use (Fig. 14; OR=0.79, 
95%CI 0.64-0.97). However, 
since the extant literature 
shows heterogeneity 
(I2=68.9%, p=0.012), this 
finding should be interpreted 
cautiously.  
Heterogeneity between groups: p = .
Overall  (I−squared = 67.4%, p = 0.015)
Citation
Illangesekare (2012)
Blank (2015)
Subtotal  (I−squared = 67.4%, p = 0.015)
Ramachandran (2010)
Kalokhe (2012)
Siemieniuk (2013)
Current ART Use
ART Use
Current ART Use
Current ART Use
Current ART Use
Current ART Use
Current ART Use
Current
0.79 (0.64, 0.97)
OR (95% CI)
1.48 (0.65, 3.34)
0.98 (0.73, 1.30)
0.79 (0.64, 0.97)
0.14 (0.02, 1.16)
0.47 (0.29, 0.75)
0.65 (0.41, 1.03)
100.00
Weight
6.55
52.37
100.00
0.96
19.44
20.69
%
  
1.4 2
Figure 15. Meta-analysis of IPV and ART Use 
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The meta-analytical 
association suggests that 
IPV is associated with 
lower odds of self-
reported adherence (Fig. 
15; OR=0.48, 95%CI 
0.30-0.75). Self-reported 
adherence also shows 
significant heterogeneity 
(I2=56.0%, p=0.044). To 
compare this outcome to 
other studies, the odds 
ratio was transformed into 
an effect size 
(standardized mean difference d=-0.404). 
There is a significant meta-analytic association between IPV and worsened viral load 
suppression (Fig. 15; OR=0.64, 95%CI 0.46-0.90), with acceptable level of agreement across 
studies (I2=41.2%, p=0.116).  
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTE: Weights are from random effects analysis
.
Overall  (I−squared = 56.0%, p = 0.044)
Blank (2015)
Trimble (2012)
Self−reported Adherence
Espino (2015)
Rose (2010)
Subtotal  (I−squared = 56.0%, p = 0.044)
Malow (2013)
Lopez (2010)
Citation
Self−reported Adherence
Self−reported Adherence
Self−reported Adherence
Self−reported Adherence
Self−reported Adherence
Self−reported Adherence
Adherence
ART
0.48 (0.30, 0.75)
0.47 (0.31, 0.73)
0.28 (0.17, 0.47)
0.85 (0.35, 2.03)
0.15 (0.03, 0.70)
0.48 (0.30, 0.75)
0.99 (0.46, 2.14)
0.45 (0.15, 1.29)
OR (95% CI)
100.00
25.72
23.84
14.91
6.71
100.00
16.97
11.85
Weight
%
  
1.4 2
NOTE: Weights are from random effects analysis
.
Overall  (I−squared = 41.2%, p = 0.116)
Sullivan (2015)
Rose (2010)
Espino (2015)
Siemieniuk (2013)
Subtotal  (I−squared = 41.2%, p = 0.116)
Illangesekare (2012)
Schafer (2012)
Blank (2015)
Viral suppression
Citation
Viral load
Viral suppression
Viral suppression
Viral suppression
Viral suppression
Viral suppression
Viral suppression
Viral suppression
suppression
0.64 (0.46, 0.90)
0.63 (0.43, 0.92)
0.04 (0.00, 0.37)
0.23 (0.05, 1.07)
0.58 (0.36, 0.94)
0.64 (0.46, 0.90)
0.91 (0.48, 1.74)
0.88 (0.33, 2.37)
0.82 (0.49, 1.37)
OR (95% CI)
100.00
%
26.18
2.20
4.30
21.76
100.00
16.01
8.91
20.65
Weight
  
1.4 2
Figure 16. Meta-analysis of IPV and self-reported ART adherence 
Figure 17. Meta-analysis of IPV and viral load suppression 
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All meta-analyses were visually inspected for potential publication bias through funnel plots and 
Egger’s test for small-study effects. There was no evidence of publication bias for current ART 
use (Fig. S1; P=0.486), self-reported adherence (Fig. S2; P=0.859), or viral suppression (Fig. S3; 
P=0.176). 
 
 
 
 
 
 
 
Fig 18. Funnel plot: ART use              Funnel plot: self-reported adherence    Funnel plot: viral suppression 
 
J. Discussion 
Uptake and adherence to ART is a key pathway through which IPV may negatively influence 
HIV-related health of women globally. Meta-analysis suggests that IPV reduces the odds of ART 
adherence among women, a finding that is consistent when adherence is measured by self-report 
(OR=0.48, 95%CI 0.30-0.75) or viral load suppression (OR=0.64 95%CI 0.46-0.90). Adherence 
offers a potential explanation for why IPV has been linked to worsened clinical outcomes among 
HIV-positive women (Liebschutz et al., 2000; Nava et al., 2011; Schafer et al., 2012; Weber et 
al., 2012). The meta-analytic effect size suggests that IPV exhibits a greater magnitude of 
association with ART adherence (d=-0.404) than other conditions such as depression, substance 
use, stigma, financial constraints, or pill burden (Langebeek et al., 2014).  
The causal pathway between IPV and engagement in HIV care and treatment is supported 
by related trauma literature. Mugavero et al. found that each additional episode of lifetime trauma 
was related to non-adherence even when controlling for depression, substance use, and race 
(Mugavero et al., 2006). Cohen et al. found that a history of any type of physical or sexual abuse 
(including in childhood) increased the odds of women declining HAART when medically eligible 
(Cohen et al., 2004). These and other studies (Cohen et al., 2004; Dale et al., 2014; Jones et al., 
2010a; Liebschutz et al., 2005; Machtinger et al., 2012a; Mugavero et al., 2006; Mugavero et al., 
2009; Pence et al., 2008) were excluded from this systematic review because they analyzed IPV 
alongside other forms of violence (eg. childhood sexual abuse, non-partner violence). While such 
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an approach may be useful conceptually, it will be crucial for future studies to prioritize clear and 
consistent measurement of IPV as a stand-alone construct.  
The current evidence base on IPV and HIV care has several important gaps. Nearly all 
studies were conducted in the United States, limiting translation to other settings globally. This 
geographic skew, though consistent with broader IPV literature (O'Reilly et al., 2010; Shah et al., 
2010), warrants urgent attention since both HIV and IPV prevalence are high in regions such as 
sub-Saharan Africa (WHO, 2013a; WHO et al., 2013). The few sub-Saharan African studies that 
do examine IPV among HIV-positive patients draw from couples who jointly take part in research 
and may come from relationships that are distinct from ‘normal’ HIV-positive patients (Darbes et 
al., 2012; Were et al., 2011).  
Measures for retention in HIV care were too disparate to be analyzed systematically. This 
shortcoming is suggestive of weaknesses in conceptualization of HIV care retention, which 
continues to lack a ‘gold standard’ measurement method (Mugavero et al., 2012). We also found 
a lack of harmonization regarding the measurement of IPV, with comprehensive, validated 
measures employed in only three studies (Kalokhe et al., 2012; Lopez et al., 2010; Trimble et al., 
2013). Since behaviourally-specific assessment of IPV helps elucidate the connections between 
violence and health outcomes (Stockman et al., 2010), future research should employ 
comprehensive measures of IPV (Garcia-Moreno et al., 2006).  
Another gap relates to the clinical nature of responding to violence disclosure in the 
research setting. Only two authors detailed specific steps taken by clinicians when women 
disclosed IPV (Schafer et al., 2012; Siemieniuk et al., 2013b). This represents a significant 
oversight given the well-established guidance around how to conduct IPV research in a clinically 
meaningful and ethically responsible way (WHO, 2001, 2013b). 
A final research gap is the extant focus on the ‘general population’ of HIV-positive 
patients. It is possible that the association between violence and HIV-related outcomes may be 
distinct among other special populations (eg. adolescents, pregnant women, men who have sex 
with men, sex workers) and these sub-groups deserve attention in future research.  
 
Limitations 
There are several limitations of the current systematic review that should inform interpretation of 
findings. We focused the systematic review on HIV-positive women, but such a conceptualization 
should be followed by future work to understand IPV towards HIV-positive men. Literature 
included (Kalokhe et al., 2012; Lopez et al., 2010; Ramachandran et al., 2010) and excluded 
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(Gari et al., 2014; Mutasa-Apollo et al., 2014; Pantalone et al., 2010; Siemieniuk et al., 2013a) 
from this review illustrates that HIV-positive men experience challenges to engagement in care 
on par or in excess to those of women.  
Papers selected for final review have important limitations around comparability, given 
the variety of populations and sampling strategies used across the studies. There were no 
longitudinal studies included in this review, which suggests that meta-analytic findings can be 
viewed as a correlation but that IPV and engagement in care may not be causally related. 
Databases used may have inadvertently limited the search, although we attempted to compensate 
for this shortcoming by reviewing all citations included in the final set of full papers assessed 
(n=67). Interrater reliability was not formally assessed with regards to the selection of articles, 
but a third colleague was consulted to review any discrepancies in the inclusion/exclusion 
process.  
 
Conclusion 
In order to ensure HIV-related health among women, it is essential to address conditions that 
impact their ability to uptake and stay engaged in care and treatment. IPV is one such condition, 
and its association with declines in ART adherence requires urgent attention. Policy makers and 
programmers are beginning to recognize the central role that violence plays in the lives of women 
living with HIV (United States Government, 2013; USAID, 2009). Yet, despite calls for violence 
screening and intervention within HIV care and treatment programs, few HIV clinics have IPV-
specific protocols in place (Nakimuli-Mpungu et al., 2012). HIV care and treatment programs can 
draw upon existing guidelines for screening and responding to IPV in the health sector (Moyer, 
2013; WHO, 2013b), or can look to a growing number of specialist programs that address IPV 
alongside HIV (Machtinger et al., 2015; Turan et al., 2013; Wagman et al., 2015a; Wyatt et al., 
2011). To ensure that women benefit from medical advances, future studies should develop and 
test interventions to address IPV within HIV clinical care. 
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Introduction 
Prevention of mother-to-child transmission (PMTCT) has reduced new infant HIV infections 
from an estimated 32% in the absence of treatment (Coutsoudis et al., 1999; Miotti et al., 1999), 
to as low as 1% (Lehman et al., 2009; Mofenson, 2010b). However, major gaps to achieving 
PMTCT coverage remain. In 21 priority African countries, PMTCT coverage is estimated to be 
65% (WHO et al., 2013). A recent meta-analysis in low- and middle-income settings suggests 
that while 75% of pregnant women adhere to antiretroviral therapy (ART) during pregnancy, only 
53% maintain adequate adherence levels in the postpartum period (Nachega et al., 2012).  
Ensuring PMTCT adherence is crucial, particularly as countries increasingly move towards 
“Option B+”, a policy that offers immediate, lifelong treatment for pregnant women living with 
HIV (World Health Organization, 2010). 
Many structural drivers influence PMTCT uptake and adherence. The literature has noted 
that structural factors such as stigma (Bond et al., 2002; Bwirire et al., 2008; Mepham et al., 
2011; Turan et al., 2011; Turan & Nyblade, 2013; Watts et al., 2010), poverty (Mepham et al., 
2011), and transport costs (Bwirire et al., 2008) inhibit women’s ability to adhere to PMTCT. 
Another key structural factor shaping access and adherence to PMTCT may be intimate partner 
violence (IPV). Fear and experience of IPV influence pregnant women’s decisions to take up HIV 
services (Antelman et al., 2001; Kilewo et al., 2001), and anticipated violence is associated with 
declines in HIV testing among pregnant women (Bajunirwe & Muzoora, 2005a; Hatcher et al., 
2011; Maman et al., 2011a; Medley et al., 2004; Pool et al., 2001; Tchendjou et al., 2011; Turan 
et al., 2011; Turan et al., 2012). A history of physical or sexual violence decreases the likelihood 
of HIV-positive women using ART when medically eligible (Cohen et al., 2004; Jones et al., 
2010b), and those who experience abuse are more likely to miss clinic visits and delay linkage to 
care (Siemieniuk et al., 2010).  
Little research to date has explored the association between IPV and PMTCT. In one 
qualitative study in South Africa, IPV was described as a common barrier to ART adherence in 
pregnancy (Mepham et al., 2011). Healthy intimate partner relationships improve PMTCT 
uptake: male involvement in antenatal care predicted better adherence to nevirapine in one South 
African study (Peltzer et al., 2011); male antenatal attendance halved the risk of MTCT in a 
Kenyan study, an association that persisted after controlling for maternal viral loads (Aluisio et 
al., 2011).  
Using qualitative research methodology, we explored IPV as a potential structural driver 
of HIV-related health among pregnant women. This research aimed to contribute to literature 
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suggesting that structural drivers shape the health and well-being of those already living with 
HIV, and may pose barriers to uptake of proven prevention strategies. 
 
Methods  
We conducted qualitative research to explore the links between IPV and HIV-related health 
among pregnant women and service providers in Johannesburg, South Africa. This research was a 
portion of a larger formative study, intended to help our team design an intervention to address 
IPV in pregnancy. In this setting, an estimated 29% of pregnant women are HIV-infected 
(National Department of Health, 2012) and between 25-35% experience physical or sexual IPV in 
the 12 months leading up to pregnancy (Dunkle et al., 2004b; Groves et al., 2012; Hoque et al., 
2009; Mbokota & Moodley, 2003).  
 
Conceptual Framework 
In order to explore the relationship 
between IPV and HIV-related health 
of pregnant women, we used an 
adapted socio-ecological conceptual 
framework (Fig. 16), which posits that 
broader structural factors and 
relationship characteristics influence a 
woman’s HIV-related health 
(Montgomery et al., 2012). This type 
of approach has been embraced by 
social scientists, who note that broader 
social and societal factors shape how 
women are able to adhere to ART 
(Hirsch, 2007) and the extent to which they experience IPV (Heise, 1998). A socio-ecological 
framework highlights that the structural context influences the conditions and health outcomes of 
both IPV and HIV.  
Figure 19. Conceptual framework for qualitative research 
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Data Collection 
We conducted an exploratory qualitative study using in-depth interviews (IDIs) and focus group 
discussions (FGDs) with a wide range of stakeholders with potential to take part in, deliver, or 
scale-up an intervention for violence in pregnancy. Participants included pregnant women, 
pregnant women experiencing IPV, health workers, non-governmental organizations, community 
leaders, and policy makers (Table 9). 
 
Table 8. Data collection methods for qualitative research 
Participant 
Group 
Group 
Size Method Sampling 
Example 
Participants Topics 
Pregnant 
women at 
ANC 
(n=13 
women 
in 4 
FGDs) 
Focus 
group 
discussions Convenience  -  
Social and structural drivers of IPV; 
Types of IPV in pregnancy; Patterns of 
help seeking and available community 
resources for violence and HIV; Barriers 
to disclosing IPV; Receptivity to an 
antenatal intervention. 
Pregnant 
abused 
women (n=5) 
Semi-
structured 
interviews Convenience  -  
Existing needs and concerns of abused 
women; Patterns of help seeking and 
available community resources for 
violence; Links between IPV and HIV; 
Receptivity to an antenatal intervention 
Policy 
Makers (n=10) 
Semi-
structured 
interviews  Purposive  
Department of 
Health managers, 
Academic 
experts 
Types of IPV in pregnancy; Current 
health sector response to IPV; Potential 
integration with HIV activities, including 
PMTCT 
Health 
Providers (n=8) 
Semi-
structured 
interviews Purposive  
Doctors, nurses, 
lay counselors in 
antenatal clinics 
Types of IPV in pregnancy; Knowledge 
and practice responding to IPV; 
Receptivity of health workers to antenatal 
intervention; Existing capacity in clinic  
Non-
Governmental 
Orgs  (n=6) 
Semi-
structured 
interviews Purposive  
Shelters, Police, 
Counseling 
services 
Psycho-social, legal and other needs of 
abused women; Referral options for 
women living with IPV 
Community 
leaders (n=4) 
Semi-
structured 
interviews Convenience 
Pastors, 
Neighbourhood 
representatives, 
Traditional healer 
Community factors that support or 
prevent women from seeking IPV 
assistance during pregnancy 
 
 
Pregnant women seeking antenatal care from two antenatal clinics were recruited for 
four FGDs (a total of n=13 women participated). Women were given group information about the 
study while they waited in queue for a clinic appointment. All FGDs were conducted in a private 
room in the clinic, led by trained moderators who were the same sex as participants and fluent in 
multiple local languages (Sotho, Zulu, Tswana). Semi-structured discussion guides explored 
several topics (Table 1). Discussions were audio-recorded after obtaining participants’ permission 
and signing an informed consent form. The discussion groups lasted for about 1 hour and 30 
minutes, and women were reimbursed R50 (US $6). Because of the group nature of focus groups, 
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additional confidentiality measures were implemented: during the informed consent process, 
researchers explained that questions about women’s individual experiences of violence or HIV 
would not be asked, but rather the discussion would address the issue as observed in the 
community.  
Pregnant women who were experiencing IPV were identified during the focus group 
discussions. Trained researchers explained that those women who had personal experience of IPV 
and were interested in participating in in-depth interviews could approach the research team 
outside of the information giving session and privately indicate their interest in taking part in an 
interview. The interviews (n=5) took place in a private room at the clinics while the pregnant 
women were still waiting to be seen by clinic staff. As shown in Table 1, the topics explored 
through structured interview guides were more focused on IPV-related help-seeking and the 
relationship between IPV and HIV. On average, these interviews lasted about 60 minutes. 
In depth interviews with Other Key Stakeholders were led by the research team and 
covered similar topics. This group was comprised of policy makers (n=10), health workers (n=8), 
non-governmental organizations (n=6), and community-based organizations (n=4). Stakeholder 
interviews focused on service provision and asked questions about available resources for women 
experiencing IPV. Some anecdotes of cases were shared, but this was not the main rationale for 
these interviews. 
Several steps were taken to ensure confidentiality and provide additional support for 
participants during the research. In keeping with ethical considerations of researching IPV in 
pregnancy, all research was conducted based on the World Health Organization guidance on 
ethical and safety considerations in researching violence against women (WHO, 2001). Study 
staff were trained to describe research as the “social barriers” to use of health services in the 
community, so as to reduce any undue risk associated with participating in a violence-related 
study. All participants were offered an information sheet containing contact information for local 
resources (counseling, legal advice, and health care). Given the high prevalence of IPV in South 
Africa it was likely that participants in categories other than ‘pregnant and experiencing IPV’ 
category had experienced or witnessed IPV. If any individual demonstrated a need for additional 
assistance, they were offered an opportunity to speak to someone about their experience of 
intimate partner violence, and given referrals to organizations that could assist them. However, no 
participants asked for this referral during the course of the formative research. 
All participation in this formative research was sought on the basis of informed consent 
and good clinical practice guidelines. Ethics approval was obtained by the World Health 
Organization (WHO A65780) and University of the Witwatersrand (HREC M110832). 
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Data Analysis 
The interview and focus group discussion data were transcribed verbatim in the language in 
which they were conducted and, as necessary, translated from the local language (Sotho, Zulu, 
Tswana) into English by professional translators. To ensure accurate translation, each transcript 
was reviewed by a researcher, and queries were resolved through discussions among the 
researchers via phone or email. All identifying information about the participant or clinic setting 
was removed and transcripts were saved by a file name with no personal details.  
Data were managed in QSR Nvivo 10, a qualitative analysis software package, following 
a two-day qualitative management and analysis training of the research team. Members of the 
research team collaboratively built an analytical framework of broad codes by creating a ‘start 
list’ of possible themes and building upon the research questions. Each broad code, or wide 
thematic basket of ideas (Miles & Huberman, 1994), was applied to each transcripts by two 
researchers using NVivo. The research team then held a series of meetings to collectively develop 
‘fine codes’ using an inductive approach – deriving meaning from the data itself rather than 
imposing pre-formed ideas (Hutchison et al., 2010). Fine codes were developed by printing out a 
full set of excerpts (from each database) related to each code, and identifying sub-themes 
emerging from the data.  
 
Results 
We found qualitative evidence of strong bidirectional links between IPV and HIV among 
pregnant women. Here, we present a conceptual framework (Fig. 18) for understanding the ways 
in which IPV is related to HIV-related health of pregnant women. 
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Figure 20. IPV and HIV-related health among pregnant women 
 
Pathway 1: HIV diagnosis leads to IPV via partner disclosure 
HIV diagnosis during pregnancy was noted to be a trigger of IPV. One pregnant woman 
described how severe violence began following her disclosure of her HIV positive status during 
pregnancy: 
“He started telling me things, hurting me emotionally, telling me that I’m a fool, and stupid, I'm 
an idiot. And then he strangled me, That’s when it started... Maybe it’s pregnancy, I don’t know. I 
told him that I am HIV positive, so I don’t know if that’s what made him to do all these things.” - 
Pregnant abused woman 1 
HIV may lead to violence because it causes relationship conflict during the disclosure process. 
Usually, the conflict is related to perceived infidelity and blaming women for “bringing” the 
disease into the relationship: 
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“Yes, if you’re HIV positive, you start blaming each other. Because maybe the husband will be 
saying the wife brought it. So sometime, there’s a connection [between HIV and violence] because 
you end up blaming each other.” –Pregnant woman, FGD 3 
Because HIV testing is coupled with antenatal care, women often learn of their HIV-status in a 
clinic during access to health care during pregnancy. Within this healthcare context, women bear 
the brunt of disclosure to partners, who tend to use women’s status as a “proxy” for their own. 
 
In addition to physical violence, pregnant women described experiencing emotional 
abuse and abandonment following disclosure of HIV to a partner:  
“I have a sister, she was pregnant, … then she came to be tested. When she tested she found out 
she is positive, and when she told her boyfriend everything turned around.  And there was violence 
at home. He started coming late and when she started asking for things for her and the baby, he 
started to react badly up until he ended up leaving her.” – Pregnant woman, FGD 2 
 
Within a context where women fear violence, blame, and abandonment, it is perhaps not 
surprising that many pregnant women chose not to disclose their HIV status to partners. Several 
pregnant women spoke about the fear of partner disclosure when women live in violent 
relationships: 
“Women who are in this abusive relationship, they do get HIV and they are scared what their 
partner will say.” - Pregnant abused woman 1 
Health workers talked about how women in violent relationships would be hesitant to disclose 
their status to partners,  
“When you counsel them…after they have tested positive and when you have to issue the treatment 
she'll be saying, ‘I am not going to disclose. I mustn't take this, I must hide it.’ Then you find out is 
it a problem for her to disclose because there's some emotional abuse or physical abuse from the 
partner.” – Female Health Worker 4 
Thus, fear of partner disclosure may be an early warning sign that pregnant women are in violent 
or unsupportive relationships and require additional assistance during antenatal care. 
 
Pathway 2: IPV worsens HIV-related health via non-adherence 
For women in violent relationships, adherence to PMTCT services was challenging, since taking 
medication or accessing health services might unintentionally alert male partners of their HIV 
status.  
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Health workers noted that non-adherence also served as warning sign that HIV-positive patients 
were in a violent relationship: 
“It was the very same patient that you had told she was HIV positive that was scared to go and 
disclose to their partner. It is the very same patient that will default on their medication because 
their partner does not know that they are taking the medication.” – Policy Maker 9 
In the antenatal clinic, an HIV diagnosis in the context of living with violence may cause patients 
to default on clinic visits: 
“But in your normal facility it is a bit difficult to avoid losing patients. I think we do. Especially 
the mere fact that you say to a patient, ‘you are HIV positive.’ And this is a patient who is facing 
domestic violence! Some will just disappear.” -Policy maker 3  
Thus, the fear of being identified by a male partner as being HIV positive may preclude women 
from returning to clinic services that are essential for their health. While no participants 
mentioned this directly, it is important to note that non-adherence to PMTCT regimens greatly 
increases the risk that pregnant or breastfeeding women will transmit HIV to the infant. 
 
Pathway 3: IPV worsens HIV-related health via mental health 
Declines in mental health were noted in women experiencing IPV in pregnancy. In response to 
persistently violent relationships, women described internalizing the abuse and assuming that they 
had done something wrong to deserve it: 
“He used to beat her while she was pregnant. She just accepted it, and sometime she’d blame 
herself. Saying maybe I’m the one who’s wrong that’s why he’s beating me.” –Pregnant woman, 
FGD 1 
Although IPV is associated with common mental health disorders in pregnancy, few patients or 
providers recognized these as having clinical implications. Most health providers equated mental 
health to severe cases of psychopathology and said they rarely encountered mental health 
disorders. For example, one health worker only considered mental health in relation to bipolar 
depression and pharmacologically treated patients: 
Mental health, yes, I remember we’ve had three that we already on treatment, and will tell you, I 
have a bipolar patient. –Health worker 8 
We found that health workers often fail to notice the mental health dynamics of IPV in 
pregnancy, choosing instead to focus on physical health sequelae of pregnancy. For example, one 
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health provider was asked about stress related to IPV, but responded only in terms of how stress 
impacts hypertension while ignoring the relevant impact on a woman’s mental health: 
Stress is one of the predisposing factors to the development of hypertension. So it is still there, this 
stress, but as a predisposing factor. Sometimes because of the pregnancy itself, you can develop 
hypertension of pregnancy. –Health worker 6 
This tendency towards equating mental health with severe illness may be related to the lack of 
capacity within South Africa’s public health system. As one policy maker explained, in 
overlooking mental health issues, current health systems make it unlikely that patients will 
receive the crucial support that they require: 
No one has time for mental health because there are so many other crises in the health system that 
need to be addressed, that are much more manifested. So that means that things like depressive 
disorder or mental health disorders, they’re not addressed - including partner depression, mental 
health and abuse and all of that. And people are not really encouraged to go and get support that 
they require. –Policy Maker 9  
 
The notion of overlooking mental health is illustrated in an interview with one pregnant, 
abused woman when she described severe physical violence as leading to a state of being ‘a little 
depressed’: 
“Interviewer (I): Are you enjoying your pregnancy so far? 
Participant (P): Being honest, a little depressed but I'm enjoying it. 
I: Ok, so the depression is from what, if I may ask? 
P: From the father of the baby. We are having problems. 
I: What did he do, if you don’t mind telling me. 
P: He strangled me and then he let his cousin beat me up.” - Pregnant abused woman 1 
Not everyone in our sample ignored the impact of mental health on a woman’s health and 
wellbeing. For example, poor mental health had concomitant effects on physical health for one 
HIV-positive participant, who described “going low” emotionally because of violence, and 
thereafter feeling worse physically: 
“I'm HIV positive and I'm in this domestic violence. And if you are HIV positive and then you have 
a partner who is abusing you emotionally... or physically hits you, people can't talk. Maybe you 
can go low, maybe you can go sick.” - Pregnant abused woman 3 
 
 108 
Pathway 4: IPV leads to secondary HIV risk via lack of relationship control 
IPV led to secondary HIV risk when women were in relationships with forced sex or without 
power to negotiate condom use.  
“When we are in relationships where our partner is abusive, sometimes we can’t even negotiate 
things like using the condom. Let’s say, for instance, you know that your partner is the kind of 
person that has other girlfriends, but because he uses power over you, you can’t negotiate those 
things.” –Pregnant woman, FGD 4 
Male partners used their control over the relationship to dictate the terms and timing of sexual 
activity. In one instance, a focus group discussion revealed a story about a newly-diagnosed HIV-
positive woman whose partner insisted that she have sex without condoms: 
There’s a friend of mine that was tested alone and she had a lot of problems. The man said, I’m 
not HIV positive, so I’m not going to test. So the man forced her to sleep with him without a 
condom. And that man said ‘No! Why? We’ve been sleeping without a condom, but because today 
you went to the clinic, you’re telling me we’ve to use a condom?’”  –Pregnant woman, FGD 1 
 
Pregnant women described balancing risks to physical safety (absence of physical harm 
to themselves or fetus) with health risks (of onwards HIV transmission to partners). They 
described making compromises between protecting themselves and the fetus and protecting 
themselves and partners from sexually transmitted infections: 
“If you are not compromising at all and you start saying "let’s use condom," he'll start having 
questions. Some things are better left unsaid, just for the safety part of it.” – Pregnant woman, 
FGD 2 
Many preferred staying silent around condom negotiation, in order to stay physically safe during 
pregnancy. 
 
Discussion 
We found that IPV and HIV-related health were connected concerns in the lives of pregnant 
women in Johannesburg. IPV and HIV seemed to have distinct pathways linking them to one 
another within the context of pregnancy. The initial HIV disclosure could serve as a trigger for 
violence in pregnancy. IPV, in turn, worsened HIV-related health through key pathways of lack 
of adherence and poor mental health. Lastly, the experience of IPV led to secondary transmission 
risk behaviors – both in terms of vertical transmission due to PMTCT non-adherence or 
secondary transmission due to risky sex. 
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According to our participants, IPV shapes HIV-related health outcomes among pregnant 
women primarily because it leads to non-adherence. While the effect of IPV on adherence has 
been confirmed in small studies in the United States (Connors et al., 2012; Lopez et al., 2010; 
Rose et al., 2010a; Trimble et al., 2013; Zierler et al., 2000), this association is yet to be explored 
among pregnant women. Pregnant and postpartum women are a crucial population within which 
to understand IPV and adherence, since non-adherence leads not only to morbidity and mortality 
of the woman but risk of onwards HIV transmission to her infant (Lehman et al., 2009; 
Mofenson, 2010b). Antenatal care provides a crucial moment to enable adherence, since a 
pregnant woman accesses the health system routinely and this is when many are first diagnosed 
with HIV.  
Poor adherence among pregnant women may relate to challenges around partner 
disclosure (Awiti Ujiji et al., 2011). In a recent systematic review of PMTCT, partner disclosure 
was associated with poor PMTCT uptake in a majority of both quantitative (6 of 9) and 
qualitative (17 of 24) studies (Gourlay et al., 2013a). We found that partner disclosure following 
HIV diagnosis in pregnancy led to enacted or feared violence. This aligns with extant literature, 
which suggests that fear of new or continued IPV may lead women to avoid disclosure of their 
status to male partners (Mepham et al., 2011). In one Nigerian study among HIV-positive 
pregnant women, the prevalence of IPV was 17% before HIV testing and increased to 63% after 
testing for HIV and disclosing status (Ezechi et al., 2009) A Zimbabwean study showed that risk 
of IPV in pregnancy was greatest among those women testing positive for HIV in antenatal care 
(Shamu et al., (in press)). Non-disclosure among pregnant women is a health risk in its own right, 
since it poses a risk for sexual transmission of HIV if the male partner is still HIV-negative 
(Bond, 2010; Desgrees-du-Lou et al., 2009; Katz et al., 2009; Orne-Gliemann & Desgrees-Du-
Lou, 2008) and may have an impact on the implementation of PMTCT (Farquhar et al., 2004b). 
A related but distinct pathway linking IPV to PMTCT uptake may be mental health. A 
growing body of literature shows that IPV leads to depression and anxiety among pregnant 
women (Beydoun et al., 2012; Groves et al., 2012; Urquia et al., 2011), yet this link has been 
largely unexplored in sub-Saharan Africa in HIV-positive populations. Our findings reflect those 
of a qualitative study in Zambia, in which IPV, mental health, and HIV are closely related in the 
experience of women (Murray et al., 2006). Such interrelated “syndemic” issues (Gielen et al., 
2007) should be explored in future sub-Saharan African studies.  
Existing research shows poor mental health has significant impact on ART adherence 
(Ammassari et al., 2004; Cook et al., 2002; Starace et al., 2002; Sumari-de Boer et al., 2011) and 
among pregnant women depressive symptoms are associated with HIV disease progression and 
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mortality (Antelman et al., 2007). It is possible that intimate partner violence is one condition 
exacerbating the relationship between mental health and HIV outcomes. Indeed, one new study 
suggests that the link between mental health and ART adherence may be partly driven by partner 
conflict (Malow et al., 2013). Despite high rates of common mental health disorders in antenatal 
care (Rochat et al., 2011), little screening or treatment exists in South Africa (Honikman et al., 
2012). Mental health will be crucial to address among HIV-positive pregnant women because of 
its strong relationship to IPV and its association with uptake of PMTCT regimens (Colebunders 
& Myer, 2013). 
Lastly, IPV may worsen secondary prevention behaviors in pregnancy. Non-adherence to 
PMTCT regimens greatly increases the risk that pregnant or breastfeeding women will transmit 
HIV to the infant (Cooper et al., 2002), potentially in drug-resistant form (Zeh et al., 2011). High 
viral loads related to non-adherence also increase the likelihood of secondary transmission to 
partners, particularly in the context of unsafe sex. Our findings echo existing knowledge by 
suggesting that IPV inhibits women’s ability to negotiate condoms (Wingood & DiClemente, 
1997). These findings explore such dynamics within the context of pregnancy, thereby suggesting 
a dual risk of mother-to-child infection and secondary transmission risk to a partner. 
Our findings echo calls for addressing IPV in pregnancy (Shamu et al., 2013a). Scholars 
note that antenatal care provides an important “window of opportunity” for women who are 
regularly accessing the health system (Bacchus et al., 2004b). Although universal screening is not 
recommended in settings with limited referral options and overstretched providers (WHO, 
2013b), some type of IPV assessment, provider training, and targeted response may be 
appropriate for South African antenatal care. Indeed, a comprehensive health response to IPV will 
likely require either screening or case-finding – both methods that may be acceptable in South 
African clinics (Christofides & Jewkes, 2010; Joyner & Mash, 2012).  
 
Limitations 
The findings of this formative research should be examined in light of several limitations. Firstly, 
this study is exploratory in nature, resulting in small sample sizes of each participant group. 
While analysis suggested that we began to reach saturation through FGDs with pregnant women, 
the IDIs with pregnant women experiencing IPV were not sufficient to reach thematic saturation 
(Morse, 1993). Secondly, the socio-ecological perspective was brought to the data analysis 
process after data collection. Ideally, this conceptual approach would have informed the entire 
data collection process, rather than simply guiding the final interpretation of findings. However, 
since this was a preliminary, exploratory study, it was designed to explore several intersecting 
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issues and we applied the conceptual framework during data analysis. Lastly, some of the 
findings may be applicable for any woman experiencing IPV, and do not necessarily highlight the 
specific context of pregnancy. Further research should explore the perinatal time-period in richer 
detail to determine whether the link between IPV and HIV is distinct during this life stage. 
 
Conclusion 
Intimate partner violence in pregnancy leads to declines in the physical and mental health of 
pregnant women. Our findings underscore the negative effects of IPV as a health issue in its own 
right and as a barrier to PMTCT. The connection between IPV and HIV adherence among 
pregnant women has yet to be explored quantitatively in sub-Saharan Africa. In future studies, it 
would be ideal to find systematic methods for recruiting more robust numbers of pregnant women 
who experience IPV and who are living with HIV. In the parent study (Woollett et al., 2014), we 
anticipate that by training health providers to ask about IPV confidentially and skillfully, it may 
be increasingly possible to reach this population.  
Beyond its marked impact on physical and mental health of women, IPV in pregnancy 
may have important implications for Option B+, as current cost effectiveness models assume that 
women are willing and able to achieve 100% adherence (Gopalappa et al., 2014). If Option B+ is 
to be adopted more broadly, the effect of IPV on adherence and mental health should be carefully 
considered. Addressing the inter-related issues of violence and HIV will be crucial to ensure that 
goals of maternal and child health are met in the sub-Saharan African region.
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Introduction 
Prevention of mother-to-child transmission (PMTCT) interventions have potential to eliminate 
vertical transmission of HIV from mothers to infants (Mofenson, 2010b). Yet, women’s 
adherence to all the steps required for successful PMTCT is often low. Within 21 priority 
countries, an estimated 65% of eligible pregnant women access HIV treatment (WHO et al., 
2013), and pooled analysis suggests that only half of women adhere to treatment postpartum 
(Nachega et al., 2012). Studies in sub-Saharan Africa suggest that partner relationship factors are 
among the most important barriers to pregnant women’s acceptance of HIV testing and other 
PMTCT behaviors (Bwirire et al., 2008; Medley et al., 2004; Turan et al., 2011). Intimate partner 
violence (IPV) may be one important predictor of adherence to HIV medication in pregnancy and 
postpartum, yet this association has been understudied in the literature to date (Hatcher et al., 
2015c). 
Among non-pregnant women, IPV victimization is associated with worse HIV-related 
health outcomes, including higher odds of antiretroviral failure, weaker immune response, 
increases in opportunistic infections, and greater risk of mortality (Schafer et al., 2012; Weber et 
al., 2012). A recent meta-analysis suggested that women’s experience of IPV was associated with 
55% lower odds of self-reported adherence and 36% decreased odds of viral suppression (Hatcher 
et al., 2015c). However, of the thirteen included studies, none were based in sub-Saharan Africa 
or among pregnant women. Since publication of the meta-analysis, only a single study has 
examined the effect of IPV on adherence in pregnant women. This Zambian study showed that 
IPV victimization was associated with 74% lower odds of adherence in pregnancy and 89% lower 
odds of adherence postpartum (Hampanda, 2016). However, the quantitative methods used by 
this seminal paper preclude a deeper understanding of how partner violence alters PMTCT 
behaviors. This is a crucial dynamic to understand, particularly since many of the same countries 
in sub-Saharan Africa with the highest rates of mother-to-child transmission also have high 
prevalence of IPV (Devries et al., 2013b). 
South Africa is one such sub-Saharan African setting where HIV and IPV are highly 
prevalent. An estimated 25 – 35% of South African pregnant women report recent physical and/or 
sexual IPV (Groves et al., 2012; Hoque et al., 2009). Similarly, antenatal HIV prevalence across 
South Africa is high, with estimates in Johannesburg reaching 29% (Department of Health, 2012). 
South Africa has made significant strides towards reducing mother-to-child transmission from 
14% in 2009 to an estimated 5% in 2012 (UNAIDS, 2013). Yet, only 54-65% of South African 
pregnant women and infants complete all recommended PMTCT steps (Stringer et al., 2010; 
Technau et al., 2014).  
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Recent qualitative studies have explored the underlying dynamics of IPV among small 
samples of women living with HIV. Among eight women reporting violence after HIV 
disclosure, Colombini et al. (2016) learned that new HIV diagnosis was a trigger for violence, 
even in relationships with no prior history of IPV. Mulranen et al. (2015b) studied postpartum 
women living with HIV in Swaziland, of whom nine reported IPV following disclosure, and 
learned that violence resulted from acute triggers like HIV status disclosure and also from 
ongoing marital tensions around fertility. In a study of pregnant and postpartum HIV-positive 
women in the United States, Njie-Carr et al. (2012) found that three women with recent violence 
avoided partner disclosure because they feared a violent reaction. Illangesekare et al. (2014) 
identified mental health as a primary pathway linking IPV to non-adherence among HIV-positive 
women reporting lifetime partner violence, of whom three were currently living with IPV. Other 
qualitative research has broadly explored violence and HIV medication adherence, but not among 
women who present with both conditions (Hatcher et al., 2014; Zunner et al., 2015). (Njie-Carr et al., 2012) (Illangasekare et al., 2014; Njie-Carr et al., 2012). 
While extant qualitative literature offers preliminary understanding that perhaps violence 
and HIV behaviors are linked, samples sizes ranging from three to nine participants rule out the 
analytical rigor required to understand why IPV alters adherence. In-depth, qualitative elucidation 
of the specific mechanisms linking IPV and HIV adherence is necessary if we are to increase the 
proportion of women adhering to PMTCT interventions. We conducted in-depth qualitative 
research with 32 women living with HIV and reporting experience of IPV in Johannesburg, South 
Africa. The purpose of the research was to explore mechanisms linking these interconnected 
issues among pregnant and postpartum women.  
 
Theoretical framework 
This research was informed by an integrated socio-ecological, dyadic conceptual framework (Fig. 
19). The socio-ecological model suggests that individual, relationship, and structural factors 
shape health outcomes (Heise, 1998), and is widely used in IPV research because it incorporates 
many complex factors that influence partner violence (WHO, 2010).  
Within the ecological model, individual factors are the personal characteristics or 
behaviours that impact one’s health. Previous literature has suggested that individual factors 
inhibiting PMTCT uptake include depression (Nachega et al., 2012; Turan et al., 2013), substance 
use (Nachega et al., 2012), internalized HIV stigma and shame (Turan et al., 2013), and costs 
associated with clinic attendance (Bwirire et al., 2008). Partner relationship factors are the 
dyadic partnership issues that frame health outcomes. Partner dynamics that worsen PMTCT 
behaviors include a lack of male involvement in antenatal care (Aluisio et al., 2011), non-
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disclosure to a partner (Gourlay et al., 2013a; Myer, 2011), and threat of further violence 
(Antelman et al., 2001). The theory of gender and power (Connell, 1985), which postulates that 
unequal power dynamics limit the ability of women to exercise personal control in relationships 
(Amaro & Raj, 2000), provides a theoretical underpinning for the associations seen between 
partner factors and PMTCT uptake. Structural factors refer to the broader social or community 
factors that impact on health. In this sphere, previous studies have noted that PMTCT is adversely 
impacted by poverty (hIarlaithe et al., 2014), lack of social support (Kirsten et al., 2011), 
community stigma around HIV (Turan et al., 2011), and weak health systems (Bwirire et al., 
2008). A socio-ecological framework recognises that similar structural factors underpin both 
violence and HIV (Maman et al., 2000) and that broader social and societal factors shape 
women’s ability to adhere to HIV medication (Hirsch, 2007) and the extent to which they 
experience IPV (Heise, 1998). 
 
Figure 21. Socio-ecological framework linking IPV to HIV-related health 
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Methods 
The goal of this qualitative research was to build understanding around why and how IPV 
influences PMTCT uptake and HIV-related health. This analysis is guided by our formative 
qualitative research with pregnant women and health providers (Hatcher et al., 2014). The 
formative research included no women living with both IPV and HIV, but instead asked 
participants to speculate about the links between violence and PMTCT. As an elucidation of 
mechanisms requires incorporation of the perspectives and knowledge of women who actually 
experience these health conditions, we now present data from in-depth interviews with a larger 
sample of women (n=32), all living with both IPV and HIV.  
Qualitative research was nested within a randomised control trial testing an intervention 
for IPV in pregnancy (Pallitto et al., 2016). Called Safe & Sound, the trial recruited 1680 
pregnant women from four antenatal clinics in Johannesburg to take part in baseline 
questionnaires. In the parent trial, women reporting recent (past-year) physical and/or sexual IPV 
(n=421) were randomised to a nurse-led empowerment counseling intervention or an enhanced 
control condition. This sub-study purposively selected the sample of 32 participants to take part 
in qualitative, in-depth interviews between May 2014–November 2015. 
The methodology for this study was informed by narrative, constructionist approaches to 
researching IPV (Allen, 2011). The narrative element of this approach posits that discussing IPV 
experiences with skillful providers can be therapeutically beneficial and that the research process 
itself serves as a form of reflection for participants (Allen, 2011). Narrative approaches to 
research on violence acknowledge that women’s stories help create coherence in otherwise 
chaotic, uncontrollable situations (Williamson, 2010). Narrative approaches use particular 
techniques during the interview process, such as validation, highlighting resistance strategies, and 
focusing on meaning and identity (Allen, 2011). The social constructionist methodology 
acknowledges that researchers are part of the research interaction and that their prior knowledge 
should be brought to light and examined (Charmaz, 2008).  
Participant sampling and recruitment 
We conducted qualitative research with 32 participants who were purposively selected from 
women taking part in baseline Safe & Sound trial questionnaires. Women recruited for this 
sample were living with HIV and experiencing IPV. In practice, this included women 
participating in the trial (ie. experiencing recent IPV), as well as women who were not eligible to 
enroll in the trial, but who had experienced IPV in their lifetime. These lifetime history 
participants had already completed a full study baseline questionnaire and agreed to be contacted 
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about further research. Study nurses guided the selection of participants based on their impression 
of women’s willingness to take part in an additional interview, their knowledge of women’s 
experiences of IPV, and women’s HIV-positive status. 
Initially, the sample size proposed for this qualitative study was 24 participants. Using 
the constant comparative method to understand the emerging constructs from the data (Charmaz, 
2003), we found that upon completion of 18 interviews, theoretical saturation had not yet been 
reached. Data on our initial research question around links between violence and PMTCT lacked 
richness and women’s stories failed to converge around specific pathways. We thus expanded the 
sample to reach 32 women using theoretical sampling to include additional women with recent 
IPV experiences. Theoretical sampling is a technique for using preliminary analysis to guide how 
data are collected further (Glaser, 1992). In this case, our initial analysis suggested that links 
between violence and PMTCT are best explored among participants with recent violence and 
with some challenges adhering to PMTCT behaviors. Displaying “challenges” with PMTCT was 
therefore used as a selection criteria for the next 14 participants. Additional women with these 
characteristics allowed us to further refine emergent concepts and test out initial impressions of 
the data with a more targeted group of participants. 
Trained nurse researchers invited women to participate through follow-up phone calls 
using locator information. All participants contacted for this sub-study were reachable by phone, 
with 7 women refusing to take part (due to living outside the province, work commitments, or not 
desiring to take part in additional research). Male partners were never informed about a woman's 
participation in the research because of the potential for an abusive partner to react violently. To 
protect participants and reduce the risk that partners would overhear the conversation, nurses 
were trained to ask “is this a safe time to speak?” before continuing. A full distress protocol 
included appropriate researcher responses in cases of violence disclosure, psychological distress, 
high emotionality, or a need for referrals. Basic elements of the distress protocol were employed 
during most interviews included in this study: a calm, non-judgmental approach to inquiry; 
watching for signs of resistance when inquiring about violence to avoid re-traumatisation; 
offering tissues if participants cried; offering a break from the interview. In cases of severe 
distress, researchers were trained to invite participants to stop the interview, a technique that was 
used with one participant, and to offer supportive referrals. In the case of current suicidal 
thinking, researchers were trained to make a direct referral to a psychiatric ward of the nearest 
hospital. In this sample, no participants revealed current suicidal thinking but several participants 
recounted a history of suicidal ideation, for which researchers offered empathetic listening and 
referrals to a nearby community psychology counseling service. 
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Data collection 
In-depth interviews were conducted face-to-face, in a private clinic room, at a convenient time for 
the woman.  Interviews were conducted by the lead author and three other trained qualitative 
researchers. The trained researchers were comprised of two South African, female nurses and two 
non-South African, female researchers. This composition of the research team helped ensure that 
some of the positionality challenges associated with language and race were addressed. However, 
all researchers held positions of relative power compared to participants, a dynamic that was 
intentionally addressed through training on a humble, inquisitive approach and the ethos among 
the research team that participants were the ‘experts’ and researchers were the ‘learners’. While 
this positionality could not be completely eliminated, the rich stories presented by most 
participants suggests comfort in sharing their stories through the research process. 
Interviews were conducted in one of three South African languages (English, Sesotho, 
isiZulu) and digitally recorded. A semi-structured in-depth interview guide explored three 
themes: the perceived relationship between IPV and HIV in women’s lives; women’s perceptions 
of how violence may influence PMTCT uptake; and, potential mechanisms through which IPV 
may impact PMTCT-related health behaviors. Interviews lasted between 26 minutes and 1 hour 
40 minutes (median 46 minutes).  
Professional transcriptionists typed verbatim transcripts from the digital recordings. Each 
transcript was reviewed by a researcher to ensure clarity and for additional detail about tone and 
non-verbal cues. Interviews conducted in the local language (Sesotho or isiZulu) were translated 
directly to English and reviewed for translation errors by the researcher who led the interview. All 
data collection materials were stored in a locked file cabinet and electronic voice files and 
transcripts were password protected and stored on an encrypted server. At the point of 
transcription, the lead researcher assigned a pseudonym unrelated to the participant’s real name 
for ease of analysis. The data presented here note the pseudonym, age, and whether the woman 
was pregnant or postpartum. 
Data analysis 
To ensure that interviews achieved adequate depth and richness, the first 6 transcripts were 
reviewed jointly to establish future questions, points of clarification, and initial themes. 
Researchers reviewed full transcripts and created detailed 'memos' to highlight initial impressions 
of the data. This review process was repeated at two other time-points (upon completion of 18 
interviews and 28 interviews). Both reviews led to tweaking of the interview guides, with major 
themes retained but sub-questions altered to enhance probing and clarity. The team developed an 
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initial coding framework based on the preliminary review of 6 transcripts and “sensitizing 
concepts”, or preliminary ideas around how to examine the data (Bowen, 2006).  
The coding framework was applied to all transcripts by two researchers using Dedoose 
qualitative analytic software. The focus of double-coding was to ensure that code application was 
consistent across transcripts and that code definitions were robust. Rather than assessing inter-
rater reliability, the team used a series of phone calls and in-person meetings to refine codes until 
consensus was reached. This process led to a refined set of thematic codes that comprised broad 
topics such as relationship characteristics, experience of violence, HIV diagnosis, PMTCT 
uptake, mental health, social support, partner HIV serostatus disclosure, and reflections on being 
asked about IPV in pregnancy. Next, the team established a system of fine codes that emerged 
inductively from the data. Fine codes were applied to a portion of transcripts by three researchers, 
ensuring that every transcript was double-coded. Examples of fine codes within the partner HIV 
disclosure section were: fear of partner response, reactive or polarized methods of disclosure, 
male partner denial of disclosure, concern for the child, supportive steps, displaced anger. During 
analysis, cases that did not fit the overall picture, called “exceptional cases”, were actively sought 
out. Trustworthiness of findings was ensured by the team approach to data analysis, coding 
discussion meetings, and by presenting initial findings to groups of colleagues and peers.  
Ethical and safety considerations 
All participants provided written, informed consent. The parent trial received approval from the 
University of the Witwatersrand Human Research Ethics Committee (M121179) and World 
Health Organization Ethics Research Committee (RPC471). This qualitative substudy received 
additional secondary analysis approval from University of the Witwatersrand (M140451). 
Given the special considerations around researching violence, all portions of this study 
were designed to adhere to the WHO ethical and safety guidance on IPV research (WHO, 2001). 
The research was presented broadly so that the specific nature of the study was not made public. 
Only when the participant and interviewer were alone, during the informed consent process, did 
the researcher provide further information that the nature of the study involved HIV and IPV. All 
qualitative researchers were intensively trained. A 30-hour technical training alongside weekly 
mentorship and debriefing by senior team members ensured all researchers had the knowledge 
and skills required to skillfully handle disclosure of violence (Reynolds, 2007).  
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Results 
Sample characteristics 
Of the 32 participants, 26 women reported IPV in pregnancy while 6 reported a prior history of 
IPV (see characteristics summarized in Table 10).  The majority of participants (75%) reported 
physical and emotional violence, with several (16%) reporting physical, sexual, and emotional 
violence. Twelve participants (38%) reported that they were non-adherent to HIV medication 
during the time of pregnancy or were not on treatment. 
 
Table 9. Descriptive statistics of sample (n=32) 
 
 
Links between violence and PMTCT adherence 
We learned that four pathways linked women’s experience of IPV with their adherence to 
PMTCT interventions. The first pathway was partner disclosure, with violent relationships 
framing a decision to hide one’s HIV status. Some women were unable to maintain careful 
PMTCT behaviors without risking disclosure, so they opted to take treatment breaks or stop 
treatment altogether. A second pathway was mental health, as IPV resulted in depressive views 
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that “life is not worth living” and led to missing doses of medication. A third pathway was partner 
control and isolation, in which men limited participant access to friends and family, which 
precluded the social support required for good adherence. In a final, protective pathway, good 
PMTCT adherence seemed linked to women’s identity as mothers, with the wellbeing of the baby 
framing decisions to stay attentive to medication.  
Below, we present each pathway alongside illustrative quotes and case examples of 
participants. While it may appear that certain women ‘belong’ primarily to one single pathway, 
this was certainly not the case within the overall analysis. Participants often related stories that 
highlighted the complex relationship across the pathways. 
Partner (Non) Disclosure: Hiding HIV from a partner 
Of the 16 women who disclosed to partners, many experienced subsequent physical violence 
(n=6) and emotional violence (n=7) that they directly linked to the disclosure act. Participants 
recalled incidents of violence that started or worsened immediately following HIV testing. 
Lulama, who was 30 years old and pregnant with her second child, made a direct link between 
her HIV status and physical and emotional violence from her partner. The partner consistently 
blamed Lulama for “giving” him HIV, and would use threats of further physical violence to show 
his disdain for her status. Thuto, a 25-year-old postpartum participant, explained that the violence 
in her relationship started when she tested HIV-positive during her first pregnancy. Thereafter, a 
severe episode of physical violence in her third pregnancy was directly related to her HIV status: 
“He came back from the shebeen [local bar] and said I was a slut, and that’s why I came with this 
disease.” 
Not all women experienced physical violence after disclosing their HIV status. A tension 
occurred in Leah’s relationship that demonstrates the blurred lines between violence and partner 
support around HIV. As a 33-year-old pregnant participant, Leah’s husband was broadly 
supportive of her taking medication, because Leah had carefully convinced him that PMTCT can 
prevent HIV in their infant. Leah’s partner would even remind her of her treatment time. Yet, 
alongside this instrumental support, he was emotionally abusive and would remind her that HIV 
would lead to her death by stating, “You will die, your children will be alone.”   
In this context of violent or psychologically harmful reactions, it is perhaps not surprising 
that 16 women opted to keep their HIV status a secret. Participants described this choice as a 
reasoned response to a dangerous situation. Six participants feared that their partners would react 
to disclosure with physical violence. For Simphiwe, a 33-year-old woman who had been with her 
partner for five years, a history of physical violence led her to keep HIV a secret. Another 
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participant, Kandi, feared physical violence because her partner explicitly stated that he would 
hurt her should she test HIV-positive. 
Fears of partner reaction led some women to be partially non-adherent to their HIV 
medications. One 32-year-old postpartum participant, Nomsa, described her fear that the father of 
her first child might murder her or the child as a response to HIV disclosure. Nomsa kept her 
status hidden by pretending the medication was for pregnancy, rather than for HIV, but admitted 
it was challenging to keep taking the pills after giving birth. Another participant, Thembi, was 26 
years-old and postpartum when she recounted how she chose not to start HIV medication in 
pregnancy because she was frightened that her partner would be physically violent when she 
asked him to use a condom. Her (incorrect) understanding of treatment came from antenatal staff 
who often say that HIV medication must be accompanied by consistent condom use. Since 
Thembi knew she could not safely use condoms, she chose to avoid HIV medication altogether. 
Her non-uptake of treatment meant that her infant acquired HIV during the course of the study.  
The act of hiding medication and withholding one’s status from partners requires 
considerable foresight and care. Lulama, 30 years and pregnant during the interview, strategically 
took medication at a time when her husband was away from the house. At 34 years and pregnant, 
Ayanda changed the container of her HIV medication so that it would appear to be other routine 
medication. Other women like Mpefe also had to carefully navigate clinic visits and medication: 
My boyfriend doesn't know about this.  I just kept it to myself. So my treatments, 
when I would come and take my treatments here by the clinic, then I would hide 
it by my place.  Even when I drink my tablets I would hide them. – Mpefe, 25 
years, Pregnant 
When Mpefe noticed her partner was nearby, she would forgo treatment altogether. Eventually, 
Mpefe decided to move out so that she could easily take her treatment without worry that her 
boyfriend might see.  
Similarly, Zama (25 years and pregnant) found it easier to adhere to medication once she 
moved out from her partner’s place. Before she would wait until he fell asleep to take her daily 
prescription: “It was a little bit tricky because I had to hide the medication. And then at times he 
would be in the same bedroom where I hide it, so I can’t take it.” For Sonja, the original response 
to disclosure was threats of violence and forced eviction from the household. In this context, 
Sonja, 23-years-old and pregnant, carefully avoided taking medication in front of her partner, 
worrying that simply seeing the medicine might trigger a violent reaction. One day, her partner 
snuck up on her in the bathroom and caught her taking the treatment. While the response was not 
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physical violence, her partner disappeared and returned home in an agitated state after a bout of 
drinking. 
A subtler rationale for hiding medication from violent partners was to withhold 
information from a person who had caused so much pain. For two women, this appeared to be a 
resistance strategy for proving to themselves that their own health was not within the realm of 
things men could control. Simphiwe professed that she made up her mind immediately after 
testing HIV positive, since “he was violent, hitting me and all that stuff. So I decided I’m not 
going to tell him.” Similarly, Zinhile explained “If he was a proper person, then I would tell him 
that I’m HIV positive, let’s go to the hospital together to test. But if he is going to put me at risk, 
why should I say that?” Zinhile met her partner’s lack of care by stubbornly refusing to share 
anything about HIV with him: 
I didn’t want him to know I have gone to the clinic. I didn’t even want him to 
know what I was doing in my life, in my future, because he didn’t want to be 
close… I didn’t even want him to see me taking the tablets, because he didn’t 
want to know, he didn’t want me. – Zinhle, 38 years, Postpartum 
 
Mental health: Poor adherence as a result of depression and anxiety 
Several women related stories of non-adherent periods, many of which resulted from depressive 
episodes that followed phases of violence. At 24 years, Thuto had recently delivered her fourth 
child, and explained the tendency to feel despondent particularly after extremely violent episodes 
or when her husband refused to buy food for the family. Thuto sometimes struggled with staying 
adherent, and explained that she had given up hope:  “Sometimes, when I’m stressed, I feel that 
its better I also died… I’ve just lost hope.” Zama expressed a concern that her infant would test 
HIV-positive, since she herself had experienced adherence struggles. Similar to several other 
participants, Zama disclosed a desire to “end everything” as a method to reduce the distress she 
was feeling about the violent relationship: 
When I was three months pregnant, that is when it started changing to being 
physical [violence]. At times I would just feel like ending everything, the stress 
and all that… I am very much worried about my baby being positive, especially 
with the fact that I was not able to take my medication as frequently as I was 
supposed to. –Zama, 25 years, Pregnant 
Ayanda’s partner had been physically abusive the night before the interview. She described the 
physical violence alongside the overwhelming nature of coping with frequent abusive episodes 
and anticipating the arrival of a new baby. The stress related to the violence was a concern 
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because Ayanda realised how episodes of IPV took priority over remembering to take her 
medication: 
You know what bothers me sometimes? That when he makes this thing [violence], 
I may forget to drink my medication. Then maybe I will just default [not comply 
with HIV visits and medications]. And what worries me is that I will default when 
I’m breastfeeding the child. –Ayanda, 34 years, Pregnant 
This notion of “forgetting” to take medication is perhaps more linked to how women are able to 
cope with various life challenges. When violence is more of a concern, or more ‘top of mind’, 
than HIV-related concerns, women may forgo the steps required for good HIV care. This finding 
denotes how subtle mental health considerations, like being too cognitively overwhelmed by the 
violence, may influence PMTCT uptake. 
Six women described periods of stopping treatment altogether due to depressive and 
suicidal feelings. The underlying emotion of stopping treatment for these women was a desire to 
end their lives. One participant, Dova, named it a “death wish” and recounted the overwhelming 
feelings of hopelessness and failure that had led her to stop taking HIV treatment: 
There was a time when I was really, really down, so I stopped taking my 
medication. I completely just stopped and I sort of had this death wish in me that 
if only this thing would, if HIV would work like really for us then it would just kill 
me. I stopped for three to four months without taking my medication. – Dova, 32 
years, Pregnant 
 
Another participant, Dintle, had tried to commit suicide by drinking poison several weeks 
prior to the interview. Her husband had been extremely violent, hitting her in front of the 
neighbours, withholding food, and publicly shaming her. She explained in subtle terms (such as 
“stress” and “feeling bad”) how her recent suicidal experience and anxiety symptoms would 
cause her to forgo treatment for periods of time: 
Participant (P): Sometimes I forget to take my treatment. It happened two months 
ago. I had pills, but I just forgot dates to go fetch my treatment.  
Researcher (R): What led you to forget? 
P: Stress, I am always thinking. 
I: What were you thinking? 
P: I was thinking about the time he threatened me. I just end up thinking about 
too many things. By the time I remember it is too late, my days have passed. – 
Dintle, 30 years, Postpartum 
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For Dintle, stopping treatment was a by-product of experiencing intense episodes of violence and 
concomitant mental health challenges. This suggests that in cases of severe depression, HIV 
treatment non-adherence can be both a mode of self-harm and a result of being overwhelmed at 
times of high distress. 
Isolation and partner control: The hidden nature of IPV and HIV 
In this sample, there were only a few examples of partners directly controlling the health of 
women through barring access to clinics or medication. At 38 years and postpartum, Zinhle 
feared blame associated with having HIV, but not necessarily a violent reprisal. Even still, the 
controlling behaviors her partner exhibited against the backdrop of physical and sexual violence 
meant that Zinhle would surreptitiously visit the clinic.  
Yet, partner control did not always lead to poor adherence. For example, Kagiso’s partner 
was suspicious when she went to the clinic, assuming she was cheating on him. At times, he 
would physically abuse her when she came home from the clinic, assuming she was unfaithful 
during her times away from home, but she described a stubborn dedication to continue seeking 
medical treatment: 
Sometimes when I go to the clinic he say hey you are not going to the clinic.  He 
asked me too many questions… But I refuse. I tell him I can’t stop going to clinic 
because this is my life! I have children. I have to live to take care of my babies. 
Sometimes when I come back to the house he beats me, accusing that I’m not 
coming from the clinic. –Kagiso, 28 years, Postpartum 
 
For many women, violent partners did not actively bar access to clinics, but indirectly 
used isolation as a type of partner control. One example is found in Lulama’s story about how 
returning from a normal day would often result in questions and threats: “He is always looking at 
what I do and wants to know what I get up to. He controls my life, he says I should always be at 
home.” The outcome of these controlling behaviors was often immense isolation and mental 
health challenges for Lulama, who was 30 years and pregnant at time of interview.  
For several participants, the feeling of isolation was pervasive, leaving them troubled and 
continually ruminating over difficult thoughts. Dova illustrated this by describing how thoughts 
of the violence were “stuck in her mind” and left her isolated and alone: 
It is just basically stuck there in my mind - all these things that have been 
happening. When you are alone, you just sit and think about it and I don’t have 
anyone. Sometimes I don’t sleep the whole night I am thinking and thinking. – 
Dova, 32 years, Pregnant 
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 Another implicit trait of the partner control and isolation pathway is the hidden nature of 
both HIV and violence. Both HIV and IPV are stigmatised, which leads to a worsened ability 
among women to find support for either condition. Several women spoke of staying silent with 
their families about the violence in their relationships. As 30-year-old, pregnant Lulama noted, 
“whatever we fight about I keep to myself most of the time.” For Neo, it was easier to pretend 
that things were fine than to disclose to her friends that she lived in a violent relationship: 
It’s hard to tell people I’ve got a problem, I’m not living a good life, with a 
partner that I’m worried, we’re always fighting, things like that. You just pretend, 
like now pretending that I’m ok but I’m not ok. – Neo, 28 years, Pospartum 
Motherhood as a coping strategy: protective pathway 
Despite immense challenges with HIV, violence, and pregnancy, many women in this sample 
exhibited unique coping strategies for adhering to treatment. For some women (n=8), the concept 
of motherhood was a source of resilience and helped them stick with HIV medications. At 32 
years and postpartum, Nomsa struggled to find clothing and food for her children, but continually 
reminded herself that treatment was an essential part of being able to care for her children: “I’m 
drinking my tablets. I’m just telling myself that I must help myself and get help. I know I need to 
work for my kids rather than die.” 
Zama did have trouble with adhering to treatment, and considered suicide during phases 
when the physical violence was particularly bad. Yet, at 25 years and pregnant, the reminder of 
her new baby would often be enough to return her to thoughts of living and trying to provide for 
her baby: “Maybe after a fight, I will be crying, stressed and then I would be like, okay, let me 
just do this [commit suicide], then I would think, ‘No, but let us give this baby a chance’.” It is 
important to note that Zama exhibited these methods of “resilience” by focusing on her baby’s 
wellbeing even as she struggled with suicidality and isolation. Her story illustrates the complex 
relationship within multiple pathways, and shows that IPV’s influence can manifest in 
complicated ways. 
Grace used the idea of caring for her children as a way to “move on with life” and leave 
her violent partner: 
Like in future I was thinking like to move on with my life. Do something for my 
life and for my kids! That’s what I want now because I’m done with living in the 
painful relationship. – Grace, 27 years, Postpartum 
Zethu’s baby similarly helped her keep “priorities straight.” As a 21-year-old pregnant woman, 
she boldly stated that HIV treatment was more important than her husband, and expressed how 
non-adherence was simply going to harm herself: “I’m doing it [PMTCT] for my baby. I don’t 
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want to stress myself so that I leave the tablets - it’s better to leave that husband and continue 
with my tablet.” Beyond Zethu’s commitment to protecting her baby, it appeared that taking care 
of her own HIV could be a subtle way to “leave that husband” and regain control over her own 
life. 
 Not every participant was able to use the notion of motherhood to feel more confident 
around HIV treatment. For example, Dova felt that the stress related to the violent relationship 
was making her a worse mother – a notion that she illustrated by describing how her suicidal 
thoughts were linked to potential infanticide: 
I have suicidal thoughts because I don’t have anyone. The only people I have are 
my kids. And the worst part is with these suicidal thoughts I am always saying, if 
I had to kill myself, I wouldn’t leave my kids behind. I would take them with. If 
there is a method whereby I would kill me and my kids, I would do it. So it is just, 
it is not well. I am not even a good mother these days. –Dova, 32 years, Pregnant 
Dova’s story reflects upon multiple pathways of mental health and isolation, suggesting again that 
pathways may have a dynamic relationship and do not necessarily stand alone as distinct 
situations. 
 
Discussion 
This is the first study, to our knowledge, to explore the relationship between violence and HIV 
adherence within a relatively robust qualitative sample of 32 pregnant and postpartum women 
reporting both HIV and IPV. It highlights that women living with HIV and IPV have unique 
challenges to maintaining healthy adherence behaviors around the time of pregnancy. Four key 
pathways emerged that link IPV to PMTCT: partner non-disclosure, poor mental health, isolation 
due to partner control, and motherhood.   
As shown in Figure 20, pathways from IPV to PMTCT outcomes tend to intersect and 
collide. Rather than falling into distinct categories, participants often presented stories that fell 
within multiple pathways. The pathways seemed to be comprised of both positive and negative 
aspects of responding to IPV. So while mental health and partner control/isolation seemed to 
worsen HIV outcomes for women, pathways of motherhood and partner non-disclosure 
highlighted unique resilience strategies used by women. This nuanced understanding of the IPV–
HIV adherence relationship can help contextualize recent conflicting evidence from sub-Saharan 
Africa. Whereas one study with pregnant women in Zambia showed that violence worsens HIV 
adherence (Hampanda, 2016), another in Kenya among female sex workers suggests that history 
of IPV actually improved odds of HIV-related health (Wilson et al., 2016). It is possible that 
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while experience of IPV may hinder women’s ability to take HIV medication, it could alternately 
(or simultaneously) spur women towards persevering with HIV treatment.  
 
Figure 22. Pathways linking intimate partner violence to PMTCT uptake 
While motherhood was a protective element and a resilience strategy for some 
participants, this finding contains critical contradictions. Our findings reflect that women’s sense 
of self around the time of pregnancy can be grounded in the infant relationship (Bhandari et al., 
2012), and that striving for motherhood may be an active coping strategy (Burnett et al., 2015; 
Foster et al., 2015). Motherhood can represent an important “turning point” when women start to 
consider leaving a violent relationship for the sake of the infant (Semaan et al., 2013: 74). 
However, there is a less positive aspect to the motherhood identity, as it necessarily expects that 
mothers will be the nurturing caretaker and sacrifice her own needs for that of her child (Hays, 
1998). When, in the context of IPV, women may not be fully able to protect their infants from 
psychological and physical harm, they may be held responsible for failure to protect the child, 
even as they themselves require protection (Lapierre, 2008). The shame associated with both IPV 
and HIV may be compounded with the shame of being a ‘bad mother’, which could only worsen 
mental and physical health outcomes. 
The pathway of partner non-disclosure seems to reveal both negative aspects of IPV as 
well as resilience strategies used by women. This tension between women being both constrained 
by the violence while also being agentic in their response has been highlighted in previous IPV 
literature (Campbell & Mannell, 2016; Turan et al., 2016). In our sample, partner non-disclosure 
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made it challenging for some women to take treatment openly and consistently (Awiti Ujiji et al., 
2011; Sayles et al., 2006). Yet, for others, non-disclosure was an important safety strategy. 
Women in this sample made strategic choices to stay safe from violent reprisals by placing 
medication in other containers, taking it at times when partners would be away, and by moving 
out from home altogether. Importantly, non-disclosure was also a method for regaining control 
over chaotic lives. It is important to note that this ‘agentic’ finding around non-disclosure 
strategies may have emerged partly because of our narrative approach to data collection. 
Constructing meaning through narratives is a particularly useful approach to violence research, as 
it restores agency and power among a group that is often considered the “helpless victim” 
(Boonzaier & van Schalkwyk, 2011: 278). Notwithstanding the methodological considerations of 
this conclusion, the strong evidence from nine women in our cohort suggests that women do use 
important strategies to avoid partner disclosure while staying faithful to HIV medication 
adherence. 
Pathways of partner control and mental health offered ‘negative’ influence on PMTCT 
behaviors. For several women, relationship control led to an inability to attend the clinic or take 
medication when desired (Lichtenstein, 2006). More often, however, partner control manifested 
as a sense of isolation and inability to define one’s own choices about health, movement outside 
the home, or taking care of the infant. The isolation caused by severe partner control meant that 
women had little access to social resources to help them (Liang et al., 2005). Isolation also 
contributed towards the mental health pathway, with women reporting increased anxiety and 
distress due to being alone.  
Our findings certainly support extant literature by suggesting that IPV leads to emotional 
trauma, anxiety, suicidal ideation, and depression among women, including in antenatal care 
(Ellsberg et al., 2008; Mahenge et al., 2013) and that poor mental health has onward impact on 
HIV medication adherence (Sumari-de Boer et al., 2012). We add to this evidence base by 
highlighting the complex underpinnings behind the IPV-mental health connection. On the more 
manageable side of the spectrum, women in violent relationships have stress and emotional 
concerns that take priority over the daily regimen of medication. For other women, on the more 
extreme side, a sense of hopelessness and being overwhelmed due to the extreme distress of 
violence led to the potential for self-harming behavior. In the six cases of women who described 
suicidal ideation, several used the act of stopping treatment as part of thoughts of ending their 
own lives. Others have noted that women’s vulnerability to abuse may create a self-image of 
being damaged, inhibiting self-care and access to regular health services (Leenerts, 1999; 
Rothenberg & Paskey, 1995). Our findings go beyond this literature by noting that HIV 
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medication – due to its very necessity for good health – can be used in a self-harming manner 
through intentional treatment interruptions. 
Limitations 
The findings of this study should be viewed in light of several limitations. All participants were 
visiting antenatal care, limiting our ability to understand these dynamics among women who 
avoid healthcare in pregnancy. Similarly, participants in this sample all reported IPV 
victimization (a majority with recent violent episodes), limiting a comparison to women living 
without IPV. Purposive selection of participants preclude our ability to generalize these data to 
the entire parent trial cohort, a limitation of most qualitative research. The urban Johannesburg 
setting has distinctions from other sub-Saharan African health settings, which makes it 
challenging to compare findings. Our narrative, social constructionist approach to interviews 
intentionally focused on techniques like validation, highlighting resistance, and locating identity 
within participant stories. Therefore, our interpretations are likely to differ from that of a ‘neutral 
observer’, as utilized within a more positivist research paradigm. Nevertheless, this study 
provides initial impressions of violence among HIV-positive pregnant/postpartum women in a 
sample that is larger than the extant literature. 
Implications for intervention, research & policy 
Several intervention strategies emerge from these data. With appropriate training, supervision, 
and tools, health workers in antenatal settings could be the first point of contact for pregnant, 
abused women. The ‘window of opportunity’ in antenatal care, when women are repeatedly 
visiting the clinic, can ensure that violence and HIV considerations are jointly addressed– 
particularly through onwards referral to services that specialise in addressing violence. The 
current method of group-based PMTCT messaging should be refined towards an individually-
tailored approach that truly addresses the concerns, confusions, and daily lives of pregnant and 
postpartum women. Open, honest discussions at this phase in a woman’s life may have benefits 
for staying safe while adhering to crucial PMTCT interventions. The notion of ‘striving for 
motherhood’ can also be harnessed during this time, to help women prioritize their own health 
and safety as another form of commitment to the infant. It is clear that the intertwined issues of 
mental health and disclosure need to be incorporated into PMTCT services, and this can be 
achieved by training antenatal staff to implement brief mental health interventions or through 
referrals. Social support in the form of skillfully-facilitated peer support groups could assist 
women with the isolation pathway that is so pervasive in abusive partnerships.  
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These qualitative findings suggest several avenues for further research. Given the 
potential positive and negative ways that violence may impact HIV adherence, future quantitative 
research should extend beyond simplistic analytic techniques. To date, the literature has been 
limited to bivariate association between violence and HIV adherence. Simple regression 
techniques may fail to account for important meditational pathways between IPV and adherence. 
In one recent study, for example, the direct association between IPV and HIV adherence was non-
significant, yet when mediated by mental health there was a strong negative path association 
(Malow et al., 2013). Specific pathways identified in this research should be explored and 
confirmed in a larger, quantitative sample using techniques that recognize the interrelated nature 
of pathways, such as structural equation modeling. 
PMTCT policy could also benefit from these qualitative findings. Current South African 
PMTCT guidelines discuss the “benefits” of partner HIV disclosure and prompt health workers to 
“encourage” disclosure and “support…partner notification” (South African Department of Health, 
2014: 37). However, no mention is made of the safety dilemmas that mothers may face in 
disclosing to a violent partner. We learned that partner non-disclosure is a strategic way to stay 
safe in a violent relationship, and that some women can manage to safely continue treatment 
without their partners finding out. Given that 25-35% of South African women experience IPV in 
pregnancy (Dunkle et al., 2004b; Groves et al., 2012), the omission of strategic non-disclosure in 
current guidelines is likely to burden health workers, who are currently unskilled at discussing 
partner dynamics. 
Conclusion 
IPV and HIV are strongly linked in the lives of childbearing women in many settings globally, 
and violence leads to adherence challenges that place maternal and infant health at risk. These 
intersecting issues deserve increased attention if we are to ensure elimination of vertical HIV 
transmission and protect the health of mothers globally. Current policy and intervention is sorely 
lacking, with little evidence that health workers and policy makers are alert to the considerations 
of violence within PMTCT programming. Pregnant and postpartum women will greatly benefit 
from antenatal care that recognizes the realities of living in violent relationships and emboldens 
women to prioritize their own health, as well as the health of their infants, during this critical 
phase. 
(Department of Health, 2014). (Boonzaier & van Schalkwyk, 2011) (Semaan et al., 2013a)
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Introduction 
Prevention of mother-to-child transmission (PMTCT) interventions have potential to eliminate 
transmission of HIV from mothers to infants (Mofenson, 2010b). Yet, for a variety of reasons, 
women’s adherence to all the steps required for successful PMTCT is often low. For example, 
only 65% of eligible pregnant women in priority countries are able to access HIV treatment 
(WHO et al., 2013) and half stay retained in HIV care throughout pregnancy (Sibanda et al., 
2013). Pooled analysis shows that while 75% of pregnant women are adherent to antiretroviral 
treatment (ART) during pregnancy, only 53% adhere to treatment postpartum (Nachega et al., 
2012).  
Adherence to ART in pregnancy is associated with lower HIV viral loads in pregnant 
women (Bardeguez et al., 2008; Kiarie et al., 2003). The implications for maternal, infant, and 
paternal health are marked, since lower viral loads mean that women are healthier and they have 
lower risk of passing HIV to infants or partners (Cohen et al., 2011; Mugo et al., 2011; Volmink 
et al., 2007). Women who report at least 90% treatment adherence postpartum have 60% lower 
relative risk of transmitting HIV to their infants by 38 weeks of age (Davis et al., 2014). Despite 
these promising health gains associated with ART adherence, across sub-Saharan African settings 
adherence tends to worsen during the postpartum phase (Henegar et al., 2015; Ngarina et al., 
2015).  
Intimate partner violence (IPV) may be one important factor related to sub-optimal ART 
adherence in pregnancy and postpartum, yet this association has been understudied in the 
literature (Gari et al., 2013). Understanding the relationship between IPV and adherence has, to 
date, been limited to cross-sectional studies among non-pregnant women. A meta-analysis of this 
evidence base suggests that women’s lifetime experience of IPV is associated with 55% lower 
odds of self-reported ART adherence and 36% decreased odds of viral suppression (Hatcher et 
al., 2015b). Following publication of the meta-analysis, one study showed that IPV victimization 
was correlated with non-adherence among pregnant, Zambian women (Hampanda, 2016). In that 
cross-sectional study, experience of lifetime IPV was associated with 74% lower odds of 
treatment adherence during pregnancy and 89% lower odds of adherence postpartum (Hampanda, 
2016). No studies have explored the relationship between recent IPV and ART adherence, and no 
studies have, to our knowledge, employed a longitudinal design. 
In order to fill the gaps in the literature around IPV and ART adherence, we conducted a 
cohort study with HIV-positive pregnant women in South Africa. Women were recruited during 
antenatal care and followed up to 24 weeks postpartum. We assessed longitudinal associations 
between experiencing recent (past 12-months) IPV at baseline and self-reported ART adherence 
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in the final month of pregnancy. We also assessed longitudinal associations between IPV during 
pregnancy and self-reported adherence postpartum. Lastly, we used structural equation modeling 
to examine pathways from recent IPV to ART adherence in pregnancy and postpartum. 
 
Methods 
This study was conducted in urban Johannesburg, South Africa, where HIV and IPV are highly 
prevalent. An estimated 25 – 35% of South African pregnant women report recent physical and/or 
sexual IPV (Groves et al., 2012; Hoque et al., 2009). Similarly, antenatal HIV prevalence across 
South Africa is high, with population-based surveys estimating 28.6% of pregnant women 
attending public clinics in Johannesburg are living with HIV (Wabiri et al., 2016). South Africa 
has made significant strides towards reducing mother-to-child transmission from 14% in 2009 to 
an estimated 5% in 2012 (UNAIDS, 2013), but only 54-65% of South African pregnant women 
and infants complete all recommended PMTCT steps (Clouse et al., 2013a; Technau et al., 2014; 
Woldesenbet et al., 2015).  
Study Recruitment and Procedures 
This analysis was nested within a randomised controlled trial testing an intervention for IPV in 
pregnancy (Pallitto et al., 2016). Called Safe & Sound, the trial recruited pregnant women 
(n=1543) from four antenatal clinics in Johannesburg to take part in baseline questionnaires. 
Women who reported any recent (past-year) physical and/or sexual IPV in the baseline 
questionnaire were invited to participate in the randomized controlled trial. For the current study, 
we followed all women randomised into the trial who were living with HIV and recent IPV 
(n=148) and we purposively followed a portion of those excluded from the trial (i.e. no recent 
physical or sexual IPV) but living with HIV (n=117), for a total of 265 women followed 
prospectively.  
Data Collection and Measures 
Data collection occurred at two timepoints: during the woman’s first antenatal clinic visit 
(baseline) and during clinic visit when the infant was between 6 weeks and 24 weeks old 
(postpartum). Baseline and postpartum visits entailed a one-hour questionnaire administered by a 
trained nurse researcher. The questionnaire was completed on paper forms in English or the local 
language of the participant’s choice (isiZulu or Sesotho). 
Adherence to antiretroviral medication in pregnancy and postpartum was measured 
through self-report using a visual analog scale (VAS). The 30-day VAS has been validated in 
South Africa and elsewhere (Peltzer et al., 2010a; Walsh et al., 2002), and shows strong 
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correlation with measures such as electronic medication monitoring and unannounced pill counts 
(Kalichman et al., 2009). To use the VAS, participants mark a point along a continuum showing 
how much ART they took in the past month (Giordano et al., 2004). We asked women at follow-
up to report on their adherence during the final month of pregnancy and during the past 30-days 
postpartum. For bivariate analysis, we dichotomized adherence at 90%, a cut-off point based on 
previous studies (Davis et al., 2014; Mepham et al., 2011; Simoni et al., 2006). For the final 
structural equation model, we analyzed VAS as a continuous variable (0 – 100% adherence). 
Intimate partner violence was measured using 13 items from the IPV instrument of the 
WHO Multi-Country Study questionnaire (Garcia-Moreno et al., 2006). This instrument measures 
physical, sexual, and psychological IPV in the past year and has been used in sites globally to 
measure IPV prevalence, including in South African studies (Dunkle et al., 2004a; Jewkes et al., 
2010; Jina et al., 2012; Townsend et al., 2011). Each item asks behaviorally-specific questions 
(e.g. “How often has your partner pushed you or shoved you or pulled your hair?”) and responses 
were scored on a four-point Likert-type scale with choices of 1 (“never”), 2 (“once”), 3 (“a few 
times”), or 4 (“many times”). We added one additional question to account for psychological 
violence in the form of forced exile from the family home: “Has your partner ever forced you to 
leave the house?” The WHO instrument was analyzed as a dichotomous outcome (any physical 
and/or sexual IPV). We used Tsai et al.’s approach to generating an IPV intensity index from 
equally weighted averages of thirteen z-scores (for which each item was standardized to a mean 
of 0 and standard deviation of 1) (Tsai et al., 2016). Higher values of this index denote greater 
intensity of IPV. The measure loaded as a single factor during confirmatory factor analysis, and 
the index had good internal reliability (baseline Chronbach’s 𝛂 = 0.86; follow-up 𝛂 = 0.88).  
Mental health was conceptualized as including anxiety, depression, and post-traumatic 
stress. The Hospital Anxiety and Depression Scale was used as a brief screener of anxiety and 
depression (Zigmond & Snaith, 1983). Women are asked about 7 symptoms of anxiety and 7 
symptoms of depression, and rate the frequency of experiencing each symptom over the past 
week on a 4-point likert scale. Summing the scores for seven anxiety items or seven depressive 
items gives an overall score for symptomology of each condition, and the scale demonstrated 
acceptable reliability (anxiety Cronbach’s 𝛂 = 0.74; depression Cronbach’s 𝛂 = 0.84). A score of 
≥ 8 is considered clinically significant, though when possible we analyzed the scores as 
continuous variables. The Harvard Trauma Questionnaire asks women to rate on a 4-point likert 
scale how often they experience a set of 15 trauma symptoms in the past week (Mollica et al., 
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1992). Mean scores ≥ 2.07 indicate probable PTSD in the South African setting (Myer et al., 
2008) and the scale demonstrated strong reliability (Cronbach’s 𝛂 = 0.86). 
Controlling behaviors was measured using 5 items from the IPV instrument of the WHO 
Multi-Country Study questionnaire (Garcia-Moreno et al., 2006). These items ask whether the 
partner has used control in the form of telling a woman what to wear, who she can see, or has 
prohibited her access to friends and family. Partner’s use of controlling behaviors were summed, 
for a total score of five if a partner used every form. As a scale, this measure demonstrated 
acceptable reliability (Cronbach’s 𝛂 = 0.79). ANC visits were measured as a proxy for health care 
engagement. Using a single item asking women to self-report the number of ANC clinic visits at 
follow-up, we calculated this as a continuous variable. Disclosure was measured by two 
dichotomous items at baseline and follow-up: “Does your partner know your HIV status?”, “Did 
you disclose it to him?”. Partner disclosure was assessed as an affirmative response to both 
questions. 
 Socio-demographics included a range of self-reported measures. Age was measured in 
self-reported years. Food insecurity was measured using the 3-item, validated Household Hunger 
Scale (Deitchler et al., 2010), and a woman was considered food secure if she had no or little 
household hunger (score of ≤ 2). Level of education was measured using self-report of the highest 
grade completed. Other covariates included time living with HIV, time on ART, and infant age at 
follow-up. Gravidity and parity were measured by asking women two questions about previous 
pregnancies. New HIV diagnosis was assessed as women who test positive for the first time 
during this pregnancy. All socio-demographics were included in models as continuous variables. 
Clinic site refers to the site of antenatal care and clustering by clinic was accounted for in final 
models. 
Data Analysis 
We conducted all analyses in Stata 13.1 (StataCorp LLC, College Station, TX). We used 
Cronbach’s alpha to test the internal consistency of included scales. We conducted bivariate 
analysis of the outcome variable (adherence in pregnancy or postpartum) and key predictors. 
Bivariate analyses (t-test, 𝝌2 test) were conducted to examine differences by adherence status for 
normally distributed variables. We assessed non-normally distributed study variables (parity, 
education, time with partner, time on ART, controlling behaviors, intensity of IPV, postpartum 
age at follow-up) using nonparametric bivariate analyses (Mann-Whitney U test). 
To measure the association between recent IPV and adherence to HIV medication, we 
initially conducted bivariate logistic regression models. We then adjusted for socio-demographics 
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associated with adherence at p ≤ 0.20, a method of ensuring conceptually important variables are 
retained in the final models. Using stepwise backwards elimination, we dropped variables with 
non-significant p-values. All odds ratios are reported at the significance level of 0.05. 
We next conducted Structural Equation Modelling (SEM) to explore relationships 
between IPV, potential mediators, and HIV adherence. The method of SEM was maximum 
likelihood estimation. First we used exploratory factor analysis to determine the correct 
measurement model for the latent variables: IPV at baseline and IPV at follow-up. For indicators 
to be retained in the final latent variable, each observed variable needed to load with a factor 
loading of at least 0.40. In the case of IPV at follow-up, this requirement led to the dropping of 
three sexual violence items. Thus, IPV at follow-up specifically measures intensity of physical 
and psychological IPV only.  
We then used bivariate regression and evidence from our previous qualitative work 
(Hatcher et al., 2016b; Hatcher et al., 2014) to guide preliminary model building. Model 
modifications were performed based on modification indices and theoretical plausibility. After 
deriving a path model solution, we regressed each observed and latent construct on the socio-
demographic predictors that showed a bivariate association: age (years); food security (household 
hunger scale); education (years completed); time since ART initiation (days). Once model fit was 
satisfactory, we trimmed non-significant paths and redrew the final model.  
The magnitudes of standardized parameters were assessed using Cohen's typology of 
small (≤0.10 or less), medium (0.30), and large (≥ 0.50) effect sizes (Cohen, 1977). Measures for 
model fit included an absolute measure (standardized root-mean-square residual (SRMR)), a 
parsimonious measure (root-mean-square error of approximation (RMSEA)) and an incremental 
measure (Bentler’s comparative fit index (CFI)) (Bentler, 1990; Steiger, 1990). Acceptable model 
fit assumed the model met the following criteria: SRMR<0.08; RMSEA<0.08 for reasonable fit 
and <0.05 for good fit; and CFI≥0.90. We report on the 𝝌2 fit statistic but note that it is less 
valuable as a measure of model fit given its tendency to inflate in large sample sizes (Hooper et 
al., 2008). 
Ethical and safety considerations 
Participation in the research was contingent on written informed consent and participants were 
reimbursed for their transportation to the clinic (equivalent of US $7). The parent trial received 
approval from the University of the Witwatersrand Human Research Ethics Committee 
(M121179) and WHO Ethics Research Committee (RPC471).  
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Given the special considerations of researching IPV, all portions of this study were 
designed to adhere to the WHO ethical guidance on IPV research (WHO, 2001). The research 
was presented broadly so that the specific nature of the study was not made public. Only when the 
participant and interviewer were alone did the researcher provide further information that the 
nature of the study involved HIV and IPV. A 30-hour technical training alongside weekly 
mentorship and debriefing by senior team members ensured all nurse researchers had the 
technical knowledge and therapeutic insight required to contain disclosure of violence. Women 
were invited to participate in the longitudinal study through follow-up phone calls using 
information they provided on their locator form. Phone calls were initiated by the nurse who 
enrolled participants in the trial initially, in order to ensure participants felt safe and comfortable. 
Male partners were never informed about a woman's participation in the research because of the 
potential for an abusive partner to react violently. In the case of phoning participants, and the risk 
that partners will hear them, nurses were trained to ask “is this a safe time to speak?” before 
continuing. A full distress protocol included appropriate researcher responses in cases of violence 
disclosure, psychological distress, high emotionality, or a need for onwards referrals. 
  
 Results 
Descriptive characteristics 
The cohort was comprised of 265 pregnant women living with HIV. Because the follow-up was 
done purposively, it is not feasible to calculate a loss-to-follow-up rate for this cohort. Table 11 
presents the distributions of each observed predictor variable, separately for adherent and non-
adherent women. Participants were between 18 and 49 years old and just over one-third had high 
school education. Participants had a median of 1 child prior to this pregnancy and had, on 
average, been with their current partner for 4 years. At baseline, 64.5% of the sample had 
experienced at least one form of recent (past 12 months) physical, sexual, and/or psychological 
violence from a partner.  
The majority of participants (92.8%) reported good ART adherence during the final 
month of pregnancy (taking ≥ 90% of treatment). Similarly, self-reported adherence during the 
postpartum period was high, with 94.3% reporting adherence during the past 30 days prior to 
postpartum follow-up visit. Many women in the cohort (58.9%) were diagnosed with HIV during 
the current pregnancy, and most had first initiated ART within the past year (median 259 days 
before follow-up visit). Most women (82.2%) had disclosed their HIV status to a male partner. 
The burden of disease related to mental health conditions was high. At baseline, 39.3% had 
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probable anxiety and half (50.9%) had probable depression. Probable PTSD occurred within one-
quarter (26.8%) of the sample.  
 
Bivariate results 
Bivariate associations between potential predictors and adherence are presented alongside the 
relevant test statistic (Table 11). Socio-demographic characteristics associated with adherence 
during the final month of pregnancy included having a high school education, being food secure, 
and more time elapsed since ART initiation. Age was the only socio-demographic predictor 
associated with postpartum adherence, with older women being more/less likely to be adherent.  
Potential mediators associated with adherence in bivariate analyses were related to 
healthcare utilization and mental health. Women reported a median of five ANC visits during the 
current pregnancy, with those reporting fewer ANC visits significantly more likely to fall into 
non-adherence groups in pregnancy and postpartum. At baseline, probable depression and anxiety 
were significantly associated with non-adherence to ART. At follow-up, only probable anxiety 
was associated with non-adherence. 
 As shown in Table 11, a significantly higher proportion of women in the non-adherent 
group experienced one or more forms of recent physical and/or sexual IPV at baseline (84.2% 
versus 47.6% in the adherent group, p=0.002). Similarly, non-adherent women were more likely 
to report any psychological violence at baseline and higher levels of controlling male partner 
behaviors at baseline (84.2%) than adherent women (55.7%, p=0.015). During the course of 
follow-up, non-adherent women were more likely to report additional incidents of physical and/or 
sexual IPV (46.7% versus 25.6% among adherent women), although this findings was only 
marginally significant (p=0.07). Non-adherent women were more likely to report new incidents 
of psychological violence during the follow-up period (66.7% versus 36.0% in adherent women, 
p=0.017). 
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Table 10. Bivariate associations between predictors and adherence in pregnancy and postpartum (n=265) 
Table	  11:	  Bivariate	  association	  between	  predictors	  and	  adherence	  in	  pregnancy	  and	  postpartum	  n=265	  
	  
	  	   Total	  cohort	  	  	  	  	   Adherence*	  in	  pregnancy	   Adherence*	  postpartum	  
	  	  
Median	  (IQR)	  
or	  Number	  (%)	  
Non-­‐
adherent	  	  
Adherent	  	   p	  value	  	  	  	   Non-­‐
adherent	  	  
Adherent	  	   p	  value	  	  	  	  
  
n=246	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Mean	  or	  %	  
n=19	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Mean	  or	  %	  
(𝝌2,	  
wilcoxon,	  
or	  t-­‐test)	  
n=250	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Mean	  or	  %	  
n=15	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Mean	  or	  %	  
(𝝌2,	  
wilcoxon,	  
or	  t-­‐test)	  
Socio-­‐demographics	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Age	  (years)	   29	  (25	  -­‐	  33)	   28.5	   29.2	   0.617	   26.6	   29.3	   0.062	  
High	  school	  education	   102	  (38.5%)	   15.8%	   40.2%	   0.040	   26.7%	   39.2%	   0.330	  
Number	  of	  children	   1	  (1	  -­‐	  2)	   1.5	   1.2	   0.720	   1.1	   1.3	   0.439	  
Time	  with	  partner	  (years)	   4	  (4	  -­‐	  7)	   4.6	   5.0	   0.943	   4.2	   5	   0.849	  
Food	  secure	   221	  (83.4%)	   57.9%	   85.4%	   0.002	   73.3%	   84.0%	   0.281	  
HIV-­‐related	  Characteristics	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Newly	  diagnosed	  	   156	  (58.9%)	   63.2%	   58.5%	   0.693	   46.7%	   59.6%	   0.323	  
Number	  of	  ANC	  visits	   5	  (4	  -­‐	  6)	   4.5	   5.6	   0.012	   4.6	   5.5	   0.074	  
Time	  since	  ART	  initiation	  (days)	   259	  (197	  -­‐	  816)	   344	   711	   0.045	   554	   692	   0.990	  
Disclosed	  to	  partner	   218	  (82.2%)	   78.9%	   82.5%	   0.694	   80.0%	   82.4%	   0.813	  
Postpartum	  duration	  (days)	   55	  (43	  -­‐	  82)	   	  -­‐	   	  -­‐	   	  -­‐	   68.8	   66.7	   0.854	  
Mental	  Health	  (at	  baseline)	   	  	   	  	   	  	  
Probable	  depression	   135	  (50.9%)	   73.7%	   49.2%	   0.040	   60.0%	   50.4%	   0.470	  
Probable	  anxiety	   104	  (39.3%)	   57.9%	   37.8%	   0.084	   53.3%	   38.4%	   0.250	  
Probable	  PTSD	   71	  (26.8%)	   31.6%	   26.4%	   0.625	   40.0%	   26.0%	   0.234	  
Mental	  Health	  (at	  follow-­‐up)	   	  	   	  	   	  	  
Probable	  depression	   96	  (36.2%)	   	  -­‐	   	  -­‐	   	  -­‐	   46.7%	   35.6%	   0.386	  
Probable	  anxiety	   42	  (15.9%)	   	  -­‐	   	  -­‐	   	  -­‐	   33.3%	   17.4%	   0.056	  
Intimate	  partner	  violence	  (past	  12-­‐months	  at	  baseline)	   	  	   	  	   	  	   	  	   	  	  
Any	  physical	  and/0r	  sexual	  IPV	   146	  (55.1%)	   84.2%	   47.6%	   0.002	   80.0%	   48.4%	   0.017	  
Any	  psychological	  violence	   153	  (57.7%)	   84.2%	   55.7%	   0.015	   100.0%	   55.2%	   0.001	  
Number	  of	  controlling	  behaviors	   2	  (0	  -­‐3)	   2.6	   1.7	   0.013	   2.3	   1.7	   0.134	  
Intimate	  partner	  violence	  (between	  baseline	  and	  follow-­‐up	  visits)	   	  	   	  	   	  	   	  	   	  	  
Any	  physical	  and/0r	  sexual	  IPV	   31	  (11.7%)	   	  -­‐	   	  -­‐	   	  -­‐	   46.7%	   25.6%	   0.074	  
Any	  psychological	  violence	   100	  (37.7%)	   	  -­‐	   	  -­‐	   	  -­‐	   66.7%	   36.0%	   0.017	  
Number	  of	  controlling	  behaviors	   1	  (0	  -­‐	  2)	   	  -­‐	   	  -­‐	   	  -­‐	   1.7	   1.1	   0.052	  
*	  Adherence	  is	  defined	  as	  ≥90%	  self-­‐reported	  adherence	  in	  final	  month	  of	  pregnancy	  and	  last	  30	  days	  postpartum	  
IQR:	  inter-­‐quartile	  range;	  ANC:	  antenatal	  care;	  ART:	  antiretroviral	  treatment;	  PTSD:	  post-­‐traumatic	  stress	  disorder	  
 
Table 11 presents the bivariate odds ratios for ART adherence, by reporting any physical 
and/or sexual violence at baseline. Women reporting IPV at baseline had 84% lower odds of 
adherence in the final month of pregnancy (odds ratio [OR]=0.16, 95% confidence interval 
[CI]=0.05-0.57) and 78% lower odds of adherence postpartum (OR=0.22, 95% CI=0.06-0.81). 
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Multivariate results 
In Table 12, models are presented to explore multivariate logistic regression for adherence in 
pregnancy and postpartum. Model 1, for each adherence time-point, controls only for socio-
demographics. During pregnancy, higher IPV intensity is associated with lower odds of 
adherence after controlling for education, food security, time on ART, and age (adjusted 
[A]OR=0.90, 95% CI=0.85-0.97). Higher IPV intensity at baseline is associated with lower odds 
of postpartum adherence after controlling for age (AOR=0.90, 95% CI=0.85-0.96).   
Model 2 adds potential covariates of health care utilization and mental health into the 
logistic regression. In pregnancy, the odds of adherence are significantly lower as IPV intensity 
increases, even when controlling for symptoms of trauma, depressive symptoms, anxiety 
symptoms, and number of ANC visits (AOR=0.93, 95% CI=0.86-0.99). IPV intensity during the 
course of follow-up and IPV intensity at baseline also retain significant associations with 
worsened adherence postpartum (AOR=0.91, 95% CI=0.84-0.99). The relationship between IPV 
intensity at baseline and postpartum adherence is partially mediated by anxiety, with increased 
anxious symptomology worsening odds of adherence (AOR=0.68, 95% CI=0.53-0.87). 
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Table 11. Adjusted associations between violence, mental health, and adherence 
Table	  12:	  Adjusted	  associations	  between	  IPV,	  mental	  health,	  and	  adherence	  
	  
   
  
Adherence	  in	  pregnancy	   	   Adherence	  postpartum	  
  
Model	  1	   Model	  2	  	   	   Model	  1	   Model	  2	  
 
Unadjusted	  OR	  (95%	  
CI)	  
Adjusted	  OR	  (95%	  
CI)	  
Adjusted	  OR	  (95%	  
CI)	  
Unadjusted	  OR	  
(95%	  CI)	  
Adjusted	  OR	  (95%	  
CI)	  
Adjusted	  OR	  (95%	  
CI)	  
Any	  physical	  and/or	  
sexual	  IPV	  at	  baseline	  
0.16	  (0.05	  to	  0.57)**	  
    
0.22	  (0.06	  to	  0.81)*	   	  	   	  	  
    	  	   	  	   	  	   	  	   	  	  
Baseline	  predictors	   	  	   	  	   	  	   	  	  
IPV	  intensity	  	   	  	   0.90	  (0.85	  to	  0.97)**	   0.93	  (0.86	  to	  0.99)*	   	  	   0.90	  (0.85	  to	  0.96)**	   0.91	  (0.84	  to	  0.99)*	  
Education	   	  	   2.24	  (1.04	  to	  4.77)*	   2.56	  (1.07	  to	  6.13)*	   	  	   	  -­‐	   	  	  
Food	  security	  	   	  	   0.79	  (0.65	  to	  0.96)*	   0.80	  (0.64	  to	  0.99)*	   	  	   	  -­‐	   	  	  
Time	  on	  ART	   	  	   1.00	  (0.99	  to	  1.00)	   1.00	  (0.99	  to	  1.22)	   	  	   	  -­‐	   	  	  
Age	   	  	   	  -­‐	   	  -­‐	   	  	   1.11	  (1.00	  to	  1.25)	   1.10	  (0.98	  to	  1.24)	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Baseline	  mediators	   	  	   	  	   	  	   	  	   	  	   	  	  
Trauma	  symptomology	   	  	   	  -­‐	   1.10	  (0.99	  to	  1.22)	   	  	   	  -­‐	   1.01	  (0/92	  to	  1.12)	  
Depressive	  
symptomology	  
	  	   	  -­‐	   0.90	  (0.76	  to	  1.08)	   	  	   	  -­‐	   1.11	  (0.92	  to	  1.35)	  
Anxiety	  symptomology	   	  	   	  -­‐	   0.83	  (0.68	  to	  1.03)	   	  	   	  -­‐	   0.84	  (0.67	  to	  1.05)	  
Number	  of	  ANC	  visits	   	  	   	  	   1.19	  (0.86	  to	  1.65)	   	  	   	  	   1.22	  (0.84	  to	  1.78)	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Follow-­‐up	  mediators	   	  	   	  	   	  	   	  	   	  	   	  	  
Depressive	  
symptomology	  
	  	   	  -­‐	   	  -­‐	   	  	   	  -­‐	   1.22	  (0.98	  to	  1.52)	  
Anxiety	  symptomology	   	  	   	  -­‐	   	  -­‐	   	  	   	  	   0.68	  (0.53	  to	  0.87)**	  
*	  p<0.05,	  **p<0.01,	  ***p<0.001	         
OR:	  odds	  ratio;	  CI:	  confidence	  interval;	  IPV:	  intimate	  partner	  violence;	  ART:	  antiretroviral	  treatment;	  ANC:	  antenatal	  care	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Structural equation models of adherence in pregnancy and postpartum 
Figure 21 shows the final structural equation model for adherence in the final month of 
pregnancy. Controlling behaviors co-vary with IPV intensity, but do not independently predict 
adherence, mental health, or health care utilization. IPV intensity moderately worsens adherence 
in pregnancy. 
IPV worsens adherence in pregnancy and also works through two mediating pathways. 
IPV considerably increases symptoms of anxiety, which in turn worsens adherence. It is 
important to note that anxiety co-varies to a strong degree with symptoms of depression and 
trauma. IPV has a strong effect on both depression and trauma symptomology. While depression 
does not directly impact on adherence, increased trauma symptomology in this sample improves 
adherence. IPV also moderately decreases the number of clinic visits, which are positively 
associated with adherence. The model fit for adherence in pregnancy was strong, as indicated by 
CFI, RMSEA and SRMR values (Goodness of model fit Chi-square=172.125 (df =139), p=0.03; 
CFI=0.981; RMSEA = 0.030; SRMR = 0.045). Table 3 presents the full measurement 
specifications of the final model. 
  
Figure 1. Final structural model of relationship between IPV, mental health, health care utilization, and adherence (n 
= 260). Relationships represented by standardized parameter estimates, with boxed indicating measured variables 
and oval representing latent variable. All relationships significant at the p<0.05 level unless noted. ª p=0.083. Model 
controls for education and food security. 
IPV: intimate partner violence; ANC: antenatal care; ε: error term. Goodness of model fit Chi-square = 172.125 (df = 
139) p = 0.03; CFI = 0.981; RMSEA = 0.030 (90% CI 0.010 - 0.040); SRMR = 0.045.
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 Figure 22 shows the final structural equation model for adherence postpartum. Mental 
health mediators are included in the model at both baseline and follow-up time points. Similarly, 
IPV and controlling behaviors are examined longitudinally, accounting for the fact that baseline 
propensity for these conditions will strongly influence follow-up experience. IPV intensity at 
baseline had a strong effect on anxiety symptomology at baseline, which independently predicted 
worse postpartum adherence. Anxiety at baseline worked through the pathway of continued 
anxiety symptoms at follow-up, which predicted worse adherence. Another important pathway 
was that IPV at baseline strongly predicted IPV at follow-up, which also led to anxiety and 
worsened adherence. There was no direct association between IPV at any stage and postpartum 
adherence, suggesting that the effect of IPV in the postpartum phase is fully mediated by mental 
health, specifically anxiety. The model fit for adherence postpartum was good, as indicated by 
acceptable values for CFI, RMSEA and SRMR (Goodness of model fit Chi-square=634.030 
(df=361), p=0.00; CFI=0.918; RMSEA=0.054; SRMR=0.060). Table 3 presents the full 
measurement specifications of the final model. 
 
Figure 2. Final structural model of longitudinal relationship between IPV, mental health, and adherence (n = 261). Relationships represented by 
standardized parameter estimates, with boxed indicating measured variables and oval representing latent variable. All relationships significant at 
the p<0.05 level unless noted. ª p=0.059. Model controls for age, education, and food security. 
IPV: intimate partner violence; B: baseline data; F: follow-up data ε: error term. Goodness of model fit Chi-square = 634.030 (df = 361) p = 0.00; 
CFI = 0.918; RMSEA = 0.054 (90% CI 0.047 - 0.061); SRMR = 0.060.
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Figure 24. Structural model of longitudinal relationship between IPV, mental health, and adherence (n=260) 
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Table 12. Structural equation model measurement 
Table	  13:	  Structural	  equation	  model	  measurement	  
     
 
Adherence	  in	  pregnancy	   	   	   Adherence	  postpartum	  
 
 
Standardised	  coefficient	   SE	   p	  value	   	  	   Standardised	  coefficient	   SE	   p	  value	  
Depressive	  symptoms	  at	  baseline	    	  	   	  	   	  	  
  
	  	  
⇦IPV	  intensity	  at	  baseline	   0.47	  (0.36	  to	  0.58)	   0.05	   <0.001	   	  	   0.49	  (0.38	  to	  0.59)	   0.05	   <0.001	  
Anxiety	  symptoms	  at	  baseline	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
⇦IPV	  intensity	  at	  baseline	   0.50	  (0.40	  to	  0.61)	   0.05	   <0.001	   	  	   0.51	  (0.42	  to	  0.61)	   0.05	   <0.001	  
Trauma	  symptoms	  at	  baseline	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
⇦IPV	  intensity	  at	  baseline	   0.45	  (0.34	  to	  0.56)	   0.06	   <0.001	  
 
	  -­‐	  	   	  -­‐	  	   	  -­‐	  	  
ANC	  Visits	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
⇦IPV	  intensity	  at	  baseline	   	  -­‐	  0.15	  (-­‐0.28	  to	  -­‐0.02)	   0.07	   0.025	   	  	   	  -­‐	  	   	  -­‐	  	   	  -­‐	  	  
Adherence	  in	  pregnancy	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
⇦Trauma	  symptoms	  at	  baseline	   0.25	  (0.10	  to	  0.41)	   0.08	   0.001	   	  	   	  -­‐	  	   	  -­‐	  	   	  -­‐	  	  
⇦Anxiety	  symptoms	  at	  baseline	   	  -­‐	  0.19	  (-­‐0.36	  to	  -­‐0.03)	   0.08	   0.018	   	  	   	  -­‐	  	   	  -­‐	  	   	  -­‐	  	  
⇦ANC	  visits	   0.10	  (-­‐0.01	  to	  0.22)	  	   0.06	   0.083	   	  	   	  -­‐	  	   	  -­‐	  	   	  -­‐	  	  
⇦IPV	  intensity	  at	  baseline	   	  -­‐	  0.22	  (-­‐0.38	  to	  -­‐0.06)	   0.08	   0.007	   	  	   	  -­‐	  	   	  -­‐	  	   	  -­‐	  	  
Depression	  at	  follow-­‐up	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
⇦Depression	  at	  baseline	   	  -­‐	  	   	  -­‐	  	   	  -­‐	  	   	  	   0.41	  (0.32	  to	  0.51)	   0.05	   <0.001	  
⇦Controlling	  behaviors	  at	  follow-­‐up	   	  -­‐	  	   	  -­‐	  	   	  -­‐	  	   	  	   0.17	  (0.04	  to	  0.30)	  	   0.07	   0.008	  
⇦IPV	  intensity	  at	  follow-­‐up	   	  -­‐	  	   	  -­‐	  	   	  -­‐	  	   	  	   0.16	  (0.02	  to	  0.31)	   0.07	   0.028	  
Anxiety	  at	  follow-­‐up	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
⇦Depression	  at	  baseline	   	  -­‐	  	   	  -­‐	  	   	  -­‐	  	   	  	   0.19	  (0.06	  to	  0.32)	   0.07	   0.003	  
⇦Anxiety	  at	  baseline	   	  -­‐	  	   	  -­‐	  	   	  -­‐	  	   	  	   0.18	  (0.08	  to	  0.30)	   0.06	   0.001	  
⇦Controlling	  behaviors	  at	  follow-­‐up	   	  -­‐	  	   	  -­‐	  	   	  -­‐	  	   	  	   0.18	  (0.08	  to	  0.30)	   0.06	   0.01	  
⇦IPV	  intensity	  at	  follow-­‐up	   	  -­‐	  	   	  -­‐	  	   	  -­‐	  	   	  	   0.15	  (0.00	  to	  0.30)	  	   0.08	   0.059	  
Adherence	  postpartum	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
⇦Anxiety	  at	  follow-­‐up	   	  -­‐	  	   	  -­‐	  	   	  -­‐	  	   	  	   	  -­‐	  0.15	  (-­‐0.28	  to	  -­‐0.04)	   0.06	   0.012	  
⇦Anxiety	  at	  baseline	   	  -­‐	  	   	  -­‐	  	   	  -­‐	  	   	  	   	  -­‐	  0.16	  (-­‐0.28	  to	  -­‐0.04)	   0.06	   0.009	  
Controlling	  behaviors	  at	  follow-­‐up	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
⇦Controlling	  behaviors	  at	  baseline	   	  -­‐	  	   	  -­‐	  	   	  -­‐	  	   	  	   0.48	  (0.40	  to	  0.57)	   0.05	   <0.001	  
IPV	  intensity	  at	  follow-­‐up	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
⇦IPV	  intensity	  at	  baseline	   	  -­‐	  	   	  -­‐	  	   	  -­‐	  	   	  	   0.56	  (0.46	  to	  0.67)	   0.05	   <0.001	  
Adjusted	  for	  age,	  food	  security,	  and	  education	  
SE:standard	  error;	  IPV:	  intimate	  partner	  violence;	  ANC:	  antenatal	  care	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Discussion 
Recent IPV identified during antenatal care was associated with lower odds of adherence to HIV 
medication in pregnancy and postpartum in an urban, South African cohort. This study is the first, 
to our knowledge, to longitudinally assess the effects of recent IPV on adherence to ART among 
pregnant or postpartum women. This association appears to be driven in part by mental health 
effects, with symptoms of anxiety mediating the relationship between IPV and HIV adherence. 
Even when accounting for mental health pathways, IPV retains a significant direct association 
with worsened ART adherence in pregnancy.  
In bivariate analysis, we found that any recent physical and/or sexual violence from a 
partner was associated with 84% lower odds of good ART adherence in the final month of 
pregnancy and 78% lower odds of adherence postpartum. This association aligns with one 
previous Zambian study which showed similar marked effects of IPV on adherence in pregnancy 
(Hampanda, 2016). This association was retained in multivariate regression models, with greater 
IPV intensity worsening adherence in a dose-response effect.  
In this study, IPV intensity independently worsened HIV adherence, but also worked 
through important mental health pathways. Anxiety, in particular, seems to act as the “pivot” 
around which IPV worsens adherence. Mental health had varied effects on adherence in our 
analyses, with anxiety worsening adherence, while trauma symptomology actually improved it. 
Post-traumatic stress symptoms may operate in an unexpected direction because clinical 
characteristics of this phenomenon may be linked to greater attention to treatment behaviors. For 
example, hyper-vigilance associated with trauma could lead someone to attentively (or 
obsessively) take pills at a certain time of day. Other literature on PTSD has suggested that ART 
adherence may be equivocal or even better in patients with traumatic symptomology (Nilsson 
Schonnesson et al., 2007; Sledjeski et al., 2005; Vranceanu et al., 2008). Trauma may worsen 
ART adherence only in certain cases, such as when patients dissociate from the traumatic event 
(Delahanty et al., 2004; Keuroghlian et al., 2011), whereas for others, symptoms of PTSD may 
lead towards self-protective behaviors or post-traumatic growth (personal resilience occurring 
after trauma) that actually improve adherence (Sherr et al., 2011). The magnitude of the effect of 
trauma on adherence is similar in the positive direction to that of anxiety in the negative direction, 
suggesting that these two mental health issues may possibly “cancel out” one another in 
traditional regression analysis. 
Another potential mediating pathway identified in this analysis is health care utilization. 
Higher intensity of IPV was related to a lower number of ANC visits. In turn, fewer ANC visits 
were predictive of lower odds of adherence in pregnancy. This aligns with literature from 
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resource-rich settings suggesting that IPV may be associated with a woman postponing the start 
of antenatal care or avoiding it altogether (Diaz-Olavarrieta et al., 2007; Dietz et al., 1997; 
Thananowan & Heidrich, 2008). Longitudinal research from the U.S. suggests that IPV leads to 
twice the odds of missing antenatal care or delaying it until third trimester (Goodwin et al., 2000; 
Subramanian et al., 2012). Our study is the first, to our knowledge, that assesses IPV and health 
care utilization among pregnant, HIV-positive women in sub-Saharan Africa. In a setting like 
urban South Africa, where 87% of women access the recommended four antenatal visits (Shisana 
et al., 2010), it is possible that IPV is a marker for the small proportion of women who are unable 
to access ANC. 
One theoretical reason for IPV’s influence on reduced ANC use could be men’s 
controlling behaviors, a pathway that has emerged in previous qualitative research (Hatcher et al., 
2014; Lichtenstein, 2006)). One reason that partner control did not statistically impact on ART 
adherence may be that it is actually a form of IPV and should not be considered as a distinct 
pathway separate from partner violence (Heise & Garcia Moreno, 2002). Alternately, partner 
control may truly have less influence on adherence than we initially hypothesized, given that few 
women in this urban South African setting reported partners who interfere with access to clinic or 
medication, as we found in our previous qualitative research (Hatcher et al., 2016b). 
Indeed, during the postpartum phase, many women seem to adhere to HIV treatment 
despite partner violence and controlling behaviors. Several explanations are worth exploring to 
make sense of this finding. Prevalence of both anxiety and depression declined in the postpartum 
period, which aligns with findings from other settings (Heron et al., 2004). IPV and controlling 
behaviors also declined postpartum, which confirms findings suggesting that IPV before 
pregnancy sometimes leads to subsequent declines in violence postpartum (Koenig et al., 2006; 
Salazar et al., 2009). As others have noted, reduced IPV postpartum may arise from enhanced 
engagement with family (Salazar et al., 2009). Many women return to their maternal home 
instead of staying with male partners in Johannesburg, which could be protective because of the 
safe physical space (as men are often barred from entering due to cultural taboos about this being 
a time for maternal family only). By living with her family, a woman may be able to access 
increased social support, which has been shown to help buffer the effects of ongoing stressors and 
mental health (Glazier et al., 2004). It is also possible that psychological resilience during the 
early weeks postpartum moderates the effects of violence and mental health on adherence. In our 
previous research, we revealed that the identity around motherhood provided a resilience strategy 
for many women in this setting, helping them adhere to ART as a method for reinforcing their 
strong bond with the infant (Hatcher et al., 2016b). Alternately, for women who do continue to 
 
148 
stay with partners postpartum, this time may represent a “honeymoon” phase if men are focused 
on the baby rather than controlling the woman. 
Limitations 
The sampling strategy recruited women in the context of a trial of IPV in pregnancy, which likely 
led to an over-sampling of women reporting recent violence. This sampling strategy precludes the 
ability to make assumptions around population prevalence of IPV or mental health. The study is 
also limited by its collection of self-report data ART adherence. Adherence data was self-reported 
and may be subject to social desirability bias (Mills et al., 2006), although some studies suggest 
that self-reported adherence is reliably predictive of positive clinical outcomes (Ferradini et al., 
2006; Oyugi et al., 2004; van Oosterhout et al., 2005; Wools-Kaloustian et al., 2006).  High 
adherence in this sample may demonstrate that women have better adherence around the time of 
pregnancy (Vaz et al., 2007; Zorrilla et al., 2003), or may suggest measurement bias. 
Nevertheless, the directionality of the relationship with IPV and adherence would trend towards 
the null if the entire cohort systematically over-reported good adherence. 
Mental health screening tools developed primarily in resource-rich setting may be less 
appropriate for sub-Saharan African settings (Tsai et al., 2013). Given the challenges associated 
with identifying culturally-specific cut-points for depression, anxiety, and PTSD, we included 
these symptoms as continuous variables in the final models. This choice recognizes that even 
when symptomology fails to meet a clinical diagnosis, it can lead to psychosocial effects that are 
important to consider in public health programming (Judd et al., 1998). Our brief mental health 
screener, HADS, may be a better measure for general distress than either anxiety or depression 
alone (Norton et al., 2013), although confirmatory factor analysis in our sample did suggest a 
two-factor loading. 
Implications for future research and programs 
IPV is a driver of worsened ART adherence and poor mental health during antenatal care and 
postpartum for women living with HIV. It will be crucial for future interventions to achieve 
reductions in IPV alongside impacting inter-related mental health outcomes. Existing IPV 
interventions for antenatal care may be effective at reducing women’s experience of further 
violence (Kiely et al., 2010; Tiwari et al., 2005). However, the field of antenatal IPV 
interventions is in its infancy and several trials have failed to show a reduction in violence 
(McFarlane et al., 2006; Parker et al., 1999; Sullivan et al., 1994). Group interpersonal therapy, as 
well as home visiting programs have been shown to improve perinatal mental health in other low-
resource settings (Rahman et al., 2013), although only one such intervention has been effective 
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among HIV-positive, African populations (Nakimuli-Mpungu et al., 2015). A novel way to 
achieve violence, HIV, and mental health goals during antenatal care is to underpin an 
intervention with trauma-informed clinical care, an approach that our team is currently testing in 
Johannesburg (Woollett & Hatcher, 2016).  
It is important to note that the same dynamics that make pregnancy an opportune moment 
for intervention – the frequent contact with the health system and regular medical services – also 
makes it a challenging phase in which to implement new interventions. Time constraints faced by 
health providers make it particularly challenging for them to ask patients about their violent 
relationships (O'Reilly et al., 2010; Roelens et al., 2006), even as women require repeated inquiry 
to gain comfort and disclose around this sensitive topic (Edin et al., 2010; Lutz, 2005). In our 
team’s formative research, we learned that additional dedicated staff are needed to implement 
mental health-responsive IPV/HIV interventions in a busy antenatal clinic (Hatcher et al., 2016c), 
yet it may not be possible for clinics to add new staff or increase provider workloads. Health 
providers in urban Johannesburg express a desire for more guidance and training around 
addressing IPV (Sprague et al., 2015), but comprehensive staff support would require additional 
investment by a public health system already burdened by responding to high levels of HIV. One 
recommendation is to test the improvements in staff retention and morale that might occur 
following a mental health-responsive IPV/HIV intervention. If, like was the case during Safe & 
Sound, staff feel appreciated and supported through the intervention, they are likely to have 
improved productivity and longevity - elements that create a more efficient and high-quality 
health system. Economic costing of these types of interventions at a clinic level may actually 
suggest that they pay for themselves in the medium-term. 
It will be important for future studies to follow women longer in the postpartum phase, 
after the “protective” period of the first three months has concluded. This period may vary across 
cultures, but in South Africa there is strong recognition that women are closer to the maternal 
family during this early postpartum time (Groves et al., 2014). In our sample, there seemed to be 
considerable resilience around HIV adherence during the early postpartum phase, although that 
finding should be viewed in light of other literature that shows adherence worsens later in the 
postpartum phase (Henegar et al., 2015; Ngarina et al., 2015). A longer follow-up period 
postpartum can answer these questions in future research. Future studies should also include 
measures of motivation, resilience, and motherhood identity to understand how these dynamics 
may improve women’s adherence despite IPV.  
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Conclusion 
IPV is an important predictor of women’s ability to stay adherent to ART around the time of 
pregnancy. Yet, to date, few PMTCT programs consider couple-related factors when developing 
clinical protocols. For example, while global guidelines for HIV testing consider the role of IPV 
(World Health Organisation, 2012), the South African clinical guidelines for PMTCT fail to 
account for violent or non-supportive partners (Department of Health, 2014). Indeed, we found 
that health workers in urban Johannesburg know little about how to address IPV in pregnancy, 
despite a willingness to learn these skills (Hatcher et al., 2016c). The development of clinical 
guidelines can draw upon existing global guidance on IPV (WHO, 2016), or can adapt programs 
that successfully reduced women’s IPV in the perinatal phase (Jack et al., 2012; Kiely et al., 
2010; Tiwari et al., 2005).  
One important caveat is that, to date, no efficacious interventions have been rigorously 
tested for reducing IPV in pregnancy in low- or middle-income settings (Ritter et al., 2016). This 
gap in the research deserves increased attention and funding if global commitments around 
maternal health and HIV-related outcomes are to be reached. If future PMTCT programs train 
health workers to assess and respond to IPV in pregnancy, they will ensure not only improved 
maternal and infant health but also increased adherence to essential HIV services. 
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A. Introduction 
This dissertation aimed to explore the extent to which IPV influences adherence to PMTCT 
services. Specifically, it aimed to examine this association between IPV and adherence among 
pregnant and postpartum women living with HIV in inner-city Johannesburg. The doctoral 
work was designed to determine plausible mechanisms through which IPV may impact on 
ART adherence in pregnancy and postpartum. I used a mixed method approach that 
incorporated multiple points of interface between data methods to strengthen my ability to 
answer research aim. Four papers were drafted, of which three have been published: 
Paper 1: Systematic review of IPV and adherence (AIDS, 2015) 
Paper 2: Bidirectional links between IPV and PMTCT (JIAS, 2014) 
Paper 3: Mechanisms linking IPV and PMTCT (SSM, 2016) 
Paper 4: IPV, mental health, and adherence in pregnancy and postpartum (in draft)* 
* The final paper will be submitted following submission of the main Safe & Sound 
Trial paper (likely late-2017) 
Below, I synthesize the findings of the four papers in light of the current literature. I also 
suggest how the findings can inform future interventions and policy. I detail how this doctoral 
research can add to theoretical knowledge and suggest next steps for research. 
 
B. Key findings 
IPV impacts ART adherence among non-pregnant and pregnant women 
Prior to undertaking this doctoral research, the literature around IPV and ART adherence was 
disparate and had yet to be examined systematically. Through the meta-analysis (Paper 1), 
our team confirmed that lifetime exposure to IPV was associated with half the odds of self-
reported adherence and 36% lower odds of viral suppression. The meta-analysis was 
comprised of only cross-sectional papers from resource-rich settings, suggesting an important 
gap in understanding the IPV-adherence relationship in resource-constrained settings such as 
South Africa. 
We bolstered the extant literature by examining recent IPV and its association with 
ART adherence in pregnant and postpartum women (Paper 2-4). Since the time of publication 
of the meta-analysis (Paper 1), a single peer-reviewed article had examined a similar dynamic 
in Zambia. Hampanda found that lifetime experience of IPV predicted 74% lower odds of 
ART adherence during pregnancy and 89% lower odds of adherence postpartum (Hampanda, 
2016). However, Hampanda’s study was cross-sectional in nature and only accounts for 
lifetime IPV, limiting the ability to confirm directionality of the association or to understand 
how recent violence is specifically related to adherence. Paper 4 adds to this literature by 
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finding a similar strong association between IPV and adherence (84% lower odds of 
adherence in the final month of pregnancy and 78% lower odds of adherence postpartum). 
However, once adjusting for key socio-demographics, IPV retains significance but the 
magnitude of effect is attenuated, suggesting that IPV may worsen adherence on its own and 
also be a marker for other predictive characteristics, such as education or food security.  
Papers 2 and 3 offered a qualitative set of evidence to support the link between IPV 
and PMTCT behaviors. I learned that women do experience barriers to PMTCT due to current 
experience of IPV or fear of future partner violence. Together, Papers 2-4 confirm a main 
study hypothesis, that IPV is predictive of HIV care and treatment behaviors among pregnant 
and postpartum women. These three doctoral papers also complement the findings of Paper 1 
by suggesting that associations between IPV and worsened adherence found in resource-rich 
settings may also exist in resource-constrained settings like urban South Africa. 
Plausible mechanisms linking IPV to PMTCT adherence  
The next important set of findings concerns the exploration of why IPV may be linked to non-
adherence in pregnant and postpartum women. I identified several mechanisms through which 
IPV may influence non-adherence (Papers 2-4). The first pathway of mental health was 
hypothesized in our original conceptual framework and retained importance in both 
quantitative and qualitative analysis. Partner disclosure, while crucial in the qualitative 
findings, did not retain significance in quantitative results, suggesting a potential 
measurement error or shortcoming of operationalizing the construct. Two pathways were 
novel, and emerged from the qualitative research as potentially important for further 
exploration in the structural equation model: resilience and health care utilization. Our 
findings also raised analytical questions about the partner control pathway, as it showed less 
prominence in both qualitative and quantitative results. 
 
Mental health is a prominent pathway linking violence to poor adherence 
We learned through qualitative research with health workers and pregnant women that mental 
health is a major, if unaddressed, concern for patients experiencing IPV (Paper 2). I found the 
burden of mental health symptoms to be very high in our cohort of HIV-positive pregnant 
women (Paper 4). At baseline, 50.9% of the cohort had depressive symptoms, while 
postpartum this rate was 36.2%. These findings align with a meta-analysis of studies among 
HIV-positive pregnant women in sub-Saharan Africa, which showed a pooled antenatal 
depression prevalence of 42.5% and a pooled postnatal depression prevalence of 30.7% 
(Sowa et al., 2015). I also found high rates of probable anxiety (39.3%) and probable PTSD 
(26.8%) at baseline. No extant literature has measured anxiety symptomology in HIV-positive 
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pregnant women, but the rate of probable PTSD in our sample is double the rate seen in one 
similar study in Tanzania (Mahenge et al., 2013). 
Women’s experience of recent (past-year) IPV at baseline was strongly related to 
cross-sectional and incident mental health symptomology (Paper 4). In the quantitative cohort 
data, recent physical and/or sexual IPV at baseline tripled the odds of probable antenatal 
depression and doubled the odds of probable postpartum depression. Any physical and/or 
sexual IPV during the follow-up period was associated with doubled odds of probable 
postpartum depression. The strength of association in our study is stronger than that of meta-
analyses from resource-rich settings that suggest IPV is related to a small increase in odds of 
antenatal depression and a 50% increased risk of postpartum depression (Beydoun et al., 
2012; Lancaster et al., 2010). Our strength of association does align with longitudinal and 
cross-sectional research in sub-Saharan Africa that finds double to four-fold risk of 
depression for those women living with IPV (Abdelhai & Mosleh, 2015; Brittain et al., 2015; 
Kaaya et al., 2010; Mahenge et al., 2013; Ogbonnaya et al., 2013). 
We learned that recent IPV doubled the odds of anxiety at both time points. While no 
evidence for anxiety is available, one cross-sectional study examined IPV and psychological 
distress specifically among HIV-infected pregnant women. The authors found that recent IPV 
was associated 3.6 times the odds of psychological distress even after controlling for other 
predictors (Bernstein et al., 2016). I also saw doubled odds of probable PTSD at baseline 
among women reporting recent IPV, aligning with cross-sectional Tanzanian data finding that 
recent IPV increased odds of PTSD during pregnancy 3-fold (Mahenge et al., 2013). 
A novel contribution of this doctoral research is the finding that there may be a 
differential impact of depression, anxiety, and trauma on adherence. I found a significant 
bivariate association between antenatal depression and adherence to ART in pregnancy. This 
finding aligns with quantitative research among pregnant women, among whom depressive 
symptoms are associated with worse adherence, treatment failure, HIV disease progression 
and mortality (Antelman et al., 2007; Hoffmann et al., 2016; Psaros et al., 2014). However, in 
the structural equation model, depression was no longer significantly associated with 
adherence. Two other studies have found that composite measures of depression are not 
associated with adherence around the time of pregnancy (Bardeguez et al., 2008; Peltzer et 
al., 2011), suggesting that there may be something particular about the perinatal period that 
buffers the effect of depression on adherence.  
Anxiety, on the other hand, had a consistent negative association with adherence in 
the structural equation models. In pregnancy, IPV led to increased anxiety, which in turn 
reduced pregnancy adherence. Postpartum, IPV at baseline strongly predicted baseline 
anxiety and IPV throughout the pregnancy predicted postpartum anxiety. Both of these 
anxious symptomology time-points had a small but persistent negative relationship with 
 
155 
postpartum adherence. PTSD symptoms, on the other hand, were associated with increased 
adherence in pregnancy. PTSD may operate in an unexpected direction because clinical 
characteristics of this phenomenon may lead towards self-protective behaviors or post-
traumatic growth that actually improve adherence (Sherr et al., 2011). Other literature on 
PTSD has suggested that ART adherence may be equivocal or even better in patients with 
traumatic symptomology (Nilsson Schonnesson et al., 2007; Sledjeski et al., 2005; Vranceanu 
et al., 2008). This is an area for further research, particularly if interventions can be developed 
to bolster post-traumatic growth among women living with HIV and IPV. 
Another important contribution is the exploration around why mental health might be 
so closely related to HIV behaviors and health outcomes. In deeper qualitative research 
(Paper 3), I found that stress and emotional concerns around IPV take priority over the daily 
regimen of medication – creating a strong rationale for why mental health may worsen 
adherence. For other women, hopelessness and being overwhelmed due to the extreme 
distress of violence created conditions for stopping medication. In qualitative research in 
Zambia, depression and hopelessness emerged as a major barrier to women’s ART uptake – 
with much of this mental health-adherence relationship due to partner dynamics like IPV and 
abandonment (Murray et al., 2009). In Tanzania, feelings of hopelessness and the futility of 
staying adherent intensified after infants were ‘saved’ from HIV and weaned from 
breastfeeding (Ngarina et al., 2013). Our study offers additional nuance by highlighting that 
several women used the act of stopping treatment as part of a strategy to end their own lives. 
In other words, treatment interruptions were used as a self-harming technique in situations 
where women feel extremely distressed by violent partnerships. This tendency towards 
suicidal ideation aligns with other qualitative research showing that some women are so 
fearful of partner violence and abandonment that they would ‘rather die’ than risk losing their 
marriage (Nachega et al., 2006; Ware et al., 2009). 
 
Women’s resilience as a protective mechanism  
We learned that a high proportion of women were adherent in pregnancy and postpartum 
despite experiencing recent IPV (Paper 4). An explanation for this finding can be drawn from 
Paper 3, where a number of women successfully navigated ART adherence in the context of a 
violent partnership. One reason for this strong adherence may be resilience, a factor starting 
to emerge as an important buffer limiting the effect of IPV on adherence. A longitudinal study 
in Kenya among 216 female sex workers found that past-year experience of IPV improved 
viral load outcomes (Wilson et al., 2016). Through qualitative interviews, Wilson et al. found 
that women were committed to taking ART despite IPV, and used personal health goals and 
social support as methods of resilience (Wilson et al., 2016).  This qualitative finding aligns 
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with a growing quantitative literature on the importance of resilience in mitigating effects of 
factors like past trauma on HIV outcomes (Dale et al., 2014; Ironson et al., 2005).  
A key driver of resilience in our cohort may have been the transition towards 
motherhood. A meta-synthesis of studies among HIV-positive women found that having a 
baby offered hope and a concrete reason for women to look to the future (Carlsson-Lalloo et 
al., 2016). The healing nature of motherhood may be particularly true of women who are 
newly-diagnosed in pregnancy. One interpretive qualitative study posited that the disruption 
of an HIV diagnosis can be transformed into ‘continuity’ when women focus on the arrival of 
the infant and the ‘new story’ of becoming a mother (Kelly et al., 2012). Women living with 
HIV may also use the transition to motherhood to recreate a sense of self that is focused on 
positive identity and being the ‘good’ mother (Sandelowski & Barroso, 2003; Sanders, 2008). 
Interestingly, this positive motherhood identity can be found in the IPV literature as well, 
with qualitative studies showing that amidst the chaos of a violent relationship, motherhood is 
often one aspect that women feel overwhelmingly positive about (Semaan et al., 2013b). 
 Beyond personal identity, there was also a strong emphasis among women in our 
qualitative research on protecting the health and wellbeing of the infant (Paper 3). This aligns 
with previous literature on motherhood and HIV, where women’s concern about their 
children takes priority over other matters (Sandelowski & Barroso, 2003; Wesley et al., 
2000). Similarly, IPV literature has shown that protecting children from an abusive partner is 
often a ‘turning point’ for women (Enander & Holmberg, 2008; O'Doherty et al., 2016). 
Qualitative studies from resource-rich settings describe how children are a powerful 
motivator for help-seeking on the part of women (Lutz, 2005; Meyer, 2010; Randell et al., 
2012; Zink et al., 2003). Ours is the first study, to our knowledge, to explore this dynamic in 
sub-Saharan Africa among HIV-positive women. In our case, the help-seeking comprises the 
use of HIV care and treatment and safe feeding, with women aiming to protect infants from 
HIV infection despite the challenges of navigating PMTCT in a violent context. 
There is a theoretical tension around over-emphasizing the ‘motherhood’ identity, 
because it reinforces the view that women are destined to be a nurturing caretaker who 
sacrifices her own needs for that of her child (Hays, 1998). As Semaan et al. explain, “while 
it is important to recognize the strength many battered women derive from motherhood, an 
overemphasis on motherhood as the main impetus for battered women’s actions may make it 
difficult for them to recognize other sources of their power,” (2013: 85). Similarly, the 
pressure to bear children can have gendered and oppressive undertones in many settings. 
Motherhood in sub-Saharan African settings often has deep associations with social status and 
becoming a ‘full person’ (Birks et al., 2013; Yeatman & Trinitapoli, 2013), a belief system 
that helps maintain the moral order of childbearing as an ethical principal (Chabal, 2009). 
Motherhood can also be seen as essential for cementing the marital relationship (Hollos & 
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Larsen, 2008; Yeatman & Trinitapoli, 2013), and there is a risk that motherhood may actually 
be operating to sustain the fundamentally patriarchal view of women  (Chase & Rogers, 
2001). Roles around motherhood and caring are complex, and scholars disagree as to how 
motherhood is oppressive or perhaps offers unique forms of relational control and agency 
(Jackson, 2015; Sen, 1987). Indeed, feminist theory has long critiqued motherhood as a 
societal means of institutionalizing an oppressive version of femininity (Connell, 2014). For 
this reason, it would be inconsistent with the theoretical underpinnings of IPV work to ask 
women to prioritize motherhood as a central rationale for adhering to PMTCT. A better 
method would be to ask women about their own priorities (be they around motherhood, 
longevity, emotional security, etc.) and then develop a tailored plan for reaching these. 
Harnessing women’s modes of resilience – including that of motherhood – will have positive 
impact on their ability to adhere to PMTCT. 
 
Antenatal clinic attendance may worsen for women with recent IPV 
In the quantitative structural equation model (Paper 4), I showed that recent IPV was related 
to a lower number of ANC visits, which was in turn related to adherence. This finding is the 
first of its kind among HIV-positive women, but confirms previous research that IPV may be 
related to worsened uptake of antenatal care. In the U.S., extant literature suggests that IPV is 
associated with women delaying antenatal care or forgoing it altogether (Dietz et al., 1997; 
Goodwin et al., 2000; Subramanian et al., 2012; Thananowan & Heidrich, 2008).  
Antenatal attendance was measured in relation to IPV in sub-Saharan Africa in a 
single population-based study, and found to be unrelated (Bitew et al., 2016). However, the 
related outcome of skilled birth attendance has been associated with women’s exposure to 
IPV. In a prospective study in Kenya, experiencing IPV during pregnancy or postpartum 
halved the odds of delivery at a health facility (Turan et al., 2012), a finding confirmed by 
population-based data from other sub-Saharan African settings (Goo & Harlow, 2012; 
Ononokpono & Azfredrick, 2014; Refaat, 2013). Moreover, gender norms around IPV at the 
population level may impact on women’s use of maternal health services. Demographic 
Health Survey data suggests that inequitable community-level beliefs around IPV reduce the 
odds of four antenatal visits in Tanzania and are associated with delayed start to prenatal 
visits in Ghana and in Uganda (Adjiwanou & LeGrand, 2014).  
 
Partner non-disclosure as a qualitative pathway  
In the qualitative research of this thesis (Papers 2 and 3), partner non-disclosure was another 
important pathways through which IPV influenced adherence. I found that pregnant and 
postpartum women who fear a violent reaction may choose not to disclose, a finding that is 
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congruous with other qualitative literature (Larsson et al., 2012; Lugalla et al., 2012; Njie-
Carr et al., 2012; Rujumba et al., 2012). One reason that non-disclosure may be related to 
worsened adherence is that women who have not disclosed state they have difficulty taking 
medication openly at home (Paper 3). In our qualitative study, many women described using 
complex strategies to avoid their partner seeing them take ART. Similarly, in one longitudinal 
study in the U.S., women’s inability to take medication openly at home halved the odds of 
being on HIV treatment at the time of follow-up (Sayles et al., 2006). Others point to the 
challenge of visiting the clinic without having disclosed (Awiti Ujiji et al., 2011), but around 
the time of pregnancy it is not challenging for women in our setting to regularly visit the 
clinic. It would be important to follow women longer postpartum to learn whether non-
disclosure may constrain clinic visits once pregnancy was no longer the underlying medical 
condition for seeking care. 
 In our quantitative findings (Paper 4), partner non-disclosure was unrelated to ART 
adherence. This contradicts other research that suggests that partner disclosure has a strong 
positive impact on adherence (Hodgson et al., 2014; Jasseron et al., 2013; Medley et al., 
2004; Spangler et al., 2014). There are multiple reasons why this may be the case. Disclosure 
is a widely varying and complex process that may have positive, negative, or neutral social 
outcomes (Parsons et al., 2004). If effects of non-disclosure have both positive and negative 
impacts on HIV adherence, this predictor may essentially “cancel itself out” in analysis. It is 
also possible that a dichotomous outcome (disclosed vs. not disclosed) is too crude to show 
effects on ART adherence. A number of nuances exist across the spectrum of disclosure 
decisions and outcomes, ranging from safe and supportive disclosure, to partner responses 
that are avoidant, to partner reactions that are severe or violent. Future studies would benefit 
from more robust measures that capture the range of women’s experience with disclosure. 
 
Partner control has less influence on adherence 
Partner control was strongly correlated with IPV, but unrelated to adherence in the 
quantitative analysis (Paper 4). While the link between partner control and adherence is 
plausible based on previous literature (Lichtenstein, 2006; Wilson et al., 2007), it is possible 
that measurement error or operationalization of the construct in our study was insufficient to 
detect an association.I measured partner control only through 5 items on WHO Multi-country 
study instrument. This approach, as yet unvalidated, may not be sensitive enough to show a 
differential impact on adherence. Experiencing any controlling behaviors may be such a 
normal occurrence in settings like urban South Africa that it could be challenging to 
determine its effects on adherence.  Another reason that partner control did not statistically 
impact on ART adherence may be that it is conceptually linked to IPV itself. Indeed, the 
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WHO definition of partner violence includes controlling behaviors as a form of IPV (Heise & 
Garcia Moreno, 2002). 
Alternately, one reason to conclude that perhaps partner control is truly less impactful 
on adherence is that this pathway similarly did not emerge in qualitative research (Paper 3). 
While several participants shared stories of partners controlling their access to the clinic, most 
were able to move freely to and from medical services. This may be distinct around the time 
of pregnancy, particularly in a setting like urban South Africa where 87% of women access 
the recommended four antenatal visits (Shisana et al., 2010). 
 
C. Future interventions 
While much progress has been made in increasing access to and retention in PMTCT services 
in sub-Saharan Africa, the latest UNAIDS estimates show coverage to be 77% (UNAIDS, 
2016b). To be certain, clinic-level interventions have demonstrated marked improvements in 
PMTCT coverage over the past decade (Ladner et al., 2015), but new interventions need to 
increase focus on the social and personal barriers to PMTCT adherence, particularly in the 
postpartum period.  
One particular shortcoming in the current evidence base is the dearth of interventions 
addressing partner dynamics as a potential driver of poor PMTCT outcomes. A systematic 
review of PMTCT interventions identified no published trials aimed at the dyadic partnership 
level (Geldsetzer et al., 2016). Of ten included interventions, all focused solely on the 
individual woman (e.g. through text messages) or on the clinic (e.g. through task-shifting or 
integration of services). Two ongoing studies that anticipate results in 2017-2018 are 
exceptions to this gap in evidence. In Kenya, a pilot program aims to address PMTCT by 
providing couples a series of three home visits comprising guidance on infant development, 
HIV, and partner dynamics (Turan et al., 2015). In South Africa, a clinic-based series of three 
group sessions and three couples counseling sessions aims to improve PMTCT adherence and 
reduce transmission to infants (Jones et al., 2014). Both in-progress studies, however, exclude 
couples experiencing severe partner violence for ethical reasons related to protecting women 
from further IPV risk. This is consistent with many couples studies and presents complex 
questions about how to engage partners already in violent relationship in such interventions.  
Despite our mixed findings on partner disclosure and its role in adherence around the 
time of pregnancy, disclosure has been shown to be an avenue for adherence interventions. A 
systematic review on the topic of women’s HIV status disclosure identified two interventions 
to improve women’s ability to safely disclose to partners from whom they feared violence 
(Kennedy et al., 2015). Wagman et al. found that by bolstering HIV testing and counselling 
protocols with skills for addressing IPV, non-pregnant women’s experience of physical and 
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sexual violence reduced at 35 months (Wagman et al., 2015b). Maman et al. did not find 
significant IPV changes in their intervention training HIV counselors to explore safe partner 
disclosure or strategic non-disclosure among pregnant women (Maman et al., 2014). One 
important shortcoming of each of these interventions is that they focused on women alone. 
Interventions working directly with male partners could offer important reductions in 
use of IPV and show PMTCT improvements. As others have noted, most PMTCT programs 
have left men out as the “forgotten half of the equation” (Mohlala et al., 2011; Morfaw et al., 
2013). Men in some settings “test by proxy” and assume that a pregnant woman’s HIV test 
matches their own serostatus (Morrill & Noland, 2006; Nachega et al., 2009). In the context 
of gender inequalities, this serves to place the responsibility of HIV testing and preventing 
infant infection only on the women’s shoulders, thereby further entrenching existing gender 
inequities (Bourgois et al., 2009; Hampanda, 2012). Men’s role in the perinatal phase needs to 
be framed carefully, with a constant eye towards the preferences of women themselves. 
Qualitative work in South Africa suggests that women are appreciative of instrumental and 
emotional support over and above partner attendance at ANC visits (Maman et al., 2011b).   
Work with men clearly needs to shift beyond ‘male involvement’, since we know that 
some male involvement can be harmful or controlling (Paper 3). For example, I learned that 
violent partners can interfere with medication adherence as a way to shame women and 
maintain psychological control. As Maman et al. caution: “It is critical that we broaden the 
lens through which we consider male involvement… to acknowledge that male involvement 
may not always be in the best interest of women.” (Maman et al., 2011b). Our research and 
others suggests that working towards ‘positive male engagement’ may be a more helpful 
framework than the more neutral term ‘male involvement’. This would focus on the quality of 
engagement, rather than simply the fact that men attend clinic with their pregnant partner 
(Maman et al., 2011b). The Kenyan intervention by Turan et al. offers one model for this 
positive male engagement approach, by building on formative findings that show men 
themselves are often deeply committed to the health of the infant and the safety of the 
pregnancy (Musoke et al., 2015; Turan et al., 2015). The home-based intervention harnesses 
this keen interest in infant and family wellbeing to launch discussions of other important 
family health topics, including HIV and IPV. 
This doctoral research also offers lessons for mental health interventions in South 
Africa. Despite high rates of common mental health disorders in antenatal care (Rochat et al., 
2011), little screening or treatment exists in South Africa (Honikman et al., 2012). In the 
general South African population, there is a mental health treatment gap of 75% (Seedat et al., 
2008), and experience from our clinics suggests the treatment gap may be even higher in 
urban, pregnant cohorts. A systematic review of 22 African studies on HIV-infected pregnant 
women and depression identified only two interventions for this group (Sowa et al., 2015). A 
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clinic-based peer-mentoring program combined with cognitive behavioral group intervention 
in Cape Town reduced depression among HIV-infected mothers at six months (Futterman et 
al., 2010). A perinatal home-visiting program in Cape Town learned that 12 home visits by a 
trained community health worker reduced depression among (HIV-infected and uninfected) 
mothers at 36 months (Tomlinson et al., 2016). Neither of these interventions had any clear 
component for the male partner. Tomlinson et al. measured IPV but found their intervention 
made no significant impact on this outcome, perhaps because there were no targeted materials 
during home visits that focused on IPV. Futterman et al. included IPV as a topic within the 
group curriculum, but did not measure the intervention effect on IPV. These examples 
suggest a need to both include IPV explicitly in future interventions and also the need to 
measure it as an intended outcome. Given the strong associations found in this doctoral 
research between IPV and adherence (Papers 1-4), promising approaches for addressing 
PMTCT need to include IPV as a central feature in future programming. 
 
D. Policy implications 
These findings can fill an important gap for policy makers, since they pointed to a robust and 
consistent association between violence and ART adherence. Small ripples in policy influence 
can be preliminarily assessed through citations of the published papers in this research. Paper 
1 was cited in The Greentree Report on Violence against Women and Girls and HIV, where 
the authors used the evidence to call for programs that “address the ways that violence 
influences… the full continuum of [HIV] care: testing, linkage to care, retention in and 
adherence to treatment and outcomes related to disease progression” (Heise & McGrory, 
2016). By November 2016, Paper 1 was cited by eleven peer-reviewed publications, 
including a high-level review of trauma-informed HIV care (Sales et al., 2016). Paper 2 was 
cited in a high-level review of the social and structural barriers to HIV prevention among 
young women (Harrison et al., 2015) and a review of trauma among HIV-infected individuals 
(LeGrand et al., 2015). By November 2016, Paper 2 was cited in eighteen peer-reviewed 
publications. 
Going forward, policy makers need to consider IPV a central factor driving non-
adherence and poor HIV-related health outcomes among pregnant and postpartum women. 
Policies around PMTCT, in particular, require revisions aligned with ensuring safety and 
human rights for women in violent relationships. Current WHO and South African PMTCT 
guidelines strongly encourage partner disclosure (Department of Health, 2014; World Health 
Organization, 2010), but I learned in the qualitative papers (Papers 2 and 3) that many women 
strategically choose to hide their status in order to stay safe from a violent reaction. In Paper 
3, the majority of the women who had disclosed to male partners recounted a bad experience 
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following partner disclosure. This points to an urgent need to train health workers to help 
women identify safe strategies for choosing non-disclosure, delayed disclosure, or immediate 
disclosure, depending on their current relationship. A cadre of health workers trained in how 
to identify and respond to violence would improve the ability of women to make informed 
choices about disclosure, and about PMTCT adherence generally.  
Policy makers have long known that investing in interventions that improve 
children’s early years is likely to have cost-effective, long-term impact on the next 
generation’s health (Heckman, 1995; Victora et al., 2008). One telling example comes from 
recent analysis of panel data for 54 low-income countries from the World Bank’s World 
Development Indicators database (Hauck et al., 2016). Hauck et al. find that the greatest gains 
in life expectancy globally can be reach by reducing HIV prevalence among infants and 
advancing gender equality. It is clear that both IPV and maternal mental health may be 
strategic levers if we are to ensure maternal adherence to PMTCT and meet these noble goals 
of achieving better life expectancy, health, and wellbeing of women, men, and children. 
 
E. Theoretical contributions 
PMTCT literature to date has largely been informed by individual-level theory that fails to 
embrace key social and structural domains that effect women’s health choices (Busza et al., 
2012; Hampanda, 2012; Phillips & Pirkle, 2011). One example of an individual-level theory 
is Andersen’s model of Health Care Utilization. This model, while useful, considers what 
each woman needs to personally motivate her to adhere to PMTCT treatment without doing 
justice to the broader social and structural drivers that may influence health behaviors.  
To overcome this theoretical challenge, I adapted the Health Care Utilization model 
by blending it with Socio-ecological Theory. Socio-ecological Theory posits that health 
behaviors are deeply embedded within interpersonal, social, and structural contexts (Krieger, 
2001). However, Socio-ecological Theory does not detail mechanisms for how IPV leads to 
challenges in HIV health behaviors. As Wingood et al. explain, “A greater understanding of 
the pathways through which IPV exerts its adverse impact [on HIV outcomes] would be 
valuable in designing more effective psychosocial interventions.” (2013: 2). 
The key theoretical contribution of this doctoral research is providing a richer 
evidence base for how IPV inhibits women’s adherence to PMTCT. As shown in Figure 23, 
the main contribution of this research lies in deepening the understanding of relationship-level 
and personal factors that predict PMTCT uptake and adherence. I identified direct links 
between IPV and ART adherence (Papers 1 and 4), and began to tease out the mechanisms for 
why IPV might inhibit PMTCT behaviors (Papers 2, 3, and 4). 
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This doctoral research can improve theoretical underpinnings of PMTCT behaviors, 
which have focused on individual and institutional factors in the extant literature (Geldsetzer et 
al., 2016). A need to better emphasize social aspects of PMTCT aligns with meta-ethnographic 
work on HIV adherence highlighting how the social dimensions of adherence require greater 
attention (Merten et al., 2010). Merten et al. explain that “in societies where the self is 
experienced in terms of inherent connection with others (high interrelatedness)… efforts to 
maintain important relationships through constant investment and renegotiations” are of even 
greater importance (2010: 29-30). If programs are to meet global goals to “reach and sustain 95% 
of pregnant women living with HIV with lifelong HIV treatment by 2018,” adding social and 
structural dimensions to PMTCT theory will be increasingly important (UNAIDS, 2016c). 
The research findings also suggest several existing social and critical theories that would 
be useful to integrate into future thinking around PMTCT adherence. This step of incorporating 
additional theory may have been bolstered by the mixed method approach to research, which 
necessarily incorporates multiple perspectives around the same area of research inquiry. While a 
similar shift towards social and critical theories has already started to take place in the IPV 
literature (Kelly, 2011), it is newer to PMTCT literature (Hampanda, 2012). My research findings 
suggest that future scholars should consider the following theories as integral to understanding 
and intervening in PMTCT adherence: 
• The theory of gender and power can help interpret the interpersonal and structural issues 
related to how IPV shapes PMTCT behaviors. Qualitative literature from sub-Saharan 
African settings has highlighted how important gender and power can be in 
understanding women’s experience of HIV testing during antenatal care (Cummings et 
al., 2006; DiCarlo et al., 2014; Matovu et al., 2014). By placing onus of testing 
responsibility on women, clinics are essentially reinforcing existing gendered power 
structures (Risman, 2004). Gender and power undergirds many of the health decisions 
that a woman makes around the time of pregnancy. For women in violent relationships, 
HIV health decisions in particular can be framed by women’s limited access to resources 
and decision-making power (Russell et al., 2013; Shamu et al., 2011). Keeping the theory 
of gender and power at the forefront of PMTCT theorization will better enable 
researchers to incorporate the structural drivers of IPV, namely gender inequality. 
• Feminist intersectionality highlights the structural underpinnings that drive both IPV and 
HIV. Like the theory of gender and power, an intersectionality framework can help make 
sense of the ways that gender intersects with economic inequality or other structural 
factors to produce health inequality. Intersectionality is starting to be embraced by the 
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IPV field (Crenshaw, 1991; Sokoloff & Dupont, 2005), but has yet to be applied to 
PMTCT (an important exception being Rujumba et al., 2012). A key position of 
intersectionality is the assumption that all institutions have a tendency to recreate 
‘inequality regimes’, or the many “interrelated practices, processes, actions, and 
meanings that result in and maintain class, gender, and racial inequalities,” (Acker, 
2006). This aligns with our findings around how women are often blamed by health care 
systems for their inability to adhere to PMTCT, rather than HIV behaviors being seen 
within a lens of gender inequality and IPV (Paper 3). Intersectionality often places 
emphasis on “giving voice” to those who are oppressed due to multiple intersecting forms 
of marginalization (Choo & Ferree, 2010; Hancock, 2007). This aligns with our approach 
to qualitative data collection during the in-depth research in Paper 3. Scholars call for 
mixed methods as a valid approach to understanding inequalities through an 
intersectional lens, since mixed methods necessarily look across levels of social 
organization to understand a research problem (Choo & Ferree, 2010). Lastly, 
intersectionality suggests that social identities are made up of multiple layers of women’s 
lives and that women can resiliently navigate these (Zinn & Dill, 1996). Such a 
theoretical view fits well with our findings around resilience and motherhood (Papers 3 
and 4), and suggest that women can draw upon multiple forms of resilience when 
thinking towards ensuring their own health in the context of HIV and IPV. 
• Life course theory has been increasingly applied to how women respond to IPV, in 
recognition that certain “turning points” or periods of transition influence help-seeking 
(Khaw & Hardesty, 2007). Pregnancy is a unique time in the developmental life course of 
women. Pregnancy often entails more frequent visits to the health clinic than other phases 
of a woman’s life (Gazmararian et al., 2000). This places antenatal providers in a position 
to build stronger relationships with pregnant women, creating what some have called a 
“window of opportunity” for intervening around IPV (Anderson et al., 2002b; O'Reilly et 
al., 2010). Because pregnancy is a “transition period”, it may be a time of increased 
receptivity to healthy changes and interventions (Hatch, 2005). This is especially true 
since children seem to influence mothers’ decisions to leave violent relationships (Davis, 
2002; Meyer, 2011). As participants in the intervention have heightened awareness of the 
effects of IPV on unborn children, they may be willing to consider help-seeking in a new 
way (Meyer, 2010). Men are also more likely to be engaged and concerned about family 
health during the pregnancy and postpartum periods (Musoke et al., 2015), although it 
can also be a time of increased stress and IPV for some couples (Jasinski & Kantor, 
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2001b). Viewing the perinatal period as a specific time along the life course can improve 
PMTCT theory by adding a crucial time dimension to future research. This also 
distinguishes work around IPV and PMTCT from extant literature around HIV care and 
treatment in the general population – highlighting the unique contributions of 
childbearing to health decisions during this phase. 
 
F. Limitations and Next Steps for Research 
There are several important limitations of this research. Most limitations can be found in Chapter 
3 and in the individual manuscripts, but several additional issues regarding the overall thesis 
deserve mention. These limitations can be addressed in future research studies. 
We measured postpartum adherence relatively early after birth (at a median of 55 days 
postpartum). Given that adherence seems to decline at later stages postpartum  
(Henegar et al., 2015; Ngarina et al., 2015), it will be crucial to follow postpartum women for a 
longer period. This is particularly important in the South African setting, where the first three 
months after delivery seem protective against IPV because many women live with their maternal 
family and may have little contact with male partners. The cohort and qualitative subsample 
(Papers 3 and 4) were drawn from pregnant women recruited during routine antenatal care. This 
means that they may have important differences from the 8% of women who do not access ANC 
in the South African setting (Shisana et al., 2010). Because our quantitative sampling method first 
identified cohort members with recent IPV and then added additional HIV-positive women 
without IPV, our data cannot provide reliable estimates of prevalence for conditions like IPV or 
mental health. Confirmatory studies in other resource-constrained settings are urgently needed. 
Others have noted the need to better understand the clinical implications of IPV for women living 
with HIV in sub-Saharan Africa (Wingood et al., 2013a). Studies should include longitudinal 
examination of how IPV changes over the perinatal phase for HIV-positive women, particularly 
since HIV adherence behaviors are known to worsen in the later postpartum phase (Henegar et 
al., 2015; Ngarina et al., 2015). This will necessitate cohort studies that span the time period from 
pregnancy through the end of breastfeeding and a definitive infant HIV diagnosis. 
Future studies should draw upon the use of validated measures of IPV, since these seem 
to be more sensitive to determining the true effect of violence on health outcomes (Jasinski & 
Kantor, 2001a; Sagrestano et al., 2002). It is possible that there may be differential effects of 
various types of violence on PMTCT uptake, and these can be examined with a comprehensive 
IPV measure like the WHO Instrument. However, the WHO Instrument has only been validated 
in one study , suggesting that additional work to understand the construct, sensitivity, and 
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specificity of this measure is warranted. An important shortcoming of the WHO Instrument is that 
it does not assess women’s views of the perceived severity of various types of violence 
(Lindhorst & Tajima, 2008). Future studies should consider this relational and situational context 
to better understand how distinct intensity of IPV influences other health behaviors and outcomes. 
Our use of ART adherence as a marker for PMTCT behaviors and desired outcomes is 
useful, but does not present a complete picture of the steps necessary for the prevention of infant 
HIV infections and the protection of maternal health. Future studies should broaden outcomes to 
measure the impact of IPV on the entire PMTCT cascade. This could include examining medical 
records for outcomes such as time to ART initiation, safe delivery in a health facility, exclusive 
breastfeeding practices, and infant HIV testing at all recommended time-points. In addition, 
future research should collect biomarkers for viral suppression (since this is a stronger indication 
of adherence than self-report).   
Because mental health is conceptualized in this research as a pathway, it is necessarily 
theorized at the individual level of the socio-ecological framework. This framing aligns with most 
studies of HIV-positive women around the time of pregnancy (Kapetanovic et al., 2014) and of 
IPV in pregnancy (Devries et al., 2013a), but may underplay the role that mental health has with 
regards to social and structural drivers. Indeed, previous research has suggested that a 
sociological orientation is stronger than an individualist biomedical model for assessing mental 
health, since inner lives of many people are shaped more by their social and structural position 
than their own individual propensity for mental illness (Aneshensel et al., 1991). Nevertheless, 
here I position mental health as an individual-level health outcome that is deeply intertwined with 
the dyadic and social condition of IPV. 
Our narrative, social constructionist approach to interviews intentionally focused on 
techniques like validation, highlighting resistance, and locating identity within participant stories 
(Paper 3). Therefore, our interpretations are likely to differ from that of a ‘neutral observer’, as 
utilized within a more positivist research paradigm. Nevertheless, this research provides 
important understandings of IPV among HIV-positive pregnant/postpartum women in a sample 
that is larger than the extant literature. 
The urban Johannesburg setting has distinctions from other sub-Saharan African health 
settings, which makes it challenging to compare findings. However, the similar quantitative 
(Hampanda, 2016) and qualitative (Colombini et al., 2016; Mulrenan et al., 2015a) findings from 
other African settings suggest that the dynamics uncovered in this doctoral research may have 
commonalities with other locations. Moreover, the alignment of quantitative findings (Paper 4) 
with the meta-analytic findings in non-pregnant populations (Paper 1) suggest that around the 
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time pregnancy, IPV may have similar relationship with adherence among women living with 
HIV around the globe. 
Lastly, this research was conducted within the context of a randomized control trial, 
which limits its application in routine clinic settings. The trial was conducted in public health 
antenatal clinics in urban Johannesburg, but it is possible that participants were different from 
other clinic patients because they were willing to take part in a trial. Also, there is a possibility 
that for participants in this research who were also randomized to the trial arm, the IPV 
intervention itself altered PMTCT behaviors. While the intervention was not targeted towards 
PMTCT, even slight alterations in women’s ability to adhere to PMTCT may have influenced 
qualitative (Paper 3) or quantitative (Paper 4) findings. In Paper 4, I tested for this difference 
using 𝝌2 difference test for two models, and found that final adherence models worked the same 
way for intervention and control participants. However, this is more challenging to tease out in 
qualitative research (Paper 3) and could have led, for example, for additional accounts of 
resiliency amongst participants who had access to the intervention.   
Future studies should build in key risk factors beyond the partner, such as the structural 
or social dynamics that underpin both IPV and HIV. I learned that food security had a persistent 
and strong association with both IPV and HIV adherence behaviors (Paper 4). This type of socio-
economic indicator will be important to include in future research. I also heard from women 
about the economic dependence that made them stay in abusive relationship despite risk to their 
(or children’s) health and safety (Paper 3). This aligns with previous qualitative research 
suggesting that HIV and fear of violence intersect with economic dependency on men (Rujumba 
et al., 2012). Quantitative examination of economic dependence would be useful to include as a 
future area of research. Given that HIV-related stigma is shown to worsen PMTCT (Bwirire et al., 
2008; Mepham et al., 2011; Turan & Nyblade, 2013; Watts et al., 2010), it will be important for 
future research on IPV to unpack how stigma from a partner operates within other partner 
dynamics to influence women’s health behaviors. 
Future research should focus on the intergenerational transmission of mental health 
(Herba et al., 2016) and intergenerational transmission of violence (Ehrensaft et al., 2003). 
Around the time of pregnancy, this view towards the next generation is particularly important. 
IPV experience and maternal mental health frame infant health outcomes. This occurs since a 
woman’s own coping and mental health challenges may alter both epigenetic characteristics 
during pregnancy (such as alterations to the fetus’ hypothalamic–pituitary–adrenal axis) and 
relational traits after birth (like insecure attachment) (Martinez-Torteya et al., 2016; Palma-
Gudiel et al., 2015; Stein et al., 2014). One approach for addressing this important research gap 
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would be to identify a cohort of mother-infant dyads and examining the social, medical, and 
intergenerational context of health for both the woman and child. 
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Chapter 9. Recommendations & 
Conclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
Photo credit: Abigail Hatcher, Safe & Sound team at a 
protest to urge South African government to establish a 
strategic plan to address gender-based violence. 
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A. Recommendations 
The research findings suggest a number of important recommendations for the PMTCT field. 
Table 14 outlines gaps in the literature that existed prior to undertaking this doctoral research. 
The key findings from my research are then summarized with particular emphasis on how they 
speak to evidence gaps. Lastly, I present recommendations and suggest their relevance for policy, 
research, and/or clinical practice. 
 
Table	  14:	  Recommendations	  based	  on	  doctoral	  research	  findings	  
    
  
Evidence	  Gap	  at	  start	  
of	  doctoral	  research	  
	  	   Key	  Findings	  from	  
doctoral	  research	  
	  	   Recommendation	  for	  policy,	  research,	  
clinical	  practice,	  and	  theory	  
	  	   Audience*	  
 
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
1	   Uncertainty	  on	  
whether	  IPV	  is	  related	  
to	  ART	  adherence	  
among	  women	  
	  	   IPV	  is	  related	  to	  ART	  
adherence	  among	  HIV-­‐
positive	  women	  in	  extant	  
literature,	  with	  considerable	  
impact	  on	  self-­‐reported	  
adherence	  and	  viral	  
suppression	  
	  	   Efforts	  to	  improve	  ART	  adherence	  should	  
address	  IPV	  .	  There	  is	  urgent	  need	  for	  
better	  policy	  guidance	  and	  healthworker	  
training	  around	  IPV	  within	  HIV	  care	  
	  	   ℗	  
 
©	  
	  	   	  	   	  	   	  	   Additional	  funding	  for	  addressing	  IPV	  
within	  HIV	  care	  and	  treatment	  could	  have	  
important	  health	  impacts	  on	  the	  large	  
proportion	  of	  HIV-­‐positive	  women	  who	  
report	  recent	  IPV	  
	  	   ℗	  
 
	  	  
2	   No	  quantitative	  
evidence	  exists	  for	  IPV-­‐
PMTCT	  adherence	  in	  
sub-­‐Saharan	  Africa	  
	  	   In	  one	  of	  first	  of	  studies	  
among	  women	  in	  SSA,	  I	  
learned	  impact	  of	  IPV	  on	  
PMTCT	  adherence	  is	  marked.	  
This	  confirms	  one	  other	  
study	  undertaken	  during	  PhD	  
period	  (Hampanda,	  2016)	  
	  	   PMTCT	  programming	  should	  include	  
assessment	  of	  IPV	  during	  individualized,	  
empathetic	  adherence	  counselling	  
	  	   	  	  
  
©	  
	  	   	  	   	  	   Additional	  research	  should	  confirm	  these	  
findings	  in	  larger,	  longitudinal	  cohorts	  
	  	   	  	   ®	   	  	  
3	   Rationale	  for	  why	  IPV	  
may	  influence	  PMTCT	  is	  
unclear	  
	  	   IPV	  influences	  	  PMTCT	  
adherence	  through	  mental	  
health.	  Anxiety,	  in	  particular,	  
seems	  to	  worsen	  adherence	  
	  	   Mental	  health	  identification	  and	  treatment	  
should	  inform	  clinical	  strategies	  to	  improve	  
ART	  adherence	  
	  	   	  	   	  	   ©	  
 
	  	   	  	   Partner	  non-­‐disclosure	  due	  
to	  IPV	  can	  impede	  
adherence,	  or	  women	  can	  
navigate	  it	  through	  
"strategic	  non-­‐disclosure"	  	  
	  	   Partner	  disclosure	  must	  be	  optional	  for	  
women	  and	  counselling	  during	  ANC	  should	  
provide	  various	  disclosure	  options:	  
voluntary	  disclosure,	  assisted	  disclosure,	  
delayed	  disclosure,	  or	  strategic	  non-­‐
disclosure	  
	  	   ℗	   	  	   ©	  
 
	  	   	  	   Controlling	  behaviors	  may	  
not	  be	  a	  pathway	  from	  IPV	  to	  
adherence,	  partly	  because	  
this	  could	  form	  an	  aspect	  of	  
IPV	  itself	  
	  	   Controlling	  behaviors	  -­‐	  an	  important	  aspect	  
of	  the	  theory	  of	  gender	  and	  power	  -­‐	  
deserve	  increased	  attention	  but	  may	  not	  
drive	  adherence	  in	  this	  setting	  	  
	  	   	  	   ®	  	   	  	  
4	   Extant	  literature	  
around	  IPV	  within	  HIV-­‐
positive	  groups	  views	  
abused	  women	  as	  
necessarily	  victims	  
	  	   Women	  in	  our	  study	  were	  
resilient	  and	  used	  strategies	  
to	  adhere	  despite	  IPV	  
	  	   Helping	  women	  remember	  their	  sources	  of	  
resilience,	  be	  they	  motherhood,	  social	  
networks,	  or	  personal	  efficacy,	  should	  form	  
a	  large	  part	  of	  tailored	  PMTCT	  counseling	  
	  	   ℗	   	  	   ©	  
	  	   	  	   Motherhood	  seems	  to	  be	  a	  
central	  feature	  of	  women	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   who	  are	  resilient	  to	  the	  
effects	  of	  IPV	  on	  adherence	  
	  	   PMTCT	  providers	  should	  pay	  close	  
attention	  to	  women's	  adherence	  	  in	  the	  
postpartum	  phasee,	  since	  they	  may	  feel	  
less	  inclined	  to	  keep	  up	  health	  behaviors	  
once	  the	  infant	  is	  "safe"	  from	  acquiring	  HIV	  
	  	  
  
	  	   ©	  
5	   PMTCT	  remains	  largely	  
atheorized	  and	  the	  
research	  and	  
intervention	  literature	  
relies	  too	  heavily	  on	  
individual-­‐level	  theories	  
	  	   Partner-­‐level	  drivers	  such	  as	  
IPV	  likely	  drive	  persistent	  
gaps	  in	  PMTCT	  coverage	  
	  	   Future	  scholars	  should	  consider	  partnership	  
factors	  a	  central	  driver	  in	  PMTCT	  behaviors	  
	  	   	  	   ®	  
 	  	   	  	   	  	   Interventions	  addressing	  partner-­‐level	  
factors	  like	  IPV	  are	  urgently	  needed.	  These	  
should	  prioritize	  male	  support	  for	  PMTCT	  
(rather	  than	  simple	  'male	  involvement')	  and	  
should	  emphasize	  women's	  safety	  and	  
choice	  
	  	  
 
®	   ©	  
	  	   	  	   	  	   	  	   	  	   Funding	  should	  be	  made	  available	  to	  
develop	  and	  test	  interventions	  for	  IPV	  
within	  HIV	  care	  and	  treatment,	  particularly	  
around	  the	  perinatal	  phase	  
	  	   ℗	   ®	   	  	  
	  	   *	  ℗	  =	  Policy-­‐makers,	  ®	  =	  Researchers,	  ©	  =	  Clinicians	   	  	   	  	   	  	  
Table 13. Recommendations based on doctoral research findings 
B. Conclusion 
This research aimed to explore how women’s experience of IPV influences their ability to safely 
adhere to PMTCT recommendations. I used mixed method research strategies in four separate, 
but inter-related, studies to answer specific study objectives. Key findings can inform the 
literature around PMTCT and contain crucial evidence to inform future policy and practice. 
Future PMTCT research should incorporate social factors, such as IPV, into studies that develop 
and test PMTCT adherence interventions. HIV programming should recognize that partner-level 
dynamics such as IPV may drive persistent gaps in PMTCT coverage in areas of sub-Saharan 
Africa. Women who experience IPV around the time of pregnancy may have different needs from 
other HIV-positive patients, and it is crucial that HIV policy incorporate safety considerations for 
working with this group. Women living with recent or past IPV are highly resilient and often 
want to protect their own health and that of their children. Future PMTCT programs and studies 
may have the opportunity to harness this resilience, but only if researchers and health care 
providers are alert to the relationship dynamics that women face. 
The United Nations and other policy makers recognize that eliminating new infant HIV 
infections is within reach (UNAIDS, 2016c). However, global goals around PMTCT are unlikely 
to be met by further tweaking to patient-level and institutional-level factors. To address the gap in 
women’s access to PMTCT, future work must incorporate IPV as a key factor impacting 
women’s ability to safely and consistently adhere to treatment. By including IPV in the HIV 
response, we can ensure not only the health of women themselves, but that of the next generation. 
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Research Tools 
Formative Research Interview Guides (Paper 2) 
 
Focus Group Discussion with pregnant women  
 
To start the conversation, each woman is asked the following questions:  
1.  How many months pregnant are you? Is this your first pregnancy? 
2.  Have you been to the health clinic for antenatal care?  
      a.    If so, when did you go for the first time?  
 
Then the facilitator asks the group the following questions:  
1. What usually happens during antenatal care visits? What are your experiences with the 
services? Is there anything else (other services)? How are the service providers? Are you 
comfortable with the waiting periods? (Ask about services provided, information or 
referrals received, HIV testing etc.) 
Are there any other issues about the ANC clinic?  
2. Are you able to keep your appointments as recommended by the provider? 
a. If not, please explain the reasons why? 
3. Where do you plan to deliver your baby? If not in the clinic, is there any reason why not?  
4. When you went to the health clinic, did anyone offer you an HIV test and give you 
information on HIV? How did you feel about it? How and when was it done? Did you 
feel you were given a choice? Can you give reasons of not testing?  
5. Do you see any connections between partner violence and HIV? Has bringing up HIV 
testing ever caused conflict at home? For example if you disclose your HIV status to your 
does it put you at risk of violence? How comfortable are you to negotiate condom use 
with your partner?   
6. Do you know anyone who has experienced violence by her partner?  
a. If yes, how did she handle it? For example, who did she talk to? 
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b. What do you think she could have done as well? 
c. What kind of assistance should have been available to her? 
7. Do you know anyone who is pregnant and have experienced violence by her partner? 
a. In your view does violence stay the same or increase during pregnancy? 
b. What is it about pregnancy that triggers violence? Depending on the answer 
given 
c. For a pregnant woman how does she handle this? 
8. How do communities respond to partner violence? Does everyone respond in the same 
way? (Probe: Problem or normal? Do people talk about it openly?) 
9. What resources are available in your communities to pregnant/women who experienced 
partner violence? (Probe: Where could they go? Who offers help? What resources are 
available to her? What are the responses?) 
a. What are the limitations of these resources? 
10. What kind of services do you believe abused women need and should be offered to them?  
11. What would be ideal intervention to be delivered to abused women in antenatal care? 
(Probe: When? Where? Under which circumstances? How? And what would they expect 
from such an intervention?) 
Thank you 
 
 
Guide for interviews with pregnant abused women  
1. How far along are you in your pregnancy ?  
2. Is this your first pregnancy? 
3. We  are aware that you in an abusive relationship and it is possible that your partner may have hurt  
you recently. Would you mind telling us what has happened?  
4. From your experience, what do you believe are the reasons for partner violence during pregnancy?  
Probe: What do you think are the main reasons why your partner hurts you? 
Probe: Why do you think it happens among others you know? 
 Probe: What is people’s attitude towards partner violence?)  
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5. Do you think that partner violence increases your chances of contracting HIV?  
If yes, how?  
Have you ever told anyone else about the violence you experienced? 
a. If Yes, who did you tell and what was their reaction?  
b. If No, why not? 
6. What kind of help is available for women who experience partner violence in the community? 
7. Have you told anyone at the health clinic that you have been hurt by your partner or a family member? 
a. If Yes, how was their response?  
b. Probe: How did the health care provider react? 
c. Would the woman have preferred a different reaction? 
d.  How did it make her feel?)  
e. If No, why not? 
8. When you went to the health clinic did anyone ask you whether you have been hurt by your 
partner or family member? 
a. If yes, how did the question make you feel?  
b. If No, how would you feel about antenatal care providers asking about this? 
Probe: if providers ask about partner violence how should it be done? 
Probe:Who should ask?  
Probe:In which environment should they ask and under which circumstances?  
What do you think the study want to get from asking questions on  partner 
violence?  
After shortly outlining the intervention: 
9. When during antenatal care do you think the intervention should take place ? 
 (Probe: e.g. first appointment, HIV testing? 
 Do you think it should be done only once or more often? 
Why? How well do you think does the intervention address the needs of abused pregnant women? 
 (Probe: What aspects are most helpful and why? 
 Is something missing?  
Is something not helpful or confusing?) 
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After showing them the study instruments: 
10. How could the questions on intimate partner violence be changed to represent/capture your 
experiences?  
11. Are the questions on women’s mental and physical health clear? 
Do you find it easy to understand their meaning? 
 
11. What other safety behaviours or community resources do you think we should include? 
 
 
Guide for interviews with health care providers  
Good day, and thank you for taking the time to meet today.  
 
1. What is your role at the clinic? How long have you been working here? 
2. How big is your clinic in terms of staff? What are the hours of the clinic? 
a. On an average day, how many patients are seen at the clinic? What is the average 
length of a routine patient visit?. 
b. Please tell me about what happens when a patient visits the clinic, for example, 
what is the order of services? 
c. Please describe your responsibilities and day to day work. 
3. Which communities are served by the health clinic? 
a. What are the main health problems you observe in your patients? 
4. Please describe the HIV testing and counseling procedures. 
5. Have you ever observed or had to care for women who have been hurt by their partners, family 
members, or others? If yes, how did you handle the case/these cases? 
6. What are existing policies if any to respond to violence against women? 
7. Do practitioners at this clinic ever ask women about experiencing violence? 
a. If NO, why do you think this is the case? 
b. If YES, how do they go about it?  
c. Is there anything that prompts them to ask about violence?  
d. Is it a routine service with every patient, or just certain ones? 
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e. Are there any existing tools, such as a list of questions to ask? 
8. What type of training, if any, have practitioners at this clinic received on how to deal with 
cases of violence? 
9. What do you think about asking women routinely about violence in your clinical setting 
and providing them with a counseling session of about 20 minutes?   
Probing questions:  
a) Would it be feasible?   
a. Time constraints?  
b. Staffing constraints?  
c. Staff training and capability? 
d. Staff attitudes? 
e. Patient attitudes? 
f. Any other issues that would make feasibility a concern? 
b) Do you think it would be important? 
a. Is this service valuable for patients? If yes, how? 
b. Is this service valuable for the clinic? If yes, how? 
c. In your view, is asking and responding to cases of violence a health sector 
responsibility? If yes, why? If no, who would be better capable to deal with this? 
 
c) Any other challenges you think there can be to doing this? 
d) How would you personally feel about asking women about violence?  
a. Are there aspects of this that may feel uncomfortable? 
b. Are there aspects that may make you feel satisfied or confident? 
 
10. What opportunities do you see for integrating violence screening and counseling into 
existing processes in your clinic?  
11. Can this be incorporated into the existing antenatal care routine?  
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12. Are there organizations where women can seek help in the case of violence by a partner? (in the 
clinic and outside) 
13. Have you ever referred anyone there?  
a. If yes what has been your experience in referring a woman to one of them? 
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Participant Information Leaflet and Informed consent to participate in the 
formative research interviews for the antenatal care study on women’s health and 
life experiences: Key Informants, Community Members, NGOs 
Every participant must receive, read and understand this document before any procedure of 
the study 
 
 
STUDY NUMBER:   
 
VERSION  : 0.1 
 
STUDY TITLE: “Addressing violence against women in antenatal care: testing an 
intervention in South Africa and Mozambique”. 
 
AN ABBREVIATED NAME FOR THIS STUDY: Violence Against Women (VAW) 
 
FUNDED BY:  World Health Organization  
 
PRINCIPAL INVESTIGATORS: Dr Sinead Delany-Moretlwe  
 
 
 
 
 
 
 
 
DATE AND START TIME OF THE INFORMED CONSENT DISCUSSION 
    : 
Date Month Year  Time 
 
 
 
To a participant:  this informed consent may contain words that you may not 
understand. Kindly ask study staff to explain these words or anything that you 
do not understand.  You may go home with a copy that was not signed to think 
about it or discuss with family or friends before you decide. 
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Introduction: 
Hi, my name is Abigail Hatcher.  I am working for the Wits Reproductive Health and HIV 
Institute (WRHI). WRHI is conducting research in reproductive health, including HIV. We are 
doing research on women’s health and life experiences including violence against women. 
We are talking to people knowledgeable about the health care system in our country, 
women’s health, reproductive health or HIV and domestic violence. The research will involve 
answering some questions about your experiences and knowledge about the topic. 
 
WRHI would like to invite you to participate in the formative research interview today.  
Violence against women is very common in this country, and violence during pregnancy can 
be especially dangerous for women’s health and the health of their babies. First let me give 
you some information about the study and then you can decide if you are willing to 
participate. The aim of our study is to develop and test a counselling intervention for abused 
pregnant women receiving antenatal care in Southern Africa that could be incorporated into 
routine antenatal clinic. We would like to ask some questions about the health care system 
in the country to better understand how this intervention might best be integrated into 
existing antenatal care programmes. 
 
PURPOSE OF THE STUDY 
WRHI is part of a group of research scientists who are trying to test an intervention 
addressing violence against pregnant women in antenatal care.  We are trying to find ways 
to discuss violence with women coming for antenatal care visits. If you decide to participate 
in this project, your responses will help us to improve the treatment of pregnant women who 
have experienced violence.  
This study is taking place in South Africa and Mozambique. We would like to ask some 
questions today. Some of the questions relate to sensitive topics that some people find 
difficult to discuss. All the information you give is voluntary which means you are not 
obligated to participate. This phase is a small study where we will interview a variety of 
people, some from the Department of Health, Non-Governmental Organizations, health care 
workers, community members, and pregnant women.  We estimate that the interview will 
take approximately 30-40 minutes. Your knowledge and insights will help us to improve our 
intervention and therefore the care of women who have experienced violence.  
 
 
 Page 3 of 6 
_____________________________________________________________________________________________________
VAWPIS and ICF/English 
 Formative Interview researchKey Informants version 0.1(08Aug2011) 
Investigator name: C MacPhail 
Date approved- Pending                                                                                                         Participants initials__________ ___ 
 
  
The researcher will make a sound recording of your conversation. After the discussion, 
someone will type a transcription of what is on the tape and will remove any mention of 
names.  The sound recording will be stored for 2 years after the data is published or for 6 
years if the data is not published. Recordings will be stored on password protected 
computers with access limited to senior members of the study team. 
 
If you decide to participate in this study, you will be asked to sign or make your mark on 
this document to make sure that you understand the study. You will be given a copy to 
keep.   
 
RISKS and/ or DISCOMFORTS: 
 We will be asking you questions about your professional engagement with the issue of the 
provision of antenatal care for pregnant women and issues related to their care. We do not 
believe that these questions will cause you any distress. If for some reason you feel 
uncomfortable, you may chose not to answer or chose to stop participating in the discussion 
at any point. All of the information that you provide is voluntary; you may say as much as 
you are comfortable saying. If these questions cause you distress for any reason, we can 
refer you to a counsellor or other local services that can provide you with assistance.     
 
POTENTIAL BENEFITS 
There may be no direct benefits to you from this study. However, you and others may 
benefit in the future from research done in this study because we will learn more about 
addressing violence in pregnant women and maybe incorporate it in the antenatal package 
of care. 
 
COSTS AND COMPENSATION 
There is no cost to you for being in this study. At the end of this visit, you will be reimbursed 
R50.00 to compensate you for your travel costs. 
 
CONFIDENTIALITY 
We will not record your name or any other identifying information on any study documents 
other than this consent form. We have been trained to respect the privacy of participants 
and the information you provide us will remain confidential. All discussions take place in a 
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private room and the information we collect will be stored in a locked cabinet, in a locked 
room and will only be accessed by the researchers in this study. Your interview may also be 
looked at by people from National Health Institute (NIH), the World Health Organization 
(WHO), Institutional Review Boards (IRB’s), and monitors/auditors. These people are trained 
to maintain confidentiality and would review your interview to ensure that the study is 
conducted to the highest quality. You will not be identified by name in any of the reports or 
publications of this study or its results. 
All the information you provide is voluntary, which means that you are not obligated to 
participate and if you do, you can say as much as you are comfortable saying.  You are free 
to stop the interview at any point or not answer any of the questions that we ask. If you 
agree to participate, all the information you provide will be kept confidential.  
 
If you have any further questions about this study, please contact the people listed below: 
Dr Catherine MacPhail 
Principal Investigator 
WRHI, Hugh Solomon Building 
Corner of Esselen and Klein 
Hillbrow  
Tel: 013 735 0293 
Mobile Number : 083 441 5415 
Prof Helen Rees 
Executive Director/ Co-Investigator 
WRHI, Hugh Solomon Building 
Esselen Street, Hillbrow 
Tel: 011 358 5300 
Fax 011 358 5400  
  
 
This study is conducted in accordance with the Department of Health Guidelines 
for the Good Practice in the Conduct of Clinical Trials in Human Participants in 
South Africa (2006), and has received ethical approval from the University of the 
Witwatersrand.  If you have questions about your rights as a research participant 
or complaints about the manner in which you were treated, or feel that study has 
caused you harm, please contact: 
Prof. Peter Cleaton-Jones 
Chairperson for the Committee for 
Human Research Ethics Committee 
University of the Witwatersrand 
Tel: 011 717 2301 
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INFORMED CONSENT:  
We would appreciate your participation and your insights are very important. 
 Do you have any questions about any of the information I have provided? 
 Yes________    No_________ 
Do you understand you are not obligated to participate? 
Yes_______     No__________ 
Do you agree to be interviewed? 
Yes________  No____________ 
 
To be completed by researcher: 
I confirm that the participant was given an opportunity to ask questions about the study, and all 
the questions asked by the participant have been answered correctly and to the best of my 
ability. I confirm that the individual has not been coerced into giving consent, and the consent 
has been given freely and voluntarily.  
   
 A copy of this ICF has been provided to the participant. 
 
 
 
 
Signature of Volunteer:  
Signature/mark 
or thumbprint 
 
 Date signed 
   
dd mm yyyy 
Print name  Time signed : 
 
 
Signature of Witness: (if necessary) 
Signature/mark 
or thumbprint 
 
 Date signed 
   
dd mm yyyy 
Print name  Time signed : 
 
 
Signature of Study Staff taking consent:  
Signature/mark 
or thumbprint 
 
 Date signed 
   
dd mm yyyy 
Print name  Time signed : 
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Investigator name: C MacPhail 
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Permission provided by participant for recording of Interview 
 
Signature of Volunteer:  
Signature/mark 
or thumbprint 
 
 Date signed 
   
dd mm yyyy 
Print name  Time signed : 
 
 
Signature of Witness: (if necessary) 
Signature/mark 
or thumbprint 
 
 Date signed 
   
dd mm yyyy 
Print name  Time signed : 
 
 
Signature of Study Staff taking consent:  
Signature/mark 
or thumbprint 
 
 Date signed 
   
dd mm yyyy 
Print name  Time signed : 
 
 
 
22? 
In-depth Interview Guide (Paper 3) 
 
Thank you for taking the time to speak with me today. We will talk for about 45 minutes about 
your pregnancy, and we can take a break whenever you would like. 
Are you ready to begin? 
 
Background (for postpartum women only) 
1) When did you deliver your baby?  
i) How was your delivery? Did you have a boy or girl? 
ii) Do you have other children? 
 
2) How has the infant been doing so far? How are you coping with a new baby in the house? 
 
3) How is the father doing? 
 
Background (for pregnant women only) 
4) When did you learn that you were pregnant? 
5) How did you feel about the new pregnancy? Was it something you were hoping for or was it more of a 
surprise? 
6) Was your partner aware of your pregnancy? How did he respond? 
 
Partner disclosure 
7) May I ask if you know your HIV status? 
 
8) When did you learn about being positive? How did you feel? 
 
9) How did your relationship change, if at all, by the HIV diagnosis?  
 
i) For example, did it get worse or better after you learned you were positive? 
 
ii) Probe for stories 
 
 
22? 
10) Have you started taking HIV medication (ART)? 
i) Are you taking one tablet each day (FDC)? 
ii) Does your doctor say you’ll carry on taking medicine – or will you stop after breastfeeding? 
iii) Some women are asked to stop after breastfeeding – how do you feel about the idea of 
stopping? 
iv) How do you feel about taking medication for your lifetime? 
11) How is it going with your HIV treatment – is it easy to manage or somewhat tricky? 
i) Probe: Taking your medication on-time 
ii) Probe: Giving your infant syrup 
iii) Probe: Getting your infant tested 
12) Did your partner know about what you had to do to take up HIV medication? 
i) If yes, was he supportive? 
 
ii) If no, did you decide not to tell him for a certain reason?  
 
13) For those who DID disclose: May we talk about how you shared your status with your partner?  
i) How did he respond to the disclosure?  
 
ii) Probe for denial / acceptance / violence 
 
14) For those who DID NOT disclose: Why did you chose not to tell your partner?  
i) Did he ever find out some other way? 
ii) Probe for fears around denial / rejection / violence 
 
Relationship control 
15) Does your partner know that you are taking medication for HIV? 
i) Do you ever have to hide your meds? 
ii) How would your partner respond if he found the medication? 
16) Sometimes partners ask women not to go to clinic. Has this ever happened to you? 
 
17) Does your partner ever like to know what you are doing or who you are seeing? 
 
 
22? 
18) How do you respond when your partner controls where you go or who you see? 
 
IPV 
19) How is your relationship since the pregnancy / delivery? 
 
20) Many women have violence in relationships. Has something like that ever happened to you? 
 
i) Has it been going on for a long time? 
 
ii) Did it seem to get worse during pregnancy and/or after baby’s birth? 
 
Note: Probe gently here, as it may not feel good for participant to share details 
21) Was there ever a time when the violence in your relationship made you worry about taking HIV 
medication?  
i) Why? (probe for stories). 
 
Mental health 
22) How do you think violence may be harming your health? 
i) Probe for physical health 
 
ii) Probe for mental / emotional health 
 
23) How are you coping with the violence? Who did you lean on for support? 
24) When you are feeling worried or depressed, does that ever change how you are able to stick with HIV 
medicines? 
i) Probe for stories. 
 
Infant feeding & health 
25) How has your infant been doing in terms of health? 
 
26) Did you ever worry that the violence in your relationship was affecting the infant?  
 
i) Probe for stories. 
 
 
2?? 
27) How is your baby eating? 
i) What does your baby eat? (probe for water, breastfeeding, bottle) 
ii) Is there anything about feeding your baby that you worry about? Does HIV and feeding worry 
you? 
iii) Was feeding ever a point of conflict in your relationship? 
 
Next steps and closure 
28) How are you feeling about the next stage (delivering the baby; raising the infant)? 
i) Affirm: “You are caring for your infant in the midst of difficult challenges” 
29) May I look over my paper to see that I’ve covered everything? 
30) Is there anything else you’d like to talk about today? 
i) If appropriate, offer assistance in referrals via Research Nurse 
I really appreciate you sharing these stories with me, and I hope that your experience helps us 
create better services for pregnant women in the future.  
You have navigated many difficult steps so far, and I know you will be able to take on the next 
steps. Thank you very much for your time. 
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Participant Information Sheet and Informed consent for  
participation in Safe & Sound in-depth interviews  
 
Every participant must receive, read and understand this document before any procedure of 
the study 
 
STUDY NUMBER: A65780 
 
VERSION: 1 
 
STUDY TITLE: “Promoting safety in antenatal care among women: testing an intervention 
in South Africa”. 
 
AN ABBREVIATED NAME FOR THIS STUDY: Safe & Sound 
 
FUNDED BY:  World Health Organization  
 
PRINCIPAL INVESTIGATOR: Nataly Woollett 
 
 
 
 
 
 
 
 
DATE AND START TIME OF THE INFORMED CONSENT DISCUSSION 
    : 
Date Month Year  Time 
 
 
 
To a participant:  this informed consent may contain words that you may not 
understand. Kindly ask study staff to explain these words or anything that you 
do not understand.  You may go home with a copy that was not signed to think 
about it or discuss with family or friends before you decide. 
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INTRODUCTION 
Hi, my name is _____________________________________.  I am working for the Wits 
Reproductive Health and HIV Institute (Wits RHI). Wits RHI is conducting research in 
reproductive health, including HIV. We are doing research on women’s health and life 
experiences during pregnancy.  
 
Part of what we would like to learn about is women’s safety during pregnancy. This is 
because many women around the globe experience violence during pregnancy. This violence 
can be bad for women’s health and the health of their babies. We are trying to find ways to 
address safety with women coming for antenatal care visits. That is why our project is called 
Safe & Sound.  
 
INVITATION 
We are inviting you to take part in another part of Safe & Sound. It is your choice if you 
would like to participate in this extra portion of research. 
 
ABOUT THE STUDY 
In this extra part, we are speaking to women for 30 to 45 minutes about their experiences 
with pregnancy. We are especially interested to learn about how women cope with violence 
and how that may influence their uptake of HIV services. 
 
The questions ask about sensitive topics that some women find difficult to discuss, and 
sometimes the questions can bring up emotions. We will ask about your emotions, your 
experiences with violence, and about HIV services like medication and breastfeeding. I will 
give you the names of some organizations that you can contact for more support in dealing 
with emotional issues if you feel that you need to do so.  
 
I will not ask you any questions about child abuse, because that is not the purpose of us 
talking today. However, I do need to let you know that because I’m a health care 
professional, if you do tell me that you or someone else is hurting your child, I must report it 
to the authorities. Again, I do not intend to discuss that part of your life with you today, but 
would prefer to focus on your own health and safety during the pregnancy.  
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All the information you provide is voluntary, which means that you are not forced to 
participate, and you can say as much as you are comfortable saying.  
 
We would appreciate your participation because we believe this research will help us 
improve the services offered in antenatal care for pregnant women.    
 
WITHDRAWAL 
You are free to stop the interview, not to answer any of the questions that we ask, and 
withdraw from the study at any point. You will receive the same services from the clinic  and 
from the Safe & Sound staff whether or not you participate in the study.  
 
POTENTIAL BENEFITS 
There may be no direct benefits to you from this study. However, you may benefit from 
discussing your experiences with a professional like myself. You and others may benefit in 
the future from research done in this study because we will learn more about addressing 
violence and HIV and maybe incorporate it in the antenatal package of care. 
 
COSTS AND COMPENSATION 
There is no cost to you for being in this study. At the end of this visit, you will be given R100 
to compensate you for your travel costs.  
 
CONFIDENTIALITY 
If you agree to participate, all the information you provide will be kept confidential and 
secret. We will not record your name or any other identifying information on any study 
documents other than this consent form. We have been trained to respect the privacy of 
participants and the information you provide us will remain confidential. All discussions take 
place in a private room and the information we collect will be stored in a locked cabinet, in a 
locked room and will only be accessed by the researchers in this study.  
 
I would like to record your interview. This way, I can ask someone who is not familiar with 
this study to type up everything we talk about today. This helps me make sure I capture all 
of your insights without having to right them down right now. 
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Once your interview is typed, we will remove all names – including your name and my 
name. They typed interview will only be looked at by people from our research team or 
ethics boards/monitors. These people are trained to maintain confidentiality and would 
review your data to ensure that the study is conducted to the highest quality. You will not be 
identified by name in any of the reports or publications of this study or its results because 
we will always report about the group as a whole, which is a total of 20 women.  
 
If you have any further questions about this study, please contact the people listed below: 
Nataly Woollett 
Principal Investigator 
WRHI, Hugh Solomon Building 
Esselen Street, Hillbrow  
Tel: 011 358 5573 
Mobile Number : 0766380564 
Abigail Hatcher 
Senior Researcher 
WRHI, Hugh Solomon Building 
Esselen Street, Hillbrow 
Tel: 011 358 5489 
Mobile Number: 084 406 7773 
 
This study is conducted in accordance with the Department of Health Guidelines 
for the Good Practice in the Conduct of Clinical Trials in Human Participants in 
South Africa (2006), and has received ethical approval from the University of the 
Witwatersrand.  If you have questions about your rights as a research participant 
or complaints about the manner in which you were treated, or feel that study has 
caused you harm, please contact: 
Prof. Peter Cleaton-Jones 
Chairperson for the Committee for 
Human Research Ethics Committee 
University of the Witwatersrand 
Tel: 011 717 2301 
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INFORMED CONSENT:  
We would appreciate your participation and your insights are very important. 
Do you have any questions about any of the information I have provided? 
Yes________    No_________ 
Do you understand you are not obligated to participate? 
Yes_______     No__________ 
Do you agree to be interviewed? 
Yes________  No____________ 
Do you agree to be recorded using this tape recorder? 
Yes________  No____________ 
 
To be completed by researcher: 
I confirm that the participant was given an opportunity to ask questions about the 
study, and all the questions asked by the participant have been answered correctly and to 
the best of my ability. I confirm that the individual has not been coerced into giving 
consent, and the consent has been given freely and voluntarily.  
   
 A copy of this ICF has been provided to the participant. 
 
 
Signature of Volunteer:  
Signature/mark 
or thumbprint 
 
 Date signed 
   
dd mm yyyy 
Print name  Time signed : 
 
 
Signature of Witness: (if necessary) 
Signature/mark 
or thumbprint 
 
 Date signed 
   
dd mm yyyy 
Print name  Time signed : 
 
 
Signature of Study Staff taking consent:  
Signature/mark 
or thumbprint 
 
 Date signed 
   
dd mm yyyy 
Print name  Time signed : 
  
Centre number Hospital record number
Screening number
SOCIO-DEMOGRAPHIC
Thank you, I am now going to ask you a few questions to learn more about you, can we continue?
1.  What race group do you consider yourself?
1= Black/African   3= White 5= Other, please specify
2= Coloured   4= Asian/Indian
2. What is your home language (the one you grew up speaking with your family)?
01= English 05= Tswana 09= Pedi/N.Sotho
02= Zulu 06= Shangaan/Tsonga 10= Venda
03= S. Sotho 07= Afrikaans 11= Swazi
04= Xhosa 08= Ndebele 12= Other, please specify
3. What is your age today in years?
4. What type of home do you live in, is it a house, a townhouse, a flat, single room or a shack?
 1= Free standing house  4= Single room
 2= Townhouse  5= Shack 
 3= Flat  6= Other, please specify 
5. How many people live in your household?
6. How many children live in your household who are under the age of 6 years?
7. In the past [4 weeks], did it happen
that there was no food to eat of any
kind in your house, because of lack 
of resources to get food
8. In the past [4 weeks], did it happen
that you or any household member
went to sleep at night hungry 
because there was not enough food
9. In the past [4 weeks], did it happen
that you or any household member
went a whole day and night without
eating anything at all because there
was not enough food?
Never
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SOCIO-DEMOGRAPHIC
10. In which country were you born?
01= South Africa 05= Namibia 09= Congo
02= Mozambique 06= Lesotho 10= Nigeria
03= Zimbabwe 07= Swaziland 11= Kenya
04= Malawi 08= DRC 12= Other, please specify
If Q10= 1, complete Q11
11. In which province of South Africa were you born?
01= Gauteng 05= Limpopo 08= Western Cape
02= Northwest 06= KZN 09= Northern Cape
03= Mpumalanga 07= Eastern Cape 10= Other, please specify
04= Free State
12. How long have you lived in Johannesburg?
If < 1 year then enter 0 in years. If < 30 days then enter 0 in Months.
13. What is your current relationship status?
 0= No current partner  3= Boy/Girlfriend, living together
 1= Married (incl. traditional), living together  4= Boy/Girlfriend, not living together
 2= Married (incl. traditional), not living together  5= Casual partner
If No current partner, go to Q17
14. How long have you been with your current partner?
If < 1 year then enter 0 in years. If < 30 days then enter 0 in Months.
15. How old is your current partner (in years)
If Don't know then enter 99
16. In which country was your current partner born?
01= South Africa 05= Namibia 09= Congo
02= Mozambique 06= Lesotho 10= Nigeria
03= Zimbabwe 07= Swaziland 11= Kenya
04= Malawi 08= DRC 12= Other, please specify
If Don't know then enter 99
17.  What is your highest level of education?
1= Never attended school 4= Completed high school
2= Less than high school 5= More than high school
3= Some high school
18. In the last 3 months, have you done any work for pay?
1= No 8= Refused
2= Yes 9= Don't know
MonthsYears
MonthsYears
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19. What is your main source of income? 
1= Self-employed 5= Partner support
2= Income from full-time employment 6= Family support (parents/grandparents)
3= Income from part-time employment 7= Other, please specify
4= Social Grant
20. Is this your first pregnancy?
 1= No
 2= Yes
If Yes, go to Q24
21. How many pregnancies have you had, including current pregnancy?
22. How many live births have you had?
23. How many living children do you have?
24. How many weeks are you into your pregnancy?
25. How many times have you visited ANC before today, during this pregnancy?
Interviewer's Initials: Interviewer's signature:
Date SDA completed: 
 Day   Month Year
Weeks
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1= No
2= Yes
8= Refused
9= Don't know
1.  Within the last year, have you been hit, slapped, kicked or otherwise No Yes
physically hurt by your partner
1 2 8 9
No Yes
2.  Within the last year, has your partner forced you to have sexual activities?
1 2 8 9
No Yes
3.  Since this pregnancy started, have you been hit, slapped, kicked or
 otherwise physically hurt by your partner? 1 2 8 9
No Yes
4.  Since this pregnancy started, has your partner forced you 
to have sexual activities? 1 2 8 9
No Yes
5.  Are you afraid of your partner? 
1 2 8 9
Interviewer's Initials: Interviewer's signature:
Date AAA completed: 
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INTIMATE PARTNER VIOLENCE
The next questions are about things that happen to many women, and that your current partner,
 or any other partner might have done to you. 
Has your current husband/partner, or any other partner ever …
1= No 8= Refused
2= Yes 9= Don't know [These response options apply to Q1 -13 a, b, d]
 1. a) Insulted you or made you feel bad about yourself? (if No or Refused or Don't know, go to Q2 )
b) Has this happened in the past 12 months? (if No or Refused or Don't know, go to Q2 )
c) In the past 12 months has this happened:
1= one time 8= Refused
2= a few times 9= Don't know
3= many times
d) Has this happened during this pregnancy?
 2. a) Belittled or humiliated you in front of other people? (if No or Refused or Don't know, go to Q3 )
b) Has this happened in the past 12 months? (if No or Refused or Don't know, go to Q3 )
c) In the past 12 months has this happened:
1= one time 8= Refused
2= a few times 9= Don't know
3= many times
d) Has this happened during this pregnancy?
 3. a) Done things to scare or intimidate you on purpose (e.g. by the way he looked at you, 
by yelling and smashing things)? (if No or Refused or Don't know, go to Q4 )
b) Has this happened in the past 12 months? (if No or Refused or Don't know, go to Q4 )
c) In the past 12 months has this happened:
1= one time 8= Refused
2= a few times 9= Don't know
3= many times
d) Has this happened during this pregnancy?
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INTIMATE PARTNER VIOLENCE (Continued)
Has your  current  husband/partner, or any  other partner  ever ...
1= No 8= Refused
2= Yes 9= Don't know
 4. a) Threatened to hurt you or someone you care about? (if No or Refused or Don't know, go to Q5 )
b) Has this happened in the past 12 months?  (if No or Refused or Don't know, go to Q5 )
c) In the past 12 months has this happened:
1= one time 8= Refused
2= a few times 9= Don't know
3= many times
d) Has this happened during this pregnancy?
No Yes
 5. a) Slapped you or thrown something at you that could hurt you? 
(if No or Refused or Don't know, go to Q6)
1 2 8 9
No Yes
b) Has this happened in the past 12 months? 
(if No or Refused or Don't know, go to Q6)
1 2 8 9
c) In the past 12 months has this happened:
1= one time 8= Refused
2= a few times 9= Don't know
3= many times
No Yes
d) Has this happened during this pregnancy?
1 2 8 9
No Yes
 6. a) Pushed you or shoved you or pulled your hair? 
(if No or Refused or Don't know, go to Q7)
1 2 8 9
No Yes
b) Has this happened in the past 12 months?  
(if No or Refused or Don't know, go to Q7)
1 2 8 9
c) In the past 12 months has this happened:
1= one time 8= Refused
2= a few times 9= Don't know
3= many times
No Yes
d) Has this happened during this pregnancy?
1 2 8 9
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INTIMATE PARTNER VIOLENCE (Continued)
Has your  current  husband/partner, or any  other partner  ever ...
1= No 8= Refused
2= Yes 9= Don't know
No Yes
 7. a) Hit you with his fist or with something else that could hurt you? 
(if No or Refused or Don't know, go to Q8)
1 2 8 9
No Yes
b) Has this happened in the past 12 months? 
(if No or Refused or Don't know, go to Q8)
1 2 8 9
c) In the past 12 months has this happened:
1= one time 8= Refused
2= a few times 9= Don't know
3= many times
No Yes
d) Has this happened during this pregnancy?
1 2 8 9
No Yes
 8. a) Kicked you, dragged you or beaten you up? 
(if No or Refused or Don't know, go to Q9)
1 2 8 9
No Yes
b) Has this happened in the past 12 months? 
(if No or Refused or Don't know, go to Q9)
1 2 8 9
c) In the past 12 months has this happened:
1= one time 8= Refused
2= a few times 9= Don't know
3= many times
No Yes
d) Has this happened during this pregnancy?
1 2 8 9
No Yes
9. a) Choked or burnt you on purpose? (if No or Refused or Don't know, go to Q10 )
1 2 8 9
No Yes
b) Has this happened in the past 12 months? 
(if No or Refused or Don't know, go to Q10)
1 2 8 9
c) In the past 12 months has this happened:
1= one time 8= Refused
2= a few times 9= Don't know
3= many times
No Yes
d) Has this happened during this pregnancy?
1 2 8 9
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INTIMATE PARTNER VIOLENCE (Continued)
Has your current  husband/partner, or any  other partner  ever ...
 1= No 8= Refused
 2= Yes 9= Don't know
No Yes
10. a) Threatened to use or actually used a gun, knife or other weapon against you?
 (if No or Refused or Don't know , go to Q11 ) 1 2 8 9
No Yes
b) Has this happened in the past 12 months? (if No or Refused or Don't know,
go to Q11 ) 1 2 8 9
c) In the past 12 months has this happened:
1= one time 8= Refused
2= a few times 9= Don't know
3= many times
No Yes
d) Has this happened during this pregnancy?
1 2 8 9
No Yes
11. a) Did your current husband/partner or any other partner ever force you to have sexual 
    intercourse by threatening you, holding you down or hurting you in some way? 1 2 8 9
    ( if No or Refused or Don't know, go to Q12 )
No Yes
b) Has this happened in the past 12 months? (if No or Refused or Don't know, go to Q12)
1 2 8 9
c) In the past 12 months has this happened:
1= one time 8= Refused
2= a few times 9= Don't know
3= many times
No Yes
d) Has this happened during this pregnancy?
1 2 8 9
12. a) Did you ever agree to have intercourse when you did not want to because you No Yes
were afraid of what your husband/ partner might do if you refused? 
(if No or Refused or Don't know, go to Q13 ) 1 2 8 9
No Yes
b) Has this happened in the past 12 months? 
    (if No or Refused or Don't know, go to Q13)
1 2 8 9
c) In the past 12 months has this happened:
1= one time 8= Refused
2= a few times 9= Don't know
3= many times
No Yes
d) Has this happened during this pregnancy?
1 2 8 9
INTIMATE PARTNER VIOLENCE AT ADMISSION V7 (20 May 2014)
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INTIMATE PARTNER VIOLENCE (Continued)
No Yes
13. a) Did your current husband/partner or any other partner ever force you to do 
something sexual (besides vaginal intercourse) that you did not want to do? 1 2 8 9
(if No or Refused or Don't know, go to Q14)
No Yes
b) Has this happened in the past 12 months?
 (if No or Refused or Don't know, go to Q14)
1 2 8 9
c) In the past 12 months has this happened: 1= one time 8= Refused
2= a few times 9= Don't know
3= many times
No Yes
d) Has this happened during this pregnancy?
1 2 8 9
(Q14: ONLY asked of women who had any shaded responses on any question in Q5-Q13)
14. Compared to before you were pregnant, did the physical and/or sexual violence
get less, stay about the same, or get worse whilst you were pregnant?
1= got less 8= Refused
2= stayed about the same 9= Don't know
3= got worse
I am now going to ask you about some situations that are true for many women. Thinking about 
your (current or most recent) husband/partner, would you say it is generally true that he:
 1= No 8= Refused
 2= Yes 9= Don't know
15. a) Has tried to keep you from seeing your friends? (if No or Refused or Don't know, go to Q16 )
b) Has this happened in the past 12 months? (if No or Refused or Don't know, go to Q16)
c) Has this happened during this pregnancy?
16. a) Has tried to restrict contact with your family of birth? (if No or Refused or Don't know, go to Q17 )
b) Has this happened in the past 12 months? (if No or Refused or Don't know, go to Q17)
c) Has this happened during this pregnancy?
17. a) Has insisted on knowing where you are all the time? (if No or Refused or Don't know, go to Q18 )
b) Has this happened in the past 12 months? (if No or Refused or Don't know, go to Q18)
c) Has this happened during this pregnancy?
INTIMATE PARTNER VIOLENCE AT ADMISSION V7 (20 May 2014)
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INTIMATE PARTNER VIOLENCE (Continued)
 1= No 8= Refused
 2= Yes 9= Don't know
18. a) Has been jealous and gotten angry if you spoke with another man?
(if No or Refused or Don't know, go to Q19)
b) Has this happened in the past 12 months? (if No or Refused or Don't know, go to Q19)
c) Has this happened during this pregnancy?
19. a) Has often been suspicious that you are unfaithful? (if No or Refused or Don't know, go to Q20 )
b) Has this happened in the past 12 months? (if No or Refused or Don't know, go to Q20)
c) Has this happened during this pregnancy?
20. a) Has your husband/partner ever taken your earnings or savings from you against your will?
(if No or Not Applicable or Refused or Don't know, go to Q21 )
1= No 8= Refused
2= Yes 9= Don't know
7= Not applicable
b) Has this happened in the past 12 months? (if No or Refused or Don't know, go to Q21 )
c) In the past 12 months has this happened:
1= one time 8= Refused
2= a few times 9= Don't know
3= many times
d) Has this happened during this pregnancy?
21. a) Has your husband/partner ever refused to contribute money for household expenses, 
 even when he has money for other things? (if No or Not Applicable or Refused or Don't know, go to Q22)
1= No 8= Refused
2= Yes 9= Don't know
7= Not applicable
b) Has this happened in the past 12 months? (if No or Refused or Don't know, go to Q22)
c) In the past 12 months has this happened:
1= one time 8= Refused
2= a few times 9= Don't know
3= many times  
d) Has this happened during this pregnancy?
INTIMATE PARTNER VIOLENCE AT ADMISSION V7 (20 May 2014)
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INTIMATE PARTNER VIOLENCE (Continued)
22. a) Has your husband/partner ever hurt your child/children? 
(if No or Not Applicable or Refused or Don't know, go to Q23)
1= No 8= Refused
2= Yes 9= Don't know
7= Not applicable
b) Has this happened in the past 12 months? (if No or Refused or Don't know, go to Q23)
c) In the past 12 months has this happened:
1= one time 8= Refused
2= a few times 9= Don't know
3= many times
d) Has this happened during this pregnancy?
23. a) Has your husband/partner ever threatened to forcefully remove you from the home? 
(if No or Not applicable or Refused or Don't know, go to Q24 )
1= No 8= Refused
2= Yes 9= Don't know
7= Not applicable
b) Has this happened in the past 12 months? (if No or Refused or Don't know, go to Q24 )
c) In the past 12 months has this happened:
1= one time 8= Refused
2= a few times 9= Don't know
3= many times
d) Has this happened during this pregnancy?
24. Do you and your husband/partner share household expenses? 
1= No 8= Refused
2= Yes 9= Don't know
7= Not Applicable
PVA (4)
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INTIMATE PARTNER VIOLENCE (Continued)
Review responses to Q5-Q13 in this PVA section. Review responses to Q1-Q4 in AAA.
If any responses in Q5-Q13 in this PVA section fall into shaded boxes, or if any responses in 
Q1-Q4 in the AAA section fall into shaded boxes, this respondent is considered IPV-positive.
If none of the responses in Q5-Q13 in this PVA section and none of the responses in 
Q1-Q4 in the AAA section fall into shaded boxes, this respondent is considered IPV-negative.
  25. What is the IPV status of participant?
1= Negative
2= Positive
Interviewer's Initials: Interviewer's signature:
Date PVA completed: 
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EXCLUSION AND ELIGIBILITY
No Yes
1. Do you fear that your current or most recent partner may take your life?
If response is YES to the above, probe to assess if participant is in imminent danger
1 2
No Yes
2. Do you fear that your partner may take your child/children's life?
1 2 7
No Yes
3. a) Are you currently thinking of hurting yourself? (if No, go to Q4 )
1 2
No Yes
b) Have you made any plans?
1 2
Please check if any of the above shaded boxes are ticked.
No Yes
4. Are any  of the shaded boxes above ticked?
1 2
5. What is the IPV status of the participant? (Look at the answer to Q25 in PVA )
1 2
* If responses to Q4 and Q5 above fall into the shaded boxes, then the woman is Eligible for the study
and should be randomized. Complete Q6= Eligible.
** If response to Q4 falls into the shaded box but the response to Q5 does not, the woman is 
Not Eligible for the study and will not be randomized but can complete the next sections
of the questionnaire. Complete Q6= Not Eligible, can continue
*** If response to Q4= Yes, the woman is Not Eligible for the study and should be immediately
referred for mental health or ChildLine services. Complete Q6= Not Eligible.
6. Is the woman eligible for the study?
1= Not eligible (End questionnaire )
2= Eligible (Go to Q7 )
3= Not eligible, can continue (Continue with GEA questionnaire )
Only complete Q7 & Q8 if Eligible
7. Subject number -
8. Randomization group
1= Control 
2= Intervention 
Interviewer's Initials: Interviewer's signature:
Date EEA completed:  Day   Month Year
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GENERAL SELF-EFFICACY SCALE
 I will read you a set of questions, and you will tell me how true each one is as it applies to you.
(Give participant "GEA visual aid")
1. I can always manage to solve
difficult problems if I try hard enough.
2. If someone opposes me, I can find
the means and ways to get what I want.
3. It is easy for me to stick to my
aims and accomplish my goals.
4. I am confident that I could deal 
efficiently with unexpected events.
5. Thanks to my resourcefulness, I know
how to handle unforeseen situations.
6. I can solve most problems if I invest
the necessary effort.
7. I can remain calm when facing difficulties
because I can rely on my coping abilities.
8. When I am confronted with a problem
I can usually find several solutions.
9. If I am in trouble, I can usually think
of a solution
10. I can usually handle whatever comes
my way.
Interviewer's Initials: Interviewer's signature:
Date GEA completed:  Day   Month Year
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HOSPITAL ANXIETY AND DEPRESSION SCALE
Thank you, I am now going to ask you a few questions to learn more about your mood and feelings 
(Give participant "HAA visual aid")
Below is a list of some of the ways you may have felt. Please indicate which answer describes best how
you have felt during the past week. 
(Read each item to respondent and mark the appropriate response. Please repeat this for all items)
During the past week,
1. I feel tense or wound up
0 1 2 3 8 9
2. I still enjoy the things I used to enjoy
3 2 1 0 8 9
3. I get a sort of frightened feeling
as if something bad is about to happen 0 1 2 3 8 9
4. I can laugh and see the funny side
of things 3 2 1 0 8 9
5. Worrying thoughts go through my mind
0 1 2 3 8 9
6. I feel cheerful
3 2 1 0 8 9
7. I can sit at ease and feel relaxed
3 2 1 0 8 9
8. I feel like I am slowed down
0 1 2 3 8 9
9. I get a sort of frightened feeling like
butterflies in the stomach 0 1 2 3 8 9
10. I have lost interest in my appearance
0 1 2 3 8 9
11. I feel restless and have to be on the move
0 1 2 3 8 9
12. I look forward with enjoyment to  things
3 2 1 0 8 9
13. I get sudden feelings of panic
0 1 2 3 8 9
14. I can enjoy a good book or radio or
TV programme 3 2 1 0 8 9
Interviewer's Initials: Interviewer's signature:
Date HAA completed:  Day   Month Year
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SEXUAL BEHAVIOUR AND PMTCT
Thank you, I am now going to ask you a few questions about your sexual experience and health,
can we continue?
 1. Was your first sexual act forced? 
("forced"  means he/multiple perpetrators physically held you down or threatened to harm you 
if you did not perform a sexual act)
1= No 8= Refused
2= Yes 9= Don't know
 2. What was your age at your first sexual act in years? 
 3. Was your first sexual act coerced? 
("Coercion" means feelings of being violated - for example you felt extreme pressure, he
threatened to start rumours, badgering, and bribing, including the use of his physical size)
1= No 8= Refused
2= Yes 9= Don't know
4. Do you have more than one sexual partner?
 1= No 8= Refused
 2= Yes 9= Don't know
 5. a) Do you know or suspect that your current or most recent partner has
had other sexual partners in the past 3 months?
(if No, Refused or Don't know, go to Q6)
1= No 8= Refused
2= Yes 9= Don't know
b) If Yes,  how many?
1= one 8= Refused
2= more than one 9= Don't know
 6. When you last had sex, did you use a condom?
 1= No 8= Refused
 2= Yes 9= Don't know
 7. Have you had sex while under the influence of alcohol or drugs in the past 3 months?
1= No 8= Refused
2= Yes 9= Don't know
SEXUAL BEHAVIOUR AND PMTCT AT ADMISSION V7 (20 May 2014)
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SEXUAL BEHAVIOUR AND PMTCT (Continued)
HIV counselling, testing and PMTCT adherence questions
8. Have you ever tested for HIV before today (If No, Refused or Don't know, go to Q10 )? 
 1= No 8= Refused
 2= Yes 9= Don't know
9. When was your last HIV test?
(999 in Month, 9999 in Year If does not remember) 
10. a) Do you know your current or most recent partner's HIV status?
(If No, Refused or Don't know, go to Q11)
 1= No 8= Refused
 2= Yes 9= Don't know
     b) As far as you know, is your partner living with HIV?
 1= No 8= Refused
 2= Yes 9= Don't know
11. May I please ask your HIV status? As far as you know today, are you living with HIV? 
(If No, Refused or Don't know, go to Q19)
 1= No 8= Refused
 2= Yes 9= Don't know
12. Does your current or most recent partner know your HIV status? 
(If No, Refused or Don't know, go to Q15)
1= No 8= Refused
2= Yes 9= Don't know
13. May I please ask how did he learn about your HIV status?
1= You disclosed your status 4= He discovered it on his own
2= Someone from the clinic disclosed your status to him 8= Refused
3= Someone else disclosed your status to him 9= Don't know
14. May I please ask how did he react to learning your status? 4= He denied or ignored it
1= He was supportive and understanding 8= Refused
2= He reacted severely and was physically or sexually violent 9= Don't know
3= He reacted severely in some other way
Now I am going to ask you about antiretroviral drugs to prevent mother-to-child-transmisson 
during pregnancy.
15. Are you enrolled at an HIV clinic? (If No, Refused, go to Q19)
 1= No 8= Refused
 2= Yes
YearMonth
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SEXUAL BEHAVIOUR AND PMTCT (continued)
1= No 7= Not Applicable
8= Refused
9= Don't know
16. Have you taken these medications during your previous pregnancies?
17. Have you taken antiretroviral medication during this pregnancy?
18. If Q16= Yes and/or Q17= Yes , Have you ever had to hide your medication from your partner? 
19. Did your partner attend ANC with you today? (if No, not applicable, refused or don't know, go to Q21 )
20. Did you have to use your partner for translation in ANC?
21. Do you have any reason to think your partner may be upset because you are speaking with me today?
(Ask participant to look at "option set 1" of SBA visual aid). Q22 - Q45 refer to current or most recent partner
Sexual Relationship Power Scale Relationship Control Subscale
22. If I asked my partner to use a condom,
he would get angry. 
23. If I asked my partner to use a condom,
he would get violent.
24. Most of the time, we do what my
partner wants to do.
25. My partner won’t let me wear certain things.
26. When my partner and I are together
I’m pretty quiet.
27. My partner has more say than I do about
important decisions that affect us. 
28. My partner tells me who I can spend
time with.
29. If I asked my partner to use a condom, 
he would think I’m having sex with other people.
30. I feel trapped or stuck in our relationship.
31. My partner does what he wants, even if I 
do not want him to.
2= Yes
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SEXUAL BEHAVIOUR AND PMTCT (continued)
32. I am more committed to our relationship
than my partner is.
33. When my partner and I disagree, 
he gets his way most of the time.
34. My partner gets more out of our
relationship than I do.
35. My partner always wants to know
where I am.
36. My partner might be having sex with
someone else.
Ask participant to look at "option set 2" Decision-Making Dominance Subscale
1= Your partner 8= Refused 
2= Both of you equally 9= Don't know
3= You
37. Who usually has more say about whose friends to go out with?
38.  Who usually has more say about whether you have sex? 
39. Who usually has more say about what you do together? 
40. Who usually has more say about how often you see one another? 
41. Who usually has more say about when you talk about serious things? 
42. In general, who do you think has more power in your relationship? 
43. Who usually has more say about whether you use condoms? 
44. Who usually has more say about what types of sexual acts you do?
45. Who had more say around you getting pregnant?
Interviewer's Initials: Interviewer's signature:
Date SBA completed:  Day   Month Year
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HARVARD TRAUMA QUESTIONNAIRE SHORT VERSION
Now I am going to ask about the types of violent things that sometimes happen in our communities. I will
ask about experiences that might have happened to you, your family, people you know and strangers.
Can we continue? Please take your time to decide how much the statement applies to you.
 1. I feel safe:
a) when I am at work
1= No 8= Refused 
2= Yes 9= Don't know
7= Not applicable
b) outside my home
1= No 8= Refused 
2= Yes 9= Don't know
c) in my home
1= No 8= Refused 
2= Yes 9= Don't know
 2. I have seen: 
1= No 8= Refused 
2= Yes 9= Don't know
a) a stranger being beaten up.
b) someone I know (not a family member) being beaten up
c)  a member of my family (other than a partner) being beaten up
3. I have been beaten up: 
1= No 8= Refused 
2= Yes 9= Don't know
a) by a stranger
b) by someone I know (not a family member or partner)
c) by a member of my family (other than a partner)
HARVARD TRAUMA AT ADMISSION V7 (20 May 2014)
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HARVARD TRAUMA QUESTIONNAIRE SHORT VERSION
1= No 8= Refused 
2= Yes 9= Don't know
4. I have seen: 
a) a stranger get stabbed or shot
b) someone I know (not a family member) get stabbed or shot
c) a member of my family (other than a partner) get stabbed or shot
5. Someone has threatened to stab me or shoot me. (if No, Refused or Don't know, go to Q6)
If Yes , please tell me who this was (more than one response possible ):
a) a stranger
b) someone I know (not a family member or partner)
c) a member of my family (other than a partner)
6. Someone has actually stabbed me or shot me. (if No, Refused or Don't know, go to Q7 )
If Yes , please tell me who this was:
a) a stranger
b) someone I know (not a family member or partner)
c) a member of my family (other than a partner)
7. Someone has tried  to force me or has actually forced me to have sex or do something
    sexual against my will me or has actually raped me. (if No, Refused or Don't know, go to Q8 )
If Yes , please tell me who this was:
a) a stranger
b) someone I know (not a family member or partner)
c) a member of my family (other than a partner)
8. When I was young, grown-ups in my home used to:
a) hit each other
b) scream at each other
c) hit me
d) scream at me
e) withhold essentials as punishment (like food)
The following are symptoms that people sometimes have after experiencing hurtful or terrifying
events in their lives. 
HARVARD TRAUMA AT ADMISSION V7 (20 May 2014)
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HARVARD TRAUMA QUESTIONNAIRE SHORT VERSION
I am going to read a set of statements, please decide how much the symptoms bothered you in the
past week (give participant "HTA visual aid - Option set 2")
9. Recurrent thoughts or memories of
the most hurtful or terrifying events
10. Feeling as though the event is
happening again
11. Recurrent nightmares
12. Feeling detached or withdrawn
from people
13. Unable to feel emotions
14. Feeling jumpy, easily startled
15. Difficulty concentrating
16. Trouble sleeping
17. Feeling on guard
18. Feeling irritable or having outbursts 
of anger
19. Avoiding activities that remind you of
 the traumatic or hurtful event
20. Inability to remember parts of the
most traumatic or hurtful events
21. Less interest in daily activities
22. Feeling as if you don't have a future
23. Avoiding thoughts or feelings associated
 with the traumatic or hurtful experience
Interviewer's Initials: Interviewer's signature:
Date HTA completed: 
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End here if IPV-NEGATIVE (Look at Q25 in PVA)
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Sometimes              
(1-3 days)
Often                  
(4-5 days)
Most of the time 
(every day of past 
week or 6 days)
Refused Don't know
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SAFETY BEHAVIOUR CHECKLIST
This section should not be included among IPV-negative women
Now I will ask you about certain actions that some women take when they feel that they are 
in danger from a partner
1= No 8= Refused
2= Yes 9= Don't know
7= Not applicable
Have you ever,
 1. Hidden money?
 2. Changed door locks in one or some of the bedrooms for safety?
 3. Established code with family or friends? e.g. send SOS texts/sms to family or friends
 4. Asked neighbours to call police if violence begins?
 5. Made sure to have your cellular phone charged at all times in case of escalating violence?
 6. Ran to a neighbour’s, family or friend’s house for safety?
 7. Locked yourself in one of the rooms for safety?
 8. Removed weapons?
Do you have the following items easily accessible to you and in your possession:
9. Social grant bank card?
10. Title deed of the house you live in ?
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SAFETY BEHAVIOUR CHECKLIST (Continued)
11. Birth certificates (yours and children)? 
12. Identity document?
13. Secret bank account?
14. Insurance policies and numbers?
15. Marriage certificate or customary marriage negotiations documents?
16. Extra cash/money?
17. Important phone numbers? e.g. POWA, SAPS, Family, Friend
18. Hidden bag with extra clothing?
Now I will ask you a few questions about your household, can we continue?
19.  Is the home you are living in registered in your name?
20.  Do you have children under the age of 16 years living with you?
(If No, go to 22a)
21. a) Do you have children under the age of 6 years living with you?
 b) If Yes , how many?
22. a) Are social grants (foster care, child support) registered in your name?
b) If No , then in whose name:
1= Partner 4= Partner's Parents
2= Mum/Dad 5= Other
3= Aunt/Uncle ________________________________
Interviewer's Initials: Interviewer's signature:
Date BCA completed: 
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COMMUNITY RESOURCES
Thank you, I am now going to ask you a few questions to learn more about the community resources
you have accessed, can we continue? 
Have you ever USED any of the following support systems to deal with violence from your partner?
 1. a) Legal or advocacy organization, e.g. POWA, Tshwaranang etc. (if No, Refused or Don't know,
go to Q2 )
1= No 8= Refused
2= Yes 9= Don't know
b) How many times?
1= one time 8= Refused
2= a few times (2-3 times) 9= Don't know
3= many times (4+ times)
c) How effective (helpful) were they in dealing with the abuse
1= Not Helpful 8= Refused
2= Helpful 9= Don't know
 2. a) Shelter/Safe house e.g. Bombani safe house (if No, Refused or Don't know, go to Q3 )
1= No 8= Refused
2= Yes 9= Don't know
b) How many times?
1= one time 8= Refused
2= a few times (2-3 times) 9= Don't know
3= many times (4+ times)
c) How effective (helpful) were they in dealing with the abuse
1= Not Helpful 8= Refused
2= Helpful 9= Don't know
 3. a) South African Police Services (SAPS) (if No, Refused or Don't know, go to Q4 )
1= No 8= Refused
2= Yes 9= Don't know
b) How many times?
1= one time 8= Refused
2= a few times (2-3 times) 9= Don't know
3= many times (4+ times)
c) How effective (helpful) were they in dealing with the abuse
1= Not Helpful 8= Refused
2= Helpful 9= Don't know
COMMUNITY RESOURCE USE AT SCREENING V7 (20 May 2014)
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COMMUNITY RESOURCES
 4. a) Magistrate Court for Protection  Orders (if No, Refused or Don't know, go to Q5 )
1= No 8= Refused
2= Yes 9= Don't know
b) How many times?
1= one time 8= Refused
2= a few times (2-3 times) 9= Don't know
3= many times (4+ times)
c) How effective (helpful) were they in dealing with the abuse
1= Not Helpful 8= Refused
2= Helpful 9= Don't know
 5. a) Legal services and/or children's court (i.e. divorce, child custody or visitation)
 (if No, Refused or Don't know, go to Q6 )
1= No 8= Refused
2= Yes 9= Don't know
b) How many times?
1= one time 8= Refused
2= a few times (2-3 times) 9= Don't know
3= many times (4+ times)
c) How effective (helpful) were they in dealing with the abuse
1= Not Helpful 8= Refused
2= Helpful 9= Don't know
 6. a) Faith Community (i.e., church, pastor, imam) (if No, Refused or Don't know, go to Q7 )
1= No 8= Refused
2= Yes 9= Don't know
b) How many times?
1= one time 8= Refused
2= a few times (2-3 times) 9= Don't know
3= many times (4+ times)
c) How effective (helpful) were they in dealing with the abuse
1= Not Helpful 8= Refused
2= Helpful 9= Don't know
 7. a) Social Welfare (Social Workers) (if No, Refused or Don't know, go to Q8 )
1= No 8= Refused
2= Yes 9= Don't know
COMMUNITY RESOURCE USE AT SCREENING V7 (20 May 2014)
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COMMUNITY RESOURCES
b) How many times?
1= one time 8= Refused
2= a few times (2-3 times) 9= Don't know
3= many times (4+ times)
c) How effective (helpful) were they in dealing with the abuse
1= Not Helpful 8= Refused
2= Helpful 9= Don't know
 8. a) Health Care Services (Clinic, Rape crisis centres) (if No, Refused or Don't know, go to Q9 )
1= No 8= Refused to answer
2= Yes 9= Don't know
b) How many times?
1= one time 8= Refused
2= a few times (2-3 times) 9= Don't know
3= many times (4+ times)
c) How effective (helpful) were they in dealing with the abuse
1= Not Helpful 8= Refused
2= Helpful 9= Don't know
 9. a) Close friends or neighbours (if No, Refused or Don't know, go to Q10 )
1= No 8= Refused
2= Yes 9= Don't know
b) How many times?
1= one time 8= Refused
2= a few times (2-3 times) 9= Don't know
3= many times (4+ times)
c) How effective (helpful) were they in dealing with the abuse
1= Not Helpful 8= Refused
2= Helpful 9= Don't know
 10. a) Partner's parents/In-laws (including sisters-in-law and brothers-in-law)
(if No, Refused or Don't know, go to Q11)
1= No 8= Refused 
2= Yes 9= Don't know
b) How many times?
1= one time 8= Refused
2= a few times (2-3 times) 9= Don't know
3= many times (4+ times)
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c) How effective (helpful) were they in dealing with the abuse
1= Not Helpful 8= Refused
2= Helpful 9= Don't know
11. a) Your own extended family
1= No 8= Refused
2= Yes 9= Don't know
b) How many times?
1= one time 8= Refused
2= a few times (2-3 times) 9= Don't know
3= many times (4+ times)
c) How effective (helpful) were they in dealing with the abuse
1= Not Helpful 8= Refused
2= Helpful 9= Don't know
Thank you very much for your patience and taking part in the study, 
do you have any questions?
Interviewer's Initials: Interviewer's signature:
Date CRA completed:  Day   Month Year
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Participant Informed consent for participation in the Safe & Sound study on 
women’s health and life experiences 
 
Every participant must receive, read and understand this document before any procedure of 
the study 
 
STUDY NUMBER: M121179 
 
VERSION: 1 
 
STUDY TITLE: “Promoting safety in antenatal care among women: testing an intervention 
in South Africa”. 
 
AN ABBREVIATED NAME FOR THIS STUDY: Safe & Sound 
 
FUNDED BY:  World Health Organization  
 
PRINCIPAL INVESTIGATORS: Nataly Woollett 
 
 
 
 
 
 
 
 
DATE AND START TIME OF THE INFORMED CONSENT DISCUSSION 
    : 
Date Month Year  Time 
 
 
 
To a participant:  this informed consent may contain words that you may not 
understand. Kindly ask study staff to explain these words or anything that you 
do not understand.  You may go home with a copy that was not signed to think 
about it or discuss with family or friends before you decide. 
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INTRODUCTION 
Hi, my name is _____________________________________.  I am working for the Wits 
Reproductive Health and HIV Institute (Wits RHI). Wits RHI is conducting research in 
reproductive health, including HIV. We are doing research on women’s health and life 
experiences during pregnancy. We are inviting  all women to who come to the antenatal 
clinic if they would like to participate in this study. The research will involve answering some 
questions about your experiences, your health, and your feelings. 
 
Part of what we would like to learn about is women’s safety during pregnancy. This is 
because many women around the globe experience violence during pregnancy. This violence 
can be bad for women’s health and the health of their babies. We are trying to find ways to 
address safety with women coming for antenatal care visits. That is why our project is called 
Safe & Sound. If you decide to participate in this study, your responses will help us to 
improve the treatment of pregnant women who come to antenatal care. 
 
First let me give you some more information about the study and then you can tell me if you 
are willing to participate.  
 
Our study aims to test a counselling intervention for pregnant women receiving antenatal 
care in South Africa. We would like to ask you some questions today and again at another 
time. As part of the study we want to test if talking to a nurse for approximately 30 minutes 
is beneficial for women who have experienced or are still experiencing violence by their 
partner. Therefore, some women will be given an opportunity to talk to their antenatal care 
nurse in more detail about their experiences in their relationship and having to do with 
violence.  
 
Whether or not you will be given this extra counseling opportunity will be decided by chance 
(like a lottery).  
 
All women I speak to, whether or not they get to take part in the counseling, will be invited 
to answer questions. The questions will take approximately 45 minutes to complete, and I 
will read them to you and ask your answers. There are no right or wrong answers, but we 
are trying to learn more about your experience while being pregnant. 
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Then, if you have been chosen by chance to receive the intervention, you will be invited to 
chat a bit longer (an extra 30 minutes) either today or at your next clinic visit. This chat will 
be between you and myself, a trained nurse, and we will discuss your relationship and things 
you can do to keep yourself and your baby safe. Then, after you deliver your baby and you 
come for your six weeks post-partum visit, we would like to spend another 30 minutes 
asking you some questions again. If you go elsewhere for your post- partum visit, we would 
like to contact you via mobile phone, if that is fine and safe for you. 
 
The questions ask about sensitive topics that some women find difficult to discuss, and 
sometimes the questions can bring up difficult emotions. We will ask about your emotions, 
your experiences with violence, and about sexual behaviour. I will give you the names of 
some organizations that you can contact for more support in dealing with emotional issues if 
you feel that you need to do so. I will also give you the name of a person you can contact if 
you have additional questions after you leave here today. 
 
I will not ask you any questions about child abuse, because that is not the purpose of us 
talking today. However, I do need to let you know that because I’m a nurse, if you do tell 
me that you or someone else is hurting your child, I must report it to the authorities. Again, 
I do not intend to discuss that part of your life with you today, but would prefer to focus on 
your health and safety during the pregnancy.  
 
All the information you provide is voluntary, which means that you are not forced to 
participate, and if you do participate, you can say as much as you are comfortable saying.  
We would appreciate your participation because we believe this research will help us 
improve the services offered in antenatal care for pregnant women.    
 
WITHDRAWAL 
You are free to stop the interview, not to answer any of the questions that we ask, and 
withdraw from the study at any point. You will receive the same services from the clinic 
whether or not you participate in the study.  
 
POTENTIAL BENEFITS 
There may be no direct benefits to you from this study. However, you may benefit from 
discussing your experiences with a nurse like myself. You and others may benefit in the 
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future from research done in this study because we will learn more about addressing 
violence in pregnant women and maybe incorporate it in the antenatal package of care. 
 
COSTS AND COMPENSATION 
There is no cost to you for being in this study. At the end of this visit, you will be given R100 
to compensate you for your travel costs. At the postpartum visit, six weeks after you deliver 
you will receive R100 for a total of R200.  
 
CONFIDENTIALITY 
If you agree to participate, all the information you provide will be kept confidential and 
secret. We will not record your name or any other identifying information on any study 
documents other than this consent form which will be stored separate from your clinic 
records and other information. We have been trained to respect the privacy of participants 
and the information you provide us will remain confidential. All discussions take place in a 
private room and the information we collect will be stored in a locked cabinet, in a locked 
room and will only be accessed by the researchers in this study. For your safety, we 
recommend that you keep your participation in this study to yourself, or if you do choose to 
talk about it please explain that it is a women’s health study. 
 
Your interview may also be looked at by people from the World Health Organization (WHO), 
Institutional Review Boards (IRB’s) and monitors/auditors. These people are trained to 
maintain confidentiality and would review your data to ensure that the study is conducted to 
the highest quality. You will not be identified by name in any of the reports or publications of 
this study or its results because we will always report about the group as a whole, which is a 
total of 1,350 women.  
 
If you have any further questions about this study, please contact the people listed below: 
Nataly Woollett 
Principal Investigator 
WRHI, Hugh Solomon Building 
Corner of Esselen and Klein 
Hillbrow  
Tel: 011 358 5573 
Mobile Number : 0766380564 
Abigail Hatcher 
Senior Researcher 
WRHI, Hugh Solomon Building 
Esselen Street, Hillbrow 
Tel: 011 358 5489 
Mobile Number: 084 406 7773 
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This study is conducted in accordance with the Department of Health Guidelines 
for the Good Practice in the Conduct of Clinical Trials in Human Participants in 
South Africa (2006), and has received ethical approval from the University of the 
Witwatersrand.  If you have questions about your rights as a research participant 
or complaints about the manner in which you were treated, or feel that study has 
caused you harm, please contact: 
Prof. Peter Cleaton-Jones 
Chairperson for the Committee for 
Human Research Ethics Committee 
University of the Witwatersrand 
Tel: 011 717 2301 
 
 
Participant questions/comments: _____________________________________ 
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
_______________________________________________________________ 
 
Interviewer responses: 
_______________________________________________________________ 
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
_______________________________________________________________ 
 
Comprehension ckecklist: 
True or False 
1. Some women will receive a counselling intervention and some will not 
2. You will not receive the same standard of care at this clinic if you do not take part in this 
study 
3. When are you due for a follow-up visit with me?  
a) 6 days postpartum  
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b) 6 weeks postpartum 
c) 6 months postpartum 
 
INFORMED CONSENT:  
We would appreciate your participation and your insights are very important. 
 Do you have any questions about any of the information I have provided? 
 Yes________    No_________ 
Do you understand you are not obligated to participate? 
Yes_______     No__________ 
Do you agree to be interviewed? 
Yes________  No____________ 
Do you agree to be randomised into the brief intervention? 
Yes________  No____________ 
 
To be completed by researcher: 
I confirm that the participant was given an opportunity to ask questions about the 
study, and all the questions asked by the participant have been answered correctly and to 
the best of my ability. I confirm that the individual has not been coerced into giving 
consent, and the consent has been given freely and voluntarily.  
   
 A copy of this ICF has been provided to the participant. 
 
 
Signature of Volunteer:  
Signature/mark 
or thumbprint 
 
 Date signed 
   
dd mm yyyy 
Print name  Time signed : 
 
 
Signature of Witness: (if necessary) 
Signature/mark 
or thumbprint 
 
 Date signed 
   
dd mm yyyy 
Print name  Time signed : 
 
 
Signature of Study Staff taking consent:  
Signature/mark 
or thumbprint 
 
 Date signed 
   
dd mm yyyy 
Print name  Time signed : 
  
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Intimate partner violence and engagement in HIV
care and treatment among women: a systematic
review and meta-analysis
Abigail M. Hatchera,b, Elizabeth M. Smoutc, Janet M. Turand,
Nicola Christofidesb and Heidi Sto¨cklc
Objective: We aimed to estimate the odds of engagement in HIV care and treatment
among HIV-positive women reporting intimate partner violence (IPV).
Design: We systematically reviewed the literature on the association between IPV and
engagement in care. Data sources included searches of electronic databases (PubMed,
Web of Science, CINAHL and PsychoInfo), hand searches and citation tracking.
Methods: Two reviewers screened 757 full-text articles, extracted data and indepen-
dently appraised study quality. Included studies were peer-reviewed and assessed IPV
alongside engagement in care outcomes: antiretroviral treatment (ART) use; self-
reported ART adherence; viral suppression; retention in HIV care. Odds ratios (ORs)
were pooled using random effects meta-analysis.
Results: Thirteen cross-sectional studies among HIV-positive women were included.
Measurement of IPV varied, withmost studies defining a ’case’ as any history of physical
and/or sexual IPV. Meta-analysis of five studies showed IPV to be significantly associ-
ated with lower ART use [OR 0.79, 95% confidence interval (95% CI) 0.64–0.97]. IPV
was associated with poorer self-reported ART adherence in six studies (OR 0.48, 95%CI
0.30–0.75) and lower odds of viral load suppression in seven studies (OR 0.64, 95% CI
0.46–0.90). Lack of longitudinal data and measurement considerations should temper
interpretation of these results.
Conclusion: IPV is associated with lower ART use, half the odds of self-reported ART
adherence and significantly worsened viral suppression among women. To ensure the
health of HIV-positive women, it is essential for clinical programmes to address
conditions that impact engagement in care and treatment. IPV is one such condition,
and its association with declines in ART use and adherence requires urgent attention.
Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.
AIDS 2015, 29:2183–2194
Keywords: antiretroviral treatment adherence, engagement in care, intimate
partner violence, meta-analysis
Introduction
Advances in HIV care and treatment have led to
remarkable health gains among those living with HIV.
Yet, many HIV-positive patients remain out of care, fail to
take up treatment or are nonadherent to antiretroviral
therapy (ART). Such challenges with engagement in HIV
are common among women [1,2] and are responsible for
a considerable proportion of morbidity and mortality
among HIV-positive women [3,4].
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There are a number of reasons for poor engagement in
HIV care, among which intimate partner violence (IPV)
has received increasing attention. IPV is defined as any
behaviour within an intimate relationship that causes
physical, psychological or sexual harm [5], and global
prevalence is estimated to be 30% [6]. IPV has been
associated with HIV infection in cross-sectional [7] and
prospective studies [8,9]. A meta-analysis of data from 28
studies showed that multiple forms of IPV are associated
with incident HIV infection in women [10]. Research
points to direct links between IPVand HIV infection, via
forced sex, as well as indirect links, via heightened HIV
risk among IPV perpetrators and a reduced ability for
women in violent relationships to negotiate condom use
[11–13].
Despite this emerging literature around HIV acquisition,
less is known about the influence of IPV for those already
living with HIV. Evidence suggests that women living
with HIV have a high likelihood of relationship violence.
Clinical samples from resource-rich settings estimate that
68–95% of HIV-positive women experience IPV in their
lifetime [14–18]. In resource-constrained settings, HIV-
positive women are twice as likely as HIV-negative
counterparts to report lifetime violence from a partner
[19]. HIV diagnosis, in itself, can trigger relationship
conflict and violence [17,20–22]. Importantly, HIV
testing, regardless of the serostatus outcome, can lead to
violence [23,24], suggesting that even this first step in
accessing care and treatment may pose an IPV risk
for women.
IPV leads to declines in HIV-related health, with studies
finding an association between IPV and virologic failure
[25,26], lower CD4þ cell counts [25], higher incidence of
opportunistic infection [26,27], marked increase in
episodic diseases (e.g. pneumonia, bronchitis, sinusitis)
[27] and greater risk of mortality [28]. Negative effects on
engagement in care and treatment may be a leading reason
for IPV being associated with poor health outcomes for
HIV-infected women.
Several plausible mechanisms could drive the relationship
between IPVand engagement in HIV care. Fear of newor
continued IPV leads women to avoid disclosure of their
status to male partners [29–31], which in turn has a
significant impact on treatment adherence [32–34].
When women are fearful of violence from their partners,
they may be more likely to default on medications or may
have other health priorities, such as physical safety, which
trump adherence [35]. Qualitative studies have explored
how fear and experience of IPV influence women’s
decisions to take up and stay retained in HIV services
[35–37]. Given the well established links between IPV
and mental health [38–43], it is possible that poor mental
health is a key explanation for how IPV impacts on ART
adherence [44–47]. Alternately, feelings of denial and
shame may preclude abused women’s abilities to seek care
openly [48], or partner control may inhibit access to
medical care [49].
Despite health risks associated with IPV among HIV-
infected persons, IPV remains an understudied factor in
the literature around HIV care and treatment [50].
Evidence on the association between IPV and adherence
has yet to be reviewed systematically. This study examined
the relationships between IPV and engagement in HIV
care and treatment (i.e. ART uptake, ART adherence
measured through self-report or by viral loads, and
retention in HIV care) through a systematic review and
meta-analysis.
Materials and methods
A systematic review and meta-analyses were conducted
on studies measuring an association between IPV and
ART use, ART adherence (self-reported), ART adher-
ence (viral suppression) and retention in HIV. The aim
was to determine the extent to which IPV is related to
engagement in HIV care and treatment among women.
Selection criteria
This review follows PRISMA reporting guidelines for
systematic reviews (see Text S1, http://links.lww.com/
QAD/A763) [51]. Studies were eligible for inclusion if
they included adult women living with HIV; presented
primary, quantitative data in a peer-reviewed manuscript
based on cross-sectional, case–control or longitudinal
data; and measured the predictor of interest (IPV) and at
least one outcome of interest. No restrictions were placed
on study setting or population.
Search strategy
Electronic searches were conducted using the following
databases: PubMed, Web of Science, CINAHL and
PsychoInfo. Articles in English or French were included if
they had been published in peer-reviewed journals before
or up to January 2015. Search terms and a full search
strategy can be found in Text S2, http://links.lww.com/
QAD/A763.
Study selection
Using the ‘online search’ function of EndNote [52], all
titles and abstracts matching the search terms were
imported. Two authors (A.M.H., E.M.S.) independently
reviewed all identified study titles and abstracts. Articles
were retained if at least one search term for predictor or
outcome concept was found. Abstracts that did not meet
all inclusion criteria were excluded and reason for
exclusion noted. Exclusion criteria included publication
factors and population characteristics (Fig. 1).
The same authors (A.M.H., E.M.S.) independently
screened full articles of all included abstracts. Full articles
2184 AIDS 2015, Vol 29 No 16
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
with discrepancy about inclusion were reviewed by a
third author (H.S.) to reach consensus. Exclusion reasons
were noted. No additional study was identified by
searching the reference lists of included articles.
Data extraction
Data were extracted on study design, setting, population,
sample size, measures used to investigate IPV and
measures used to assess engagement in HIV care. As
meta-analysis required data from among women only and
in dichotomous outcomes, authors of several articles
(n¼ 7) were contacted directly via e-mail and asked to
abstract 2 2 tables in Excel: numbers of women
reporting IPV vs. not and reporting engagement in care
vs. not. Authors of all seven articles requiring additional
information were willing and able to provide these data.
Quality appraisal
A quality appraisal was conducted on all included
studies using an adapted Critical Appraisal Skills
Programme (CASP) quality appraisal tool (Text S3,
http://links.lww.com/QAD/A763) [53]. The quality
appraisal form includes 15 questions about study quality
for which articles received a numeric score representing
the extent to which they met the criteria: 0 (non
responsive), 1 (partially responsive) or 2 (fully responsive).
Data analysis
Meta-analyses were conducted separately for dichoto-
mous engagement in care outcomes. Dichotomous
outcomes were deemed appropriate, as key outcomes
of interest were either inherently dichotomous (i.e.
current ARTuse) or represented nonnormally distributed
continuous data (i.e. adherence, viral suppression). An
assessment was made by the authorship team to ensure
that ‘clinical heterogeneity’ was acceptable to lend each
outcome to meta-analysis [54].
Quantitative outcomes were extracted into an Excel
table. This included details on overall IPV prevalence in
the study, cases and noncases among women with IPV
and without IPV, and correlation coefficients. Pooled
Meta-analysis of partner violence and adherence Hatcher et al. 2185
Original search
n = 757
Duplicates
n = 136
Title / abstract screening
n = 621
 
 
 
 
 
 
• Non-peer review (1)
• No analysis (29)
• Pop < 18 years (43)
• Men only (20)
• Childhood sexual
  Abuse only (40)
• Adherence to non-HIV  
  medication (7)
• Adherence/uptake of
  post-exposure prophy
  -laxis (49)
• Qualitative (31)
• Irrelevant (eg. animal
  research) (313)  
 
Full text review
(up to january 2015)
n = 75
 
 
 
• TOTAL Excluded (62)
• No primary data (36)
• Lacked predictor or
  outcome of interest
  (51)  
• IPV measured as com-
  posite with other types
  of violence (7)
• No women studied (3)
• Paper unavailable (0) 
 
 
 
ART Adherence
(self-report)
n = 6
ART uptake
n = 5
• PubMed (133)
• Web of sci (459)
 
 
• Psycinfo (86)
• CINAHL (79)
 
Retention in HIV care
n = 5
ART Adherence
(viral load suppression)
n = 7 
Included
n = 13a
Fig. 1. Flowchart of primary study selection. aFive studies examined more than one outcome.
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unadjusted odds ratio (OR) estimates [with correspond-
ing 95% confidence intervals (95% CIs)] were calculated
using random effects meta-analysis in STATA [55]. No
adjustment was made for potential confounders, given
that few studies reported covariate data. Heterogeneity
among studies was estimated using the I2 statistic, with
significant heterogeneity detected at the P less than 0.05
level. Sensitivity analysis for publication bias was under-
taken through visual inspection of funnel plots [56] and
Egger’s test statistic (with small-study effects being
detectable at a conservative P< 0.10 level) [57]. To aid
comparison with other systematic reviews, the self-
reported adherence outcome was transformed to a
standardized mean difference [58].
Results
Our search strategy identified 621 unique records, of
which 554 were excluded during abstract screening
(Fig. 1). Full texts were obtained for 75 articles, of which
62 were excluded upon further screening. A total of 13
studies measured the association between IPVand at least
one of the primary outcomes: ART uptake, ART
adherence (self-report), ART adherence (viral suppres-
sion) and retention in HIV care.
Key features of included articles
Table 1 presents the key characteristics and outcomes of
the 13 included studies [25,59–70]. Most studies (n¼ 11)
were conducted in the United States and sample sizes
across all studies were relatively small, with a median of
234 participants. All 13 studies were cross-sectional. Most
studies (n¼ 12) were conducted among the general HIV-
infected population, with Kalokhe et al. [60] conducting
their study among high-risk crack/cocaine users.
Measures of intimate partner violence
Measures of IPV were based on self-reports across all 13
studies. As summarized in Table 1, several studies used
brief, unvalidated screening tools to assess violence
[59,62–64]. Validated instruments included the Severity
of Violence Against Women Scale [25,66], the Conflict
Tactics Scale [61], the Slapped, Threatened, and Throw
instrument [60], and the Women’s Experience of
Battering (WEB) scale [25,67–69]. Ryerson Espino
et al. [68] bolstered the WEB scale to include dimensions
of forced sex and fears around physical safety. Siemieniuk
et al. [71] trained clinic researchers to conduct a
standardized screening using a single introductory
question about any domestic abuse, after which women
were considered to have IPV if they spoke in a semi-
structured way about violence as an adult within a current
or past partner.
Eleven studies used lifetime experience of IPV as the
exposure of interest, whereas two analysed IPV in the past
2186 AIDS 2015, Vol 29 No 16
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12 months [59,66]. Although several other articles
included measures of recent violence (past 12 months
[61,68]; past 5 months [63]), the authors did not conduct
analysis using the ‘recent violence’ data.
Ethical considerations
Quality scores are reported in Table 1. All studies reported
informed consent procedures and ethical review. How-
ever, Siemieniuk et al. [65] and Schafer et al. [25] were the
only authors to detail specific steps taken by clinicians
when women disclosed IPV.
Current antiretroviral therapy use
Five studies measured current ART use. Three studies
used self-report of a single question (’are you currently on
ART?’) to assess ART use at the time of interview
[60,63,67]. Two assessed current ARTuse via clinical data
routinely collected in the HIV clinic [59,65].
No individual studies found a statistically significant
relationship between IPV and current ART use among
women. Siemieniuk et al. [65] found that participants
who experienced IPV were more likely to report ART
non-use, but this association did not reach statistical
significance (P¼ 0.069). Kalokhe et al. [60] found lower
current ART use among 343 male and female cocaine
users who had ever experienced IPV (P¼ 0.001), but this
finding was not significant among the sub-sample of 175
women. Ramachandran et al. [63] found that men and
women reporting a history of IPV were less likely to be
using ART (66%) than nonabused counterparts (93%,
P¼ 0.04), but data were not available among women
only. Illangasekare et al. [59] found no significant
association between experience of lifetime IPV and
ART use in a sample of 196 HIV-infected women (risk
ratio 0.73, 95% 95% CI 0.39–1.42). Blackstock et al. [67]
found no significant relationship between lifetime IPV
and ART use (risk ratio 1.01, 95% CI 0.88–1.16).
Antiretroviral therapy adherence measured by
self-report
Six studies included self-reported measures of ART
adherence. Two used the AIDS Clinical Trials Group
Questionnaire, which measures good adherence as
greater than 90% in the past 3 days and 30 days
[61,68]. Trimble et al. [66] used an adaptation of the
Morisky Medication Adherence Scale, in which good
adherence was defined as scores of 7 or higher.
Participants in study by Malow et al. [62] noted the
percentage of time they tookmedicine as prescribed, with
good adherence defined as 95% or greater. Blackstock
et al. [67] used the Case Adherence Index (CAI),
dichotomized into poor adherence (10) or good
adherence (>10). Rose et al. [64] asked the patient’s
physician to rate on a scale of 0–10 how adherent they
believed the patient to be, with good adherence assessed
as at least 9.
Of the six studies that assessed ART adherence using self-
report, three found significant outcomes among women.
Trimble et al. [66] found that mean adherence scores on the
MMAS were significantly lower among women who
reported IPV (M¼ 5.49, SD¼ 2.06) than among those
without (M¼ 6.57, SD¼ 1.57, P< 0.001). Using a
dichotomous outcome, this translated to lower odds of
good adherence among women reporting IPV (OR 0.28,
95% CI 0.17–0.47). Rose et al. [64] found poorer
adherence among women with IPV as measured by the
continuous outcome of physician-reported scale (r¼ -0.38,
P< 0.05). As a dichotomous outcome, women with IPV
had loweroddsof good adherence (OR0.15, 95%CI0.03–
0.70). Blackstock et al. [67] found that self-reported
adherence was significantly worse among women who
reported IPV (risk ratio 0.74, 95% CI 0.72–0.88). Lopez
et al. [61] found that amongwomen, ‘extreme IPV’ (e.g. use
of a weapon) was associated with decreased adherence as a
continuous variable (r¼ -0.26, P¼ 0.026). When using
‘any IPV’ as the exposure of interest, Lopez et al. [61] did not
find a significant difference (OR 0.45, 95%CI 0.15–1.29).
Ryerson Espino et al. [68] did not find a significant
association, with a similar proportion of women reporting
good adherence with (36.1%) and without IPV (40.0%).
Malow et al. [62] did not find a significant direct association
between IPVand nonadherence, but when using structural
equation modelling, did find that partner conflict led to
depression, which in turn was related to nonadherence.
Antiretroviral therapy adherence measured by
viral load
Seven studies assessed adherence using patient medical
records of viral load suppression. Dichotomized out-
comes for viral load suppression used the clinically
relevant cut-off at the time of study: 500 copies/ml [65],
400 copies/ml [59] and 200 copies/ml [64,67–70].
Of the seven studies measuring viral load suppression,
three found a significant association with IPV. Siemieniuk
et al. [65] found that women experiencing IPVwere more
likely to have viral loads greater than 500 copies/ml than
IPV-negative counterparts (P¼ 0.027). Rose et al. [64]
also found a significant association, with the frequency of
IPV related to increased HIV viral load (r¼ 0.44,
P< 0.01). Ryerson Espino et al. [68] found viral load
suppression significantly lower among women reporting
IPV (76.4%) than their counterparts (93.3%, X2¼ 4.01
P< 0.05). Illangasekare et al. [59] found no significant
association between viral load of more than 400 copies/ml
among those with IPV (59.6%) or without IPV (61.8%).
ORs reported in studies by Blank et al. [70], Schafer et al.
[25] and Sullivan et al. [69] were nonsignificant [(OR
1.05, 95%CI 0.65–1.70); (OR 1.14, 95%CI 0.42–3.07);
(OR 0.72, 95% CI 0.47–1.10), respectively].
Retention in HIV care
Five studies measured retention in HIV care. Blackstock
et al. [67] and Blank et al. [70] defined retention by any
2188 AIDS 2015, Vol 29 No 16
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self-reported HIV medical care in the past 6 months.
Kalokhe et al. [60] used self-report and asked participants
‘In the past 12 months have you gone to a doctor or clinic
for HIV care?’. Siemieniuk et al. [65] used patient medical
records and defined poor retention in care as ever having
had an interruption in clinical care greater than 365 days.
Schafer et al. [25] classified patients as having a high clinic
no show rate (NSR 33% missed visits) and low NSR
(<33% missed visits). Because these retention measures
have important conceptual differences, they were deemed
too heterogeneous to lend this outcome to meta-analysis.
Siemieniuk et al. [65] found that interruptions in clinical
care were more common among women with a history of
IPV (20.4 vs. 11.9%, P¼ 0.032). Kalokhe et al. [60] found
that IPV positive participants were more likely to be out
of care in the past 12 months (29.4 vs. 18.8%, P¼ 0.01).
Neither Blackstock et al. [67] nor Blank et al. [70] found a
significant relationship between IPVand any self-reported
medical care in the past 6 months (OR 0.92, 95% CI
0.68–1.24). Schafer found no significant relationship
between IPV and a high no show rate among women
(OR¼ 1.11 (0.27–4.60) [25].
Meta-analysis of engagement in care outcomes
A meta-analysis suggests that IPV is associated signifi-
cantly with lower odds of current ART use (Fig. 2; OR
0.79, 95% CI 0.64–0.97). However, as the extant
literature shows heterogeneity (I2¼ 68.9%, P¼ 0.012),
this finding should be interpreted cautiously.
The meta-analytical association suggests that IPV is
associated with lower odds of self-reported adherence
(Fig. 3; OR 0.48, 95% CI 0.30–0.75). Self-reported
adherence also shows significant heterogeneity
(I2¼ 56.0%, P¼ 0.044). To compare this outcome with
other studies, the OR was transformed into an effect size
(standardized mean difference d¼ -0.404).
There is a significant meta-analytic association between
IPV and worsened viral load suppression (Fig. 4; OR
0.64, 95% CI 0.46–0.90), with an acceptable level of
agreement across studies (I2¼ 41.2%, P¼ 0.116).
All meta-analyses were visually inspected for potential
publication bias through funnel plots and Egger’s test for
small-study effects. There was no evidence of publication
bias for current ARTuse (Fig. S1, http://links.lww.com/
QAD/A763; P¼ 0.486), self-reported adherence (Fig.
S2, http://links.lww.com/QAD/A763; P¼ 0.859) or
viral suppression (Fig. S3, http://links.lww.com/QAD/
A763; P¼ 0.176).
Discussion
Uptake and adherence to ART is a key pathway through
which IPV may negatively influence HIV-related health
of women globally. A meta-analysis suggests that IPV
reduces the odds of ART adherence among women, a
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finding that is consistent when adherence is measured by
self-report (OR 0.48, 95% CI 0.30–0.75) or viral load
suppression (OR 0.64, 95% CI 0.46–0.90). Adherence
offers a potential explanation for why IPV has been linked
to worsened clinical outcomes among HIV-positive
women [25–28]. The meta-analytic effect size suggests
that IPVexhibits a greater magnitude of association with
ART adherence (d¼ -0.404) than other conditions such
as depression, substance use, stigma, financial constraints,
lack of social support, or pill burden [72].
The causal pathway between IPVand engagement in HIV
care and treatment is supported by related trauma
literature. Mugavero et al. [73] found that each additional
episode of lifetime trauma was related to nonadherence
even when controlling for depression, substance use and
race. Cohen et al. [74] found that a history of any type of
physical or sexual abuse (including in childhood)
increased the odds of women declining HAART when
medically eligible. These and other studies [73–80] were
excluded from this systematic review because they
analysed IPV alongside other forms of violence (e.g.
childhood sexual abuse, nonpartner violence). Although
such an approach may be useful conceptually, it will be
crucial for future studies to prioritize measurement of
IPV as a stand-alone construct.
The current evidence base on IPV and HIV care has
several important gaps. Nearly all studies were conducted
in the United States, limiting translation to other settings
globally. This geographic skew, though consistent with
broader IPV literature [81,82], warrants urgent attention,
as both HIVand IPV prevalence are high in regions such
as sub-Saharan Africa [83,84]. The few sub-Saharan
African studies that do examine IPVamong HIV-positive
patients draw from couples who jointly take part in
research and may come from relationships that are distinct
from ‘normal’ HIV-positive patients [85,86].
Measures for retention in HIV care were too disparate to
be analysed systematically. This shortcoming is suggestive
of weaknesses in conceptualization of HIV care retention,
which continues to lack a ‘gold standard’ measurement
method [87]. We also found a lack of harmonization
regarding the measurement of IPV, with comprehensive,
validated measures employed in only three studies
[60,61,66]. As behaviourally specific assessment of IPV
helps elucidate the connections between violence and
health outcomes [88], future research should employ
comprehensive measures of IPV [89].
Another gap relates to the clinical nature of responding to
violence disclosure in the research setting. Only two
authors detailed specific steps taken by clinicians when
women disclosed IPV [25,65]. This represents a
significant oversight given the well established guidance
around how to conduct IPV research in a clinically
meaningful and ethically responsible way [90,91].
A final research gap is the extant focus on the ‘general
population’ of HIV-positive patients. It is possible that the
association between violence and HIV-related outcomes
may be distinct among other special populations (e.g.
adolescents, pregnant women, men who have sex with
men, sex workers) and these subgroups deserve attention
in future research.
Limitations
There are several limitations of the current systematic
review that should inform interpretation of findings. We
focused the systematic reviewonHIV-positivewomen, but
such a conceptualization should be followed by futurework
to understand IPV towards HIV-positive men. Literature
included [60,61,63] and excluded [92–95] from this review
illustrates that HIV-positive men experience challenges to
engagement in care on par or in excess to those of women.
Articles selected for final review have important limitations
around comparability, given the variety of populations and
sampling strategies used across the studies. There were no
longitudinal studies included in this review, which suggests
that meta-analytic findings can be viewed as a correlation,
but that IPV and engagement in care may not be causally
related. Databases used may have inadvertently limited the
search, although we attempted to compensate for this
shortcoming by reviewing all citations included in the final
set of full articles assessed (n¼ 67). Interrater reliability was
not formally assessedwith regard to the selection of articles,
but a third colleague was consulted to review any
discrepancies in the inclusion/exclusion process.
Conclusion
In order to ensure HIV-related health among women, it is
essential to address conditions that impact their ability to
uptake and stay engaged in care and treatment. IPV is one
such condition, and its association with declines in ART
adherence requires urgent attention. Policy makers and
programmers are beginning to recognize the central role
that violence plays in the lives of women living with HIV
[96,97]. Yet, despite calls for violence screening and
intervention within HIV care and treatment programs,
few HIV clinics have IPV-specific protocols in place [98].
HIV care and treatment programmes can draw upon
existing guidelines for screening and responding to IPV in
the health sector [91,99], or can look to a growing
number of specialist programmes that address IPV
alongside HIV [100–103]. To ensure that women benefit
from medical advances, future studies should develop and
test interventions to address IPV within HIV clinical care.
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Abstract
Introduction: Prevention of mother-to-child transmission (PMTCT) has the potential to eliminate new HIV infections among
infants. Yet in many parts of sub-Saharan Africa, PMTCT coverage remains low, leading to unacceptably high rates of morbidity
among mothers and new infections among infants. Intimate partner violence (IPV) may be a structural driver of poor PMTCT
uptake, but has received little attention in the literature to date.
Methods: We conducted qualitative research in three Johannesburg antenatal clinics to understand the links between IPV and
HIV-related health of pregnant women. We held focus group discussions with pregnant women (n13) alongside qualitative
interviews with health care providers (n10), district health managers (n10) and pregnant abused women (n5). Data were
analysed in Nvivo10 using a team-based approach to thematic coding.
Findings: We found qualitative evidence of strong bidirectional links between IPV and HIV among pregnant women. HIV
diagnosis during pregnancy, and subsequent partner disclosure, were noted as a common trigger of IPV. Disclosure leads to
violence because it causes relationship conflict, usually related to perceived infidelity and the notion that women are ‘‘bringing’’
the disease into the relationship. IPV worsened HIV-related health through poor PMTCT adherence, since taking medication or
accessing health services might unintentionally alert male partners of the women’s HIV status. IPV also impacted on HIV-related
health via mental health, as women described feeling depressed and anxious due to the violence. IPV led to secondary HIV risk
as women experienced forced sex, often with little power to negotiate condom use. Pregnant women described staying silent
about condom negotiation in order to stay physically safe during pregnancy.
Conclusions: IPV is a crucial issue in the lives of pregnant women and has bidirectional links with HIV-related health. IPV may
worsen access to PMTCT and secondary prevention behaviours, thereby posing a risk of secondary transmission. IPV should be
urgently addressed in antenatal care settings to improve uptake of PMTCT and ensure that goals of maternal and child health are
met in sub-Saharan African settings.
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Introduction
Prevention of mother-to-child transmission (PMTCT) has
reduced new infant HIV infections from an estimated 32% in
the absence of treatment [1,2], to as low as 1% [3,4]. However,
major gaps in achieving PMTCTcoverage remain. In 21 priority
African countries, PMTCTcoverage is estimated to be 65% [5].
A recent meta-analysis in low- and middle-income settings
suggests that while 75% of pregnant women adhere to anti-
retroviral therapy (ART) during pregnancy, only 53% maintain
adequate adherence levels in the postpartum period [6].
Ensuring PMTCT adherence is crucial, particularly as countries
increasingly move towards ‘‘Option B,’’ a policy that offers
immediate, lifelong treatment for pregnant women living with
HIV [7].
Many structural drivers influence PMTCT uptake and
adherence. The literature has noted that structural factors
such as stigma [813], poverty [11] and transport costs [10]
inhibit women’s ability to adhere to PMTCT. Another key
structural factor shaping access and adherence to PMTCTmay
be intimate partner violence (IPV). Fear and experience of IPV
influence pregnant women’s decisions to take up HIV services
[14,15], and anticipated violence is associated with declines in
HIV testing among pregnant women [12,1622]. A history of
physical or sexual violence decreases the likelihood of HIV-
positive women using ART when medically eligible [23,24],
and those who experience abuse are more likely to miss clinic
visits and delay linkage to care [25].
Little research to date has explored the association between
IPV and PMTCT. In one qualitative study in South Africa, IPV
was described as a common barrier to ART adherence in
pregnancy [11]. Healthy intimate partner relationships im-
prove PMTCT uptake: male involvement in antenatal care
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predicted better adherence to nevirapine in one South African
study [26]; male antenatal attendance halved the risk of MTCT
in a Kenyan study, an association that persisted after control-
ling for maternal viral loads [27].
Using qualitative research methodology, we explored IPV as
a potential structural driver of HIV-related health among preg-
nant women. This research aimed to contribute to literature
suggesting that structural drivers shape the health and well-
being of those already living with HIV, andmay pose barriers to
uptake of proven prevention strategies.
Methods
We conducted qualitative research to explore the links bet-
ween IPV and HIV-related health among pregnant women and
service providers in Johannesburg, South Africa. This research
was a portion of a larger formative study, intended to help our
team design an intervention to address IPV in pregnancy. In
this setting, an estimated 29% of pregnant women are HIV
positive [28] and between 25 and 35% experience physical or
sexual IPV in the 12 months leading up to pregnancy [2932].
Conceptual framework
To explore the relationship between IPV and HIV-related
health of pregnant women, we used an adapted socio-
ecological conceptual framework (Figure 1), which posits that
broader structural factors and relationship characteristics
influence a woman’s HIV-related health [33]. This type of
approach has been embraced by social scientists, who note
that broader social and societal factors shape how women
are able to adhere to ART [34] and the extent to which they
experience IPV [35]. A socio-ecological framework highlights
that the structural context influences the conditions and
health outcomes of both IPV and HIV.
Data collection
We conducted an exploratory qualitative study using in-depth
interviews (IDIs) and focus group discussions (FGDs) with
a wide range of stakeholders with the potential to take
part in, deliver, or scale-up an intervention for violence in
pregnancy. Participants included pregnant women, pregnant
women experiencing IPV, health workers, non-governmental
organizations, community leaders and policy makers (Table 1).
Pregnant women seeking antenatal care from two antena-
tal clinics were recruited for four FGDs (a total of n13
women participated). Women were given group information
about the study while they waited in queue for a clinic
appointment. All FGDs were conducted in a private room in
the clinic, led by trainedmoderators whowere the same sex as
participants and fluent in multiple local languages (Sotho,
Zulu, Tswana). Semi-structured discussion guides explored
several topics (Table 1). Discussions were audio-recorded after
obtaining participants’ permission and signing an informed
consent form. The discussion groups lasted for about 1 hour
and 30 minutes, and women were reimbursed R50 (US $6).
Because of the nature of focus groups, additional confiden-
tiality measures were implemented: during the informed
consent process, researchers explained that questions about
women’s individual experiences of violence or HIV would not
be asked, but rather the discussion would address the issue as
observed in the community.
Pregnant women who were experiencing IPV were identi-
fied during the FGDs. Trained researchers explained that
those women who had personal experience of IPV and were
interested in participating in IDIs could approach the research
team outside of the information giving session and privately
indicate their interest in taking part in an interview. The
interviews (n5) took place in a private room at the clinics
while the pregnant women were still waiting to be seen by
clinic staff. As shown in Table 1, the topics explored through
structured interview guides were more focused on IPV-
related help seeking and the relationship between IPV and
HIV. On average, these interviews lasted about 60 minutes.
In depth interviews withOther Key Stakeholderswere led by
the research team and covered similar topics. This group
comprised policy makers (n10), health workers (n8), non-
governmental organizations (n6) and community-based
organizations (n4). Stakeholder interviews focused on
service provision and asked questions about available re-
sources for women experiencing IPV. Some anecdotes of cases
were shared, but this was not the main rationale for these
interviews.
Several steps were taken to ensure confidentiality and
provide additional support for participants during the re-
search. In keeping with ethical considerations of researching
IPV in pregnancy, all researches were conducted based on the
World Health Organization’s guidance on ethical and safety
considerations in researching violence against women [36].
Study staff were trained to describe research as the ‘‘social
barriers’’ to use health services in the community, so as to
reduce any undue risk associated with participating in a
violence-related study. All participants were offered an
information sheet containing contact information of local
resources (counselling, legal advice and health care). Given the
high prevalence of IPV in South Africa, it was likely that
participants in categories other than ‘‘pregnant and experien-
cing IPV’’ category had experienced or witnessed IPV. If any
individual demonstrated a need for additional assistance, that
individual was offered an opportunity to speak to someoneFigure 1. Conceptual framework.
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about his or her experience of IPV, and given referrals
to organizations that could assist him or her. However, no
participants asked for this referral during the course of the
formative research.
All participation in this formative research was sought
on the basis of informed consent and good clinical prac-
tice guidelines. Ethics approval was obtained by the World
Health Organization (WHO A65780) and University of the
Witwatersrand (HREC M110832).
Data analysis
The interview and FGD data were transcribed verbatim in the
language in which they were conducted and, as necessary,
translated from the local language (Sotho, Zulu, Tswana) into
English by professional translators. To ensure accurate trans-
lation, each transcript was reviewed by a researcher, and
queries were resolved through discussions among the re-
searchers via phone or email. All identifying information about
the participant or clinic setting was removed and transcripts
were saved by a file name with no personal details.
Data were managed in QSR Nvivo 10, a qualitative analysis
software package, following a two-day qualitative manage-
ment and analysis training of the research team. Members of
the research team collaboratively built an analytical frame-
work of broad codes by creating a ‘‘start list’’ of possible
themes and building upon the research questions. Each broad
code, or wide thematic basket of ideas [37], was applied to
each transcript by two researchers using NVivo. The research
team then held a series of meetings to collectively develop
‘‘fine codes’’ using an inductive approach  deriving meaning
from the data itself rather than imposing pre-formed ideas
[38]. Fine codes were developed by printing out a full set of
excerpts (from each database) related to each code and
identifying sub-themes emerging from the data.
Results
We found qualitative evidence of strong bidirectional links
between IPV and HIV among pregnant women. Here, we
present a conceptual framework (Figure 2) for understanding
the ways in which IPV is related to HIV-related health of
pregnant women.
Pathway 1: HIV diagnosis leads to IPV via partner disclosure
HIV diagnosis during pregnancy was noted to be a trigger of
IPV. One pregnant woman described how severe violence
began following disclosure of her HIV-positive status during
pregnancy:
He started telling me things, hurting me emotionally,
telling me that I’m a fool, and stupid, I’m an idiot.
And then he strangled me, That’s when it started . . .
Maybe it’s pregnancy, I don’t know. I told him that
I am HIV positive, so I don’t know if that’s what
made him to do all these things.  Pregnant abused
woman 1
HIV may lead to violence because it causes relationship
conflict during the disclosure process. Usually, the conflict is
Table 1. Data collection methods
Participant group Group size Method Sampling Example participants Topics
Pregnant women
at ANC
n13
women in 4
FGDs
Focus group
discussions
Convenience  Social and structural drivers of IPV; types of IPV
in pregnancy; patterns of help seeking and
available community resources for violence and
HIV; barriers to disclosing IPV; receptivity to an
antenatal intervention
Pregnant abused
women
n5 Semi-
structured
interviews
Convenience  Existing needs and concerns of abused women;
patterns of help seeking and available
community resources for violence; links
between IPV and HIV; receptivity to an
antenatal intervention
Policy makers n10 Semi-
structured
interviews
Purposive Department of Health
managers, academic
experts
Types of IPV in pregnancy; current health sector
response to IPV; potential integration with HIV
activities, including PMTCT
Health providers n8 Semi-
structured
interviews
Purposive Doctors, nurses, lay
counsellors in antenatal
clinics
Types of IPV in pregnancy; knowledge and
practice responding to IPV; receptivity of health
workers to antenatal intervention; existing
capacity in clinic
Non-governmental
organizations
n6 Semi-
structured
interviews
Purposive Shelters, police, counselling
services
Psycho-social, legal and other needs of abused
women; referral options for women living
with IPV
Community
leaders
n4 Semi-
structured
interviews
Convenience Pastors, neighbourhood
representatives, traditional
healer
Community factors that support or prevent
women from seeking IPV assistance during
pregnancy
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related to perceived infidelity and blaming women for
‘‘bringing’’ the disease into the relationship:
Yes, if you’re HIV positive, you start blaming each
other. Because maybe the husband will be saying
the wife brought it. So sometime, there’s a connec-
tion [between HIV and violence] because you end up
blaming each other.  Pregnant woman, FGD 3
Because HIV testing is coupled with antenatal care, women
often learn of their HIV status in a clinic during access to
health care during pregnancy.Within this health care context,
women bear the brunt of disclosure to partners, who tend to
use women’s status as a ‘‘proxy’’ for their own.
In addition to physical violence, pregnant women de-
scribed experiencing emotional abuse and abandonment
following disclosure of HIV to a partner:
I have a sister, she was pregnant, . . . then she came
to be tested. When she tested she found out she is
positive, and when she told her boyfriend every-
thing turned around. And there was violence at
home. He started coming late and when she started
asking for things for her and the baby, he started
to react badly up until he ended up leaving her.
 Pregnant woman, FGD 2
Within a context where women fear violence, blame and
abandonment, it is perhaps not surprising that many
pregnant women chose not to disclose their HIV status to
partners. Several pregnant women spoke about the fear of
partner disclosure when women live in violent relationships:
Women who are in this abusive relationship, they do
get HIV and they are scared what their partner will
say.  Pregnant abused woman 1
Health workers talked about how women in violent relation-
ships would be hesitant to disclose their status to partners:
When you counsel them . . . after they have tested
positive and when you have to issue the treatment
she’ll be saying, ‘I am not going to disclose. I mustn’t
take this, I must hide it’. Then you find out is it a
problem for her to disclose because there’s some
emotional abuse or physical abuse from the partner.
 Female Health Worker 4
Thus, fear of partner disclosure may be an early warning sign
that pregnant women are in violent or unsupportive relation-
ships and require additional assistance during antenatal care.
Pathway 2: IPV worsens HIV-related health via
non-adherence
For women in violent relationships, adherence to PMTCT
services was challenging, since taking medication or acces-
sing health services might unintentionally alert male partners
of their HIV status.
Health workers noted that non-adherence also served
as warning sign that HIV-positive patients were in a violent
relationship:
Figure 2. IPV and HIV-related health among pregnant women.
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It was the very same patient that you had told she
was HIV positive that was scared to go and disclose
to their partner. It is the very same patient that will
default on their medication because their partner
does not know that they are taking the medication.
 Policy Maker 9
In the antenatal clinic, an HIV diagnosis in the context of
living with violence may cause patients to default on clinic
visits:
But in your normal facility it is a bit difficult to avoid
losing patients. I think we do. Especially the mere
fact that you say to a patient, ‘‘you are HIV positive.’’
And this is a patient who is facing domestic
violence! Some will just disappear.  Policy maker 3
Thus, the fear of being identified by a male partner as being
HIV positive may preclude women from returning to clinic
services that are essential for their health. While no partici-
pants mentioned this directly, it is important to note that non-
adherence to PMTCT regimens greatly increases the risk that
pregnant or breastfeeding women will transmit HIV to the
infant.
Pathway 3: IPV worsens HIV-related health via mental
health
Declines in mental health were noted in women experiencing
IPV in pregnancy. In response to persistent violent relation-
ships, women described internalizing the abuse and assum-
ing that they had done something wrong to deserve it:
He used to beat her while she was pregnant. She
just accepted it, and sometime she’d blame herself.
Saying maybe I’m the one who’s wrong that’s why
he’s beating me.  Pregnant woman, FGD 1
Although IPV is associated with common mental health
disorders in pregnancy, few patients or providers recognized
these as having clinical implications. Most health providers
equated mental health to severe cases of psychopathology
and said they rarely encountered mental health disorders.
For example, one health worker only considered mental
health in relation to bipolar depression and pharmacologi-
cally treated patients:
Mental health, yes, I remember we’ve had three
that we already on treatment, and will tell you, I
have a bipolar patient.  Health worker 8
We found that health workers often fail to notice the mental
health dynamics of IPV in pregnancy, choosing instead to
focus on physical health sequelae of pregnancy. For example,
one health provider was asked about stress related to IPV, but
responded only in terms of how stress impacts hypertension
while ignoring the relevant impact on a woman’s mental
health:
Stress is one of the predisposing factors to the
development of hypertension. So it is still there, this
stress, but as a predisposing factor. Sometimes
because of the pregnancy itself, you can develop
hypertension of pregnancy.  Health worker 6
This tendency towards equating mental health with severe
illness may be related to the lack of capacity within South
Africa’s public health system. As one policy maker explained,
in overlooking mental health issues, current health systems
make it unlikely that patients will receive the crucial support
that they require:
No one has time for mental health because there
are so many other crises in the health system that
need to be addressed, that are much more mani-
fested. So that means that things like depressive
disorder or mental health disorders, they’re not
addressed  including partner depression, mental
health and abuse and all of that. And people are not
really encouraged to go and get support that they
require.  Policy Maker 9
The notion of overlooking mental health is illustrated in an
interview with one pregnant, abused woman when she
described severe physical violence as leading to a state of
being ‘‘a little depressed’’:
Interviewer (I): Are you enjoying your pregnancy so
far?
Participant (P): Being honest, a little depressed but
I’m enjoying it.
I: Ok, so the depression is from what, if I may ask?
P: From the father of the baby. We are having
problems.
I: What did he do, if you don’t mind telling me.
P: He strangled me and then he let his cousin beat
me up.  Pregnant abused woman 1
Not everyone in our sample ignored the impact of mental
health on a woman’s health and wellbeing. For example, poor
mental health had concomitant effects on physical health
for one HIV-positive participant, who described ‘‘going low’’
emotionally because of violence, and thereafter feeling
worse physically:
I’m HIV positive and I’m in this domestic violence.
And if you are HIV positive and then you have a
partner who is abusing you emotionally . . . or
physically hits you, people can’t talk. Maybe you
can go low, maybe you can go sick.  Pregnant
abused woman 3
Pathway 4: IPV leads to secondary HIV risk via lack of
relationship control
IPV led to secondary HIV risk when women were in rela-
tionships with forced sex or without power to negotiate
condom use.
When we are in relationships where our partner
is abusive, sometimes we can’t even negotiate
things like using the condom. Let’s say, for instance,
you know that your partner is the kind of person
that has other girlfriends, but because he uses
power over you, you can’t negotiate those things.
 Pregnant woman, FGD 4
Male partners used their control over the relationship to
dictate the terms and timing of sexual activity. In one
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instance, a FGD revealed a story about a newly diagnosed
HIV-positive woman whose partner insisted that she have sex
without condoms:
There’s a friend of mine that was tested alone and
she had a lot of problems. The man said, I’m not HIV
positive, so I’m not going to test. So the man forced
her to sleep with him without a condom. And that
man said ‘No! Why? We’ve been sleeping with
out a condom, but because today you went to the
clinic, you’re telling me we’ve to use a condom?’
 Pregnant woman, FGD 1
Pregnant women described balancing risks to physical safety
(absence of physical harm to themselves or foetus) with
health risks (of onwards HIV transmission to partners). They
described making compromises between protecting them-
selves and the foetus and protecting themselves and partners
from sexually transmitted infections:
If you are not compromising at all and you start
saying ‘‘let’s use condom,’’ he’ll start having ques-
tions. Some things are better left unsaid, just for the
safety part of it.  Pregnant woman, FGD 2
Many preferred staying silent on condom negotiation, in
order to stay physically safe during pregnancy.
Discussion
We found that IPV and HIV-related health were connected
concerns in the lives of pregnant women in Johannesburg. IPV
and HIV seemed to have distinct pathways linking them to
one another within the context of pregnancy. The initial HIV
disclosure could serve as a trigger for violence in pregnancy.
IPV, in turn, worsened HIV-related health through key path-
ways of lack of adherence and poor mental health. Finally, the
experience of IPV led to secondary transmission risk beha-
viours  both in terms of vertical transmission due to PMTCT
non-adherence or secondary transmission due to risky sex.
According to our participants, IPV shapes HIV-related health
outcomes among pregnant women primarily because it leads
to non-adherence. While the effect of IPV on adherence has
been confirmed in small studies in the United States [3943],
this association is yet to be explored among pregnant women.
Pregnant and postpartum women are a crucial population
within which to understand IPV and adherence, since non-
adherence leads not only to morbidity and mortality of the
woman but also to risk of onwards HIV transmission to her
infant [3,4]. Antenatal care provides a crucial moment to
enable adherence, since a pregnant woman accesses the
health system routinely and this is when many are first
diagnosed with HIV.
Poor adherence among pregnant women may relate to
challenges around partner disclosure [44]. In a recent sys-
tematic review of PMTCT, partner disclosure was associated
with poor PMTCT uptake in a majority of both quantitative
(6 of 9) and qualitative (17 of 24) studies [45]. We found that
partner disclosure following HIV diagnosis in pregnancy led to
enacted or feared violence. This aligns with extant literature,
which suggests that fear of new or continued IPV may lead
women to avoid disclosure of their status to male partners [11].
In one Nigerian study among HIV-positive pregnant women,
the prevalence of IPV was 17% before HIV testing and
increased to 63% after testing for HIV and disclosing status
[46]. A Zimbabwean study showed that the risk of IPV in
pregnancy was greatest among those women testing positive
for HIV in antenatal care [47]. Non-disclosure among pregnant
women is a health risk in its own right, since it poses a risk for
sexual transmission of HIV if the male partner is still HIV
negative [4851] andmay have an impact on the implementa-
tion of PMTCT [52].
A related but distinct pathway linking IPV to PMTCT uptake
may be mental health. A growing body of literature shows
that IPV leads to depression and anxiety among pregnant
women [29,53,54], yet this link has been largely unexplored in
sub-Saharan Africa in HIV-positive populations. Our findings
reflect those of a qualitative study in Zambia, in which IPV,
mental health and HIV are closely related in the experience of
women [55]. Such interrelated ‘‘syndemic’’ issues [56] should
be explored in future sub-Saharan African studies.
Existing research shows poor mental health has significant
impact on ART adherence [5760] and among pregnant
women depressive symptoms are associated with HIV disease
progression and mortality [61]. It is possible that IPV is one
condition exacerbating the relationship between mental
health and HIV outcomes. Indeed, one new study suggests
that the link between mental health and ART adherence may
be partly driven by partner conflict [62]. Despite high rates of
common mental health disorders in antenatal care [63], little
screening or treatment exists in South Africa [64]. Mental
health will be crucial to address among HIV-positive pregnant
women because of its strong relationship to IPV and its
association with the uptake of PMTCT regimens [65].
Finally, IPVmay worsen secondary prevention behaviours in
pregnancy. Non-adherence to PMTCT regimens greatly in-
creases the risk that pregnant or breastfeeding women will
transmit HIV to the infant [66], potentially in drug-resistant
form [67]. High viral loads related to non-adherence also
increase the likelihood of secondary transmission to partners,
particularly in the context of unsafe sex. Our research reflects
existing knowledge by suggesting that IPV inhibits women’s
ability to negotiate condoms [68]. These findings explore such
dynamics within the context of pregnancy, thereby suggesting
a dual risk of mother-to-child infection and secondary trans-
mission risk to a partner.
Our findings echo calls for addressing IPV in pregnancy [69].
Scholars note that antenatal care provides an important
‘‘window of opportunity’’ for women who are regularly ac-
cessing the health system [70]. Although universal screening is
not recommended in settings with limited referral options and
overstretched providers [71], some type of IPV assessment,
provider training and targeted response may be appropriate
for South African antenatal care. Indeed, a comprehensive
health response to IPV will likely require either screening or
case-finding  both methods that may be acceptable in South
African clinics [72,73].
Limitations
The findings of this formative research should be examined in
light of several limitations. Firstly, this study is exploratory in
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nature, resulting in small sample sizes of each participant
group. While analysis suggested that we began to reach
saturation through FGDs with pregnant women, the IDIs with
pregnant women experiencing IPV were not sufficient to
reach thematic saturation [74]. Secondly, the socio-ecological
perspective was brought to the data analysis process after
data collection. Ideally, this conceptual approach would have
informed the entire data collection process, rather than
simply guiding the final interpretation of findings. However,
since this was a preliminary, exploratory study, it was
designed to explore several intersecting issues and we applied
the conceptual framework during data analysis. Finally, some
of the findings may be applicable for any woman experiencing
IPV, and do not necessarily highlight the specific context of
pregnancy. Further research should explore the perinatal
time-period in detail to determine whether the link between
IPV and HIV is somehow distinct during this life stage.
Conclusions
IPV in pregnancy leads to declines in the physical and mental
health of pregnant women. Our findings underscore the
negative effects of IPV as a health issue in its own right and
as a barrier to PMTCT. The connection between IPV and HIV
medication adherence among pregnant women has yet
to be explored quantitatively in sub-Saharan Africa. In future
studies, it would be ideal to find systematic methods for
recruiting more robust numbers of pregnant women who
experience IPV and who are living with HIV. In the parent
study [75], we anticipate that by training health providers to
ask about IPV confidentially and skilfully, it may be increas-
ingly possible to reach this crucial population.
Beyond its marked impact on physical and mental health
of women, IPV in pregnancy may have important implications
for Option B, as current cost-effectiveness models assume
that women are willing and able to achieve 100% adherence
[76]. If Option B is to be adopted more broadly, the effect
of IPV on adherence and mental health should be carefully
considered. Addressing the inter-related issues of violence
and HIV will be crucial to ensure that goals of maternal and
child health are met in the sub-Saharan African region.
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a b s t r a c t
Prevention of mother-to-child transmission (PMTCT) can virtually eliminate HIV infection among infants,
yet up to one-third of women miss PMTCT steps. Little is known about how partner dynamics such as
intimate partner violence (IPV) inﬂuence pregnant and postpartum women's adherence to PMTCT. We
conducted 32 qualitative interviews with HIV-positive pregnant and postpartum women in Johannes-
burg who experienced IPV. Trained researchers conducted in-depth interviews over the period of May
2014eNov 2015 using narrative and social constructionist approaches. Interviews were transcribed
verbatim and analyzed thematically and inductively using Dedoose qualitative software. Twenty-six
women experienced recent IPV and one-third had poor adherence to PMTCT. Women's experience of
partner violence inﬂuenced PMTCT behaviors through four pathways. First, fear of partner disclosure led
some women to hide their HIV status to avoid a violent reaction. Despite strategic non-disclosure, several
maintained good adherence by hiding medication or moving out from their partner's home. Second, IPV
caused feelings of depression and anxiety that led to intentionally or accidentally missing medication.
Five women stopped treatment altogether, in a type of passive suicidality, hoping to end the distress of
IPV. Third, men's controlling behaviors reduced access to friends and family, limiting social support
needed for good adherence. Fourth, in a protective pathway, women reported good adherence partly due
to their mothering role. The identity around motherhood was used as a coping technique, reminding
women that their infant's wellbeing depended on their own health. PMTCT is essential to prevent ver-
tical HIV transmission, but women living with IPV face multiple pathways to non-adherence. Addressing
IPV in antenatal care can support the health of women and infants and may enhance PMTCT coverage.
© 2016 Elsevier Ltd. All rights reserved.
1. Introduction
Prevention of mother-to-child transmission (PMTCT) in-
terventions have potential to eliminate vertical transmission of HIV
frommothers to infants (Mofenson, 2010). Yet, women's adherence
to all the steps required for successful PMTCT is often low. Within
21 priority countries, an estimated 65% of eligible pregnant women
access HIV treatment (WHO et al., 2013), and pooled analysis sug-
gests that only half of women adhere to treatment postpartum
(Nachega et al., 2012). Studies in sub-Saharan Africa suggest that
partner relationship factors are among the most important barriers
to pregnant women's acceptance of HIV testing and other PMTCT
behaviors (Bwirire et al., 2008; Medley et al., 2004; Turan et al.,
2011). Intimate partner violence (IPV) may be one important pre-
dictor of adherence to HIV medication in pregnancy and post-
partum, yet this association has been understudied in the literature
to date (Hatcher et al., 2015).
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Among non-pregnant women, IPV victimization is associated
with worse HIV-related health outcomes, including higher odds of
antiretroviral failure, weaker immune response, increases in
opportunistic infections, and greater risk of mortality (Schafer et al.,
2012; Weber et al., 2012). A recent meta-analysis showed that
women's experience of IPV was associated with 55% lower odds of
self-reported adherence and 36% decreased odds of viral suppres-
sion (Hatcher et al., 2015). However, of the thirteen included
studies, none were based in sub-Saharan Africa or among pregnant
women. Since publication of the meta-analysis, only a single study
has examined the effect of IPV on adherence in pregnant women.
This Zambian study showed that IPV victimization was associated
with 74% lower odds of adherence in pregnancy and 89% lower odds
of adherence postpartum (Hampanda, 2016). However, the quan-
titative methods used by this seminal paper preclude a deeper
understanding of how partner violence alters PMTCT behaviors.
This is a crucial dynamic to understand, particularly since many of
the same countries in sub-Saharan Africa with the highest rates of
mother-to-child transmission also have high prevalence of IPV
(Devries et al., 2013).
South Africa is one such sub-Saharan African setting where HIV
and IPV are highly prevalent. An estimated 25e35% of South African
pregnant women report recent physical and/or sexual IPV (Groves
et al., 2012; Hoque et al., 2009). Similarly, antenatal HIV preva-
lence across South Africa is high, with estimates in Johannesburg
reaching 29% (Department of Health, 2012). South Africa has made
signiﬁcant strides towards reducing mother-to-child transmission
from 14% in 2009 to an estimated 5% in 2012 (UNAIDS, 2013). Yet,
only 54e65% of South African pregnant women and infants com-
plete all recommended PMTCT steps (Stringer et al., 2010; Technau
et al., 2014).
Recent qualitative studies have explored the underlying dy-
namics of IPV among small samples of women living with HIV.
Among 8women reporting violence after HIV disclosure, Colombini
et al. learned that newHIV diagnosis was a trigger for violence, even
in relationships with no prior history of IPV (Colombini et al., 2016).
Mulranen et al. studied postpartum women living with HIV in
Swaziland, of whom 9 reported IPV following disclosure, and
learned that violence resulted from acute triggers like HIV status
disclosure and also from ongoing marital tensions around fertility
(Mulrenan et al., 2015). In a study of pregnant and postpartum HIV-
positive women in the United States, Njie-Carr et al. found that 3
women with recent violence avoided partner disclosure because
they feared a violent reaction (Njie-Carr et al., 2012). Illangesekare
et al. identiﬁed mental health as a primary pathway linking IPV to
non-adherence among HIV-positive women reporting lifetime
partner violence, of whom 3 were currently living with IPV
(Illangasekare et al., 2014). Other qualitative research has broadly
explored violence and HIV medication adherence, but not among
women who present with both conditions (Hatcher et al., 2014;
Zunner et al., 2015).
While extant qualitative literature offers preliminary under-
standing that perhaps violence and HIV behaviors are linked,
samples sizes ranging from 3 to 9 participants rule out the
analytical rigor required to understand why IPV alters adherence.
In-depth, qualitative elucidation of the speciﬁc mechanisms linking
IPV and HIV adherence is necessary if we are to increase the pro-
portion of women adhering to PMTCT interventions. We conducted
in-depth qualitative research with 32 women living with HIV and
reporting experience of IPV in Johannesburg, South Africa. The
purpose of the research was to explore mechanisms linking these
interconnected issues among pregnant and postpartum women.
1.1. Theoretical framework
This research was informed by socio-ecological conceptual
framework applied to infant andmaternal health (Fig. 1). The socio-
ecological model suggests that individual, relationship, and struc-
tural factors shape health outcomes (Heise, 1998), and is widely
used in IPV research because it incorporates many complex factors
that inﬂuence partner violence (WHO, 2010).
Within the ecological model, individual factors are the personal
characteristics or behaviours that impact one's health. Previous
literature has suggested that individual factors inhibiting PMTCT
uptake include depression (Nachega et al., 2012; Turan et al., 2013),
substance use (Nachega et al., 2012), internalized HIV stigma and
shame (Turan et al., 2013), and costs associated with clinic atten-
dance (Bwirire et al., 2008). Partner relationship factors are the
dyadic partnership issues that frame health outcomes. Partner
dynamics that worsen PMTCT behaviors include a lack of male
involvement in antenatal care (Aluisio et al., 2011), non-disclosure
to a partner (Gourlay et al., 2013; Myer, 2011), and threat of further
violence (Antelman et al., 2001). The theory of gender and power
(Connell, 1985), which postulates that unequal power dynamics
limit the ability of women to exercise personal control in re-
lationships (Amaro and Raj, 2000), provides a theoretical under-
pinning for the associations seen between partner factors and
PMTCT uptake. Structural factors refer to the broader social or
community factors that impact on health. In this sphere, previous
studies have noted that PMTCT is adversely impacted by poverty
(hIarlaithe et al., 2014), lack of social support (Kirsten et al., 2011),
community stigma around HIV (Turan et al., 2011), andweak health
systems (Bwirire et al., 2008). A socio-ecological framework rec-
ognizes that similar structural factors underpin both violence and
HIV (Maman et al., 2000) and that broader social and societal fac-
tors shape women's ability to adhere to HIV medication (Hirsch,
2007) and the extent to which they experience IPV (Heise, 1998).
2. Methods
The goal of this qualitative research was to build understanding
aroundwhy and how IPV inﬂuences PMTCT uptake and HIV-related
health. This analysis is guided by our formative qualitative research
with pregnant women and health providers (Hatcher et al., 2014).
The formative research included no women living with both IPV
and HIV, but instead asked participants to speculate about the links
between violence and PMTCT. As an elucidation of mechanisms
requires incorporation of the perspectives and knowledge of
women who actually experience these health conditions, we now
present data from in-depth interviews with a larger sample of
women (n ¼ 32), all living with both IPV and HIV.
Qualitative research was nested within a randomised control
trial testing an intervention for IPV in pregnancy (Pallitto et al. in
press). Called Safe & Sound, the trial recruited 2016 pregnant
women from four antenatal clinics in Johannesburg to take part in
baseline questionnaires. In the parent trial, women reporting
recent (past-year) physical and/or sexual IPV (n ¼ 421) were
randomised to a nurse-led empowerment counseling intervention
or an enhanced control condition. This sub-study purposively
selected the sample of 32 participants to take part in qualitative, in-
depth interviews between May 2014eNovember 2015.
The methodology for this study was informed by narrative,
constructionist approaches to researching IPV (Allen, 2011). The
narrative element of this approach posits that discussing IPV ex-
periences with skillful providers can be therapeutically beneﬁcial
and that the research process itself serves as a form of reﬂection for
participants (Allen, 2011). Narrative approaches to research on
violence acknowledge that women's stories help create coherence
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in otherwise chaotic, uncontrollable situations (Williamson, 2010).
Narrative approaches use particular techniques during the inter-
view process, such as validation, highlighting resistance strategies,
and focusing on meaning and identity (Allen, 2011). The social
constructionist methodology acknowledges that researchers are part
of the research interaction and that their prior knowledge should
be brought to light and examined (Charmaz, 2008).
2.1. Participant sampling and recruitment
We conducted qualitative research with 32 participants who
were purposively selected fromwomen taking part in baseline Safe
& Sound trial questionnaires. Women recruited for this sample
were living with HIV and experiencing IPV. In practice, this
included women participating in the trial (ie. experiencing recent
IPV), as well as women who were not eligible to enroll in the trial,
but who had experienced IPV in their lifetime. Both trial and life-
time history participants had already completed a full study base-
line questionnaire and agreed to be contacted about further
research. Study nurses guided the selection of participants based on
their impression of women's willingness to take part in an addi-
tional interview, their knowledge of women's experiences of IPV,
and women's HIV-positive status.
Initially, the sample size proposed for this qualitative study was
24 participants. Using the constant comparative method to un-
derstand the emerging constructs from the data (Charmaz, 2003),
we found that upon completion of 18 interviews, theoretical satu-
ration had not yet been reached. Data on our initial research
question around links between violence and PMTCT lacked richness
and women's stories failed to converge around speciﬁc pathways.
We thus expanded the sample to reach 32 women using theoretical
sampling to include additional womenwith recent IPV experiences.
Theoretical sampling is a technique for using preliminary analysis
to guide how data are collected further (Glaser, 1992). In this case,
our initial analysis suggested that links between violence and
PMTCT are best explored among participants with recent violence
andwith some challenges adhering to PMTCT behaviors. Displaying
“challenges” with PMTCT was therefore used as a selection criteria
for the next 14 participants. Additional women with these char-
acteristics allowed us to further reﬁne emergent concepts and test
out initial impressions of the data with a more targeted group of
participants.
Trained nurse researchers invited women to participate through
follow-up phone calls using locator information. All participants
contacted for this sub-study were reachable by phone, with 7
women refusing to take part (due to living outside the province,
work commitments, or not desiring to take part in additional
research). Male partners were never informed about a woman's
participation in the research because of the potential for an abusive
partner to react violently. To protect participants and reduce the
risk that partners would overhear the conversation, nurses were
trained to ask “is this a safe time to speak?” before continuing. A full
distress protocol included appropriate researcher responses in
cases of violence disclosure, psychological distress, high emotion-
ality, or a need for referrals. Basic elements of the distress protocol
were employed during most interviews included in this study: a
calm, non-judgmental approach to inquiry; watching for signs of
resistance when inquiring about violence to avoid re-
traumatisation; offering tissues if participants cried; offering a
break from the interview. In cases of severe distress, researchers
were trained to invite participants to stop the interview, a tech-
nique that was used with one participant, and to offer supportive
referrals. In the case of current suicidal thinking, researchers were
trained tomake a direct referral to a psychiatric ward of the nearest
hospital. In this sample, no participants revealed current suicidal
thinking but several participants recounted a history of suicidal
Fig. 1. Socio-ecological framework linking IPV to HIV-related health.
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ideation, for which researchers offered empathetic listening and
referrals to a nearby community psychology counseling service.
2.2. Data collection
In-depth interviews were conducted face-to-face, in a private
clinic room, at a convenient time for the woman. Interviews were
conducted by the lead author and four other trained qualitative
researchers. The trained researchers were comprised of two South
African, female nurses and two non-South African, female re-
searchers. This composition of the research team helped ensure
that some of the positionality challenges associated with language
and racewere addressed. However, all researchers held positions of
relative power compared to participants, a dynamic that was
intentionally addressed through training on a humble, inquisitive
approach and the ethos among the research team that participants
were the ‘experts’ and researchers were the ‘learners’. While this
positionality could not be completely eliminated, the rich stories
presented by most participants suggests comfort in sharing their
stories through the research process.
Interviews were conducted in one of three South African lan-
guages (English, Sesotho, isiZulu) and digitally recorded. A semi-
structured in-depth interview guide explored three themes: the
perceived relationship between IPV and HIV in women's lives;
women's perceptions of how violence may inﬂuence PMTCT up-
take; and, potential mechanisms through which IPV may impact
PMTCT-related health behaviors. Interviews lasted between 26 min
and 1 h 40 min (median 46 min).
Professional transcriptionists typed verbatim transcripts from
the digital recordings. Each transcript was reviewed by a researcher
to ensure clarity and for additional detail about tone and non-
verbal cues… Interviews conducted in the local language
(Sesotho or isiZulu) were translated directly to English and
reviewed for translation errors by the researcher who led the
interview. All data collection materials were stored in a locked ﬁle
cabinet and electronic voice ﬁles and transcripts were password
protected and stored on an encrypted server. At the point of tran-
scription, the lead researcher assigned a pseudonym unrelated to
the participant's real name for ease of analysis. The data presented
here note the pseudonym, age, and whether the woman was
pregnant or postpartum.
2.3. Data analysis
To ensure that interviews achieved adequate depth and rich-
ness, the ﬁrst 6 transcripts were reviewed jointly to establish future
questions, points of clariﬁcation, and initial themes. Researchers
reviewed full transcripts and created detailed 'memos' to highlight
initial impressions of the data. This review process was repeated at
two other time-points (upon completion of 18 interviews and 28
interviews). Both reviews led to tweaking of the interview guides,
with major themes retained but sub-questions altered to enhance
probing and clarity. The team developed an initial coding frame-
work based on the preliminary review of 6 transcripts and “sensi-
tizing concepts”, or preliminary ideas around how to examine the
data (Bowen, 2006).
The coding framework was applied to all transcripts by two
researchers using Dedoose qualitative analytic software. The focus
of double-coding was to ensure that code application was consis-
tent across transcripts and that code deﬁnitions were robust.
Rather than assessing inter-rater reliability, the team used a series
of phone calls and in-person meetings to reﬁne codes until
consensus was reached. This process led to a reﬁned set of thematic
codes that comprised broad topics such as relationship character-
istics, experience of violence, HIV diagnosis, PMTCT uptake, mental
health, social support, partner HIV serostatus disclosure, and re-
ﬂections on being asked about IPV in pregnancy. Next, the team
established a system of ﬁne codes that emerged inductively from
the data. Fine codes were applied to a portion of transcripts by
three researchers, ensuring that every transcriptwas double-coded.
Examples of ﬁne codes within the partner HIV disclosure section
were: fear of partner response, reactive or polarized methods of
disclosure, male partner denial of disclosure, concern for the child,
supportive steps, displaced anger. During analysis, cases that did
not ﬁt the overall picture, called “exceptional cases”, were actively
sought out. Trustworthiness of ﬁndings was ensured by the team
approach to data analysis, coding discussion meetings, and by
presenting initial ﬁndings to groups of colleagues and peers.
2.4. Ethical and safety considerations
All participants provided written, informed consent. The parent
trial received approval from the University of the Witwatersrand
Human Research Ethics Committee (M121179) and World Health
Organization Ethics Research Committee (RPC471). This qualitative
substudy received additional secondary analysis approval from
University of the Witwatersrand (M140451).
Given the special considerations around researching violence,
all portions of this study were designed to adhere to the WHO
ethical and safety guidance on IPV research (WHO, 2001). The
research was presented broadly so that the speciﬁc nature of the
study was not made public. Only when the participant and inter-
viewer were alone, during the informed consent process, did the
researcher provide further information that the nature of the study
involved HIV and IPV. All qualitative researchers were intensively
trained. A 30-h technical training alongsideweekly mentorship and
debrieﬁng by senior teammembers ensured all researchers had the
knowledge and skills required to skillfully handle disclosure of
violence (Reynolds, 2007).
3. Results
3.1. Sample characteristics
Of the 32 participants, 26 women reported IPV in pregnancy
while 6 reported a prior history of IPV (see characteristics
Table 1
Descriptive statistics of sample (n ¼ 32)
Characteristics Number or Median Percentage or IQRa
Sociodemographics
Age 30 years (26e32)
High school education 10 (31.3%)
Employed 13 (40.6%)
Country of origin
South Africa 19 (59.4%)
Zimbabwe 12 (37.5%)
Malawi 1 (3.1%)
Relationship characteristics
Type of violence
Emotional only 3 (9.4%)
Physical and emotional 24 (75.0%)
Physical, sexual, and emotional 5 (15.6%)
Recent (vs. lifetime) 26 (81.3%)
Living with partner 11 (34.4%)
Partner age 34 years (31e36)
Length of relationship 4.5 years (2e5)
HIV-related characteristics
Pregnant at time of interview 14 (43.8%)
Time since HIV diagnosis 2 years (1e5)
Non-adherent to ART in pregnancy 12 (37.5%)
a IQR: interquartile range; ART: antiretroviral therapy.
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summarized in Table 1). Themajority of participants (75%) reported
physical and emotional violence, with several (16%) reporting
physical, sexual, and emotional violence. Twelve participants (38%)
reported that they were non-adherent to HIV medication during
the time of pregnancy or were not on treatment.
3.2. Links between violence and PMTCT adherence
We learned that four pathways linked women's experience of
IPVwith their adherence to PMTCT interventions. The ﬁrst pathway
was partner disclosure, with violent relationships framing a deci-
sion to hide one's HIV status. Somewomenwere unable tomaintain
careful PMTCT behaviors without risking disclosure, so they opted
to take treatment breaks or stop treatment altogether. A second
pathway was mental health, as IPV resulted in depressive views
that “life is not worth living” and led to missing doses of medica-
tion. A third pathway was partner control and isolation, in which
men limited participant access to friends and family, which pre-
cluded the social support required for good adherence. In a ﬁnal,
protective pathway, good PMTCT adherence seemed linked to
women's identity as mothers, with the wellbeing of the baby
framing decisions to stay attentive to medication.
Below, we present each pathway alongside illustrative quotes
and case examples of participants. While it may appear that certain
women ‘belong’ primarily to one single pathway, this was certainly
not the case within the overall analysis. Participants often related
stories that highlighted the complex relationship across the
pathways.
3.3. Partner (non) disclosure: hiding HIV from a partner
Of the 16 women who disclosed to partners, many experienced
subsequent physical violence (n¼ 6) and emotional violence (n¼ 7)
that they directly linked to the disclosure act. Participants recalled
incidents of violence that started or worsened immediately
following HIV testing. Lulama, who was 30 years old and pregnant
with her second child, made a direct link between her HIV status
and physical and emotional violence from her partner. The partner
consistently blamed Lulama for “giving” him HIV, and would use
threats of further physical violence to show his disdain for her
status. Thuto, a 25-year-old postpartum participant, explained that
the violence in her relationship started when she tested HIV-
positive during her ﬁrst pregnancy. Thereafter, a severe episode
of physical violence in her third pregnancy was directly related to
her HIV status: “He came back from the shebeen [local bar] and said
I was a slut, and that's why I came with this disease.”
Not all women experienced physical violence after disclosing
their HIV status. A tension occurred in Leah's relationship that
demonstrates the blurred lines between violence and partner
support around HIV. As a 33-year-old pregnant participant, Leah's
husband was broadly supportive of her taking medication, because
Leah had carefully convinced him that PMTCT can prevent HIV in
their infant. Leah's partner would even remind her of her treatment
time. Yet, alongside this instrumental support, he was emotionally
abusive and would remind her that HIV would lead to her death by
stating, “You will die, your children will be alone.”
In this context of violent or psychologically harmful reactions, it
is perhaps not surprising that 16 women opted to keep their HIV
status a secret. Participants described this choice as a reasoned
response to a dangerous situation. Six participants feared that their
partners would react to disclosure with physical violence. For
Simphiwe, a 33-year-oldwomanwho had beenwith her partner for
ﬁve years, a history of physical violence led her to keep HIV a secret.
Another participant, Kandi, feared physical violence because her
partner explicitly stated that hewould hurt her should she test HIV-
positive.
Fears of partner reaction led some women to be partially non-
adherent to their HIV medications. One 32-year-old postpartum
participant, Nomsa, described her fear that the father of her ﬁrst
child might murder her or the child as a response to HIV disclosure.
Nomsa kept her status hidden by pretending the medication was
for pregnancy, rather than for HIV, but admitted it was challenging
to keep taking the pills after giving birth. Another participant,
Thembi, was 26 years-old and postpartum when she recounted
how she chose not to start HIV medication in pregnancy because
she was frightened that her partner would be physically violent
when she asked him to use a condom. Her (incorrect) under-
standing of treatment came from antenatal staff who often say that
HIV medication must be accompanied by consistent condom use.
Since Thembi knew she could not safely use condoms, she chose to
avoid HIV medication altogether. Her non-uptake of treatment
meant that her infant acquired HIV during the course of the study.
The act of hiding medication and withholding one's status from
partners requires considerable foresight and care. Lulama, 30 years
and pregnant during the interview, strategically took medication at
a timewhen her husbandwas away from the house. At 34 years and
pregnant, Ayanda changed the container of her HIV medication so
that it would appear to be other routine medication. Other women
like Mpefe also had to carefully navigate clinic visits and
medication:
My boyfriend doesn't know about this. I just kept it to myself. So my
treatments, when I would come and take my treatments here by
the clinic, then I would hide it by my place. Even when I drink my
tablets I would hide them. e Mpefe, 25 years, Pregnant
When Mpefe noticed her partner was nearby, she would forgo
treatment altogether. Eventually, Mpefe decided to move out so
that she could easily take her treatment without worry that her
boyfriend might see.
Similarly, Zama (25 years and pregnant) found it easier to
adhere to medication once she moved out from her partner's place.
Before she would wait until he fell asleep to take her daily pre-
scription: “It was a little bit tricky because I had to hide the
medication. And then at times he would be in the same bedroom
where I hide it, so I can't take it.” For Sonja, the original response to
disclosure was threats of violence and forced eviction from the
household. In this context, Sonja, 23-years-old and pregnant,
carefully avoided taking medication in front of her partner,
worrying that simply seeing the medicine might trigger a violent
reaction. One day, her partner snuck up on her in the bathroom and
caught her taking the treatment. While the response was not
physical violence, her partner disappeared and returned home in
an agitated state after a bout of drinking.
A subtler rationale for hiding medication from violent partners
was to withhold information from a person who had caused so
much pain. For two women, this appeared to be a resistance
strategy for proving to themselves that their own health was not
within the realm of things men could control. Simphiwe professed
that she made up her mind immediately after testing HIV positive,
since “he was violent, hitting me and all that stuff. So I decided I'm
not going to tell him.” Similarly, Zinhile explained “If he was a
proper person, then I would tell him that I'm HIV positive, let's go to
the hospital together to test. But if he is going to put me at risk, why
should I say that?” Zinhile met her partner's lack of care by stub-
bornly refusing to share anything about HIV with him:
I didn't want him to know I have gone to the clinic. I didn't even
want him to know what I was doing in my life, in my future,
because he didn't want to be close… I didn't even want him to see
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me taking the tablets, because he didn't want to know, he didn't
want me. e Zinhile, 38 years, Postpartum
3.4. Mental health: poor adherence as a result of depression and
anxiety
Several women related stories of non-adherent periods, many of
which resulted from depressive episodes that followed phases of
violence. At 24 years, Thuto had recently delivered her fourth child,
and explained the tendency to feel despondent particularly after
extremely violent episodes or when her husband refused to buy
food for the family. Thuto sometimes struggled with staying
adherent, and explained that she had given up hope: “Sometimes,
when I'm stressed, I feel that its better I also died… I've just lost
hope.” Zama expressed a concern that her infant would test HIV-
positive, since she herself had experienced adherence struggles.
Similar to several other participants, Zama disclosed a desire to
“end everything” as a method to reduce the distress she was feeling
about the violent relationship:
When I was three months pregnant, that is when it started
changing to being physical [violence]. At times I would just feel like
ending everything, the stress and all that… I am very much worried
about my baby being positive, especially with the fact that I was not
able to take my medication as frequently as I was supposed to.
eZama, 25 years, Pregnant
Ayanda's partner had been physically abusive the night before
the interview. She described the physical violence alongside the
overwhelming nature of copingwith frequent abusive episodes and
anticipating the arrival of a new baby. The stress related to the
violence was a concern because Ayanda realised how episodes of
IPV took priority over remembering to take her medication:
You know what bothers me sometimes? That when he makes this
thing [violence], I may forget to drink mymedication. Then maybe I
will just default [not comply with HIV visits and medications]. And
what worries me is that I will default when I'm breastfeeding the
child. eAyanda, 34 years, Pregnant
This notion of “forgetting” to take medication is perhaps more
linked to how women are able to cope with various life challenges.
When violence is more of a concern, or more ‘top of mind’, than
HIV-related concerns, women may forgo the steps required for
good HIV care. This ﬁnding denotes how subtle mental health
considerations, like being too cognitively overwhelmed by the
violence, may inﬂuence PMTCT uptake.
Six women described periods of stopping treatment altogether
due to depressive and suicidal feelings. The underlying emotion of
stopping treatment for these womenwas a desire to end their lives.
One participant, Dova, named it a “death wish” and recounted the
overwhelming feelings of hopelessness and failure that had led her
to stop taking HIV treatment:
Therewas a timewhen I was really, really down, so I stopped taking
my medication. I completely just stopped and I sort of had this
death wish in me that if only this thing would, if HIV would work
like really for us then it would just kill me. I stopped for three to four
months without taking my medication. e Dova, 32 years, Pregnant
Another participant, Dintle, had tried to commit suicide by
drinking poison several weeks prior to the interview. Her husband
had been extremely violent, hitting her in front of the neighbours,
withholding food, and publicly shaming her. She explained in
subtle terms (such as “stress” and “feeling bad”) how her recent
suicidal experience and anxiety symptoms would cause her to
forgo treatment for periods of time:
Participant (P): Sometimes I forget to take my treatment. It
happened two months ago. I had pills, but I just forgot dates to go
fetch my treatment.
Researcher (R): What led you to forget?
P: Stress, I am always thinking.
I: What were you thinking?
P: I was thinking about the time he threatened me. I just end up
thinking about too many things. By the time I remember it is too
late, my days have passed. e Dintle, 30 years, Postpartum
For Dintle, stopping treatment was a by-product of experiencing
intense episodes of violence and concomitant mental health chal-
lenges. This suggests that in cases of severe depression, HIV treat-
ment non-adherence can be both a mode of self-harm and a result
of being overwhelmed at times of high distress.
3.5. Isolation and partner control: the hidden nature of IPV and HIV
In this sample, there were only a few examples of partners
directly controlling the health of women through barring access to
clinics or medication. At 38 years and postpartum, Zinhile feared
blame associated with having HIV, but not necessarily a violent
reprisal. Even still, the controlling behaviors her partner exhibited
against the backdrop of physical and sexual violence meant that
Zinhile would surreptitiously visit the clinic.
Yet, partner control did not always lead to poor adherence. For
example, Kagiso's partner was suspicious when she went to the
clinic, assuming she was cheating on him. At times, he would
physically abuse her when she came home from the clinic,
presuming she was unfaithful during her times away from home,
but she described a stubborn dedication to continue seeking
medical treatment:
Sometimes when I go to the clinic he say hey you are not going to
the clinic. He asked me toomany questions… But I refuse. I tell him
I can't stop going to clinic because this is my life! I have children. I
have to live to take care of my babies. Sometimes when I come back
to the house he beats me, accusing that I'm not coming from the
clinic. eKagiso, 28 years, Postpartum
For many women, violent partners did not actively bar access to
clinics, but indirectly used isolation as a type of partner control. One
example is found in Lulama's story about how returning from a
normal day would often result in questions and threats: “He is al-
ways looking at what I do and wants to know what I get up to. He
controls my life, he says I should always be at home.” The outcome
of these controlling behaviors was often immense isolation and
mental health challenges for Lulama, who was 30 years and preg-
nant at time of interview.
For several participants, the feeling of isolation was pervasive,
leaving them troubled and continually ruminating over difﬁcult
thoughts. Dova illustrated this by describing how thoughts of the
violence were “stuck in her mind” and left her isolated and alone:
It is just basically stuck there in mymind - all these things that have
been happening.When you are alone, you just sit and think about it
and I don't have anyone. Sometimes I don't sleep the whole night I
am thinking and thinking. e Dova, 32 years, Pregnant
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Another implicit trait of the partner control and isolation
pathway is the hidden nature of both HIV and violence. Both HIV
and IPV are stigmatised, which leads to a worsened ability among
women to ﬁnd support for either condition. Several women spoke
of staying silent with their families about the violence in their re-
lationships. As 30-year-old, pregnant Lulama noted, “whatever we
ﬁght about I keep to myself most of the time.” For Neo, it was easier
to pretend that things were ﬁne than to disclose to her friends that
she lived in a violent relationship:
It's hard to tell people I've got a problem, I'm not living a good life,
with a partner that I'm worried, we're always ﬁghting, things like
that. You just pretend, like now pretending that I'm ok but I'm not
ok. e Neo, 28 years, Postpartum
3.6. Motherhood as a coping strategy: protective pathway
Despite immense challenges with HIV, violence, and pregnancy,
many women in this sample exhibited unique coping strategies for
adhering to treatment. For some women (n ¼ 8), the concept of
motherhood was a source of resilience and helped them stick with
HIV medications. At 32 years and postpartum, Nomsa struggled to
ﬁnd clothing and food for her children, but continually reminded
herself that treatment was an essential part of being able to care for
her children: “I'm drinking my tablets. I'm just telling myself that I
must help myself and get help. I know I need to work for my kids
rather than die.”
Zama did have trouble with adhering to treatment, and
considered suicide during phases when the physical violence was
particularly bad. Yet, at 25 years and pregnant, the reminder of her
new baby would often be enough to return her to thoughts of living
and trying to provide for her baby: “Maybe after a ﬁght, I will be
crying, stressed and then I would be like, okay, let me just do this
[commit suicide], then I would think, ‘No, but let us give this baby a
chance'.” It is important to note that Zama exhibited these methods
of “resilience” by focusing on her baby's wellbeing even as she
struggled with suicidality and isolation. Her story illustrates the
complex relationship within multiple pathways, and shows that
IPV's inﬂuence can manifest in complicated ways.
Grace used the idea of caring for her children as a way to “move
on with life” and leave her violent partner:
Like in future I was thinking like to move on with my life. Do
something for my life and for my kids! That's what I want now
because I'mdonewith living in the painful relationship.e Grace, 27
years, Postpartum
Zethu's baby similarly helped her keep “priorities straight.” As a
21-year-old pregnant woman, she boldly stated that HIV treatment
was more important than her husband, and expressed how non-
adherence was simply going to harm herself: “I'm doing it
[PMTCT] for my baby. I don't want to stressmyself so that I leave the
tablets - it's better to leave that husband and continue with my
tablet.” Beyond Zethu's commitment to protecting her baby, it
appeared that taking care of her own HIV could be a subtle way to
“leave that husband” and regain control over her own life.
Not every participant was able to use the notion of motherhood
to feel more conﬁdent around HIV treatment. For example, Dova
felt that the stress related to the violent relationship was making
her a worse mother e a notion that she illustrated by describing
how her suicidal thoughts were linked to thoughts of hurting her
children:
I have suicidal thoughts because I don't have anyone. The only
people I have are my kids. And the worst part is with these suicidal
thoughts I am always saying, if I had to kill myself, I wouldn't leave
my kids behind. I would take them with. If there is a method
whereby I would kill me and my kids, I would do it. So it is just, it is
not well. I am not even a good mother these days. eDova, 32 years,
Pregnant
Dova's story reﬂects upon multiple pathways of mental health
and isolation, suggesting again that pathways may have a dynamic
relationship and do not necessarily stand alone as distinct
situations.
4. Discussion
This is the ﬁrst study, to our knowledge, to explore the rela-
tionship between violence and HIV adherence within a relatively
robust qualitative sample of 32 pregnant and postpartum women
reporting both HIV and IPV. It highlights that women living with
HIV and IPV have unique challenges to maintaining healthy
adherence behaviors around the time of pregnancy. Four key
pathways emerged that link IPV to PMTCT: partner non-disclosure,
poor mental health, isolation due to partner control, and
motherhood.
As shown in Fig. 2, pathways from IPV to PMTCT outcomes tend
to intersect and collide. Rather than falling into distinct categories,
participants often presented stories that fell within multiple
pathways. The pathways seemed to be comprised of both positive
and negative aspects of responding to IPV. So while mental health
and partner control/isolation seemed to worsen HIV outcomes for
women, pathways of motherhood and partner non-disclosure
highlighted unique resilience strategies used by women. This
nuanced understanding of the IPVeHIV adherence relationship can
help contextualize recent conﬂicting evidence from sub-Saharan
Africa. Whereas one study with pregnant women in Zambia
showed that violence worsens HIV adherence (Hampanda, 2016),
another in Kenya among female sex workers suggests that history
of IPV actually improved odds of HIV-related health (Wilson et al.,
2016). It is possible that while experience of IPV may hinder
women's ability to take HIV medication, it could alternately (or
simultaneously) spur women towards persevering with HIV
treatment.
While motherhood was a protective element and a resilience
strategy for some participants, this ﬁnding contains critical con-
tradictions. Our ﬁndings reﬂect that women's sense of self around
the time of pregnancy can be grounded in the infant relationship
(Bhandari et al., 2012), and that striving for motherhood may be an
active coping strategy (Burnett et al., 2015; Foster et al., 2015).
Motherhood can represent an important “turning point” when
women start to consider leaving a violent relationship for the sake
of the infant (Semaan et al., 2013: 74). However, there is a less
positive aspect to the motherhood identity, as it necessarily expects
that mothers will be the nurturing caretaker and sacriﬁce her own
needs for that of her child (Hays, 1998). When, in the context of IPV,
women may not be fully able to protect their infants from psy-
chological and physical harm, they may be held responsible for
failure to protect the child, even as they themselves require pro-
tection (Lapierre, 2008). The shame associated with both IPV and
HIV may be compounded with the shame of being a ‘bad mother’,
which could only worsen mental and physical health outcomes.
The pathway of partner non-disclosure seems to reveal both
negative aspects of IPV as well as resilience strategies used by
women. This tension between women being both constrained by
the violence while also being agentic in their response has been
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highlighted in previous IPV literature (Campbell andMannell, 2016;
Turan et al., 2016). In our sample, partner non-disclosure made it
challenging for some women to take treatment openly and
consistently (Awiti Ujiji et al., 2011; Sayles et al., 2006). Yet, for
others, non-disclosure was an important safety strategy. Women in
this sample made strategic choices to stay safe from violent re-
prisals by placing medication in other containers, taking it at times
when partners would be away, and by moving out from home
altogether. Importantly, non-disclosure was also a method for
regaining control over chaotic lives. It is important to note that this
‘agentic’ ﬁnding around non-disclosure strategies may have
emerged partly because of our narrative approach to data collec-
tion. Constructing meaning through narratives is a particularly
useful approach to violence research, as it restores agency and
power among a group that is often considered the “helpless victim”
(Boonzaier and van Schalkwyk, 2011: 278). Notwithstanding the
methodological considerations of this conclusion, the strong evi-
dence from nine women in our cohort suggests that women do use
important strategies to avoid partner disclosure while staying
faithful to HIV medication adherence.
Pathways of partner control andmental health offered ‘negative’
inﬂuence on PMTCT behaviors. For several women, relationship
control led to an inability to attend the clinic or take medication
when desired (Lichtenstein, 2006). More often, however, partner
control manifested as a sense of isolation and inability to deﬁne
one's own choices about health, movement outside the home, or
taking care of the infant. The isolation caused by severe partner
control meant that women had little access to social resources to
help them (Liang et al., 2005). Isolation also contributed towards
the mental health pathway, with women reporting increased
anxiety and distress due to being alone.
Our ﬁndings certainly support extant literature by suggesting
that IPV leads to emotional trauma, anxiety, suicidal ideation, and
depression among women, including in antenatal care (Ellsberg
et al., 2008; Mahenge et al., 2013) and that poor mental health
has onward impact on HIV medication adherence (Sumari-de Boer
et al., 2012). We add to this evidence base by highlighting the
complex underpinnings behind the IPV-mental health connection.
On the more manageable side of the spectrum, women in violent
relationships have stress and emotional concerns that take priority
over the daily regimen of medication. For other women, on the
more extreme side, a sense of hopelessness and being over-
whelmed due to the extreme distress of violence led to the po-
tential for self-harming behavior. In the six cases of women who
described suicidal ideation, several used the act of stopping treat-
ment as part of thoughts of ending their own lives. Others have
noted that women's experience of abuse may create a self-image of
being damaged, inhibiting self-care and access to regular health
services (Leenerts, 1999; Rothenberg and Paskey, 1995). Our ﬁnd-
ings go beyond this literature by noting that HIV medication e due
to its very necessity for good healthe can be used in a self-harming
manner through intentional treatment interruptions.
4.1. Limitations
The ﬁndings of this study should be viewed in light of several
limitations. All participants were visiting antenatal care, limiting
our ability to understand these dynamics amongwomenwho avoid
healthcare in pregnancy. Similarly, participants in this sample all
reported IPV victimization (a majority with recent violent epi-
sodes), limiting a comparison to women living without IPV. Pur-
posive selection of participants preclude our ability to generalize
these data to the entire parent trial cohort, a limitation of most
qualitative research. The urban Johannesburg setting has distinc-
tions from other sub-Saharan African health settings, which makes
it challenging to compare ﬁndings. Our narrative, social construc-
tionist approach to interviews intentionally focused on techniques
like validation, highlighting resistance, and locating identity within
participant stories. Therefore, our interpretations are likely to differ
from that of a ‘neutral observer’, as utilized within a more positivist
research paradigm. Nevertheless, this study provides initial im-
pressions of violence among HIV-positive pregnant/postpartum
women in a sample that is larger than the extant literature.
4.2. Implications for intervention, research & policy
Several intervention strategies emerge from these data. With
appropriate training, supervision, and tools, health workers in
antenatal settings could be the ﬁrst point of contact for pregnant,
abused women. The ‘window of opportunity’ in antenatal care,
Fig. 2. Pathways linking intimate partner violence to PMTCT uptake.
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when women are repeatedly visiting the clinic, can ensure that
violence and HIV considerations are jointly addressede particularly
through onwards referral to services that specialise in addressing
violence. The current method of group-based PMTCT messaging
should be reﬁned towards an individually-tailored approach that
truly addresses the concerns, confusions, and daily lives of pregnant
and postpartumwomen. Open, honest discussions at this phase in a
woman's life may have beneﬁts for staying safe while adhering to
crucial PMTCT interventions. The notion of ‘striving for mother-
hood’ can also be harnessed during this time, to help women pri-
oritize their own health and safety as another form of commitment
to the infant. It is clear that the intertwined issues of mental health
and disclosure need to be incorporated into PMTCT services, and
this can be achieved by training antenatal staff to implement brief
mental health interventions or through referrals. Social support in
the form of skillfully-facilitated peer support groups could assist
women with the isolation pathway that is so pervasive in abusive
partnerships.
These qualitative ﬁndings suggest several avenues for further
research. Given the potential positive and negative ways that
violence may impact HIV adherence, future quantitative research
should extend beyond simplistic analytic techniques. To date, the
literature has been limited to bivariate association between
violence and HIV adherence. Simple regression techniques may fail
to account for important meditational pathways between IPV and
adherence. In one recent study, for example, the direct association
between IPV and HIV adherence was non-signiﬁcant, yet when
mediated by mental health there was a strong negative path as-
sociation (Malow et al., 2013). Speciﬁc pathways identiﬁed in this
research should be explored and conﬁrmed in a larger, quantitative
sample using techniques that recognize the interrelated nature of
pathways, such as structural equation modeling.
PMTCT policy could also beneﬁt from these qualitative ﬁndings.
Current South African PMTCT guidelines discuss the “beneﬁts” of
partner HIV disclosure and prompt health workers to “encourage”
disclosure and “support … partner notiﬁcation” (South African
Department of Health, 2014: 37). However, no mention is made of
the safety dilemmas thatmothersmay face in disclosing to a violent
partner. We learned that partner non-disclosure is a strategic way
to stay safe in a violent relationship, and that some women can
manage to safely continue treatment without their partners ﬁnding
out. Given that 25e35% of South African women experience IPV in
pregnancy (Dunkle et al., 2004; Groves et al., 2012), the omission of
strategic non-disclosure in current guidelines is likely to burden
health workers, who are currently unskilled at discussing partner
dynamics.
5. Conclusion
IPV and HIV are strongly linked in the lives of childbearing
women in many settings globally, and violence leads to adherence
challenges that place maternal and infant health at risk. These
intersecting issues deserve increased attention if we are to ensure
elimination of vertical HIV transmission and protect the health of
mothers. Current policy and intervention is sorely lacking, with
little evidence that health workers and policy makers are alert to
the considerations of violence within PMTCT programming. Preg-
nant and postpartum women will greatly beneﬁt from antenatal
care that recognizes the realities of living in violent relationships
and emboldens women to prioritize their own health, as well as the
health of their infants, during this critical phase.
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